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Summary	
The	 growth	 inhibitory	 actions	 of	 antihormones	 in	 the	 treatment	 of	 oestrogen	receptor-positive	 (ER+)	 breast	 cancer	 are	 compromised	 by	 the	 development	 of	resistance.	 There	 is	 emerging	 evidence	 that	 antihormones	 can	 rapidly	 induce	expression	of	genes	 that	enable	cells	 to	survive	 the	 initial	 impact	of	 these	agents	and	ultimately	aid	the	acquisition	of	resistance.		The	 aims	of	 this	 thesis	were	 to	 identify	 novel	 antihormone-induced	pro-survival	genes	 in	 a	 panel	 of	 ER+	 breast	 cancer	 cell	 lines	 and	 to	 determine	whether	 such	genes	 contribute	 to	 the	 limited	 efficacy	 of	 antihormones	 during	 response	 and	subsequently	contribute	to	the	emergence	of	resistant	cell	growth.		Microarray	 analysis,	 together	 with	 a	 stringent	 filtering	 process,	 identified	14	pro-survival	genes	significantly	induced	by	at	least	one	antihormone	treatment	(10	 day	 tamoxifen,	 fulvestrant	 or	 oestrogen	 deprivation)	 in	 ER+	 MCF-7	 breast	cancer	 cells,	 with	 increased	 expression	 maintained	 into	 cell	 models	 of	antihormone-resistance.	Of	 these	15	genes,	5	 (GABBR2,	CLU,	CTNND2,	BCL3	and	TSC22D3)	were	significantly	 induced	by	all	antihormone	treatments.	PCR	and/or	Western	blotting	demonstrated	antihormone-induced	expression	of	these	5	genes	in	T47D	(ER+/HER2-),	BT474	and	MDA-MB-361	(ER+/HER2+)	cell	lines.	The	role	of	BCL3	and	CLU	during	antihormone	response	and	resistance	were	next	investigated.	siRNA-mediated	BCL3	knockdown	had	no	effect	on	cell	 survival	but	reduced	 proliferation	 of	 tamoxifen-resistant	 (TAMR)	 and	 oestrogen	 deprivation-resistant	 (XR)	 cells.	 Immunoprecipitation	 and	 immunofluorescence	 studies	revealed	nuclear	localisation	and	direct	association	of	BCL3	and	p50	in	TAMR	and	XR	cells.	However,	during	 response,	BCL3	was	 located	 in	 the	nucleus	and	p50	 in	the	cytoplasm.	In	contrast,	siRNA-mediated	CLU	knockdown	reduced	proliferation	of	fulvestrant-treated	MCF-7	cells	but	was	without	effect	on	the	growth	of	resistant	cells.	To	conclude,	this	thesis	has	identified	one	antihormone-induced	gene	(CLU),	which	appears	 to	 limit	 response,	 and	 a	 second	 (BCL3),	 which	 appears	 to	 promote	 the	growth	of	antihormone-resistant	cells,	potentially	via	activation	of	NFκB-mediated	gene	transcription.	
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1 Introduction	
1.1 Incidence	of	breast	cancer	Breast	cancer	is	the	most	common	female	cancer	in	the	UK	and	women	have	a	1	in	8	lifetime	risk	of	developing	the	disease.	The	incidence	of	female	breast	cancer	has	increased	since	the	1970s.	This	increase	has	been	attributed	to	earlier	detection	as	a	 result	 of	 the	 introduction	 of	 national	 screening	programmes	 in	 the	 late	 1980s.	However,	 despite	 the	 increase	 in	 incidence,	 female	 breast	 cancer	mortality	 rates	have	decreased	in	the	last	40	years	with	improved	detection,	increased	awareness	and	more	effective	treatments	resulting	in	almost	8	out	of	10	women	surviving	the	disease	beyond	10	years	(2012	statistics)1.	Unfortunately,	however,	breast	cancer	is	the	second	most	common	cause	of	cancer	death	among	women	in	the	UK	(2012)	with	32	women	dying	 from	 the	disease	every	 single	day1.	Thus,	 further	 research	and	 improved	 treatments	 are	 required	 to	 target	breast	 cancer	 in	patients	whose	disease	progresses	on	current	therapies.		
1.2 Risk	factors	of	breast	cancer	The	majority	of	breast	 cancers	 are	 sporadic	 and	 result	 from	 the	accumulation	of	uncorrected	mutations	 in	 somatic	 genes.	However,	 there	 are	 several	 risk	 factors	that	 are	 associated	 with	 the	 development	 of	 breast	 cancer,	 with	 increased	concentrations	 of	 the	 female	 steroid	 hormone	 oestrogen	 being	 the	 most	significant2.	Additionally,	 in	support	of	 the	endocrine	status	 link,	 less	 than	1%	of	breast	 cancers	 are	 diagnosed	 in	 men	 (2012	 statistics)1.	 Factors	 that	 increase	lifetime	exposure	to	oestrogen	include	increasing	age,	women	who	are	younger	at	menarche	 and	 older	 at	 menopause3.	 Furthermore,	 exposure	 to	 exogenous	oestrogens	from	the	use	of	hormone	replacement	therapy	and	oral	contraceptives	are	 also	 associated	 with	 increased	 risk	 of	 developing	 breast	 cancer4–6.	Interestingly,	 breast	 cancer	 incidence	 rates	 are	 highest	 in	 developed	 Western	countries	and	significantly	less	in	developing	countries,	particularly	middle	Africa1.	This	 may	 be	 due	 to	 women	 in	 developing	 countries	 having	 more	 children	 and	breastfeeding	 for	 longer7	 which	 suppresses	 ovulation,	 both	 contributing	 to	 a	reduced	exposure	to	oestrogen.		
	 2	
Furthermore,	 approximately	 a	 quarter	 of	 breast	 cancers	 are	 hereditary,	characterised	by	a	young	age	at	diagnosis	and/or	first	degree	relatives	affected	by	the	disease8.	In	particular,	it	has	been	shown	that	women	diagnosed	before	the	age	of	 50,	 with	 a	 history	 of	 breast	 cancer	 in	 at	 least	 one	 first-degree	 relative,	 are	associated	 with	 an	 approximately	 two-fold	 relative	 risk9.	 This	 risk	 has	 been	attributed	 to	 the	 inheritance	 of	 autosomal	 dominant	 breast	 cancer	 susceptibility	genes.	 Mutations	 in	 two	 breast	 cancer	 tumour	 suppressor	 genes,	 BRCA1	 and	BRCA2,	have	been	identified	and	account	for	a	substantial	proportion	of	high	risk	families.	Indeed,	a	meta-analysis	has	revealed	an	average	cumulative	lifetime	risk	of	 65%	 to	 develop	 breast	 cancer	 in	BRCA1	 carriers	 compared	 to	 45%	 in	BRCA2	mutation	 carriers10.	 However,	 BRCA1	 and	 BRCA2	 genes	 are	 only	 involved	 in	approximately	30%	of	 breast	 cancer	 cases	with	 a	 hereditary	 component11.	 Thus,	with	 the	 rapid	 expansion	 of	 next	 generation	 DNA	 sequencing,	 more	 recent	research	 is	 discovering	 new	 susceptibility	 genes.	 For	 example,	 the	 BRCA2-interacting	protein	PALB2	has	emerged	as	a	new	breast	cancer	susceptibility	gene.	Indeed,	 a	 recent	 study	 has	 revealed	 an	 estimated	 cumulative	 risk	 of	 35%	 to	develop	breast	cancer	in	PALB2	mutation	carriers12.		
1.3 Oestrogen	and	breast	cancer	Oestrogen	exposure	has	been	long	established	as	a	cause	of	breast	cancer	and	for	maintaining	its	growth.	Indeed,	breast	cancer	growth	appears	to	be	dependent	on	oestrogens	 and	 in	 particular	 the	 predominant	 circulating	 oestrogen,	 17β-oestradiol	(E2),	as	demonstrated	by	an	increase	in	breast	cancer	cell	line	growth	in	response	 to	 this	 hormone13.	 This	 dependency	 is	 reflected	 by	 the	 increased	incidence	 of	 breast	 cancer	 in	women	who	 are	 exposed	 to	 increased	 endogenous	and	exogenous	oestrogens	 (as	previously	described	 in	 section	1.2).	 Interestingly,	the	mitotic	 effects	 of	 oestrogens	 appear	 to	 accelerate	 the	 development	 of	 breast	cancer	 at	 several	 stages	 along	 the	 progression	 from	 early	 mutation	 to	 tumour	metastasis14.	 Additionally,	 increased	 cell	 division	 induced	 by	 oestrogen	 may	increase	 the	 risk	 of	 DNA	 damage	 not	 being	 repaired,	 ultimately	 resulting	 in	mutations15.		The	 first	 recognition	 that	 the	 ovaries	 influence	 the	 development	 of	 the	 normal	human	 female	 breast	was	 in	 1775	when	 Sir	 Percival	 Pott	 demonstrated	 that	 the	
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removal	 of	 the	 ovaries	 of	 a	 young	 woman	 resulted	 in	 breast	 atrophy16.	 Over	 a	decade	 later	 in	 1882,	 the	 first	 evidence	 of	 the	 relationship	 between	 ovarian	function	and	breast	cancer	was	discovered	by	Thomas	William	Nunn	who	reported	the	 case	 of	 a	 perimenopausal	 woman	 whose	 breast	 cancer	 regressed	 6	 months	after	menopause.	 Later,	 in	 1889,	 Albert	 Schinzinger	 first	 proposed	 the	 theory	 of	surgical	 oophorectomy	 as	 a	 treatment	 for	 advanced	 disease	 and	 as	 prophylaxis	against	 local	 recurrence17.	 This	 surgical	 procedure	 was	 later	 first	 performed	 by	George	Beatson	 in	 1896	 and	 led	 to	 the	 regression	 of	mammary	 tumours	 of	 pre-menopausal	women18.	Importantly,	removal	of	the	ovaries	was	used	as	an	effective	treatment,	 together	 with	 surgical	 breast	 tumour	 excision,	 for	 much	 of	 the	 20th	century.	
1.4 Oestrogen	receptor		Oestrogen-induced	 cell	 proliferation	 and	 survival	 is	 mediated	 through	 its	 two	receptors	which	 are	members	 of	 the	 nuclear	 receptor	 family	 of	 ligand-activated	transcription	 factors19:	 oestrogen	 receptor	 alpha	 (ERα)	 and	 oestrogen	 receptor	beta	 (ERβ).	 The	 oestrogen	 receptor	 (later	 denoted	 ERα)	was	 first	 discovered	 by	Elwood	 Jensen	 in	1958	and	was	 later	cloned	and	sequenced	 in	1986	by	Green	et	al20.	 By	 the	 beginning	 of	 the	 1970s,	 the	 theory	 had	 been	 established	 that	 breast	cancers	 exhibiting	 a	 high	 expression	 of	 the	 receptor	 protein	 would	 respond	 to	endocrine	 treatment;	 however,	 there	 was	 very	 little	 evidence	 supporting	 this	hypothesis.	 In	 1974,	 overwhelmingly	 supportive	 data	 was	 presented	 which	revealed	clinically	important	separation	of	endocrine	therapy	responders	and	non-responders	 according	 to	 the	 detection	 of	 the	 oestrogen	 receptor	 in	 the	 primary	tumour,	 as	 summarised	by	McGuire14.	More	 recently,	 a	novel	 oestrogen	 receptor	was	discovered	in	1996	and	named	ERβ22.	The	original	oestrogen	receptor	is	now	commonly	referred	to	as	ERα.		Both	ERα	and	ERβ	consist	of	six	functional	domains	(A-F)	that	serve	specific	roles	(Figure	1).	The	A/B	domain	located	at	the	N-terminus	contains	activation	function	1	(AF1)	which	is	responsible	for	regulating	transcriptional	activity	in	a	hormone-independent	 manner23.	 The	 highly	 conserved	 C	 domain	 encompasses	 the	 DNA	binding	 domain	 (DBD)	 which	 is	 responsible	 for	 binding	 oestrogen	 response	elements	 (ERE)	 in	 the	 promoter	 regions	 of	 target	 oestrogen-responsive	 genes.	
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Domain	 E	 comprises	 the	 ligand-binding	 domain	 (LBD)	 which	 contains	 a	hydrophobic	 ‘pocket’	 that	 binds	 E2	 inducing	 a	 conformational	 change,	 thus	allowing	helix	12	to	seal	the	E2	within	the	pocket.	Additionally,	domain	E	contains	activation	 function	 2	 (AF2)	 responsible	 for	 activating	 transcription	 in	 a	 ligand-dependent	manner	24.		
ERα	 and	 ERβ	 confer	 a	 high	 degree	 of	 homology	 between	 their	 DBD	 (more	 than	95%)	and	LBD	(approximately	55%).	However,	the	AF1	domain	and	hinge	regions	are	the	least	conserved	with	30%	and	36%	sequence	similarity,	respectively25,26.	A	significant	 functional	 difference	 between	 these	 receptors	 is	 related	 to	 the	 AF1	domain.	 Indeed,	 ERα	 contains	 a	 constitutive	 AF1	 that	 functions	 to	 enhance	transcriptional	 response	 of	 the	 receptor,	 whereas	 the	 equivalent	 region	 of	 ERβ	exhibits	 negligible	 transcriptional	 activity	 and	 contains	 a	 repressor	 domain	 that	decreases	 the	 transcriptional	 activity	 of	 the	 receptor25.	 These	 differences	 have	been	 suggested	 to	 contribute	 to	 the	 varying	 responses	 of	 these	 receptors	 to	various	 ligands.	 An	 additional	 difference	 between	 these	 receptors	 includes	 their	tissue	 distribution.	 ERα	 is	 predominantly	 expressed	 in	 the	 breast	 and	 uterus,	whereas	high	ERβ	expression	is	apparent	in	the	ovary,	prostate	and	lung27,28.	Both	receptors	are	expressed	at	low	levels	in	the	normal	breast29;	however,	ERα	is	the	 dominant	 subtype	 in	 breast	 cancer	 as	 detected	 by	 immunohistochemistry	 in	breast	 cancer	 biopsies.	 Although	 ERβ	 expression	 has	 been	 detected	 in	 breast	cancer,	 its	function	remains	elusive	with	studies	reporting	contrasting	roles,	with	some	 suggesting	 a	 role	 in	 cell	 proliferation	 and	 tumour	 progression	 and	 others	suggesting	 a	 potential	 role	 in	 tumour	 suppression30–33.	 ERα	 is	 expressed	 in	
	
Figure	1	Schematic	structure	of	the	oestrogen	receptor	depicting	six	domains.	The	A	
and	 B	 domains	 at	 the	 N	 terminus	 contain	 the	 ligand-independent	 transcriptional	
activation	function	1	(AF1),	 the	C	domain	contains	 the	DNA	binding	domain	(DBD)	
responsible	 for	 binding	 to	 the	 oestrogen	 response	 elements	 in	 the	 promoters	 of	
target	 genes,	 the	D	 domain	 corresponds	 to	 the	 hinge	 region,	 the	 E	 domain	 is	 the	
ligand	 binding	 domain	 (LBD)	 and	 also	 contains	 the	 ligand-dependent	
transcriptional	activation	factor	2	(AF2)	and	lastly	the	F	domain	at	the	C-terminus.	
Figure	adapted	from	Fan	et	al.456.		
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approximately	 70%	 of	 breast	 cancers	 and	 is	 a	 hallmark	 of	 hormone-dependent	growth.	 Consequently,	 the	 growth	 inhibitory	 actions	 of	 antihormones	 for	 the	treatment	 of	 breast	 cancer	 result	 from	 the	 blocking	 of	 ERα	 (termed	 ER	 for	 the	remainder	of	this	project)	signalling	and	downstream	cell	growth	and	survival.		
1.5 Oestrogen	receptor	signalling	
1.5.1 Genomic	ER	signalling	
1.5.1.1 Classical	pathway		In	the	absence	of	E2,	ERs	are	located	in	the	nucleus	and	exist	as	inactive	monomers	bound	 to	 a	 multi-chaperone	 protein	 complex	 containing	 heat	 shock	 proteins	(HSP)34,35.	Upon	E2	binding	to	the	LBD	of	the	ER,	HSP	complexes	are	released	and	the	 receptor	 undergoes	 a	 series	 of	 modifications,	 conformational	 changes,	phosphorylations	and	dimerisation36,37.	The	ER	dimer	binds	to	a	13	base	pair	DNA	consensus	 sequence,	 known	 as	 the	 ERE	 characteristic	 of	 oestrogen-regulated	genes,	 in	 the	 promoter	 region	 of	 target	 genes	 to	 induce	 up	 regulation	 of	 pro-proliferative	 and	 pro-survival	 genes	 (e.g.	 cyclin	 D1	 and	 survivin)	 and	 down	regulation	 of	 anti-proliferative	 and	 pro-apoptotic	 genes	 (e.g.	 cyclin-dependent	kinase	inhibitor	1A	(p21)	and	Bcl2-antagonist/killer	1)38.	However,	recruitment	of	E2:ER	dimers	to	the	promoter	of	target	genes	induces	transcription	providing	that	AF1	 and/or	 AF2	 are	 activated.	 In	 most	 cells	 AF1	 and	 AF2	 act	 synergistically,	however	certain	gene	promoters,	possibly	depending	on	the	cellular	milieu,	can	be	independently	transactivated	by	either	activation	function	alone34,39,40.		AF2	becomes	active	upon	ligand	binding.	E2	binds	within	the	hydrophobic	‘pocket’	of	 the	 LBD	 which	 is	 sealed	 by	 helix	 12,	 thus	 exposing	 the	 AF2	 region	 and	generating	binding	surfaces	for	co-regulatory	proteins,	including	coactivators	and	corepressors41,42.	 Coactivators	 contain	 histone	 acetyltransferase	 activity	 which	targets	 histones	bound	 to	DNA,	 directing	 an	 allosteric	 change	 in	 the	nucleosome	conformation	and	destabilising	higher-order	structure	to	render	the	nucleosomal	DNA	more	 accessible	 to	 transcription	 factors43–45.	 Ultimately,	 histone	 acetylation	allows	 transcription	 factors	 to	 gain	 access	 to	 the	 transcriptionally	 repressed	chromatin,	to	modulate	transactivation	of	target	genes.	The	most	characterised	ER	coactivators	are	the	p160	protein	family,	comprised	of	SRC1,	GRIP1	and	AIB146–48.	
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In	contrast,	 corepressors	 function	 through	several	mechanisms	but	appear	 to	act	most	 prominently	 through	 modification	 of	 chromatin49.	 Indeed,	 corepressors	recruit	 histone	 deacetylase	 complexes	 which	 reverse	 the	 activity	 of	 histone	acetyltransferases,	promote	chromatin	condensation	thus	limiting	the	accessibility	of	the	transcription	machinery,	to	ultimately	repress	gene	transcription.	NCOR	and	SMRT	 are	 the	 best	 characterised	 corepressors	 of	 ER	 and	 function	 by	 recruiting	histone	deacetylase	complexes50,51.	Critically,	AF1	is	activated	in	the	absence	of	E2	by	 phosphorylation	 following	 the	 activation	 of	 growth	 factor	 receptors	 (such	 as	epidermal	growth	factor	receptor	(EGFR))	and	downstream	kinase	signalling	(e.g.	mitogen-activated	 protein	 kinase	 (MAPK))52.	 Indeed,	 epidermal	 growth	 factor	(EGF)-mediated	 activation	 of	 the	 Ras-Raf-MAPK	 cascade	 results	 in	 the	phosphorylation	 of	 serine	 118	 of	 the	 ER53.	 Several	 serine	 phosphorylation	 sites	have	 been	 identified	 on	 the	 ER,	 however,	 the	 major	 oestrogen-induced	phosphorylation	 site	 is	 serine	 167	 mediated	 by	 casein	 kinase	 254.	 AF1	phosphorylation	 at	 specific	 serine	 residues	 recruits	 coactivators	 exclusive	 or	identical	to	those	recruited	by	AF2	to	induce	transcription	of	E2-regulated	genes,	thus	inducing	cell	growth	and	survival	in	a	ligand-independent	manner55.		
1.5.1.2 Non-classical	pathway		ERs	 can	 also	 regulate	 the	 transcription	 of	 genes	 lacking	 ERE	 sequences.	 This	mechanism	occurs	independent	of	direct	DNA	binding	of	the	ER	and	hence	can	be	activated	by	ERs	lacking	a	DBD.	Instead,	ERs	bind	via	protein-protein	interactions	to	 other	 transcriptional	 factors	 such	 as	 activator	 protein-1	 (AP-1)	 and	 nuclear	factor	 kappa	 B	 (NF-κB),	 stabilising	 their	 direct	 binding	 to	 promoter	 regions	 of	target	genes,	thus	enhancing	transcription56–58.	Specifically,	E2	induction	of	cyclin	D1,	which	lacks	ERE	sites,	is	mediated	by	ER	binding	to	transcription	factors	such	as	SP1	which	are	recruited	to	the	regulatory	regions	of	 the	target	gene	to	 induce	transcription59.	 Additionally,	 SP1	 is	 crucial	 for	 E2	 activation	 of	 the	 insulin-like	growth	 factor-I	 receptor	 (IGF-1R)	 via	 this	 non-classical	 pathway60.	 Alternatively,	E2	also	negatively	 regulates	genes	via	 this	non-classical	 system.	 In	particular,	E2	represses	interleukin	6	(IL-6)	expression	by	direct	interaction	of	the	ER	with	NF-κB,	 inhibiting	 its	 binding	 to	 the	 IL-6	 promoter	 thus	 preventing	 subsequent	transcription61.	Together,	via	this	non-classical	pathway,	ER	can	function	to	either	
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stabilise	 transcription	 factor	 binding	 to	 response	 elements	 thus	 inducing	transcription	or	alternatively	can	prevent	binding	of	transcription	factors	to	DNA	to	repress	transcription.		Interestingly,	 several	 E2-responsive	 genes	 lacking	 an	ERE	 site	 contain	 both	 half-ERE	sites	and	non-classical	sites.	An	example	is	the	promoter	of	the	progesterone	receptor	 (PR)	 which	 contains	 an	 ERE-half	 site	 and	 SP1	 binding	 sites.	 Thus,	 E2-induced	PR	expression	can	be	mediated	by	direct	binding	of	the	ER	to	the	half-site,	indirectly	 by	 interaction	 of	 ER	with	 proteins	 bound	 to	 the	 SP1	 sites,	 or	 by	 both	methods	combined62.		
1.5.2 Non-genomic	ER	signalling	In	 addition	 to	 the	 nuclear	 transcriptional	 events,	 E2	 also	 exerts	 rapid	 actions	within	minutes	independent	of	gene	transcription.	These	non-genomic	events	have	been	attributed	to	the	presence	of	ER	at	the	plasma	membrane.	Indeed,	activated	E2:ER	 complexes	 at	 the	 membrane	 have	 been	 shown	 to	 directly	 interact	 and	activate	 tyrosine	 kinase	 receptors,	 including	 IGF-1R63	 and	 EGFR64,	 resulting	 in	enhanced	signalling	via	MAPK	and	phosphoinositide-3-kinase	(PI3K)	pathways.		Moreover,	 additional	 functional	 domains	 of	 the	 ER	 provide	 docking	 stations	 for	scaffold	 proteins	 and	 signalling	 molecules	 to	 promote	 further	 interactions	 with	various	 proteins	 to	 modulate/enhance	 ER	 signalling	 cascades.	 For	 instance,	 the	scaffold	 protein	 MNAR	 modulates	 the	 interaction	 of	 E2-activated	 ER	 with	 Src	kinase,	leading	to	an	increase	in	Src	activity	and	stimulation	of	the	MAPK	signalling	pathway65.	 Similar	 to	 genomic	 actions,	 non-genomic	 activity	 is	 influenced	by	 the	presence	 of	 signal	 transduction	 molecules	 and	 downstream	 targets	 in	 the	 cell.	Thus,	responses	are	likely	to	be	diverse	and	cell	type	specific66.		
1.5.3 Convergence	of	genomic	and	non-genomic	ER	signalling		The	 genomic	 and	 non-genomic	 actions	 of	 E2	 are	 interconnected	 by	 signal	transduction	 pathways.	 E2-activated	 membrane	 ER	 triggers	 protein	 kinase	cascades,	 leading	 to	 the	 phosphorylation	 of	 target	 transcription	 factors;	 e.g.	 E2-mediated	 activation	 of	 MAPK	 signalling	 enhances	 DNA	 binding	 of	 AP-1	transcription	 factor	 complex,	 thus	 increasing	 its	 transcriptional	 activity67,68.	 Such	MAPK	 and	 PI3K	 signalling	 pathways	 downstream	 of	 membrane	 ER	 may	 also	
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Figure	2	Schematic	diagram	of	 the	pathways	utilised	by	 the	oestrogen	 receptor	 (ER)	 to	
regulate	 gene	 expression.	 (1)	 Classical	 signalling:	 oestradiol	 (E2):ER	 complexed	 with	
coactivators	(CoA)	binds	to	oestrogen	response	elements	(ERE)	located	in	the	promoter	
of	target	genes.	(2)	Non-classical	signalling:	E2:ER	binds	to	transcription	factors	 (TF)	 to	
induce	 transcription	 of	 genes	 lacking	 ERE	 sites.	 (3)	 Ligand-independent	 genomic	
activation:	activation	of	protein	kinases	cascades	downstream	of	growth	factor	receptor	
(GFR)	activation	results	in	the	phosphorylation	(P)	of	ER	in	the	absence	of	E2.	GF:	growth	
factor.	(4)	Non-genomic	signalling:	membrane-associated	E2:ER	activates	protein	kinase	
cascades	 results	 in	 the	 activation	 of	 transcription	 factors	 and/or	 ER	 to	 induce	
transcription.	
phosphorylate	 nuclear	 ER	 in	 a	 ligand-independent	 manner	 to	 promote	 the	expression	of	E2-regulated	genes53.	Together,	ERs	 can	 regulate	 genes	 expression	by	at	 least	 four	mechanisms.	These	include	the	classical	mechanism	of	direct	E2:ER	binding	to	EREs,	the	non-classical	mechanism	 of	 nuclear	 E2:ER	 binding	 to	 transcription	 factors	 via	 protein-protein	interactions	to	induce	transcription	of	target	genes,	ligand-independent	activation	of	 nuclear	 ER	 following	 activation	 of	 growth	 factor	 pathways	 and	 finally,	 non-genomic	 membrane-associated	 ER	 activation	 of	 signal	 transduction	 pathways	leading	to	activation	of	transcription	factors	and/or	ER	(Figure	2).	
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1.6 Therapeutic	approaches	to	block	E2	action	and	ER	activity	Clinically,	 the	 hormone	 receptor	 (ER	 and/or	 PR)	 and	 human	 epidermal	 growth	factor	 receptor	 2	 (HER2)	 status	 of	 breast	 cancers	 are	 prognostic	 and	 predictive	factors	 used	 to	 select	 patients	 for	 treatments	 with	 antihormone	 or	 anti-HER2	therapies.	The	majority	of	breast	cancers	(70%)	are	ER	positive	(ER+),	with	80%	of	which	 being	 ER+/HER2-negative	 (HER2-)69	 while	 the	 remainder	 overexpress	HER2	 (ER+/HER2-positive	 (HER2+))70.	 Antihormones	 which	 subvert	 E2/ER	signalling	 and	 prevent	 downstream	 cell	 growth	 and	 survival	 are	 the	 mainstay	therapy	for	ER+/HER2-	disease.	However,	ER+/HER2+	tumours	have	a	decreased	benefit	 from	 antihormones	 but	 achieve	 a	 greater	 response	 to	 HER2-targetted	therapies71,72.			Antihormones	 can	 be	 broadly	 classified	 into	 two	 groups:	 firstly,	 the	 anti-oestrogens	tamoxifen	and	fulvestrant	which	competitively	inhibit	E2	binding	to	the	ER	with	the	 latter	also	 inducing	down	regulation	of	 the	ER	protein,	and	secondly	the	 aromatase	 inhibitors	 (AIs)	 which	 block	 the	 conversion	 of	 androgens	 into	biologically	 active	 oestrogens,	 to	 deprive	 the	 environment	 of	 oestrogen	 and	consequently	 prevent	 E2	 activation	 of	 the	 ER	 (Figure	 3).	 Antihormones	 are	invaluable	adjuvant	treatments	 for	early	ER+	breast	cancer	patients	post-surgery	to	increase	survival	rates	or	potentially	cure73.	Furthermore,	these	agents	are	also	used	 in	 advanced	 metastatic	 disease	 to	 limit	 tumour	 growth74	 and	 in	 the	neoadjuvant	setting	to	reduce	the	tumour	volume	to	facilitate	breast	surgery75.			
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Figure	3	The	mechanism	of	action	of	oestradiol	(E2),	tamoxifen	(T),	fulvestrant	(F)	and	
aromatase	 inhibitors.	 (1)	 E2-activated	 oestrogen	 receptor	 (ER)	 dimers	 bind	 to	 the	
oestrogen	response	elements	 (ERE)	 in	 the	promoter	region	of	 target	genes,	activation	
function	 1	 (AF1)	 and	 2	 (AF2)	 are	 activated	 and	 recruit	 coactivators	 (CoA)	 to	 induce	
gene	transcription.	(2)	Tamoxifen	bound	ER	dimers	bind	to	the	ERE	of	target	genes	but	
only	 AF1	 is	 active.	 In	 tissues	 with	 strong	 AF-1	 activity,	 CoA	 are	 recruited	 and	
transcription	 of	 target	 genes	 is	 initiated.	 However,	 in	 tissues	 exhibiting	 strong	 AF-2	
activity,	 tamoxifen	 inhibits	 transcription.	 (3)	 Fulvestrant	 causes	 rapid	degradation	of	
the	 ER	 and	 impairs	 both	 AF1	 and	 AF2	 domains	 resulting	 in	 complete	 inhibition	 of	
transcription.	(4)	Aromatase	inhibitors	prevent	the	synthesis	of	E2	from	its	androgenic	
precursors	 thus	 inhibiting	 E2-driven	 gene	 transcription	 (adapted	 from	 Johnston	 &	
Dowsett92).	
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1.6.1 Selective	ER	Modulator	(SERM):	Tamoxifen	The	 non-steroidal	 anti-oestrogen	 tamoxifen	 competitively	 inhibits	 E2	 binding	 to	the	 ER	 and	 consequently	 prevents	 transcription	 of	 oestrogen-regulated	 genes.	Upon	binding	 to	 the	LBD	of	nuclear	ER,	 tamoxifen	 induces	receptor	dimerisation	similar	 to	 E2.	 Significantly,	 however,	 the	 bulky	 side	 chain	 of	 tamoxifen	 prevents	helix	 12	 from	 sealing	 the	 binding	 pocket,	 thus	 preventing	 the	 exposure	 and	formation	of	a	transcriptionally	competent	AF2	conformation	and	hence	inhibiting	AF2-mediated	 transcription76.	 However,	 tamoxifen	 is	 without	 effect	 on	 AF1	transcriptional	 activity77.	 Critically,	 in	 tissues	 where	 AF1	 activity	 is	 strong	 (e.g.	uterus),	 tamoxifen	 exerts	 agonistic	 effects.	 The	 nature	 of	 AF1	 activation	 by	tamoxifen	 is	 largely	 undefined	 but	 it	 may	 involve	 ER	 phosphorylation	 and	recruitment	 of	 coactivators78.	 The	 predominance	 of	 AF1	 and	 AF2	 in	 driving	 ER-mediated	transcription	within	tissues	has	resulted	in	tissue	selectivity	of	agonistic	and	antagonistic	tamoxifen	activity	and	the	derivation	of	the	abbreviation	SERM	to	describe	its	mechanism	of	action.	In	the	hormone	responsive	breast,	ER	activity	is	dominantly	mediated	by	AF2-driven	 transcription	 and	 tamoxifen	 functions	 as	 an	antagonist79,	whereas	in	the	bone	and	uterus,	ER-mediated	transcription	is	driven	by	AF1	 and	 consequently	 tamoxifen	behaves	 as	 an	 agonist39,80.	 Furthermore,	 the	tissue-dependent	 activity	 of	 tamoxifen	 is	 also	 regulated	 by	 the	 presence	 of	coactivators	 and	 corepressors.	 Tamoxifen	 bound	 ER	 favours	 recruitment	 of	corepressor	molecules	 to	 the	complex	 to	 inhibit	 its	agonistic	activity81.	However,	decreased	availability	of	corepressors	has	been	shown	to	cause	a	shift	in	tamoxifen	function	from	antagonistic	to	agonistic82.	Together,	tamoxifen	is	an	anti-oestrogen	in	 tissues	 with	 strong	 AF2-mediated	 ER	 transcription,	 however,	 in	 tissues	 with	predominantly	 AF1-mediated	 E2	 activity	 and	 in	 the	 presence	 of	 reduced	availability	of	 corepressors	and	altered/increased	growth	 factor	 signalling	which	phosphorylates	 AF1	 in	 a	 ligand	 independent	 manner,	 tamoxifen	 behaves	 as	 a	partial	agonist	and	such	events	may	ultimately	contribute	to	tamoxifen	resistance.		Since	the	early	2000s	tamoxifen	was	the	first	line	treatment	for	ER+	breast	cancer	patients.	However,	its	agonistic	activity	in	certain	ER+	tissues	results	in	toxic	side	effects,	 including	 greater	 risk	 of	 endometrial	 cancer	 and	 venous	thromboembolisms,	 and	has	 subsequently	 led	 to	 the	development	 and	 increased	
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popularity	 of	AIs.	Over	 the	past	 decade	 several	 clinical	 trials	 have	demonstrated	superiority	 of	 AIs	 over	 tamoxifen	 as	 a	 first	 line	 adjuvant	 treatment	 for	postmenopausal	 women83.	 As	 such,	 tamoxifen	 is	 primarily	 used	 as	 first	 line	therapy	 in	 ER+	 premenopausal	 women	 (since	 ovarian	 function	 cannot	 be	controlled	by	AIs).	Tamoxifen	is	approved	for	use	in	both	women	(premenopausal	and	postmenopausal)84	and	men85	in	the	adjuvant	setting	and	with	advanced	ER+	disease.	 Five	 years	 of	 adjuvant	 tamoxifen	 treatment	 has	 been	 shown	 to	significantly	 reduce	 recurrence	 rates	 and	mortality	 rates	 throughout	 the	 first	 10	years	 and	 15	 years	 from	 the	 start	 of	 treatment	 respectively86.	 Furthermore,	alternating	tamoxifen	with	an	AI87	and	extending	tamoxifen	treatment	from	5	to	10	years	 both	 produce	 a	 further	 reduction	 in	 mortality	 and	 recurrence88.	 More	recently,	 tamoxifen	has	been	approved	as	a	preventive	mechanism	for	women	at	high	risk	of	developing	ER+	disease89.	
1.6.2 AIs	In	 premenopausal	 women	 the	 ovaries	 represent	 the	 main	 supply	 of	 oestrogen.	However,	after	the	menopause,	oestrogen	production	from	the	ovaries	ceases	but	production	persists	in	extra-ovarian	tissues,	particularly	peripheral	adipose	tissue	and	 indeed	 the	 breast	 tumour	 itself	 by	 the	 enzyme	 aromatase90.	 In	postmenopausal	women	aromatase	activity	serves	as	the	main	supply	of	oestrogen	production,	 hence	 stimulating	 the	 growth	 of	 breast	 cancer	 cells.	 Aromatase,	 a	member	of	the	cytochrome	P450	family,	converts	androgens,	such	as	testosterone	and	androstenedione,	to	oestrogens,	such	as	E2	and	oestrone.	AIs	block	aromatase	activity,	thus	depleting	the	environment	of	oestrogens	and	prevent	E2	activation	of	the	ER.	Indeed,	AIs	have	been	shown	to	reduce	oestrogen	to	an	undetectable	level	in	postmenopausal	ER+	breast	cancer	patients91.	AIs	 are	 classified	 as	 steroidal	 (Type	 1)	 and	 non-steroidal	 (Type	 2).	 Steroidal	inhibitors	mimic	 the	 structure	of	 androstenedione	 (natural	 aromatase	 substrate)	and	bind	to	the	substrate	binding	site	of	the	aromatase	enzyme.	These	agents	are	then	converted	into	reactive	intermediates	which	bind	to	the	enzyme	resulting	in	an	 irreversible	 inactivation	 of	 aromatase92.	 Exemestane	 is	 the	 only	 orally	 active	steroidal	 AI	 used	 clinically93.	 In	 contrast,	 non-steroidal	 inhibitors	 non-covalently	bind	 the	 heme	 moiety	 of	 aromatase,	 occupying	 the	 substrate	 binding	 site	 thus	
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preventing	androgen	binding94.	This	competitive	antagonism	is	reversible	as	non-steroidal	AIs	can	be	displaced	from	the	active	site	by	endogenous	ligands.	The	non-steroidal	AIs	in	clinical	use	include	anastrozole	and	letrozole.		AIs	 are	 only	 approved	 for	 use	 in	 postmenopausal	 women	 with	 ER+	 disease.	Specifically,	anastrozole	initially	approved	as	the	first	line	treatment	for	metastatic	disease	 has	 recently	 become	 the	 gold	 standard	 therapy	 for	 postmenopausal	women	 in	 the	 adjuvant	 setting,	 following	 the	 results	 from	 the	 ATAC	 	 (Arimidex,	Tamoxifen,	 Alone	 or	 in	 Combination)	 trial	 where	 anastrozole	 was	 shown	 to	 be	superior	to	tamoxifen95.	Letrozole	is	also	approved	for	first	line	adjuvant	therapy,	in	 addition	 to	 extended	 therapy	 following	 standard	 5	 year	 tamoxifen	 treatment.	Exemestane	 is	 currently	 used	 in	 the	 adjuvant	 setting	 following	 2-3	 years	 of	adjuvant	tamoxifen	therapy	to	complete	5	year	endocrine	treatment96.	AIs	are	not	effective	 in	 reducing	 oestrogen	 levels	 in	 premenopausal	 women	 without	concurrent	 suppression	 of	 ovarian	 function.	 The	 initial	 transient	 reduction	 of	oestrogen	 levels	 induced	 by	 AIs	 in	 premenopausal	 women	 triggers	 feedback	stimulation	 to	 the	 ovaries	 resulting	 in	 a	 subsequent	 rise	 in	 oestrogen	 levels97.		Furthermore,	in	perimenopausal	women,	AIs	can	induce	reactivation	of	the	ovaries	which	is	unfavourable	for	breast	cancer	patients93.			
1.6.3 Selective	ER	Down-regulator	(SERD):	Fulvestrant	The	intramuscularly	administered	steroidal	ER	antagonist	fulvestrant	(trade	name	faslodex)	 is	 a	 7-alkylsulphinyl	 analogue	 of	 E2	 and	 is	 structurally	 distinct	 from	SERMs98.	Accordingly,	fulvestrant	exhibits	a	higher	affinity	for	the	ER	compared	to	tamoxifen98.	Like	E2	and	tamoxifen,	 fulvestrant	binds	to	the	ER,	however	 its	 long	bulky	 side	 chain	 severely	 alters	 the	 conformation	 of	 the	 receptor,	 preventing	receptor	dimerisation	and	binding	to	DNA99,100.		Furthermore,	fulvestrant	has	been	demonstrated	to	disrupt	the	shuttling	of	the	ER	between	 the	 nucleus	 and	 cytoplasm,	 thereby	 blocking	 nuclear	 localisation	 of	 the	receptor101.	Fulvestrant	also	 induces	degradation	of	 the	receptor	protein	without	affecting	its	mRNA	level,	via	the	ubiquitin-proteasome	pathway102.	More	recently,	it	has	been	suggested	that	even	if	any	fulvestrant-ER	complexes	are	present	in	the	nucleus,	 fulvestrant	 mobilises	 the	 receptor	 into	 the	 nuclear	 matrix	 which	 is	
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necessary	 for	 its	 polyubiquitination	 via	 a	 mechanism	 involving	 the	 NEDD8	ubiquitin-like	 protein	 and	 the	 Uba3-containing	 NEDD8-activiating	 enzyme	 and	subsequent	 degradation	 by	 the	 26S	 proteasome103,104.	 Unlike	 tamoxifen,	fulvestrant	 also	 impairs	 both	 the	 AF1	 and	 AF2	 domains	 of	 the	 ER,	 resulting	 in	complete	 ER	 antagonist	 activity	while	 showing	 no	 agonistic	 activity	 and	 as	 such	fulvestrant	is	described	as	a	‘pure	antioestrogen’105.	In	summary,	fulvestrant	binds	to,	blocks	and	induces	rapid	degradation	of	ERs	resulting	in	complete	abrogation	of	oestrogen	signalling	and	transcription	of	oestrogen-regulated	genes.		Several	phase	III	studies	have	shown	that	fulvestrant	is	as	effective	as	anastrozole	for	postmenopausal	women	with	advanced	disease	which	had	progressed	on	prior	endocrine	therapy,	which	subsequently	 led	to	the	approval	of	250	mg	per	month	fulvestrant	as	second	 line	 treatment	 for	such	patients106,107.	However,	 in	 the	 first	line	setting,	250	mg	fulvestrant	did	not	confer	additional	benefits	over	tamoxifen	in	postmenopausal	 women108.	 More	 recently,	 studies	 including	 the	 CONFIRM	(Comparison	 of	 Faslodex	 in	 Recurrent	 or	 Metastatic	 Breast	 Cancer)	 trial	 have	demonstrated	 a	 further	 benefit	 of	 fulvestrant	 at	 a	 higher-dose	 regimen	 (500	mg	per	month	plus	 an	 additional	 500	mg	on	day	14	of	 the	 first	month	only)	 for	 the	treatment	 of	 advanced	 ER+	 disease	 in	 postmenopausal	 women	 following	 prior	endocrine	 failure109.	 Based	 on	 these	 data,	 fulvestrant	 is	 now	 approved	 at	 this	higher	dose.		The	 efficacy	 of	 fulvestrant	 at	 the	 higher	 dose	 has	 also	 been	 studied	 in	 the	neoadjuvant	and	first	line	settings.	The	phase	II	NEWEST	(Neoadjuvant	Endocrine	Therapy	 for	 Women	 with	 Estrogen-Sensitive	 Tumours)	 study	 comparing	 the	biological	and	clinical	activity	of	fulvestrant	250	mg	and	500	mg	in	the	neoadjuvant	setting	 of	 postmenopausal	 women	 with	 ER+	 locally	 advanced	 breast	 cancer,	revealed	that	the	higher	dose	of	fulvestrant	was	superior,	resulting	in	a	significant	decrease	 in	 protein	 expression	 of	 the	 proliferation	 marker	 Ki67,	 ER	 and	 ER-regulated	 PR110.	 In	 the	 first	 line	 setting,	 the	 FIRST	 (Fulvestrant	 First-Line	 Study	Comparing	 Endocrine	 Treatments)	 trial	 compared	 the	 efficacy	 of	 500	 mg	fulvestrant	with	anastrozole	for	advanced	ER+	disease	in	postmenopausal	women.	Fulvestrant	was	 as	 effective	 as	 anastrozole	 for	 clinical	 benefit	 rate	 and	objective	response	rate111.	Additionally,	 fulvestrant	is	associated	with	a	significantly	longer	
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time	to	progression	compared	with	anastrozole	and	therefore	may	provide	longer-lasting	 disease	 control	 if	 given	 first	 line	 to	 advanced	 disease	 postmenopausal	patients112.		Further	 studies	 including	 FACT	 (Fulvestrant	 and	 Anastrozole	 Combination	Therapy)	and	SWOG	(Southwest	Oncology	Group)	trials	are	exploring	the	potential	benefit	 of	 fulvestrant	 alongside	 anastrozole	 in	 postmenopausal	 women.	Specifically,	 the	 FACT	 trial	 investigated	 whether	 fulvestrant	 (500	 mg	 on	 day	 1	followed	 by	 250	 mg	 on	 days	 15	 and	 29	 and	 thereafter	 every	 fourth	 week)	combined	with	 anastrozole	was	 superior	 compared	 to	 anastrozole	 alone	 in	 ER+	breast	 cancer	with	 relapse	 after/during	 primary	 treatment.	 The	 results	 revealed	no	advantage	of	the	combined	therapy	versus	the	monotherapy	in	this	population	with	 two-thirds	 of	 which	 having	 been	 exposed	 to	 previous	 adjuvant	antioestrogens113.	Notably	the	dose	of	fulvestrant	in	this	study	was	lower	than	that	approved,	 thus	a	500	mg	per	month	dose	may	provide	greater	clinical	benefit.	 In	contrast,	 postmenopausal	 women	 with	 previously	 untreated	 metastatic	 ER+	disease	 have	 demonstrated	 a	 greater	 clinical	 benefit	 from	 a	 combination	 of	fulvestrant	and	anastrozole	therapy	compared	to	anastrozole	alone,	exemplified	by	the	SWOG	trial114.		
1.7 Endocrine	resistance	Antihormones	have	contributed	to	a	substantial	decrease	in	mortality	over	recent	decades;	 however,	 their	 growth	 inhibitory	 actions	 are	 compromised	 by	 the	development	 of	 resistance.	 	 Indeed,	 more	 than	 40%	 of	 ER+	 patients	 acquire	resistance	 and	virtually	 all	 advanced	disease	patients	 eventually	 relapse.	 In	both	instances,	resistance	is	associated	with	accelerated	tumour	growth	and	increased	aggressive	 behaviour,	 ultimately	 resulting	 in	 poorer	 patient	 outlook.	 Thus,	 it	 is	imperative	to	understand	the	mechanisms	of	resistant	growth	to	provide	enhanced	therapeutic	options	for	such	patients.		
1.7.1 ER	status	The	growth	inhibitory	action	of	antihormones	has	been	predominantly	attributed	to	 the	 ability	 of	 these	 agents	 to	 block	 the	 transcriptional	 activity	 of	 the	 ER	 and	prevent	activation	of	genes	involved	in	cell	proliferation	and	survival.	Accordingly,	
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ER	expression	 is	 the	main	predictor	of	antihormone	response,	 thus	alterations	 in	its	 expression	 and	 activity	 have	 been	 extensively	 studied	 as	 a	 mechanism	responsible	for	endocrine	resistance.	In	fact,	approximately	20%	of	antihormone-treated	 ER+	 patients	 lose	 expression	 of	 the	 receptor	 and	 become	 insensitive	 to	further	 therapy115,116.	 Several	 mechanisms	 have	 been	 described	 to	 cause	 such	down-regulation	 or	 complete	 loss	 of	 the	 ER.	 At	 the	 epigenetic	 level,	hypermethylation	of	CpG	islands	within	the	ER	promoter	have	been	demonstrated	to	 contribute	 to	 the	 absence	 of	 ER	 gene	 expression	 in	 breast	 cancer	 cells117,118.	Accordingly,	treatment	of	ER	negative	(ER-)	breast	cancer	cells	with	demethylating	agents	 resulted	 in	 the	 re-expression	 of	 the	 ER	 gene119.	 However,	 further	 studies	are	 required	 to	 decipher	 the	 mechanisms	 involved	 and	 elucidate	 whether	methylation	acts	solely	or	partially	to	silence	ER	expression.		Moreover,	 ER-	 tumours	 frequently	 overexpress	 growth	 factor	 receptors,	 such	 as	EGFR	 and	 HER2,	 suggesting	 that	 up	 regulation	 of	 these	 proteins	 may	 provide	alternative	 growth	 signalling	 pathways.	 To	 further	 investigate	 the	 mechanisms	underlying	 the	 role	 of	 up	 regulated	 growth	 factor	 signalling	 in	 oestrogen-independent	growth,	120	previously	constructed	an	ER+	MCF-7	in	vitro	model	with	constitutively	 active	 MAPK	 signalling.	 These	 genetically	 engineered	 cell	 lines	exhibited	oestrogen-independent	growth,	 resistance	 to	antihormone	 therapy	and	more	 surprisingly	 a	 complete	 loss	 of	 ER	mRNA	 and	 protein.	 MAPK	 activity	 was	demonstrated	 to	 be	 responsible	 for	 the	 down	 regulation	 of	 ER	 expression,	 since	abrogation	 of	 such	 signalling	 resulted	 in	 rapid	 restoration	 of	 ER.	 Additionally,	constitutive	activation	of	HER2	and	EGFR	in	ER+	breast	cancer	cells	also	promoted	MAPK-induced	down	regulation	of	ER	which	was	reversed	by	abrogation	of	MAPK	activity120.	 Although	 the	 mechanisms	 involved	 in	 MAPK-induced	 ER	 down	regulation	are	largely	unknown,	a	subsequent	study	by	the	same	group	proposed	a	potential	role	for	NF-κB	in	this	process121.		More	recent	research	is	addressing	the	role	of	microRNAs	in	regulating	ER	stability	and	representing	a	novel	mechanism	responsible	for	ER	loss.	MicroRNAs	are	small	non-coding	RNAs	that	negatively	regulate	gene	expression	by	degrading	mRNA	or	inhibiting	 translation122.	 Indeed,	 microRNA-221	 and	 -222	 have	 been	 shown	 to	decrease	 ER	 protein	 expression	 in	 MCF-7	 and	 T47D	 breast	 cancer	 cells123.	
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Significantly,	 microRNA-221/222-transfected	 MCF-7	 and	 T47D	 cells	 became	resistant	to	tamoxifen,	suggesting	that	 these	microRNAs	may	be	potential	 targets	for	 restoring	 ER	 expression	 and	 re-sensitising	 cells	 to	 antihormone	 therapy.	Similarly,	 microRNA-206	 has	 also	 been	 demonstrated	 to	 repress	 ER	 mRNA	 and	protein	expression	in	MCF-7	cells124.	Moreover,	 expression	 of	 ER	 spliced	 variants	 have	 been	 associated	with	 reduced	endocrine	 response.	 In	particular,	 a	 novel	 variant	 of	 ER	 termed	ERα36	has	been	identified	 and	 cloned.	 This	 ERα36	 differs	 from	 the	 original	 ER	 as	 it	 lacks	 both	transcriptional	activation	function	domains	(AF1	and	AF2)	but	retains	the	DBD	and	LBD125.	 ERα36	 is	 predominantly	 located	 at	 the	 plasma	 membrane	 and	 in	 the	cytoplasm	 and	 mediates	 membrane-initiated	 oestrogen	 signalling	 including	activation	of	 the	MAPK/ERK	pathway	and	 stimulation	of	 growth126.	 Significantly,	ERα36-mediated	 activation	 of	 the	 MAPK/ERK	 pathway	 was	 shown	 to	 be	unaffected	 by	 tamoxifen;	 instead	 tamoxifen	 promoted	 cell	 growth	 of	 ERα36-overexpressing	cells.	 In	support	of	 this	 in	vitro	 study,	ERα36	expression	has	also	been	 examined	 in	 clinical	 breast	 cancer	 specimens.	 Indeed,	 ER+	 tumours	expressing	high	levels	of	ERα36	were	associated	with	poorer	survival	and	achieved	less	 benefit	 from	 tamoxifen	 therapy127.	 More	 recently,	 Zhang	 &	 Wang	 have	revealed	 that	 short	 term	 tamoxifen	 treatment	 in	 fact	 up	 regulates	 ERα36	expression	 in	 MCF-7	 cells,	 with	 increased	 ERα36	 concentrations	 reported	 in	 a	tamoxifen	resistant	MCF-7	cell	model128.	Accordingly,	down	regulation	of	ERα36	in	the	 tamoxifen	 resistant	 cells	 restored	 tamoxifen	 sensitivity,	 thus	 suggesting	 that	increased	ERα36	expression	contributes	to	the	emergence	of	tamoxifen	resistance.		Furthermore,	 ERα36	 expression	 is	 highly	 correlated	 with	 HER2	 expression	 and	positive	 regulatory	 loops	 exist	 between	 ERα36	 and	 EGFR	 as	well	 as	 ERα36	 and	HER2.	EGFR	and	HER2	signalling	induces	promoter	activity	of	ERα36	which	in	turn	stabilises	 the	EGFR	protein	and	downstream	oestrogen-ERα36	signalling	 induces	HER2	 promoter	 activity127,129,130.	 Accordingly,	 ERα36	 down	 regulation	 in	 HER2-overexpressing	 cells	 also	 resulted	 in	 the	 down	 regulation	 of	 EGFR	 and	 HER2,	confirming	the	existence	of	these	regulatory	loops131.	Disruption	of	these	loops	via	the	 dual	 EGFR	 and	 HER2	 tyrosine	 kinase	 inhibitor,	 lapatanib,	 successfully	increased	 the	 sensitivity	 of	 stably	 transfected	 HER2+	 MCF-7	 cells	 and	 HER2-
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overexpressing	 BT474	 cells	 to	 tamoxifen.	 These	 findings	 suggest	 that	 one	 of	 the	mechanisms	by	which	ER+	breast	cancer	cells	escape	tamoxifen	challenge	may	be	via	elevated	expression	of	ERα36-HER2/EGFR	regulatory	loops.	As	 previously	 described	 (section	 1.5.1.1),	 oestrogen-mediated	 tumour	 growth	 is	controlled	 by	 interactions	 between	 the	 ER	 and	 co-regulatory	 proteins,	 including	coactivators	and	corepressors.	Coactivators	function	to	enhance	ER-mediated	gene	transcription,	whereas	corepressor	proteins	function	to	suppress	transcription.	E2	binding	 to	 the	 ER	 triggers	 the	 release	 of	 the	 corepressors	 and	 subsequently	 the	recruitment	 of	 coactivators.	 In	 contrast,	 tamoxifen	 favours	 recruitment	 of	corepressors	 to	 the	 ER	 to	 inhibit	 transcription	 (as	 described	 in	 section	 1.1.1).	However,	 a	 shift	 in	 the	 balance	 of	 coactivators	 and	 corepressors	 and	overexpression	 of	 the	 former	 can	 directly	 influence	 the	 agonistic	 versus	antagonistic	properties	of	SERMs	like	tamoxifen,	to	enhance	their	agonistic	activity	leading	 to	resistance.	To	 this	 regard,	 the	ER	coactivator	AIB1	has	been	 identified	and	 widely	 studied	 as	 a	 potential	 mechanism	 involved	 in	 promoting	 resistance.	Indeed,	 breast	 cancer	 cells	 exhibit	 increased	 AIB1	 levels	 compared	with	 normal	duct	epithelial	cells48,132.	Increased	AIB1	expression	has	been	demonstrated	to	be	a	marker	of	tamoxifen	resistance	in	HER2-overexpressing	tumours	and	is	associated	with	 increased	 relapse	 and	 death	 of	 tamoxifen-treated	 patients	 with	 HER3-overexpressing	 tumours133,134.	 Patients	 with	 AIB1-	 and	 HER2-overexpressing	tumours	displayed	45%	10	year	disease-free	 survival	 (DFS)	on	 tamoxifen	versus	75%	10	year	DFS	for	all	other	patients.	Moreover,	patients	with	HER3-	and	AIB1-overexpressing	tumours	exhibited	only	30%	10	year	DFS	on	tamoxifen	compared	with	70%	10	year	DFS	on	tamoxifen	for	all	other	patients.	These	findings	are	not	surprising	 since	 AIB1	 is	 phosphorylated	 and	 functionally	 activated	 by	 MAPK135,	thus	it	is	likely	that	HER2/HER3-mediated	MAPK	activation	triggers	the	activation	of	 AIB1	 in	 breast	 cancer	 cells,	 therefore	 contributing	 to	 the	 reduction	 of	 the	antagonistic	and	enhanced	agonistic	effects	of	tamoxifen,	leading	to	the	emergence	of	resistance.		In	the	presence	of	antioestrogens,	such	as	tamoxifen,	corepressors	are	recruited	to	inhibit	ER-mediated	gene	transcription.	Studies	have	demonstrated	that	inhibition	of	 the	 corepressor	 NCOR	 in	 tamoxifen-treated	 MCF-7	 cells	 converted	 this	
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antihormone	into	an	agonist,	evidenced	by	an	increase	in	ER	activity82.	In	a	MCF-7	mouse	model	 system,	NCOR	 levels	were	decreased	 in	 tumours	 that	had	acquired	resistance	 to	 tamoxifen	 compared	 to	 those	 retaining	 a	 response	 to	 the	 drug82.	Similarly,	 in	 ER+	 breast	 cancer	 tissue	 samples,	 NCOR	 levels	 decreased	 during	tumour	 progression	 and	 low	 levels	 were	 associated	 with	 significantly	 shorter	relapse-free	 survival136,137.	 Together,	 these	 studies	 support	 the	 possibility	 that	reductions	 in	 corepressor	 levels	 during	 tamoxifen	 therapy	 may	 enhance	 the	agonist	effects	of	the	antihormone	on	the	ER	and	promote	resistance.		
1.7.2 Breast	cancer	stem	cells	Cancer	stem	cells	(CSCs)	are	defined	as	a	heterogeneous	population	of	cancer	cells	that	have	 the	ability	 to	seed	new	tumour	growth.	Breast	CSCs	(BCSCs)	were	 first	recognised	by	Al-Hajj	et	al.138	who	identified	a	subpopulation	of	breast	cancer	cells	able	 to	 form	 tumours	 in	 immunocompromised	 mice.	 These	 cells	 were	characterised	 by	 expression	 of	 the	 cell	 surface	 marker	 profile	 CD44+/CD22-.	Following	the	 identification	of	 tumour-initiating	CD44+/CD22-	BCSCs,	Ginestier	et	al.139	 have	 more	 recently	 identified	 a	 second	 marker,	 the	 enzyme	 aldehyde	dehydrogenase	 (ALDH),	 characteristic	 of	 BCSCs.	 Interestingly,	 in	 primary	 breast	xenografts,	 CD44+/CD22-	 and	 ALDH	 identified	 overlapping	 but	 non-identical	 cell	populations,	 both	 capable	 of	 forming	 tumours	 in	 immunocompromised	 mice.	Additionally,	 BCSCs	 possessing	 both	 CSC	 markers	 (CD44+/CD22-	 and	 ALDH)	displayed	the	greatest	tumour-initiating	capacity139.	More	 recent	 studies	 have	 shown	 that	 BCSCs	 exist	 in	 distinct	 mesenchymal-like	(epithelial-mesenchymal	 transition	 (EMT))	 and	 epithelial-like	 (mesenchymal-epithelial	 transition	 (MET))	 states	 characterised	 by	 expression	 of	 distinct	 CSC	markers140.	 During	 EMT,	 epithelial	 cells	 lose	 cell-cell	 adhesion	 and	 acquire	 a	mesenchymal	phenotype,	 allowing	 them	 to	detach	 from	 the	primary	 tumour	 site	and	metastasise	at	distant	sites141.	MET,	the	reverse	of	EMT,	is	characterised	by	E-cadherin	 expression	 of	 the	 epithelial	 phenotype	 and	 has	 been	 proposed	 as	 a	mechanism	 for	 establishment	 of	 the	metastatic	 neoplasm142.	 Subsequent	 studies	have	revealed	that	mesenchymal-like	CSCs	are	characterised	as	CD44+/CD22-,	are	primarily	 quiescent	 and	 are	 located	 at	 the	 tumour	 invasive	 front.	 In	 contrast,	epithelial-like	 CSCs	 express	 ALDH,	 are	 proliferative	 and	 located	 centrally	 within	
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tumours140.	 Importantly,	 BCSCs	 display	 cellular	 plasticity	 that	 enables	 them	 to	transition	 between	 EMT	 and	 MET	 states,	 likely	 regulated	 by	 the	 tumour	microenvironment	and	potentially	involved	in	allowing	tumour	cells	to	invade	and	form	metastasis.		CSCs	have	been	largely	studied	as	key	tumour-initiating	cells	that	exhibit	inherent	resistance	 to	 chemotherapy	 (as	 reviewed	 by	 Abdullah	 &	 Chow143).	 Indeed,	 Li	 et	al.144	demonstrated	enhanced	expression	of	tumour-initiating	CD44+/CD22-	cells	in	primary	 breast	 cancer	 biopsies	 following	 neoadjuvant	 chemotherapy	 treatment	compared	to	biopsies	obtained	prior	to	treatment.	This	suggests	that	CD44+/CD22-	cells	 are	more	 resistant	 to	 chemotherapy	 and	 therefore	 allow	 tumour	 regrowth	and	 relapse.	 This	 is	 proposed	 to	 be	 due	 to	mechanisms	 including	more	 efficient	DNA	damage	 checkpoints	 and	 enhanced	 survival	 pathways	 in	 CSCs	 compared	 to	the	more	differentiated	tumour	cell	population145,146.		There	 is	now	a	 large	body	of	evidence	suggesting	a	potential	role	 for	CSCs	 in	 the	development	of	endocrine	resistance.	Of	significance	interest,	normal	breast	tissue	and	 breast	 carcinoma	 CD44+/CD22-	 cells	 exhibit	 low	 or	 absent	 ER	 expression	compared	to	more	differentiated	tumour	cells147,148.	Thus,	BCSCs	are	highly	likely	to	 be	 endocrine	 resistant	 due	 to	 the	 lack	 of	 the	 target	 receptor.	 Moreover,	increased	 EGFR	 signalling	 has	 been	 demonstrated	 in	 stem	 cells	 of	 the	 normal	mammary	gland	and	in	malignant	CSCs	of	the	breast149–151.	Accordingly,	inhibition	of	EGFR	significantly	reduced	the	CSC	population,	evidenced	by	a	decrease	in	self-renewal	 capacity151.	 Interestingly,	 as	 mentioned	 in	 section	 1.7.4,	 endocrine	resistant	 cells	 have	 enhanced	 growth	 factor	 tyrosine	 kinase	 signalling,	 including	EGFR	and	HER2.	Therefore,	it	is	possible	that	acquisition	of	increased	EGFR/HER2	signalling	in	ER+	antihormone	resistant	cells	potentially	results	from	the	selection	of	 CSC-like	 cells	 by	 endocrine	 therapies152.	 Accordingly,	 increased	 CSCs,	demonstrated	 by	 the	 expression	 of	 stem	 cell	 surface	 markers	 and	 their	 self-renewal	 capacity,	 have	 been	 identified	 in	 tamoxifen-resistant	 cells	 compared	 to	tamoxifen-treated	wild	 type	MCF-7	 cells153.	 Similarly,	 in	 vitro	 and	 in	 vivo	 studies	have	 demonstrated	 that	 tamoxifen	 treatment	 of	 ER+	 breast	 cancer	 cells	contributes	to	an	increase	in	cells	with	self-renewing	capacity	that	express	 lower	levels	 of	 ER154.	 More	 recently,	 Karthik	 et	 al.155	 have	 revealed	 a	 potential	
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mechanism	 mediated	 by	 tamoxifen	 to	 enhance	 the	 CSC	 population.	 Indeed,	 the	authors	showed	that	 tamoxifen	 induced	mammalian	target	of	rapamycin	(mTOR)	signalling	 in	 CSCs	 which	 was	 antagonised	 by	 mTOR	 inhibitors.	 The	PI3K/AKT/mTOR	pathway	drives	cell	growth	and	survival	and	hyperactivation	of	this	pathway	is	implicated	in	ER+	breast	cancer	and	in	resistance	to	antihormone	therapy	(as	reviewed	by	Ciruelos	Gil156	and	described	in	section	1.7.4).	Thus,	 it	 is	possible	 that	 tamoxifen-induced	 mTOR	 activation	 in	 BCSCs	 plays	 a	 role	 in	expanding	this	resistant	cell	population.		
1.7.3 Cell	cycle	regulators	The	cell	cycle	functions	as	a	tightly	regulated	process	comprised	of	several	distinct	phases	 required	 for	 cell	 division	 and	 replication:	 G0	 (quiescence),	 G1	 (pre-DNA	synthesis),	S	phase	(DNA	synthesis),	G2	and	M	phase	(mitosis).	Disruption	of	 the	cell	cycle	regulation	contributes	to	unrestrained	growth,	a	hallmark	of	cancer.	The	progression	 from	 G1	 to	 S	 phase	 is	 regulated	 by	 the	 interaction	 between	 cyclin-dependent	 kinases	 (CDKs)	 and	 cyclin	 proteins.	 CDKs	 are	 a	 group	 of	serine/threonine	 kinases	 that	 cooperate	 with	 cyclins	 to	 regulate	 cell	 cycle	checkpoints.	 CDK4	 and	 CDK6	 interact	 with	 cyclin	 D1	 and	 CDK2	 interacts	 with	cyclin	E1	during	G1	and	subsequently	phosphorylate	 the	retinoblastoma	protein.	This	 results	 in	 the	 inactivation	 of	 the	 retinoblastoma	 protein	 and	 release	 of	transcription	factors	that	allow	progression	to	the	S	phase157,158.		Several	 cell	 cycle	 regulators	 have	 been	 recognised	 as	 potential	 players	 in	endocrine	resistance.	Of	these,	the	nuclear	transcription	factor	MYC	and	cyclins	D1	and	 E1	 have	 been	 the	most	 comprehensively	 studied.	 These	 regulatory	 proteins	promote	progression	and	completion	of	 the	cell	cycle	by	shortening	arrest	 in	 the	G1	 phase.	 Indeed,	 oestrogens	 rapidly	 induce	 expression	 of	 MYC,	 cyclin	 D1,	CDK4/6-cyclin	D1	complexes,	 cyclin	E1	and	CDK2-cyclin	E1	complexes	 to	 induce	cell	proliferation159–163.	Conversely,	antihormone	therapy	has	an	 inhibitory	effect,	preventing	cell	cycle	progression	and	promoting	arrest	 in	G1164,165.	Paradoxically,	however,	 the	 acquisition	 of	 antihormone	 resistance	 is	 associated	 with	 up	regulation	 of	 these	 key	 cell	 cycle	 regulators166,167.	 Indeed,	 constitutive	 and	inducible	 expression	 of	 MYC	 and	 cyclin	 D1	 have	 been	 shown	 to	 rescue	 breast	cancer	cells	 from	antihormone-induced	growth	arrest	enabling	 them	to	complete	
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the	 cell	 cycle161,168–170.	 Furthermore,	 overexpression	 of	 these	 proteins,	 which	occurs	 in	 approximately	 30-45%	 of	 breast	 cancers,	 is	 associated	 with	 reduced	antihormone	 response171.	 Studies	 have	 shown	 that	 overexpression	 of	 cyclins	 D1	and	E1	are	able	to	abrogate	tamoxifen-	and	fulvestrant-mediated	growth	arrest172–174.		In	addition,	cyclin	D1	can	bind	and	activate	the	ER	in	a	ligand-independent	manner	with	such	an	event	not	inhibited	by	antihormone	treatment175–177.	This	suggests	an	additional	 mechanism	 by	 which	 overexpression	 of	 cyclin	 D1	 contributes	 to	endocrine	resistance	through	sustaining	ER	transcriptional	activity	and	activation	of	downstream	proliferation	and	survival	genes.		Furthermore,	CDK4/6	inhibitors	are	currently	in	clinical	development.	Palbociclib,	a	highly	selective	CDK4/6	inhibitor,	thus	blocking	retinoblastoma	phosphorylation	and	thereby	inducing	G1	arrest,	has	been	the	most	extensively	studied.	An	in	vitro	study	revealed	that	ER+	and	HER2-overexpressed	breast	cancer	cell	lines	were	the	most	 sensitive	 to	growth	 inhibition	by	palbociclib	while	basal	 subtypes	were	 the	most	resistant178.	Additionally,	palbociclib	acted	synergistically	with	tamoxifen	 in	ER+	 antihormone	 sensitive	 cell	 lines,	 and	 enhanced	 the	 sensitivity	 of	 tamoxifen-resistant	 cells	 to	 the	 antihormone.	 Based	 on	 these	 data,	 a	 clinical	 study	 was	conducted	 to	 test	 the	 safety	 and	 efficacy	 of	 palbociclib	 in	 combination	 with	antihormones	in	ER+	breast	cancer.	Initially,	a	phase	I	study	confirmed	the	safety	of	 palbociclib	 in	 combination	 with	 letrozole	 in	 patients	 with	 ER+	 and	 HER2-	advanced	 breast	 cancer	 and	 determined	 the	 optimal	 recommended	 dosage179.	 A	large	randomised	phase	II	study	was	subsequently	conducted	to	assess	the	safety	and	 efficacy	 of	 palbociclib	 in	 combination	 with	 letrozole	 compared	 to	 letrozole	alone	 in	 the	 first-line	 treatment	 of	 postmenopausal	 women	 with	 advanced	 ER+	HER2-	 breast	 cancer.	 The	 results	 from	 this	 study	 revealed	 that	 patients	 treated	with	 the	 combination	 therapy	 had	 significantly	 longer	 progression-free	 survival	(20.2	 months)	 compared	 to	 letrozole	 treatment	 alone	 (10.2	 months)180.	Significantly,	following	the	results	of	this	study,	in	February	2015	the	US	Food	and	Drug	 Administration	 granted	 accelerated	 approval	 of	 palbociclib	 in	 combination	with	 letrozole	 for	 the	 treatment	 of	 postmenopausal	 women	 with	 ER+	 HER2-	advanced	 breast	 cancer	 as	 initial	 endocrine-based	 therapy	 for	 their	 metastatic	
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disease181.	A	double-blinded	phase	III,	placebo-controlled	study	(NCT01740427)	in	a	 similar	 patient	 population,	with	 the	 aim	 of	 confirming	 the	 phase	 II	 findings,	 is	currently	underway.	Additionally,	 a	phase	 III	 study	of	palbociclib	 in	 combination	with	fulvestrant	in	ER+	HER2-	metastatic	breast	cancer	patients	previously	treated	with	endocrine	therapy	(NCT01942135)	is	ongoing.		
1.7.4 Growth	factor	signalling		The	majority	of	patients	who	acquire	resistance	to	tamoxifen	continue	to	express	the	ER182.	Indeed,	up	to	20%	of	such	patients	respond	to	second	line	antihormone	therapy	including	AIs	and	fulvestrant,	suggesting	that	the	ER	continues	to	regulate	growth	during	resistance106,107.		Hyperactivation	of	growth	factor	signalling	has	been	heavily	implicated	in	driving	resistance.	Such	signalling	circumvents	 the	 inhibitory	effects	of	antihormones	via	bidirectional	 cross-talk	and	modulation	of	 the	ER	 to	promote	growth	despite	 the	presence	 of	 endocrine	 therapy.	 When	 extreme,	 growth	 factor	 pathways	 drive	tumour	 growth	 and	 survival	 in	 an	 ER-independent	 manner	 evidenced	 by	 a	significant	 number	 of	 patients	 who	 fail	 to	 respond	 to	 second	 line	 antihormone	therapy,	indicating	a	loss	of	reliance	on	ER-mediated	growth121,183.		
1.7.4.1 ER-dependent	This	phenomenon	has	been	widely	documented	for	the	receptor	tyrosine	kinases	(RTK)	EGFR,	HER2	and	IGF-1R.	Activation	of	these	receptors	stimulates	cell	growth	via	 downstream	 MAPK	 and	 PI3K	 pathways.	 Studies	 in	 antihormone-resistant	breast	 cancer	 cell	 lines,	 like	 their	 clinical	 counterparts,	 have	 shown	 increased	expression	 of	 these	 receptors,	 their	 ligands	 and	 associated	 downstream	 kinases	compared	 to	 that	 observed	 in	 the	parental	 cell	 lines184–188.	 Critically,	 besides	 the	capacity	 to	 promote	 cell	 growth	 in	 their	 own	 right,	 such	 signalling	 can	phosphorylate	 the	 ER	 and	 its	 co-regulatory	 proteins,	 altering	 the	 receptor	transcriptional	 activity	 and	 ultimately	 contributing	 to	 antihormone-resistant	proliferation.	 Specifically,	 MAPK	 and	 PI3K	 signalling	 can	 phosphorylate	 key	residues	within	the	AF1	region	of	the	ER	(serine	118	and	serine	167)	thus	allowing	persistent	 activation	 of	 nuclear	 ER53,189.	 Such	 activation	 of	 the	 ER	 promotes	re-expression	of	oestrogen	regulated	genes	in	a	ligand-independent	manner	and	in	
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the	 presence	 of	 antihormone190,191.	 Indeed,	 tamoxifen-resistant	 and	 long	 term	oestrogen	deprived	breast	cancer	cells	exhibit	increased	levels	of	phosphorylated	ER	 at	 serine	118	 and	167	with	 consequent	 re-expression	 of	 oestrogen-regulated	genes192–196.	 Significantly,	 EGFR/MAPK-mediated	 ER	 phosphorylation	 at	 serine	118	 and	 subsequent	 continued	 activation	 of	 the	 ER	 in	 tamoxifen-resistant	 cells	results	in	the	re-expression	of	the	EGFR	ligand	amphiregulin196,	thus	generating	a	self-propagating	 EGFR-driven	 autocrine	 growth-regulatory	 loop	 in	 these	 cells	 in	which	 amphiregulin	 expression	 is	 induced	 by	 ligand-independent	 serine	 118	 ER	phosphorylation.		Moreover,	 despite	 reduced	expression	of	 IGF-1R	 signalling	 in	MCF-7	 cells	during	antihormone	 response,	 EGFR-activated	 ER	 in	 tamoxifen	 resistant	 cells	 promotes	the	expression	of	insulin-like	growth	factor	(IGF)-II	and	consequently	re-activates	IGF-1R	signalling197.	Importantly,	there	is	considerable	evidence	implicating	EGFR	and	IGF-1R	cross-talk	in	breast	cancer	cells.	Besides	its	effects	on	cell	proliferation	and	 survival,	 IGF-II-induced	 activation	 of	 IGF-1R	 in	 tamoxifen	 resistant	 cells	 has	also	 been	 shown	 to	 phosphorylate	 and	 thus	 activate	 EGFR	 signalling	 via	 a	 c-src	dependent	mechanism198.	Additionally,	this	pathway	also	contributes	to	increased	ER	phosphorylation	on	serine	118	in	tamoxifen-resistant	cells197.	This	cross-talk	is	however	 unidirectional	 with	 EGF	 failing	 to	 induce	 phosphorylation	 of	 IGF-1R.	Complementing	 these	 cell	 lines	 studies,	 IGF-1R	expression	and	activity	have	also	been	detected	 in	ER+/EGFR+	 tamoxifen-resistant	 clinical	 samples	 supporting	 the	role	 for	 such	 signalling	 in	 promoting	 the	 growth	 of	 acquired	 tamoxifen-resistant	tumours198.		Furthermore,	 there	 is	 increasing	evidence	 implicating	aberrant	 fibroblast	growth	factor	 receptor	 (FGFR)	 signalling	 in	 breast	 cancer	 cells,	 capable	 of	 promoting	endocrine	 resistance.	 The	 FGFR	 family	 comprises	 of	 four	members,	 all	 of	 which	have	 been	 implicated	 in	 breast	 cancer:	 FGFR1,	 FGFR2,	 FGFR3	 and	 FGFR4199.	Similarly	 to	 the	 abovementioned	 RTKs,	 activation	 of	 FGFRs	 promotes	 cell	proliferation	 via	 downstream	 MAPK	 and	 PI3K/AKT	 signalling	 pathways.	 FGFR1	amplification,	 observed	 in	 approximately	 10%	 of	 breast	 cancers200,	 has	 been	demonstrated	 to	 promote	 endocrine	 resistance.	 Turner	 et	 al.201	 revealed	 that	FGFR1-amplified	breast	cancer	cell	lines	are	resistant	to	tamoxifen	therapy,	which	
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is	 reversed	 by	 small	 interfering	 (si)RNA	 targeting	 FGFR1.	 This	 in	 vitro	 data	strongly	suggests	that	FGFR1	overexpression	drives	endocrine	therapy	resistance,	and	 this	 observation	 is	 supported	 by	 the	 poor-prognosis	 exhibited	 by	 FGFR1-overexpressing	 tumours	 treated	 with	 adjuvant	 tamoxifen	 therapy.	 Similarly,	increased	 FGFR3	 expression	 has	 been	 demonstrated	 in	 tamoxifen-resistant	tumours	compared	to	tamoxifen-sensitive	tumours202.	In	vitro,	FGFR3	activation	in	MCF-7	 cells	 stimulated	 MAPK	 and	 PI3K	 signalling	 pathways	 concurrent	 with	decreasing	 the	 sensitivity	 of	 these	 cells	 to	 tamoxifen	 and	 fulvestrant	 treatment.	Interestingly,	although	activation	of	FGFR	and	EGFR	stimulate	similar	downstream	pathways	(i.e.	MAPK	and	PI3K),	unlike	EGFR,	FGFR	signalling	did	not	influence	ER	activity	 but	 instead	 appeared	 to	 override	 ER	 activity202.	 Furthermore,	 in	 a	tamoxifen-resistant	 breast	 cancer	 cell	 model,	 FGFR3	 activation	 induced	 cell	proliferation	 independent	 of	 ER	 activation.	 Furthermore,	 increased	 FGFR4	expression	 has	 been	 associated	 with	 endocrine	 resistance.	 In	 tamoxifen	 treated	patients	with	recurrent	disease,	increased	FGFR4	expression	predicts	antihormone	failure	 together	 with	 decreased	 progression-free	 survival203.	 Together,	 these	studies	 suggest	 that	 activation	 of	 FGFRs	 might	 be	 an	 important	 mechanism	 by	which	 breast	 cancer	 cells	 escape	 antihormone	 challenge,	 subsequently	contributing	to	the	resistant	phenotype.		As	 mentioned	 above,	 growth	 factor	 signalling	 can	 also	 phosphorylate	 ER	co-regulatory	 proteins	 to	 activate	 ER-mediated	 gene	 transcription.	 The	 most	widely	studied	 is	 the	coactivator	AIB1.	 Indeed,	HER2-driven	MAPK	signalling	not	only	 induces	 ligand-independent	activation	of	 the	ER	but	has	also	been	shown	to	phosphorylate	 and	 activate	 AIB1.	 Thus,	 tumours	 with	 high	 expression	 of	 both	HER2	and	AIB1	are	less	responsive	to	tamoxifen	therapy	due	to	an	increase	in	ER	coactivator	 activity	 mediated	 by	 HER2	 signalling,	 subsequently	 increasing	 the	agonistic	 activity	 of	 tamoxifen133.	 The	 level	 of	 AIB1	 expression	 in	 HER2+	 breast	cancer	may	 provide	 an	 important	 predictive	marker	 for	 tamoxifen	 resistance195.	Interestingly,	AIs	are	more	effective	than	tamoxifen	therapy	for	HER2+	tumours204.	However,	this	was	not	confirmed	in	a	larger	study	that	followed.	This	more	recent	study	 demonstrated	 that	 although	 letrozole	 is	 more	 effective	 than	 tamoxixen	therapy	for	ER+	disease,	it	is	irrespective	of	HER2	expression205.	It	is	possible	that	
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the	 correlation	 between	 HER2	 and	 AIB1	 and	 the	 consequent	 activation	 of	 the	coactivator	 is	 less	 important	for	potent	oestrogen	deprivation	therapy,	compared	to	tamoxifen	therapy	which	exhibits	agonistic	and	antagonistic	properties	greatly	influenced	by	the	equilibrium	of	coactivator	and	corepressor	proteins.		
1.7.4.2 ER-independent	Although	 growth	 factor	 signalling	 contributes	 to	 increased	 ER	 phosphorylation	and	 transcriptional	 activation,	 paradoxically,	 sustained	 hyperactivation	 of	 such	signalling	 has	 also	 been	 associated	 with	 reducing	 ER	 expression.	 These	antihormone	resistant	tumours	are	comprised	of	ER-	and	growth	factor	receptor-overexpressing	cells	that	are	no	longer	reliant	on	ER	signalling	for	cell	growth	and	as	 such	 are	 not	 growth	 inhibited	 by	 further	 antihormone	 therapy121.	 Indeed,	several	 studies	 have	 demonstrated	 that	 exposure	 of	 ER+	 cells	 to	 growth	 factors,	such	as	EGF,	can	down-regulate	ER	protein	expression206.	Similarly,	transfection	of	constitutively	 active	 HER2,	 MEK1	 and	 Raf1	 into	 breast	 cancer	 cells	 results	 in	 a	decrease	 in	 ER	protein	 expression120,207–209.	More	 recent	 findings	 have	 identified	the	 transcription	 factor	 NF-κB	 as	 an	 intermediary	 in	 hyperactivated	 MAPK-induced	ER	down-regulation121.	Interestingly,	NF-κB	is	also	elevated	in	de	novo	ER-	breast	cancer	exhibiting	increased	EGFR	and	HER2	activity210,211	and	has	also	been	associated	with	increased	AKT	activity	in	tamoxifen	resistance212.	To	this	regard,	it	is	 conceivable	 that	 sustained	 hyperactivation	 of	 growth	 factor	 pathways	contributes	to	an	ER-	and	endocrine-independent	phenotype.		
1.7.4.3 Combination	of	ER-dependent	and	ER-independent	growth	factor	
signalling	mechanisms	implicated	in	driving	antihormone-resistance	Together,	 hyperactivation	 of	 EGFR,	 HER2	 and	 IGF-1R	 in	 endocrine	 resistance	induces	a	vicious	circle	between	these	signalling	pathways	and	the	ER	to	promote	cell	proliferation	and	survival	via	ER	genomic	and	non-genomic	activities	(Figure	4).	 Accordingly,	 potent	 targeting	 of	 these	 ER	 activities	 by	 oestrogen	 deprivation	and	 ER	 down	 regulation	 (fulvestrant)	 therapy	 are	 effective	 in	 ER+	 HER2+	patients204.	Sadly,	however,	growth	factor	signalling	pathways	develop	the	ability	to	drive	tumour	growth	and	survival	in	an	ER-independent	manner,	thus	tumours	also	become	resistant	to	AIs	and	fulvestrant.	Such	pathways	include	growth	factor-activation	of	MAPK	and	PI3K	which	in	turn	activates	transcription	factors	such	as	
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NF-κB213	 to	 induce	expression	of	proliferation	and	survival	genes	(e.g.	cyclins	D1	and	E1	and	MYC)	in	an	ER-independent	manner214.			
	
1.7.4.4 Therapeutic	targeting	of	growth	factor	signalling	in	resistance	Several	 pre-clinical	 studies	 have	 targeted	 these	 up	 regulated	 growth	 factor	signalling	pathways.	Indeed,	the	EGFR	inhibitor	gefitinib	and	the	HER2	monoclonal	antibody	 trastuzumab	 have	 both	 been	 studied	 as	 a	 monotherapy	 to	 inhibit	
	
Figure	4	Cross-talk	between	oestrogen	receptor	(ER)	and	growth	factor	receptor	(GFR)	
signalling	pathways.	Besides	 cell	 survival	 and	growth	 (1),	 activation	of	GFRs	 such	as	
epidermal	 growth	 factor	 receptor	 (EGFR)	 and	 human	 epidermal	 growth	 factor	
receptor	2	 (HER2)	can	phosphorylate	 the	ER	 in	a	 ligand-independent	manner	 and	 in	
the	 presence	 of	 antihormones	 (e.g.	 tamoxifen	 (T))	 to	 induce	 transcription	 of	
oestrogen-regulated	 genes	 (such	 as	 the	 EGFR	 ligand	 amphiregulin)	 to	 generate	 an	
autocrine-driven	growth	regulatory	loop	(2).	GFR	signalling	can	also	phosphorylate	co-
regulatory	 proteins	 to	 activate	 ER-mediated	 gene	 transcription	 (3)	 in	 addition	 to	
activating	 transcription	 factors	 (TF)	 to	 induce	 transcription	 (4).	 ERE:	 oestrogen	
response	elements.	
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resistant	 cell	 growth	 and	 also	 as	 a	 combination	 therapy	 alongside	 antihormones	during	 response	 to	 delay	 or	 prevent	 the	 emergence	 of	 resistant	 growth.	 As	previously	 mentioned,	 tamoxifen-	 and	 fulvestrant-resistant	 MCF-7	 cells	 exhibit	increased	 EGFR	 and	 HER2	 activity.	 Thus,	 blockade	 of	 EGFR	 and	 HER2	 in	 these	resistant	 cell	 models	 using	 gefitinib	 and	 trastuzumab,	 respectively,	 has	 been	shown	 to	 inhibit	 cell	 growth184,185.	 Additionally,	 targeted	 therapy	 of	 the	downstream	 kinases,	 including	 MAPK	 and	 PI3K/AKT,	 has	 also	 been	 shown	 to	inhibit	resistant	cell	growth184,185.	More	recent	findings	have	shown	that	gefitinib	treatment	of	tamoxifen	resistant	breast	cancer	cells	which	have	developed	an	ER-	phenotype	(likely	due	to	sustained	MAPK	signalling	and	NF-κB	activity)	results	in	a	decrease	in	expression	of	MAPK	signalling	proteins	with	a	parallel	 increase	in	ER	protein	expression,	thus	re-sensitising	the	resistant	cells	to	tamoxifen215.	However,	functional	 E2/ER	 signalling	 in	 wild	 type	 MCF-7	 cells	 represses	 EGFR	 and	 HER2	expression	 and	 as	 such	 are	 unaffected	 by	 gefitinib	 and	 trastuzumab	treatment184,185.	 Interestingly,	 blockade	 of	 ER	 signalling	 by	 antihormones	 during	response	contributes	 to	an	 induction	of	EGFR	expression.	Thus,	a	combination	of	gefitinib	 and	 tamoxifen	 or	 fulvestrant	 therapy	 during	 antihormone	 response	 has	been	 shown	 to	 induce	 greater	 inhibition	 of	 proliferation	 and	 promotion	 of	apoptosis	 compared	 to	 either	 therapy	 alone216.	 This	 combination	 therapy	prevented	 early	 induction	 of	 EGFR/MAPK	 signalling	 during	 response	 and	significantly	delayed	the	development	of	resistance.	In	support	of	this	study	in	cell	lines,	 gefitinib	 has	 also	 been	 shown	 to	 improve	 the	 growth	 inhibitory	 actions	 of	tamoxifen	and	delay	the	emergence	of	resistant	growth	in	vivo217.	Based	on	the	pre-clinical	rationale	for	enhanced	benefit,	there	have	been	a	number	of	 phase	 II	 studies	 of	 gefitinib/trastuzumab	 in	 combination	 with	 endocrine	therapy218–221.	 Specifically,	 patients	 with	 ER+	 newly	 diagnosed	 metastases	 or	disease	 that	 had	 recurred	 after	 adjuvant	 tamoxifen	 therapy	 demonstrated	increased	 progression-free	 survival	 from	 gefitinib	 plus	 tamoxifen	 therapy	compared	 to	 gefitinib	 plus	 placebo219.	 Similarly,	 anastrozole	 and	 gefitinib	 and	anastrozole/letrozole	 and	 trastuzumab	 combination	 therapies	 also	 resulted	 in	increased	 clinical	 benefit	 in	 ER+	 metastatic	 breast	 cancer	 patients218,220,221.	However,	 the	 benefit	 of	 such	 combination	 therapies	 is	 short-lived	 with	 the	
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emergence	 of	 aggressive	 resistance	 growth	 which	 remains	 a	 significant	 clinical	problem222–224.	 Indeed,	 studies	 have	 revealed	 that	 gefitinib-	 and	 trastuzumab-resistant	 growth	 is	 dominated	 by	 IGF-1R	 signalling,	 indicating	 an	 ability	 of	 the	tumour	cells	to	switch	to	an	alternative	growth	factor	pathway	in	the	presence	of	the	drug222,225,226.	Importantly,	further	studies	are	clearly	required	to	decipher	and	prevent	the	emergence	of	resistant	cell	growth.	
1.7.5 PI3K	and	AKT	signalling	The	PI3K/AKT/mTOR	pathway	plays	a	crucial	role	in	cell	proliferation,	growth	and	survival.	 Dysregulation	 of	 this	 signal	 transduction	 pathway	 occurs	 in	 several	tumour	 types,	 including	 breast	 cancer,	 and	 has	 been	 implicated	 in	 tumour	progression	and	antihormone	resistance227.	Following	activation	by	growth	factor	RTKs	 or	 G-protein-coupled	 receptors228,229,	 PI3K	 phosphorylates	phosphatidylinositol	 4,5	 bisphosphate	 (PIP2)	 to	 produce	 phosphatidylinositol	3,4,4-triphosphate	 (PIP3),	 which	 subsequently	 recruits	 proteins	 containing	pleckstrin	 homology	 (PH)	 domains	 to	 the	 plasma	 membrane.	 Such	 PH	 domain-containing	 proteins	 include	 AKT	 and	 its	 activating	 kinase	 PDK1230.	 PDK1	 binds	PIP3	 at	 the	 plasma	membrane	 and	 phosphorylates	 AKT,	which	 in	 turn	 regulates	downstream	proteins	to	promote	cell	cycle	progression	and	survival231.	Activated	AKT	 stimulates	 mTOR-containing	 complex	 1	 (TORC1)	 activity	 to	 positively	regulate	 protein	 translation	 and	 synthesis232,233.	 Additionally,	 AKT	 promotes	 cell	survival	through	phosphorylation	of	Mdm2,	a	protein	that	binds	to	and	inhibits	the	activation	 of	 the	 p53	 tumour	 suppressor	 protein234,	 and	 through	 inactivation	 of	pro-apoptotic	 BCL-2	 family	 members	 including	 BAD235.	 PI3K	 activity	 is	antagonised	by	the	negative	regulatory	proteins,	phosphatase	and	tensin	homolog	(PTEN)	 and	 inositol	 polyphosphate-4-phosphatase	 type	 II	 (INPP4B),	 which	catalyse	the	dephosphorylation	of	PIP3	and	PIP2,	respectively236,237.	The	PI3K/AKT/mTOR	pathway	is	frequently	altered	early	in	ER+	breast	cancer	to	promote	cell	proliferation	and	survival,	ultimately	contributing	to	the	progression	of	the	disease238.	Such	alterations	include	activating	mutations	or	amplifications	of	the	genes	encoding	PI3K	(p110α)239,240,	PDK1241,	AKT1239,	and	 loss	of	 function	or	reduced	 expression	 of	 the	 genes	 encoding	 PTEN242–244	 and	 INPP4B237,245.	Furthermore,	 significant	 cross-talk	 between	 the	 PI3K/AKT/mTOR	 pathway	 and	
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the	ER	has	been	demonstrated.	Indeed,	as	mentioned	elsewhere	(sections	1.7.4.1,	1.7.6.1	and	1.7.6.2),	signalling	through	the	PI3K/AKT/mTOR	pathway	activates	ER	transcriptional	activity	in	a	ligand-independent	manner	via	direct	phosphorylation	of	 the	ER	 at	 serine	167	by	AKT246.	Additionally,	 vice	 versa,	 the	ER	promotes	 the	transcription	 of	 genes	upstream	of	 the	PI3K/AKT/mTOR	pathway,	 such	 as	RTKs	and	 their	 ligands.	As	previously	discussed	 (section	1.5.2),	 E2-activated	ER	 at	 the	plasma	membrane	stimulates	PI3K	signalling	via	activation	of	RTKs,	including	IGF-1R	and	EGFR63,64,	ultimately	enhancing	tumour	cell	proliferation	and	survival.		Unsurprisingly,	 the	 increased	 growth	 factor	 RTK	 signalling	 present	 in	 endocrine	resistance	 (as	 discussed	 in	 section	 1.7.4)	 results	 in	 hyperactivated	 downstream	PI3K/AKT/mTOR	 signalling	 and	 consequently	 resistant	 cell	 growth	 and	 survival.	Additionally,	 reduction	 of	 PTEN	 expression	 has	 been	 shown	 to	 enhance	 PI3K	signalling,	 reduce	 antihormone	 sensitivity	 and	 ultimately	 promote	 endocrine	resistance	 in	 ER+/HER2-	 breast	 cancer	 cells	 in	 vitro	 and	 in	 vivo247.	 Accordingly,	combined	treatment	with	an	AKT	inhibitor	or	mTOR	inhibitor	plus	fulvestrant	was	shown	 to	 inhibit	 PI3K	 downstream	 signalling,	 induce	 apoptosis	 and	 accelerate	regression	 of	 reduced-PTEN-expressing	 xenograft	 tumours.	 Interestingly,	 a	correlation	between	increased	PI3K	activity	and	decreased	ER	expression	has	been	documented	 in	 ER+	 breast	 cancer.	 Indeed,	 Creighton	 et	 al.248	 have	 reported	 a	negative	 correlation	 between	 ER	 level	 and	 PI3K	 activity	 in	 ER+	 tumours.	Additionally,	 the	 authors	 demonstrated	 increased	 PI3K	 activity	 in	 the	 more	aggressive	luminal	B	tumours,	compared	to	those	of	the	less	aggressive	luminal	A	subtype.	 This	 increase	 in	 PI3K	 activity	 in	 the	 luminal	 B	 tumours	was	 associated	with	 lower	 ER	 levels.	 Notably,	 PI3K	 inhibition	 in	 ER+	 cell	 lines	 resulted	 in	 an	increase	in	ER	expression	and	ER	target	genes	and	increased	the	sensitivity	of	the	cells	 to	 tamoxifen.	Together,	hyperactivated	PI3K	signalling	 in	ER+	breast	cancer	may	 reduce	 ER	 expression,	 which	 is	 a	 hallmark	 of	 endocrine	 resistance	 (as	previously	 discussed	 in	 section	 1.7.1).	 Accordingly,	 targeting	 of	 PI3K	 in	 these	tumours,	 may	 increase	 ER	 expression	 and	 subsequently	 re-sensitise	 the	 cells	 to	antihormone	therapy.		Several	 clinical	 trials	 targeting	 the	 PI3K/AKT/mTOR	 pathway	 have	 been	conducted.	One	key	study	 in	 the	advanced	setting	evaluated	everolimus	 (inhibits	
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mTOR	via	allosteric	binding	 to	 the	mTORC1)	 in	 combination	with	exemestane	 in	patients	who	had	progressed	on	aromatase	inhibitor	treatment.	The	Breast	Cancer	Trials	of	Oral	Everolimus-2	(BOLERO-2)	is	an	on	going	randomised	phase	III	study	of	postmenopausal	women	with	ER+/HER2-	disease.	The	 interim	results	 showed	that	 the	 combination	 therapy	 prolonged	 progression-free	 survival	 compared	 to	exemestane	 treatment	 alone	 (6.9	 versus	 2.8	months),	 providing	 support	 for	 this	combination	therapy	in	hormone-resistant,	advanced	disease	249.			
1.7.6 Antihormone-induced	compensatory	signalling		Classically,	 oestrogen	 induces	 expression	 of	 target	 genes	 bearing	 EREs	 in	 their	promoter	region,	as	previously	described	in	section	1.5.1.1.	Surprisingly,	however,	it	 has	 been	 shown	 that	 transcriptional	 repression	 of	 oestrogen-regulated	 genes	comprises	the	bulk	(70%)	of	expression	changes	present	in	ER+	breast	cancer	cells	upon	 E2	 challenge	 (Frasor	 et	 al.	 2003).	 The	 underlying	mechanisms	 involved	 in	E2-mediated	 transcriptional	 repression	 are	 beginning	 to	 emerge.	 One	 proposed	mechanism	is	competition	for	coactivators	by	E2-repressed	gene	promoters.	This	mechanism	has	been	 suggested	 to	be	 responsible	 for	 oestrogen-suppression	 and	antihormone-induction	of	HER2	in	ER+	breast	cancer	cells.	A	region	within	the	first	intron	 of	 the	 HER2	 gene	 has	 been	 shown	 to	 act	 as	 an	 oestrogen	 suppressible	enhancer	 in	 ER+	 breast	 cancer	 cells	 and	 appears	 to	 mediate	 ER-dependent	suppression	 of	 HER2	 expression250.	 Subsequent	 studies	 by	 Newman	 et	 al.251	revealed	 that	 the	 ER	 and	 AP-2	 transcription	 factor	 compete	 for	 the	 limiting	coactivator,	 SRC-1.	 SRC-1-mediated	 activation	 of	 the	 AP-2	 transcription	 factor	results	 in	 activation	 of	 the	 HER2	 promoter	 and	 subsequently	 increases	 HER2	expression252.	 However,	 in	 the	 presence	 of	 oestrogen	 and	 subsequent	 ER	activation,	the	AF2	domain	of	the	receptor	provides	a	strong	binding	site	for	SRC-1	and	sequesters	 the	coactivator,	 thus	preventing	AP-2	activation	and	downstream	HER2	 expression251.	 In	 contrast,	 following	 antihormone	 treatment,	 SRC-1	 is	released	 from	 the	 ER	 and	 available	 to	 bind	 and	 activate	 AP-2,	 thus	 promoting	HER2	expression.	A	 second	 mechanism	 involved	 in	 E2-mediated	 transcriptional	 repression	comprises	the	recruitment	of	corepressor	proteins	by	the	E2:ER	complex	to	some	gene	promoters.	This	has	been	demonstrated	for	several	genes.	For	example,	Stossi	
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et	al.253	have	shown	that	E2-bound	ER	is	able	to	repress	expression	of	the	negative	regulator	of	the	cell	cycle,	cyclin	G2,	by	recruitment	of	the	corepressor	NCOR	and	histone	 deacetylase	 complexes,	 leading	 to	 chromatin	 condensation	 and	transcriptional	 repression	 (as	 previosuly	 described	 in	 section	 1.5.1.1).	 E2-mediated	repression	of	E-cadherin	expression	in	ER+	breast	cancer	cells	has	also	been	attributed	to	the	recruitment	of	the	corepressor,	scaffold	attachment	factor	B,	to	 the	 ER254.	 This	 E2-induced	 suppression	 of	 E-cadherin	 was	 reversed	 by	tamoxifen	 treatment.	 Furthermore,	 E2-activated	 ER	 has	 been	 shown	 to	 recruit	DEAD	box	RNA	helicase	97	(DP97)	corepressor	to	the	promoter	of	the	HER2	gene,	subsequently	suppressing	its	expression.	Accordingly,	silencing	of	DP97	enhanced	HER2	expression255.	A	 third	 mechanism	 proposed	 for	 E2-mediated	 gene	 repression	 includes	 E2:ER	protein/protein	 interactions	 with,	 and	 subsequent	 sequestering	 of,	 additional	transcription	 factors	 to	 prevent	 their	 activity.	 Such	 interactions	 have	 been	implicated	 between	 the	 ER	 and	 two	 distinct	 transcription	 factor	 families,	 NF-κB	and	C/EBP,	 and	 shown	 to	 be	 involved	 in	 E2-mediated	 IL-6	 repression	 in	 human	osteoblast	and	MCF-7	cell	lines61.	IL-6,	secreted	by	osteoblasts,	plays	a	role	in	the	regulation	of	bone	metabolism	by	activating	osteoclast	 cells	which	mediate	bone	resorption.	 NF-κB	 and	 C/EBPβ	 are	 strong	 activators	 of	 the	 IL-6	 promoter;	however,	 in	 the	 presence	 of	 E2,	 activated	 ER	 directly	 interacts	 with	 both	transcription	 factors,	 suppressing	 their	 transcriptional	 activity	 at	 the	 IL-6	promoter	 and	 downstream	 bone	 resorption.	 Thus,	 by	 inhibiting	 IL-6	 promoter	activity,	E2	inhibits	bone	resorption	and	consequently	disrupts	bone	metabolism61.	Accordingly,	 this	 study	 supports	 the	 development	 of	 osteoporosis	 commonly	observed	 in	 post-menopausal	 women	 and	 provides	 a	 mechanism	 of	 prevention	mediated	 by	 oestrogen	 treatment.	 Further	 examples	 of	 protein/protein	interactions	 between	 transcription	 factors	 and	 the	 E2:ER	 complex	 includes	E2-mediated	repression	of	transforming	growth	factor	(TGF)-β	in	MCF-7	cells	via	an	association	between	activated	ER	and	the	transcription	factor	SMAD3256.	TGF-β	has	been	considered	as	a	tumour	suppressor	in	early	breast	cancer	disease	but	at	later	 stages,	 TGF-β	 evolves	 into	 a	 promoter	 of	 tumour	 progression	 and	invasion257,258.	
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Many	 of	 the	 oestrogen-suppressed	 genes	 are	 anti-proliferative	 and	pro-apoptotic259,	 thus	 the	 benefit	 of	 antihormone	 therapy	 is	 achieved	 by	counteracting	 the	 repressive	 events	 induced	 by	 oestrogen,	 triggering	 re-expression	 of	 these	 growth	 repressors.	 However,	 it	 is	 also	 plausible	 that	oestrogens	suppress	and	antihormones	induce	genes	involved	in	cell	proliferation	and	survival,	with	emerging	evidence	supporting	this	hypothesis	(as	described	for	the	pro-proliferative/pro-survival	genes	EGFR,	AKT,	BCL-2	and	14-3-3ζ	in	sections	1.7.6.1	 and	 1.7.6.2	 below)197,216,259.	 Such	 events	 may	 potentially	 limit	 the	anti-tumour	activity	of	antihormones,	providing	survival	mechanisms	to	a	cohort	of	 tumour	 cells	 early	 during	 response	 and	 ultimately	 aid	 the	 emergence	 of	resistant	growth.	Such	genes	may	provide	targets	for	novel	therapies	to	reverse	or	prevent	 the	 development	 of	 resistance.	 Indeed,	 the	 growth	 inhibitory	 actions	 of	antihormones	are	 incomplete,	with	some	cells	evading	 the	 initial	 impact	of	 these	agents,	resulting	in	limited	anti-tumour	responses.	Studies	in	ER+	MCF-7	cells	have	shown	that	tamoxifen	exerts	significant	anti-proliferative	effects	as	early	as	week	2	post-treatment.	 However,	 only	 a	 modest	 increase	 in	 apoptosis	 was	 observed	 in	parallel	with	partial	 suppression	of	 the	 cell	 survival	protein,	BCL-2.	Additionally,	the	 emergence	 of	 highly	 proliferative	 tamoxifen-resistant	 cells	 was	 apparent	 as	early	as	week	5	post-treatment	216.	
1.7.6.1 Proof	of	principle:	oestrogens	suppress	and	antihormones	induce	EGFR	
expression	As	 briefly	 described	 in	 section	 1.7.4.4,	 oestrogen	 challenge	 has	 been	 shown	 to	suppress	 EGFR	 at	 the	 transcriptional	 level	 in	 several	 ER+	 breast	 cancer	 cell	models260,261.	 In	 turn,	 EGFR	 expression	 is	 up	 regulated	 by	 antihormones	 during	response,	with	 induction	occurring	 from	as	 early	 as	 one	week	with	 tamoxifen	 in	MCF-7	cells216.	The	tamoxifen-induced	EGFR	maintained	residual	activity	through	downstream	 MAPK	 and	 AKT,	 cross-talked	 with	 the	 ER	 maintaining	phosphorylation	 of	 serine	 118/serine	 167	 with	 some	 expression	 of	 the	 ER-regulated	 pro-survival	 gene	 BCL-2.	 Consequently,	 the	 anti-tumour	 effects	 of	tamoxifen	 were	 incomplete,	 with	 only	 partial	 inhibitory	 effects	 on	 proliferation	and	minimal	induction	of	apoptosis216.	By	three	months,	the	majority	of	tamoxifen-treated	 cells	 exhibited	 increased	 EGFR	 expression	 with	 substantial	 downstream	
	 34	
kinase	activity.	 Interestingly,	 these	events	were	paralleled	with	the	emergence	of	tamoxifen	resistance,	coincident	with	restoration	of	ER	activity	and	expression	of	ER-regulated	 growth	 factor	 ligands,	 particularly	 amphiregulin,	 completing	 an	EGFR-driven	 autocrine	 growth-regulatory	 loop	 facilitated	 by	 IGF-1R185,196.	Together,	 these	 studies	 provide	 proof	 of	 principle	 that	 antihormone-induced	signalling	genes	have	substantial	potential	to	limit	the	initial	anti-tumour	response	of	ER+	cells,	providing	early	protective	mechanisms	to	a	cohort	of	cells	from	which	resistance	subsequently	emerges.		
1.7.6.2 Antihormone-induced	pro-survival	genes		There	 is	now	considerable	evidence	 implicating	 the	role	of	antihormone-induced	pro-proliferative	 genes	 in	 endocrine	 resistance.	 However,	 the	 role	 played	 by	antihormone-induced	pro-survival	genes	remains	 largely	unexplored.	Since	 these	agents	are	weak	promoters	of	apoptosis,	this	may	reflect	a	significant	capacity	for	induction	 of	 pro-survival	 mechanisms	 by	 such	 drugs	 during	 response.	 Indeed,	antihormones	have	been	shown	to	induce	activation	of	the	pro-survival	gene	AKT	in	 the	 ER+	 breast	 cancer	 cell	 line	 MCF-7262,263	 with	 such	 activation	 of	 AKT	associated	 with	 a	 decreased	 sensitivity	 of	 MCF-7	 cells	 to	 the	 growth	 inhibitory	actions	 of	 endocrine	 agents246,264.	 Furthermore,	 increased	 activity	 of	 AKT	 is	maintained	 through	 to	 the	 development	 of	 tamoxifen-resistance	 suggesting	 that	the	 AKT	 signalling	 pathway	 may	 play	 a	 role	 in	 the	 acquisition	 of	 resistance263.	Immunohistochemical	 analysis	 of	 antihormone-treated	 tumour	 specimens	identified	a	 correlation	between	shorter	disease	 free	 survival	and	activated	AKT,	suggesting	that	there	is	a	link	between	the	AKT	pathway	and	antihormone	therapy	failure	 in	 patients265.	 Several	 studies	 have	 now	 indicated	 that	 one	 significant	mechanism	 by	 which	 AKT	 contributes	 to	 antihormone	 failure	 and	 resistance	 is	through	aberrant	activation	of	the	ER.	AKT	has	been	shown	to	phosphorylate	key	serine	residues	on	the	AF1	domain	of	the	ER	resulting	in	transcriptional	activation	of	 the	 receptor	 in	 a	 ligand-independent	 manner246.	 Interestingly,	 the	 previously	mentioned	 cross-talk	 between	 the	RTKs	EGFR	 and	 IGF-R1	with	 the	ER	has	 been	shown	 to	 involve	 AKT266.	 Indeed,	 treatment	 of	 MCF-7	 cells	 with	 EGF	 or	 IGF-I	results	 in	 rapid	 phosphorylation	 and	 thus	 activation	 of	 AKT	 with	 a	 concurrent	increase	in	ER	activity	via	the	AF1	domain266.	Similarly,	in	tamoxifen	resistant	cells	
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derived	 from	 MCF-7	 cells,	 the	 growth	 factor	 ligands	 EGF	 and	 TGFa	 have	 been	shown	to	induce	phosphorylation	of	AKT263.		Furthermore,	 tamoxifen	 has	 also	 been	 shown	 to	 induce	 up	 regulation	 of	 the	anti-apoptotic	 proteins	 BCL-2	 and	 BCL-XL	 thus	 decreasing	 the	 anti-tumour	response	 to	 tamoxifen267,268.	 Additionally,	 the	 survival	 of	 ER+	breast	 cancer	 cells	treated	 with	 oestrogen	 deprivation	 (to	 mimic	 AI	 therapy)	 is	 supported	 by	increased	 activity	 of	 BCL-2269.	 More	 recently,	 increased	 expression	 of	 the	 pro-survival	 gene	14-3-3ζ	 has	 been	 shown	 to	 promote	 endocrine	 resistance.	 In	 turn,	down-regulation	of	14-3-3ζ	in	antihormone-resistant	cells	reversed	resistance	and	restored	antihormone	sensitivity,	paralleled	with	reduced	expression	of	signature	genes	involved	in	cell	proliferation	and	survival270.		Taken	 together,	 these	 limited	 studies	 reveal	 promising	 results	 for	 the	 role	 of	pro-survival	genes	 in	the	development	of	endocrine	resistance,	particularly	those	promoted	 by	 antihormone	 treatment.	 Importantly	 however,	 further	 studies	 are	clearly	 required	 to	 identify	 novel	 pro-survival	 genes	 induced	 by	 antihormones	during	response	that	may	play	a	role	in	the	development	of	endocrine	resistance.	Such	 findings	may	provide	novel	 therapeutic	strategies	 to	reverse	or	prevent	 the	development	of	resistance.	
1.7.6.3 Antihormone-induced	autophagy	Autophagy	is	an	evolutionary	conserved	process	responsible	for	the	degradation	of	proteins	 and	 the	 turnover	 of	 organelles	 to	 maintain	 homeostasis.	 Autophagy	 is	characterised	by	the	segregation	of	cytoplasm	and/or	intracellular	organelles	into	double	 membrane-bound	 vesicles,	 referred	 to	 as	 autophagosomes.	 The	autophagosomes	next	 fuse	with	 lysosomes	where	the	vesicle	content	 is	degraded	and	essential	proteins/amino	acids	are	 recycled	and	provided	back	 to	 the	 cell	 in	order	to	preserve	energy271,272.	Both	pro-survival	and	pro-apoptotic	functions	have	been	 attributed	 to	 autophagy,	 however	 the	 latter	 remains	 controversial	 and	 less	well-defined.	 With	 regard	 to	 a	 pro-survival	 role,	 a	 deficiency	 in	 nutrients	stimulates	 the	 activation	 of	 autophagy	 to	 produce	 amino	 acids	 essential	 for	metabolism	 and	 survival273.	 Similarly,	 in	 cancer	 cells,	 autophagy	 is	 stimulated	 to	
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protect	cells	from	low	nutrient	supply	(e.g.	the	cells	comprising	the	inner	part	of	a	solid	tumour	that	have	limited	access	to	a	blood	supply)	and	therapeutic	insult274.		In	 breast	 cancer,	 emerging	 evidence	 is	 supporting	 a	 pro-survival	 role	 for	autophagy	in	the	development	of	endocrine	resistance	as	demonstrated	by	studies	in	 antihormone	 responsive	 and	 resistant	 cell	 lines.	 Significantly,	 short	 term	tamoxifen	 treatment	 induced	 autophagy	 in	 the	 antihormone-responsive	 MCF-7	and	 T47D	 cells	 and	 in	 a	 tamoxifen-resistant	 MCF-7,	 HER2-overexpressing	 cell	line275.	 Indeed,	 following	 combination	 treatment	 of	 tamoxifen	 and	 autophagy	knockdown	 in	 MCF-7	 and	 T47D	 cells,	 cell	 viability	 was	 significantly	 reduced	compared	to	either	treatment	alone275.	Additionally,	in	tamoxifen	resistant	MCF-7-HER2	cells,	autophagy	knockdown	and	tamoxifen	treatment	dramatically	reduced	cell	 viability,	 suggesting	 that	autophagy	down-regulation	was	able	 to	 re-sensitise	the	 cells	 to	 the	 antihormone.	 Additionally,	 a	 similar	 study	 by	 Samaddar	 et	 al.276	also	 revealed	 that	 tamoxifen	 and	 fulvestrant	 induced	 autophagy	 in	 MCF-7	 cells.	Furthermore,	 the	 antihormone-induced	 autophagy	 was	 demonstrated	 to	 play	 a	critical	role	in	cell	survival	and	facilitated	the	development	of	acquired	endocrine	resistance.	Accordingly,	inhibition	of	autophagy	in	the	tamoxifen	resistant	cells	led	to	the	restoration	of	tamoxifen	sensitivity,	evidenced	by	an	increase	in	cell	death.	Together,	 these	 studies	 suggest	 that	 autophagy	 is	 induced	 early	 during	antihormone	 response	 and	 may	 represent	 a	 protective	 mechanism	 to	 allow	 the	cells	to	escape	the	growth	inhibitory	actions	of	these	agents	and	allow	cell	survival	during	 antihormone	 challenge,	 consequently	 facilitating	 the	 development	 of	antihormone	resistance.		
1.8 Gene	expression	profiling	Following	 the	 completion	 of	 the	 sequencing	 of	 the	 human	 genome	 came	 the	emergence	of	microarray	technologies.	Such	technologies	allow	thousands	of	genes	in	a	 tumour	sample	 to	be	analysed	simultaneously,	creating	a	genome-wide	gene	expression	 profile.	 Indeed,	 microarray	 gene	 expression	 profiling	 studies	 have	enhanced	our	understanding	of	the	complexity	and	heterogeneity	of	breast	cancer	and	 have	 confirmed	 that	 it	 is	 by	 no	 means	 a	 single	 disease.	 Early	 microarray	studies	by	Perou	and	colleagues277	 revealed	 that	ER+	and	ER-	breast	cancers	are	fundamentally	distinct	at	the	transcriptomic	level	and	can	further	be	divided	into	
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four	 molecular	 subtypes,	 including	 luminal	 A,	 luminal	 B,	 basal	 and	 HER2277–279.	Several	studies	have	now	demonstrated	that	breast	cancer	comprises	a	collection	of	diseases,	expressing	different	transcriptional	profiles,	have	distinct	risk	factors,	clinical	presentation,	histological	features,	response	to	therapy	and	outcome280–282.	These	 studies	 have	 also	 shown	 that	 treatment	 response	 is	 governed	 by	 the	underlying	molecular	characteristics	of	the	tumours	and	indeed	have	identified	an	obvious	potential	role	for	microarray	profiling	as	a	means	of	predicting	prognosis	and	treatment	response.		Several	 groups	have	developed	gene	 signatures	aiming	 to	predict	prognosis.	The	first	 gene	 signature	 consisted	 of	 70	 genes	 shown	 to	 identify	 patients	 with	 good	prognosis	 characterised	 by	 a	 5-year	 minimum	 risk	 of	 developing	 distant	metastasis	 in	 systemic	 therapy-naïve	 patients283.	 Subsequent	 studies	 have	demonstrated	 that	 the	 70-gene	 signature	 classifies	 the	 majority	 of	 ER-	 breast	cancers	 as	 poor	 prognosis	 with	 a	 high	 histological	 grade284–286.	 Further	 studies	have	led	to	the	development	of	several	additional	prognostic	signatures,	including	Oncotype	DX.	This	genetic	test	analyses	21	genes	to	determine	the	10-year	distant	recurrence	risk	of	ER+,	node	negative	breast	cancers	 treated	with	 tamoxifen	and	subsequently	 identifies	high-risk	patients	that	would	benefit	 from	the	addition	of	chemotherapy	 to	 their	 endocrine	 treatment287.	However,	 such	genetic	 tests/gene	signatures	provide	only	prognostic	data	and	fail	to	identify	therapeutic	targets	that	may	 improve	 response.	 Furthermore,	 several	 patients	 present	 with	 de	 novo	resistance	while	all	advanced	disease	patients	eventually	acquire	resistance.		Several	studies	have	employed	microarrays	to	explore	oestrogen	response	genes,	and	 in	 turn	 have	 evaluated	 the	 effectiveness	 of	 the	 different	 classes	 of	antihormones	 in	 reversing	 these	 profiles38.	 However,	 these	 studies	 have	predominantly	focused	on	the	growth-inhibitory	effects	induced	by	antihormones,	as	 opposed	 to	 exploring	 the	 increases	 in	 oestrogen-repressed,	 antihormone-induced	signalling	genes	that	may	serve	to	limit	antihormone	response.		
1.9 Aims	and	objectives	Antihormones	 are	 the	 mainstay	 therapy	 for	 ER+	 breast	 cancer	 and	 have	contributed	 to	a	substantial	decrease	 in	mortality	over	recent	decades.	However,	
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their	 growth	 inhibitory	 actions	 are	 limited	 by	 de	 novo	 and	 acquired	 resistance	resulting	in	increased	metastatic	capacity,	disease	progression	and	poorer	patient	outlook.	To	delay,	prevent	or	ultimately	 treat	 resistance,	 it	 is	 imperative	 that	we	understand	 the	 complexities	 of	 the	 underlying	 signalling	 mechanisms	 that	 limit	antihormone	 response.	 The	 identification	 of	 novel	 antihormone-induced	 pro-survival	 genes/proteins	 will	 further	 our	 understanding	 of	 the	 multitude	 of	mechanisms	that	together	determine	antihormone	response	in	ER+	breast	cancer	and	confirm	the	concept	of	drug-induced	events	contributing	substantially	 to	 the	emergence	of	resistance.		To	 this	 regard,	 the	work	 in	 this	 thesis	 focuses	 on	pro-survival	 genes	 induced	by	antihormone	treatment	during	 initial	 response	whose	expression	may	contribute	substantially	to	the	emergence	of	resistance.	Four	antihormone-sensitive	cell	lines	are	 to	 be	 used	 to	 reflect	 the	 heterogeneity	 present	 in	 clinical	 ER+	 breast	 cancer	(ER+/HER2-:	 MCF-7	 and	 T47D,	 ER+/HER2+:	 BT474	 and	 MDA-MB-361).	Microarray	technology	will	be	utilised	to	identify	novel	pro-survival	genes	induced	following	short-term	antihormone	treatment	in	each	cell	model.	These	studies	will	further	 extend	 into	 cell	 models	 of	 antihormone-resistant	 breast	 cancer	 to	determine	whether	expression	of	such	genes	are	maintained	and	hence	play	a	role	in	the	emergence	of	resistance.	Such	studies	may	identify	these	pro-survival	genes	as	 potential	 novel	 therapeutic	 targets	 both	 in	 the	 antihormone-responsive	 and	 –resistant	 settings	 and	 the	 overexpression	 of	 these	 proteins	 could	 be	 utilised	 as	potential	novel	biomarkers	indicative	of	endocrine	resistance.	Thus,	the	objectives	of	this	thesis	are:	
• To	 identify,	 via	 Affymetrix	 gene	 expression	 profiling,	 novel	 pro-survival	genes	induced	by	a	range	of	currently-used	endocrine	therapies	(tamoxifen,	fulvestrant	 and	 oestrogen	 deprivation)	 in	 a	 panel	 of	 ER+	 human	 breast	cancer	 cell	 lines.	 Subsequently,	 a	 robust	 filtering	 procedure,	 including	ontological	 investigation	and	polymerase	chain	reaction	(PCR)	verification	of	the	array	profiles,	will	be	used	to	prioritise	candidate	genes.		
• To	 investigate	 the	 protein	 expression	 of	 the	 candidate	 pro-survival	 genes	identified,	to	further	verify	the	microarray	profile.	
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• To	determine	whether	these	genes/proteins	persist	 into,	and	hence	play	a	significant	role	in,	antihormone	resistance.	
• To	 address	 the	 targeting	 potential	 of	 these	 proteins	 in	 model	 systems.	siRNA	will	 be	 used	 to	 target	 these	 proteins	 in	 antihormone	 resistance	 to	determine	 whether	 this	 strategy	 can	 promote	 apoptosis	 and	 also	 in	combination	with	antihormone	therapy	to	determine	whether	this	strategy	can	improve	the	anti-tumour	response	of	these	agents.	
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2 Materials	and	Methods	
Tissue	 culture	 medium	 and	 constituents	 were	 purchased	 from	 Life	Technologies,	UK.	Tissue	culture	plastics	were	purchased	from	Nunc,	Roskilde,	Denmark	 supplied	 by	 Fisher	 Scientific,	 Loughborough,	 UK.	 All	 chemicals	 and	reagents	 were	 purchased	 from	 Sigma-Aldrich	 (Poole,	 UK)	 unless	 stated	otherwise.	
2.1 	Cell	culture	
2.1.1 Routine	maintenance	of	cell	lines	All	 four	 ER+	 human	 breast	 cancer	 cell	 lines,	 obtained	 from	 American	 Type	Culture	Collection	(ATCC;	Manassa,	VA,	USA),	were	grown	in	vitro	in	phenol-red	RPMI	 medium	 supplemented	 with	 foetal	 calf	 serum	 (FCS;	 5%	 in	 MCF-7	 and	T47D	and	10%	in	BT474	and	MDA-MB-361),	penicillin-streptomycin	(10	IU/ml	to	 10	 µg/ml)	 and	 fungizone	 (2.5	µg/ml)	 in	 a	 37°C/5%	CO2	 incubator	 (NuAire	NU-5510E	incubator,	Triplered,	UK).	The	characteristics	of	each	of	the	cell	lines	used	 are	 shown	 in	 Table	 1.	 The	 cell	medium	was	 changed	 every	 3	 days	 until	approximately	 70%	 confluency	 was	 reached	 and	 subsequent	 passaging	 was	required.	 Cell	 growth	 was	 assessed	 visually	 by	 a	 phase-contrast	 microscope	(Inverso	TC100	inverted	microscope,	Fisher	Scientific,	UK).		The	cells	were	passaged	by	discarding	the	medium	and	replacing	it	with	trypsin	(0.05%	w/v)	and	EDTA	(0.02%	w/v).	The	proteolytic	enzyme	trypsin	detaches	adherent	cells	 from	the	 flask	and	 the	chelating	agent	EDTA	binds	calcium	and	magnesium	 ions	 present	 in	 the	 medium	 that	 may	 potentially	 inhibit	 trypsin	activity.	Once	the	cells	had	completely	detached	from	the	flask	(approximately	3	to	5	minutes	in	the	37°C/5%	CO2	incubator),	they	were	transferred	to	a	sterile	universal	tube	and	an	equal	volume	of	growth	medium	was	added	to	neutralise	the	trypsin/EDTA	solution.	The	cells	were	collected	and	the	trypsin/EDTA	was	removed	 by	 centrifugation	 (Mistral	 2000	 centrifuge,	 Fisher	 Scientific,	 UK)	 at	1000	rpm	for	5	minutes.	The	supernatant	was	discarded	and	the	cell	pellet	was	re-suspended	in	an	appropriate	volume	of	growth	medium	(between	5	and	10	ml)	and	mixed	by	gentle	pipetting	 to	dissociate	cell	 clumps	 into	single	cells.	A	
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proportion	of	the	cell	suspension	was	diluted	in	growth	medium	(1:10	dilution)	and	added	to	a	new	flask	which	was	 incubated	at	37°C/5%	CO2	until	 required	for	experimentation	or	further	passaging.			
Table	1	Molecular	classification	of	 the	human	breast	cancer	cell	models	used	in	
this	project.		
Cell	
Line	 Classification	 ER	 PR	 HER2	 TP53	 Source	 Tumour	Type	
BT474	 Luminal	B	 +	 +	 +	 +	 Primary	breast	tumour	
Invasive	ductal	carcinoma	
MDA-
MB-
361	
Luminal	B	 +	 -	 +	 -	 Metastatic	site:	brain	 Adenocarcinoma	
MCF-7	 Luminal	A	 +	 +	 -	 +/-	 Pleural	effusion	 Invasive	ductal	carcinoma	
T47D	 Luminal	A	 +	 +	 -	 M	 Pleural	effusion	 Invasive	ductal	carcinoma	
ER:	 oestrogen	 receptor;	 PR:	 progesterone	 receptor;	 HER2:	 human	 epidermal	
growth	 factor	 receptor	 2;	 TP53:	 tumour	protein	 p53;	M:	mutant.	 Adapted	 from	
Neve	et	al.288	and	Holliday	&	Speirs289.	
2.1.2 Experimental	cell	culture		The	cells	were	trypsinised	and	re-suspended	in	phenol-red-free	RPMI	medium	(to	 remove	 the	 unwanted	 oestrogenic	 properties	 of	 phenol-red290,291)	supplemented	with	5%	or	10%	FCS	or	charcoal	stripped	FCS	(sFCS)	(dependent	on	the	cell	line),	penicillin-streptomycin	(10	IU/ml	to	10	µg/ml),	fungizone	(2.5	µg/ml)	 and	 glutamine	 (4	mM).	 The	 cell	 suspension	was	 dispersed	 in	 to	 single	cells	by	passing	through	a	25G	syringe	and	needle	and	the	cell	number	of	100	µl	of	 this	 solution	 was	 measured	 by	 an	 automatic	 cell	 counter	 (Scepter	 2.0	automatic	 cell	 counter,	 Merck	 Millipore,	 UK)	 according	 to	 manufacturer’s	
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instructions.	 Cells	 (0.5	 x	 106)	 were	 seeded	 onto	 60	 mm	 culture	 dishes	 and	allowed	 to	 adhere	 overnight	 prior	 to	 the	 addition	 of	 antihormone	 treatments	and	 the	 appropriate	 controls	 (E2	 or	 untreated	 medium).	 Table	 2	 lists	 the	treatments	used	throughout	the	study,	their	concentration	and	source.	The	cells	were	maintained	at	37°C/5%	CO2	and	the	medium	(±	treatment)	were	renewed	every	 3	 days.	 The	 cells	 were	 harvested	 following	 10	 day	 treatment	 (unless	stated	otherwise).		
Table	2	Treatments	used	in	this	study,	their	concentration,	diluent	and	source.	
Treatment	 Concentration	 Diluent	 Source	
Oestradiol	 10-9	M	 Ethanol	 AstraZeneca,	UK	
Tamoxifen	 10-7	M	 Ethanol	 T5648,	(Sigma-Aldrich,	UK)	
Fulvestrant	 10-7	M	 Ethanol	 AstraZeneca,	UK	
Charcoal	stripped	
FCS	
	 	 In-house	(see	below)	
2.1.3 Charcoal	Stripped	FCS	(sFCS)	FCS	 was	 stripped	 of	 steroids	 to	 mimic	 the	 oestrogen	 depriving	 actions	 of	aromatase	inhibitor	therapies.	FCS	was	adjusted	to	pH	4.2	by	the	addition	of	5	M	HCl	and	allowed	to	equilibrate	for	30	minutes	at	4°C.	A	charcoal	solution	(11.1	%	activated	charcoal,	0.06	%	dextran	T	70	in	distilled	water)	was	prepared	and	stirred	vigorously	for	1	hour.	To	every	100	ml	of	FCS,	5	ml	of	charcoal	solution	was	added	and	stirred	gently	at	4°C	for	16	hours.	To	remove	the	charcoal,	 the	solution	 was	 centrifuged	 (Labofuge	 400R	 centrifuge,	 Heraeus,	 Germany)	 at	12,000	 rpm	 for	 40	 minutes	 and	 the	 supernatant	 was	 coarse	 filtered	 through	Whatman	filter	paper	No.	4	several	times.	The	solution	was	adjusted	to	pH	7.2	using	5	M	NaOH	and	filter	sterilised	through	a	0.2	µM	Supor	Vacucap	membrane	to	remove	any	contaminating	microorganisms.	The	sFCS	was	stored	at	-20°C.		
2.1.4 Generation	of	resistant	cell	lines	
In	 vitro	 cell	 models	 of	 acquired	 resistance	 to	 antihormones	 were	 previously	generated	 by	 the	 Breast	 Cancer	 Molecular	 Pharmacology	 Group.	 The	tamoxifen-resistant	 cell	 lines	 were	 developed	 by	 culturing	 MCF-7	 and	 T47D	cells	 in	 phenol-red-free	 RPMI	 supplemented	 with	 5%	 sFCS,	 antibiotics	(fungizone	 (2.5	 µg/ml)	 and	 penicillin-streptomycin	 (10	 IU/ml	 to	 10	 µg/ml)),	
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glutamine	 (4	mM)	 and	 tamoxifen	 (100	nM)	 for	 6	months.	 Tamoxifen-resistant	MCF-7	 cells	 were	 denoted	 TAMR	 and	 the	 T47D	 cells	 denoted	 T47D	 TAMR.	Likewise,	 the	 fulvestrant-resistant	 cell	 model	 (FASR)	 was	 generated	 by	culturing	 MCF-7	 cells	 in	 phenol-red-free	 RPMI	 plus	 5%	 sFCS,	 antibiotics,	glutamine	 (4	 mM)	 and	 fulvestrant	 (100	 nM)	 for	 6	 months184.	 The	 model	 of	acquired	 resistance	 to	 severe	 oestrogen	 deprivation	 (denoted	 XR),	 was	generated	 by	 the	 long	 term	 culture	 of	 MCF-7	 cells	 in	 phenol-red-free	 RPMI	supplemented	with	5%	heat	inactivated	(65°C	for	30	minutes)	sFCS,	antibiotics	and	glutamine	(4	mM)292.	The	medium	was	changed	every	3-4	days	and	the	cells	were	 passaged	 when	 necessary	 by	 trypsinisation	 (section	 2.1.1).	 Upon	acquisition	of	resistance,	as	determined	by	the	ability	of	 these	cells	 to	grow	in	the	presence	of	antihormone/severe	oestrogen	deprivation,	with	growth	rates	mirroring	those	observed	in	the	wild-type	parental	cells,	the	resistant	cells	were	cultured	for	several	months	to	achieve	a	stable	resistant	phenotype	prior	to	the	commencement	of	any	experimental	work.	These	TAMR,	T47D	TAMR,	FASR	and	XR	 cell	 models,	 developed	 by	 exposure	 to	 antihormones	 for	 6	 months	 are	referred	to	as	short-term	resistant	cell	models	throughout	this	thesis.	Long-term	resistant	cell	models,	derived	from	the	four	ER+	cell	lines,	were	also	generated	 by	 the	 Breast	 Cancer	 Molecular	 Pharmacology	 Group.	 TAMR	 and	FASR	cells	were	developed	by	culturing	MCF-7,	T47D,	BT474	and	MDA-MB-361	cells	in	phenol-red-free	RPMI	supplemented	with	FCS	(5%	for	MCF-7	and	T47D,	10%	 for	 BT474	 and	 MDA-MB-361),	 antibiotics	 and	 glutamine	 (4	mM)	 plus	tamoxifen	(100	nM)	or	 fulvestrant	(100	nM),	respectively	 for	3	years.	XR	cells	were	developed	by	culturing	MCF-7,	T47D	and	BT474	cells	 in	phenol-red-free	RPMI	supplemented	with	heat	 inactivated	(65°C	for	30	minutes)	sFCS	(5%	for	MCF-7	and	T47D,	10%	for	BT474),	antibiotics	and	glutamine	(4	mM)	for	3	years.	The	medium	was	 changed	 every	 3-4	 days	 and	 the	 cells	 were	 passaged	when	necessary	by	trypsinisation	(section	2.1.1).	Similarly	to	the	short-term	resistant	cell	models,	 the	 long-term	 resistant	 cells	were	 cultured	 for	 several	months	 to	achieve	 a	 stable	 resistant	 phenotype	 prior	 to	 the	 commencement	 of	 any	experimental	work.	 These	 cell	models	 are	 referred	 to	 long-term	 resistant	 cell	models	throughout	this	thesis.	
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2.2 Microarray	gene	expression		Prior	 to	 the	 commencement	 of	 this	 project,	 triplicate	 mRNA	 samples	 from	MCF-7	 cells	 treated	 with	 E2,	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprived	conditions	(and	 fulvestrant	 treated	BT474,	MDA-MB-361	and	T47D),	routinely	prepared	 by	 the	 tissue	 culture	 staff	 of	 the	 breast	 cancer	 group,	 were	microarrayed	 by	 Cardiff	 University	 Central	 Biotechnology	 Services	 (CBS)	 at	Cardiff	University.	Additionally,	the	resistant	cell	models	(with	the	exception	of	short-term	T47D	TAMR	cells)	 and	wild-type	 controls	were	 also	microarrayed.	The	 analysis	 of	 the	 gene	 expression	 data	 generated	 during	 antihormone	response	 and	 short-term	 resistance	was	 the	 initial	 focus	 point	 of	 this	 project.	The	cell	culture	preparation	and	the	microarray	procedure	are	described	below:	
2.2.1 Cell	lysis	MCF-7	 cells	 were	 seeded	 at	 3	 x	 106	 cells	 per	 150	 mm	 diameter	 dish	 in	phenol-red-free	RPMI	medium	plus	5%	sFCS	and	allowed	to	adhere	for	24	hours	prior	 to	 the	 addition	 of	 E2-control	 and	 antihormone	 treatments	 for	 10	 days.	Similarly,	 the	 untreated	 control	 and	 the	 resistant	 cell	 models	 were	 grown	 in	150	mm	 dishes	 in	 phenol-red-free	 RPMI	 and	 5%	 or	 10%	 sFCS	 or	 FCS	 and	supplemented	with	the	respective	treatments	(section	2.1.4).		The	cell	medium	was	removed	and	the	cells	were	washed	with	10	ml	of	tissue	culture	 grade	 PBS	 for	 10	 seconds.	 The	 PBS	 was	 removed	 and	 the	 wash	 was	repeated	two	times.	After	the	final	wash,	the	PBS	was	thoroughly	removed	and	1.5	 ml	 of	 Tri-Reagent	 (Sigma-Aldrich,	 UK)	 was	 rocked	 over	 the	 plate	 for	 1	minute	 to	 ensure	 complete	 coverage	 of	 cells	 with	 reagent.	 The	 lysate	 was	scraped	using	a	disposable	cell	scraper,	collected	and	divided	equally	in	to	two	1.5	ml	micro-centrifuge	tubes.	The	tubes	were	gently	inverted	twice	and	placed	on	dry	ice.	This	was	repeated	for	every	sample.	Once	complete,	the	frozen	tubes	were	stored	at	-80°C	prior	to	RNA	isolation.	
2.2.2 RNA	isolation	The	cell	 lysates	were	 removed	 from	 the	 -80°C	 freezer	and	 thawed	on	 ice.	The	volume	of	each	sample	was	adjusted	 to	1	ml	by	addition	of	extra	Tri-Reagent.	The	tubes	were	gently	inverted	and	allowed	to	equilibrate	to	room	temperature	
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for	 5	 minutes.	 Chloroform	 (200	 μl)	 was	 added	 to	 the	 samples	 and	 mixed	thoroughly	 by	 vortexing	 for	 20	 seconds	 and	 then	 left	 to	 stand	 at	 room	temperature	for	10	minutes.	The	tubes	were	spun	at	16,000	g	for	10	minutes	in	a	precooled	centrifuge	(4°C;	Labofuge	400R	centrifuge,	Heraeus,	Germany).	The	samples	 separated	 in	 to	 three	 phases:	 the	RNA	 is	 contained	within	 the	 upper	aqueous	 phase,	 the	 mid	 phase	 contains	 DNA	 and	 the	 lower	 phenolic	 phase	contains	 protein.	 The	 upper	 RNA	 phase	was	 carefully	 removed	 avoiding	 DNA	contamination	from	the	mid	phase,	and	transferred	to	a	clean	micro-centrifuge	tube.	 Room	 temperature	 isopropanol	 (500	 µl)	 was	 added	 to	 the	 RNA	 to	precipitate	it.	The	samples	were	briefly	vortexed	and	allowed	to	stand	at	room	temperature	 for	10	minutes	before	spun	again	 for	10	minutes	at	16,000	g	 in	a	precooled	 centrifuge	 (4°C).	 The	 RNA	 pelleted	 at	 the	 base	 of	 the	 tube.	 The	supernatant	 was	 carefully	 removed	 and	 500	 µl	 of	 70%	 ethanol	 made	 up	 in	sterile	 RNase/DNase-free	 water	 was	 added	 to	 wash	 the	 pellet	 and	 the	 tubes	were	spun	again	for	10	minutes	in	a	precooled	centrifuge	(4°C)	at	16,000	g.	The	ethanol	was	 discarded	 and	 the	 tubes	were	 inverted	 to	 drain	 away	 any	 excess	ethanol.	 The	 pellet	was	 air	 dried	 for	 5	minutes	 before	 being	 re-suspended	 in	50	µl	of	RNase-free	water.		
2.2.3 RNA	concentration	and	purity	The	purity	and	concentration	of	the	RNA	was	determined	by	spectrophotometry	(Jenway	7315	 spectrophotometer,	 Fisher	 Scientific,	UK).	The	RNA	was	diluted	1/1000	 in	 sterile	 water	 and	 the	 absorbance	 was	 measured	 at	 260	 nm	 and	280	nm	wavelengths.	The	concentration	was	calculated	as	follows:		
RNA	concentration	(μg/ml)	=	(absorbance	at	260	nm)	X	(dilution	factor	i.e.	1000)	
X	(extinction	coefficient	of	single	stranded	RNA	i.e.	40	μg/ml).	The	 purity	 of	 the	 RNA	 was	 calculated	 by	 the	 A260/A280	 ratio.	 A	 ratio	 of	between	1.8	and	2	(of	the	spectrophotometric	readings	at	260	nm	and	280	nm)	indicated	that	the	RNA	was	pure.		
2.2.4 Agarose	gel	electrophoresis	The	integrity	of	each	sample	was	assessed	by	gel	electrophoresis.	A	2%	agarose	gel	 was	 prepared	 in	 1	 X	 Tris-acetate-EDTA	 buffer	 (TAE;	 pH8)	 supplemented	
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with	RedSafe	nucleic	acid	stain	(1:20,000;	Chembio	Ltd,	UK).	Once	solidified	the	gel	was	placed	 in	an	electrophoretic	 tank	(Gel	unit	MH-1510,	Fischer,	UK)	and	immersed	in	1	X	TAE	buffer.	The	wells	were	loaded	with	1	μg	of	RNA	made	up	to	5	μl	with	sterile	water	and	mixed	with	5	μl	of	loading	buffer	(40%	sucrose	and	0.25%	w/v	bromophenol	blue	made	up	in	sterile	water	and	filter	sterilised).	The	gel	 was	 run	 at	 100V	 for	 30	minutes	 and	 visualised	 on	 a	 UV	 transilluminator	(G:BOX	 chemi	 XR5,	 Syngene,	 Fisher,	 UK)	 and	 analysed	with	GeneSys	 software	(Syngene,	 Fisher,	 UK).	 Two	 strong	 clean	 bands	 representing	 the	 18s	 and	 28s	ribosomal	RNA	confirmed	that	 the	RNA	was	pure	and	 intact.	This	was	evident	for	all	RNA	samples	examined	in	this	project.	The	RNA	samples	were	stored	at	-80°C.	
2.2.5 DNase	treatment	of	isolated	RNA	The	isolated	RNA	from	each	sample	was	DNase	treated	to	remove	any	genomic	contamination.	 RNase-free	 DNase	 reagents	 provided	 with	 the	 Qiagen	 RNeasy	Micro	Kit	were	used	for	this	protocol.	In	a	sterile	micro-centrifuge	tube	45	µg	of	RNA	adjusted	to	87.5	µl	by	the	addition	of	RNase-free	water,	10	µl	of	kit	buffer	and	 2.5	 µl	 of	 kit	 DNase	 I	 solution	 were	 mixed	 and	 incubated	 at	 room	temperature	for	10	minutes.	To	each	of	the	100	µl	RNA	solutions,	350	µl	of	RLT	buffer	 from	 the	 kit	 (supplemented	 with	 β-mercaptoethanol	 according	 to	manufactures	 instructions)	 was	 added	 and	 mixed	 thoroughly	 before	 the	addition	 of	 250	 µl	 100%	 ethanol	which	 was	 again	mixed	 thoroughly.	 RNeasy	MinElute	 spin	 columns	 were	 inserted	 into	 2	 ml	 kit	 collection	 tubes	 and	 the	entire	contents	(700	µl)	of	each	micro-centrifuge	were	transferred	into	the	spin	column.	 The	 lids	 were	 closed	 and	 the	 tubes	 were	 spun	 at	 10,000	 g	 for	15	seconds	in	a	benchtop	microcentrigue	(Biofuge,	Heraeus,	Germany).	The	flow	through	 was	 discarded	 and	 the	 membrane-bound	 RNA	 was	 washed	 by	 the	addition	of	700	µl	of	RW1	buffer	to	the	column.	The	tubes	were	spun	again	for	15	 seconds	 at	 10,000	 g	 and	 the	 flow	 through	 and	 collection	 tubes	 were	discarded.	The	columns	were	placed	into	clean	2	ml	collection	tubes	and	500	µl	of	 RPE	 buffer	 was	 added	 to	 the	 column	 to	 wash	 the	 membrane-bound	 RNA	again.		The	lids	were	closed	and	the	tubes	were	spun	for	15	seconds	at	10,000	g.	The	 flow	 through	was	discarded	and	500	µl	of	80%	ethanol	was	added	 to	 the	
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columns	 before	 being	 spun	 for	 2	minutes	 at	 10,000	 g.	 The	 flow	 through	 and	collection	 tubes	 were	 discarded.	 The	 columns	 were	 placed	 in	 to	 clean	 2	 ml	collection	 tubes	 and	 spun,	 with	 the	 lids	 open,	 for	 5	 minutes	 at	 10,000	 g	 to	thoroughly	dry	the	columns	and	remove	any	excess	ethanol.	The	columns	were	transferred	 into	 sterile	 1.5	 ml	 micro-centrifuge	 tube	 and	 14	 µl	 of	 RNase-free	sterile	water	was	added	to	the	centre	of	 the	column	membrane.	The	 lids	were	closed	and	the	tubes	were	spun	for	1	minute	at	13,000	g	to	elute	the	RNA.	The	columns	 were	 discarded	 and	 the	 micro-centrifuge	 tubes	 containing	 12	 µl	 of	eluted	 RNA	 were	 placed	 on	 ice.	 The	 RNA	 concentration	 and	 integrity	 were	determined	(as	described	2.2.3	and	2.2.4)	and	the	samples	were	aliquoted	and	stored	at	-80°C.	
2.2.6 Affymetrix	microarray	Triplicate	 RNA	 preparations	 of	 10	 day	 control	 and	 antihormone-treated	 cells	and	 resistant	 cell	 models	 (with	 the	 exception	 of	 short-term	 resistant	 T47D	TAMR	cells)	were	sent	to	CBS.	Initially,	the	quality	of	the	RNA	was	assessed	to	ensure	 no	 contamination	 or	 degradation	 and	 once	 considered	 suitable	 these	samples	 were	 ran	 on	 Affymetrix	 Human	 Genome	 U133Aplus2	 gene	 chips	(containing	 approximately	 23,000	 gene	 probes	 representing	 approximately	14,500	genes)	 following	standard	Affymetrix	procedures.	Briefly,	 the	RNA	was	reverse	 transcribed	and	 the	resulting	complimentary	 (c)DNA	underwent	an	 in	
vitro	 transcription	reaction	with	 the	 incorporation	of	a	biotin	 label	which	was	then	hybridised	to	the	gene	chip	(as	shown	in	Figure	5).	The	gene	chip	was	then	stained	with	a	fluorescent	molecule	that	binds	biotin	and	scanned	to	determine	the	relative	expression	 levels	of	all	genes.	The	Affymetrix	Microarray	Suite	5.0	software	 determined	 and	 subtracted	 background	 and	 non-specific	hybridisation,	 in	 addition	 to	 generating	 appropriate	output	 files	 for	uploading	onto	 the	 online	 bioinformatics	 software	 GeneSifter	(https://login.genesifter.net/).		
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2.2.7 GeneSifter	analysis	of	microarray	data	Triplicate	 raw	 data	 uploaded	 to	 GeneSifter	 was	 first	 log	 transformed	 and	median	 normalised	 prior	 to	 analysis.	 Initial	 array	 analysis	 was	 performed	 on	MCF-7	 cells	 treated	 for	 10	 days	 with	 tamoxifen,	 fulvestrant	 and	 oestrogen	deprivation.	This	project	interrogated	this	GeneSifter-assembled	array	resource	to	 identify	 up	 regulated	 expression	 of	 a	 pre-defined	 list	 of	 pro-survival	 genes	(n=248;	assembled	using	ontology	and	website	resources;	Appendix		Table	15)	with	 antihormone	 treatment	 versus	 E2-treated	 control.	 Heatmaps	 and	 log2	intensity	 plots	 generated	 by	 GeneSifter	 were	 utilised	 to	 visualise	 the	 level	 of	gene	 expression.	 In	 the	majority	 of	 cases,	 the	 Affymetrix	 gene	 chip	 contained	more	than	one	probe	for	each	gene.	All	of	the	available	probes	for	the	genes	of	interest	were	analysed	to	determine	whether	a	consistent	profile	was	achieved	across	 all	 probes	 for	 a	 given	 gene,	 providing	 further	 confidence	 that	 any	antihormone-induced	 change	 in	 expression	was	 robust.	 Particular	 importance	
	
Figure	5	Diagram	of	 Affymetrix	microarray	 procedure.	RNA	 extracted	 from	 cells	
was	 reverse	 transcribed	and	 the	 resulting	 complimentary	 (c)DNA	underwent	an	
vitro	 transcription	 (back	 to	 RNA	 known	 as	 cRNA)	 with	 the	 incorporation	 of	 a	
biotin	 label.	 The	 labelled	 sample	 was	 hybridised	 to	 Human	 Genome	 (HG)-
U133Aplus2	 gene	 chips	 which	 contain	 approximately	 23,000	 gene	 probes.	 The	
gene	 chip	 was	 then	 stained	 and	 scanned	 to	 determine	 the	 expression	 level	 of	
genes.	
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was	 placed	 on	 the	 ‘jetset’	 probe	 for	 each	 gene	 of	 interest.	 The	 ‘jetset’	 probe	characterises	the	optimal	probe	to	represent	a	gene	that	is	detected	by	multiple	probes	 which	 may	 deliver	 inconsistent	 or	 even	 contradictory	 measurements.	Jetset	 in	 an	 online	 tool	 created	 by	 the	 Technical	 University	 of	 Denmark	 and	gives	each	Affymetrix	probe	a	score	based	on	three	factors:	i)	specificity	of	the	probe	 to	 the	 target	 gene,	 ii)	 ability	 of	 the	 probe	 to	 detect	 as	 many	 splice	isoforms	of	the	target	gene	as	possible	to	estimate	the	overall	gene	expression	and	 iii)	 probe	 targeting	 the	 gene	 at	 a	 position	 near	 the	 3’	 end	 of	 the	corresponding	transcript,	as	 it	has	been	shown	that	probes	too	far	 from	the	3’	end	 are	 likely	 to	 have	 a	 reduced	 signal	 intensity	 and	 are	 susceptible	 to	 false	signal	 changes293.	 Together,	 each	 probe	 is	 scored	 according	 to	 specificity,	coverage	 and	 robustness	 against	 transcript	 degradation.	 The	 probe	 with	 the	highest	 overall	 score	 for	 a	 given	 gene	 represents	 the	 optimal	 probe	 and	 is	termed	the	‘jetset’	probe.		GeneSifter	 also	 generates	detection	 call	 results	 for	 each	gene.	These	detection	call	 algorithms	 indicate	 whether	 the	 expression	 of	 a	 transcript	 is	 reliably	measured,	reduces	the	number	of	false	positive	findings,	thus	providing	further	confidence	that	a	change	 in	gene	expression	 is	robust294.	An	 ‘absent’	detection	call	 indicated	 unreliable	 detection	 of	 gene	 expression,	 a	 ‘marginal’	 call	represented	 partial	 detection	 of	 expression	 and	 a	 ‘present’	 detection	 call	signified	 reliable	 detection	 of	 gene	 expression.	 These	 detection	 calls	 were	utilised	 to	 remove	data	 that	was	not	 reliably	detected	before	 further	 analysis.	Specifically,	 probes	with	 a	 ‘marginal’	 or	 ‘present’	 detection	 call	 in	 at	 least	 one	antihormone	 treatment	 were	 selected.	 Next,	 the	 microarray	 profiles	 of	 these	genes	 of	 interest	 were	 examined	 in	 MCF-7	 short-term	 antihormone-resistant	models.	Again,	expression	of	probes	with	a	‘marginal’	or	‘present’	detection	call	maintained	from	antihormone-response	into	the	appropriate	resistance	setting	were	selected	(e.g.	‘marginal’/’present’	call	in	tamoxifen-treated	MCF-7	cells	and	in	the	TAMR	cells).	The	genes	of	interest	filtered	based	on	common	profile	and	detection	 calls	 underwent	 further	 analysis	 to	 identify	 the	 most	 robustly	 up	regulated	genes.	This	 included	ANOVA	with	Tukey	post-hoc	 testing	 to	 identify	significant	 (p	 <0.05)	 genes,	 in	 additional	 to	 examination	 of	 the	 fold	 change	 in	
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gene	expression	 to	 identify	 gene	probes	up	 regulated	by	greater	 than	1.5	 fold	change	in	at	least	one	antihormone	treatment.	
2.3 Ontological	investigation	of	the	genes	of	interest	identified	by	
microarray	analysis	Ontological	 studies	 were	 performed	 on	 the	 genes	 of	 interest	 identified	 by	microarray	analysis	to	aid	prioritisation	of	these	genes	for	further	investigation.	Specifically,	the	multiple	names/aliases	of	the	genes	of	interest	(obtained	from	GeneCards	 (http://www.genecards.org/))	 along	 with	 several	 key	 words	 (e.g.	‘breast	 cancer’	 ‘cancer’	 ‘antihormone’	 ‘resistance’	 ‘survival’)	 were	 searched	 in	PubMed	 (http://www.ncbi.nlm.nih.gov/pubmed)	 to	 identify	 any	 reported	associations	 with	 cancer,	 antihormone-response	 and	 –resistance	 in	 the	literature.	 For	 one	 gene	 in	 particular,	 the	 ontological	 studies	 revealed	genes/proteins	 essential	 for/implicated	 in	 its	 function	 (e.g.	 genes	 involved	 in	the	 synthesis	 of	 the	 ligand	 where	 the	 gene	 of	 interest	 was	 a	 receptor)	 and	subsequently,	heatmaps	and	log2	profiles	were	generated	to	examine	the	profile	of	such	genes	in	our	cell	models.		
2.4 Reverse	transcription–PCR	verification	of	the	genes	of	interest	
identified	by	microarray	analysis		Following	 the	 identification	 by	 microarray	 and	 ontological	 analysis	 of	pro-survival	genes	significantly	induced	by	10	day	antihormone	treatment	with	significant	 induction	 maintained	 in	 to	 antihormone-resistance,	 reverse	transcription	(RT)	and	subsequent	PCR	was	performed	to	verify	this	data	and	to	determine	 the	 high	 priority/expressing	 genes.	 Independent	 triplicate	 MCF-7	cells	 treated	 for	 10	days	with	 antihormones	 and	 the	 short-term	MCF-7	TAMR	and	XR	cells	were	prepared,	 lysed	and	 the	RNA	was	 isolated	equivalent	 to	 the	microarray	 samples	 (as	 described	 in	 sections	 2.2.1-2.2.4).	 RT-PCR	 was	performed	on	these	samples	to	verify	the	microarray	profile.	RT-PCR	was	also	performed	on	additional	ER+	cell	lines	(T47D,	BT474	and	MDA-MB-361)	treated	for	 10	 days	with	 antihormones	 and	 the	 T47D-TAMR	 short-term	 resistant	 cell	line	 to	 determine	whether	 the	 increase	 in	 expression	 of	 the	 genes	 of	 interest	was	evident	for	more	than	one	cell	line	to	consider	the	heterogeneity	of	breast	cancer.		
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2.4.1 RT	RT	 is	 the	 synthesis	of	 complementary	DNA	 (cDNA)	 from	a	RNA	 template.	The	cDNA	generated	 is	necessary	 for	PCR	amplification.	A	mastermix	solution	was	prepared	with	 the	 following	 reagents:	 10	 μl	 of	 deoxynucleotide	 triphosphates	(dNTPs;	2.5	mM,	Invitrogen,	UK)	consisting	of	all	four	bases:	dATP,	dTTP,	dGTP	and	dCTP,	4	μl	5	X	RT	buffer	 (Tetro	reverse	 transcriptase	kit,	Bioline	Ltd,	UK)	and	 2	 μl	 of	 random	 hexamers	 (100	 µM,	 Fisher	 Scientific,	 UK)	 which	 contain	short	 single	 stranded	 random	 hexanucleotides	 that	 act	 as	 primers	 for	 DNA	synthesis.	The	volumes	described	are	for	one	RNA	sample.		To	the	11.5	μl	of	mastermix	solution,	1	μg	of	RNA	in	7.5	μl	of	sterile	water	was	added.	This	reaction	mix	was	denatured	at	95°C	for	5	minutes	(Prime	V	Techne	thermal	 cycler,	 Fisher	 Scientific,	 UK)	 and	 then	 cooled	 rapidly	 on	 ice	 for	 5	minutes.	The	 sample	was	pulse	 spun	 in	a	microcentrifuge	 (Heraeus	Fresco	17	microcentrifuge,	 Thermo	 Scientific,	 UK)	 and	 returned	 back	 to	 the	 ice.	 The	reverse	 transcriptase	 enzyme	 MMLV	 (1	 μl;	 Tetro	 reverse	 transcriptase	 kit,	Bioline	Ltd,	UK)	and	an	RNAse	inhibitor	(0.5	µ;	RiboSafe	RNase	inhibitor,	Bioline	Ltd,	UK)	were	 added	 to	 give	 a	 final	 volume	of	 20	 μl.	 The	 sample	was	 reverse	transcribed	in	the	thermal	cycler	using	the	following	parameters:	1. Annealing:	22°C	for	10	minutes	2. RT	extension:	42°C	for	40	minutes	3. Denaturing:	95°C	for	5	minutes	The	cDNA	samples	generated	were	stored	at	-20°C	until	required.		
2.4.2 PCR	PCR	 is	 a	 technique	used	 to	 amplify	 a	 specific	 region	of	DNA	 that	 lies	between	two	regions	of	known	DNA	sequence.	A	pair	of	short	DNA	fragments	known	as	oligonucleotide	 primers	 are	 synthesised	 to	 be	 complementary	 to	 the	 DNA	sequences	on	both	strands	of	the	DNA,	flanking	the	target	sequence/region	that	is	 to	be	amplified.	 In	 the	presence	of	dNTPs	(comprising	 the	 four	bases	dATP,	dTTP,	dGTP	and	dCTP),	the	thermal	stable	DNA	polymerase,	Taq,	synthesises	a	new	strand	of	DNA	from	the	end	of	one	primer	using	the	target	sequence	as	a	template.	The	reaction	involves	repeated	cycles	of	heat	denaturation	to	separate	
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the	double	stranded	DNA,	followed	by	cooling	to	allow	annealing	of	the	primers	to	their	complementary	sequences	and	extension	of	the	annealed	primers	with	the	DNA	polymerase.	DNA	synthesis	proceeds	across	the	target	region,	between	the	two	primers.	The	products	formed	from	the	first	cycle	of	the	reaction	serve	as	DNA	 templates	 for	 subsequent	 cycles.	Thus,	with	each	cycle,	 the	amount	of	DNA	synthesised	doubles	to	that	of	the	previous	cycle,	resulting	in	exponential	accumulation	of	the	PCR	product.	
2.4.3 Primer	Design		The	oligonucleotide	primers	used	were	designed	using	ThermoFisher	Scientific	OligoPerfect™Designer	(https://tools.thermofisher.com/content.cfm?pageid=97	16	 &icid=fr-oligo-6?CID=fl-oligoperfect)	 using	 gene	 sequences	 obtained	 from	the	 National	 Center	 for	 Biotechnology	 Information	 (NCBI)	 database		(http://www.ncbi.nlm.nih.gov/nuccore)	 for	 the	 genes	 of	 interest.	 From	 these	sequences,	the	OligoPerfect™	Designer	identified	potential	primer	pairs	and	also	allowed	consideration	of	product	 size,	melting	 temperature	and	percentage	of	guanine	and	cytosine	bases	which	is	 indicative	of	the	formation	of	undesirable	primer-dimer	formation.	Once	selected,	the	primer	pairs	were	inputted	into	the	online	 programme	 Basic	 Local	 Alignment	 Search	 Tool	 (BLAST;	http://blast.ncbi.nlm.nih.gov/).	 BLAST	 compares	 nucleotide	 sequences	 across	the	human	genome	and	identifies	regions	of	similarity	between	sequences.	The	primer	sequences	used	within	this	project	were	inputted	into	BLAST	to	ensure	that	they	were	specific	to	the	gene	of	interest.			
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Table	3	Oligonucleotide	sequences,	product	size,	optimised	cycle	number	and	annealing	temperature.	
bp:	base	pairs.	*CLU	primer	sequence	designed	according	to	Prochnow	et	al.295.	
Gene	 Forward	Primer	Sequence	(5’→3’)	 Reverse	Primer	Sequence	(5’→3’)	 Product	Size	(bp)	 Cycle	Number	 Annealing	Temperature	(°C)	β-Actin	 GGAGCAATGATCTTGATCTT	 CCTTCCTGGGCATGGAGTCCT	 202	 25	 55	BAG1	 GCTCCTATCTGTTTTCTCCT	 CCTTCTCTTTGCCCTTCCT	 570	 36	 60	BCL2L1	 GCTATGATCCTGTCCCTCCA	 TGGCTTCTCACTGGTCTCCT	 340	 38	 60	BCL3	 CTGGCTGTGATCACCACATT	 TCGTTGTGGCAGTTCTTGAG	 497	 30	 55	CLU	 CGACTCACCCACAGACAAGA	 GAGTCACCTGAGCCTGGAAG	 298	 36	 57	CLU*	 ACAGGGTGCCGCTGACC	 TTCAGGCAGGGCTTACACTCT	 400	 	 55	CXCR4	 TTCTACCCCAAT GACTTGTG	 ATGTAGTAAGGC AGCCAACA	 206	 39	 55	CTNND2	 TGGCACCCATCAATAGTCAA	 AATCACTTGGTGCAGTGTGC	 390	 34	 55	DDAH2	 GATCTGGCCAAAGCTCAAAG	 TCGCGTTCTCGTCTCCTATT	 259	 30	 55	ERC1	 ACAGCTCTCAGCAGCTACAG	 CTGCTGTACCAGACGATCCT	 445	 36	 55	GABBR2	 ACAACAGAGCCCTCTCGAAC	 GAGACCATGACTCGGAAGGA	 180	 39	 58	HBXIP	 GCAGCACTTGGAAGACACAA	 GTGATGCCATCGTGTTTCTG	 231	 36	 55	IGFBP5	 CCCTTTATCCCTGCACTCTC	 GGCTTCTCCTCGTCCTGCCG	 330	 40	 55	PSEN1	 TGAGTTGGGGAAAAGTGAC	 CATAAGAAGAACAGGGTGG	 316	 40	 57	TSC22D3	 CCCTGACAAGAGCAGGTCTC	 GCCTTCACGAAACAGAGGAG	 301	 34	 55	
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2.4.4 PCR	Procedure	All	 reagents	 and	 samples	 were	 kept	 on	 ice.	 A	 mastermix	 was	 prepared	 in	 a	sterile	eppendorf	tube	using	the	following	reagents:		
• 18	μl	sterile	RNA/DNAse	free	water	
• 2.5	μl	PCR	10	X	NH4	buffer	(BIOTAQ	DNA	polymerase	kit,	Bioline	Ltd,	UK)	
• 0.75	μl	MgCl2	(50	mM;	BIOTAQ	DNA	polymerase	kit,	Bioline	Ltd,	UK)	
• 2	μl	dNTPs	(2.5	mM)	
• 0.625	 μl	 of	 each	 primer	 of	 gene	 of	 interest	 (20	 μM;	 Invitrogen,	ThermoFisher	Scientific,	UK)	
• 0.2	 μl	 TAQ	 DNA	 polymerase	 (5	 units/μl;	 BIOTAQ	 DNA	 polymerase	 kit,	Bioline	Ltd,	UK).	The	 volumes	 described	 are	 per	 individual	 cDNA	 sample.	 The	 mastermix	 was	thoroughly	mixed	and	0.5	μl	(equal	to	0.05	μg	RNA)	of	cDNA	was	added	to	give	a	final	volume	of	25	μl.	A	drop	of	mineral	oil	was	added	on	top	of	each	sample	to	prevent	 evaporation	 during	 the	 PCR	 reaction.	 The	 sample	was	 amplified	 in	 a	thermal	cycler	using	the	parameters	shown	in	Table	4.	The	PCR	products	(10	μl)	were	mixed	with	5	μl	of	 loading	buffer	and	 loaded	on	 to	a	2%	agarose	gel	 for	visualisation	 (as	 detailed	 in	 2.2.4).	 A	 DNA	marker	 (5	 µl,	 100	 bp	 DNA	 ladder,	Fisher,	 UK)	 was	 mixed	 with	 5	 µl	 loading	 buffer	 and	 loaded	 alongside	 the	samples	to	allow	the	product	size	to	be	determined.	To	ensure	equal	loading	on	such	 gels	 and	 to	 allow	 for	 normalisation,	 the	 housekeeping	 gene	 β-actin	 was	amplified	 in	 parallel	 following	 the	 same	 parameters	 shown	 in	 Table	 4	 for	 25	cycles.	The	gel	was	visualised	on	a	UV	transilluminator	(G:BOX).	Densitometry	analysis	was	performed	using	GeneSys	software.	Raw	densitometry	values	were	normalised	to	β-actin	loading	control.	
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Table	 4	 Polymerase	 chain	 reaction	 programme.	 Shown	 is	 the	 standard	 PCR	
programme.		
Stage	 Number	of	
Cycles	
Temperature	(°C)	 Duration	
(seconds)	
1	 1	 Denaturing:	95	
Annealing:	55	Extension:	72	
120	
60	300	
2	 25-39	 Denaturing:	94	
Annealing:	55-60*	Extension:	72	
30	
60	60	
3	 1	 Denaturing:	94	
Annealing:	55	
Extension:	60	Finish:	4	
60	
60	
300	∞	
*The	number	of	cycles	and	annealing	temperature	were	optimised	for	each	gene	
of	interest.	
2.5 	Sodium	dodceyl	sulphate-polyacrylamide	gel	electrophoresis	
and	Western	blotting	to	verify	the	genes	of	interest	identified	by	
microarray	analysis		Following	 the	 initial	 identification	 by	 microarray	 analysis	 and	 subsequent	RT-PCR	 verification	 of	 pro-survival	 genes	 significantly	 induced	 by	 10	 day	antihormone	 treatment	 with	 induction	 maintained	 in	 to	antihormone-resistance,	 sodium	 dodecyl	 sulphate-polyacrylamide	 gel	electrophoresis	 (SDS-PAGE)	 and	 Western	 blotting	 was	 performed	 to	 confirm	expression	of	these	genes	at	the	protein	level.	This	was	important	to	ensure	that	the	mRNA	of	target	proteins	was	translated	in	to	protein	to	perform	its	function.		Western	blot	is	a	method	used	to	identify	and	analyse	specific	proteins	within	a	complex	protein	mixture,	such	as	cell	lysate.	Briefly,	proteins	are	denatured	and	
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separated	 according	 to	 their	 molecular	 weight	 by	 gel	 electrophoresis.	 The	proteins	are	then	transferred	to	a	nitrocellulose	membrane	which	is	incubated	with	 primary	 antibodies	 specific	 to	 the	 protein	 of	 interest.	 The	 unbound	antibody	 is	 washed	 off,	 and	 the	 membrane	 is	 probed	 with	 a	 horseradish	peroxidase	 (HRP)-labelled	 secondary	 antibody	 which	 binds	 to	 the	 already	bound	primary	antibody.	The	unbound	antibody	is	washed	off	and	the	specific	protein	 of	 interest	 is	 detected	 on	 the	membrane.	 The	membrane	 is	 incubated	with	 an	 enhanced	 chemiluminiescent	 (ECL)	 substrate	 which	 reacts	 with	 the	HRP	bound	to	the	secondary	antibody	and	subsequently	produces	a	signal.		The	signal	produced	represents	the	protein	of	interest	and	the	thickness	of	the	band	corresponds	to	the	amount	of	protein	present.	
2.5.1 Protein	isolation	MCF-7,	 T47D,	 BT474	 and	 MDA-MB-361	 cells	 (0.5	 x	 106)	 were	 seeded	 onto	60	mm	 dishes	 and	 treated	 with	 antihormones	 for	 10	 days	 as	 described	 in	section	 2.1.2.	 Similarly,	 the	 resistant	 cell	 models	 and	 wild	 type	 control	 were	seeded	onto	60	mm	dishes.	The	 cell	medium	was	 removed	and	 the	 cells	were	washed	with	2	ml	of	 tissue	culture	grade	PBS.	The	PBS	was	removed	and	the	wash	was	repeated	two	times.	After	the	final	wash,	the	PBS	was	removed	by	aspiration	and	250	µl	of	ice	cold	lysis	buffer	(50	mM	Trizma	base,	150	mM	NaCl,	5	mM	EGTA	and	1%	v/v	TritonX	100,	 distilled	 water,	 pH	 7.6)	 supplemented	 with	 a	 protease	 and	 phosphatase	inhibitors	 (HALT	 protease	 and	 phosphatase	 inhibitor	 cocktail	 (100X),	ThermoFisher	 Scientific,	 UK)	 was	 added	 to	 each	 cell	 dish.	 The	 dishes	 were	incubated	 on	 ice	 and	 the	 cell	 lysates	 were	 collected	 using	 a	 disposable	 cell	scraper	 and	 then	 transferred	 into	 a	 1.5	 ml	 microcentrifuge	 tubes.	 The	 tubes	were	spun	at	14,000	x	g	for	15	minutes	at	4°C.	The	supernatant	was	aliquoted	and	stored	at	-20°C	until	required.	
2.5.2 Protein	isolation	of	nuclear	and	cytoplasmic	cell	fractions	Antihormone-resistant	and	wild	type	control	cells	were	grown	in	60	mm	dishes.	The	cell	medium	was	removed,	the	dishes	were	placed	on	ice	and	the	cells	were	washed	two	times	with	tissue	culture	grade	PBS.	After	the	final	wash,	200	μl	of	
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PBS	 was	 added	 to	 the	 cells	 and	 they	 were	 collected	 using	 a	 disposable	 cell	scraper	 and	 then	 transferred	 into	 a	 1.5	 ml	 microcentrifuge	 tubes.	 The	 tubes	were	centrifuged	at	1000	rpm	for	5	minutes	at	4°C.	The	pellet	was	re-suspended	in	 5	 pellet	 volumes	 of	 cytoplasmic	 extract	 buffer	 (10	mM	HEPES,	 60	mM	KCl,	1	mM	 EDTA,	 1	 mM	 phenylmethylsulfonyl	 fluoride	 (PMSF;	 ThermoFisher	Scientific,	UK)	and	1	mM	DTT,	distilled	water,	pH	7.6)	supplemented	with	NP40	(0.075%)	and	incubated	on	ice	for	5	minutes.	The	tubes	were	centrifuged	again	at	 1000	 rpm	 for	 5	minutes	 at	 4°C	 and	 the	 supernatant	 containing	 the	cytoplasmic	 fraction	 was	 added	 to	 a	 fresh	 eppendorf	 tube	 and	 kept	 on	 ice.	Cytoplasmic	extract	buffer	(100	μl)	without	NP40	was	added	to	the	pellet	which	contained	the	cell	nuclei,	and	mixed	gently	by	pipetting	prior	to	centrifugation	at	1000	rpm	for	5	minutes	at	4°C.	The	supernatant	was	discarded	and	the	pellet	was	re-suspended	in	2	pellet	volumes	of	nuclear	extract	buffer	(20	mM	Tris-HCl,	420	mM	NaCl,	1.5	mM	MgCl2,	0.2	mM	EDTA,	1	mM	PMSF,	1	mM	DTT	and	25%	v/v	 glycerol,	 distilled	water,	 pH	 8)	 and	 incubated	 on	 ice	 for	 10	minutes	with	intermittent	 vortexing	 to	 disperse	 the	 pellet.	 The	 cytoplasmic	 and	 nuclear	extract	were	centrifuged	at	14,000	rpm	for	10	minutes	at	4°C.	The	supernatants	were	transferred	to	fresh	eppendorf	tubes	and	stored	at	-20°C	until	required	for	SDS-PAGE	and	Western	blotting.	
2.5.3 Protein	assay	A	 protein	 assay	 adapted	 from	 the	 Bradford	 assay	was	 used	 to	 determine	 the	protein	 concentration	 of	 each	 cell	 lysate.	 A	 standard	 curve	 of	 known	concentrations	(0,	5,	10,	15,	20	and	25	µg/ml)	of	bovine	serum	albumin	(BSA)	diluted	in	distilled	H20	were	prepared	in	1.5	ml	microcentrifuge	tubes.	The	cell	lysates	of	unknown	protein	concentration	were	diluted	in	distilled	H2O	(1/200).	Bio-Rad	Dye	Concentrate	(100	µl;	Bio-Rad	Laboratories	Ltd,	UK)	was	added	to	400	µl	of	 the	standard	and	test	samples.	The	reaction	mixtures	were	vortexed	and	left	to	stand	for	10	minutes	before	being	transferred	in	triplicate	(3	x	130	µl)	 to	 a	 96	well	 plate.	 The	 absorbance	was	measured	 at	 595	 nm	 (OD595)	 in	 a	plate	reader	(Multiscan	EX	355,	Thermo	Scientific,	UK).	A	standard	curve	of	the	known	protein	concentrations	was	generated	and	the	concentration	of	the	cell	lysate	samples	was	calculated	from	this.		
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2.5.4 Protein	sample	preparation	Prior	 to	 separation	 by	 electrophoresis,	 the	 proteins	 were	 first	 denatured.	Proteins	 (20	µg)	were	diluted	 in	 an	equal	 volume	 (1:1)	of	2	X	Lamelli	 sample	loading	buffer	 (4%	w/v	SDS,	20	%	v/v	glycerol,	120	mM	TRIS	pH	6.8,	1.54	%	w/v	DTT,	0.01%	w/v	bromophenol	blue	and	distilled	water)	and	heated	at	95°C	for	 5	 minutes.	 SDS	 is	 an	 anionic	 detergent	 which	 causes	 complex	 secondary,	tertiary	 and	 quaternary	 proteins	 to	 be	 denatured	 in	 addition	 to	 applying	 a	negative	charge	to	the	proteins	in	proportion	to	their	mass.	Consequently,	when	an	electrical	 field	 is	applied	each	protein	will	migrate	 towards	the	anode.	DTT	further	 denatures	 the	 proteins	 by	 reducing	 the	 disulphide	 bonds.	 Glycerol	increases	the	density	of	each	sample	making	it	easier	to	load	in	to	the	wells	and	bromophenol	blue	is	a	coloured	tracking	dye	which	allows	the	migration	of	the	proteins	through	the	polyacrylamide	gel	during	electrophoresis	to	be	visualised.		
2.5.5 SDS-PAGE	SDS-PAGE	 is	 a	 method	 used	 to	 separate	 proteins	 according	 to	 their	 size.	 All	SDS-PAGE	gels	were	prepared	in	a	gel	casting	apparatus	(Bio-Rad	Laboratories	Ltd,	UK).	SDS-PAGE	uses	two	polyacrylamide	gels:	a	resolving	gel	and	a	stacking	gel.	 The	 resolving	 gel	 is	 basic	 (pH	 8.8)	 and	 has	 a	 higher	 percentage	 of	acrylamide,	thus	making	the	pores	in	the	gel	smaller	and	consequently	proteins	are	separated	based	on	their	size	as	the	smaller	proteins	travel	more	easily	and	rapidly	 through	 the	 gel.	 The	 percentage	 of	 acrylamide	 in	 the	 resolving	 gel	 is	dependent	on	the	molecular	weight	of	the	protein	of	interest;	as	the	percentage	of	 acrylamide	 increases,	 the	 pore	 size	 decreases	 and	 consequently	 smaller	proteins	 are	 resolved	 better.	 The	 upper	 stacking	 gel	 is	 acidic	 (pH	 6.8)	with	 a	lower	percentage	of	acrylamide	and	consequently	larger	pores,	and	functions	to	allow	the	proteins	to	stack	in	to	one	band	at	the	interface	between	the	two	gels	allowing	proteins	to	migrate	in	to	the	resolving	gel	at	the	same	time.		
2.5.6 Polyacrylamide	gel	preparation	A	 resolving	 gel	 between	7.5%	and	15%	acrylamide	was	 prepared	 to	 separate	proteins	between	8	and	200	kDa.	Once	prepared	(Table	5),	the	gel	was	poured	and	100	µl	of	 isopropanol	was	added	on	top	to	remove	any	air	bubbles	and	to	level	the	surface.	Once	set,	the	isopropanol	was	poured	off	and	the	stacking	gel	
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(Table	5)	was	prepared	and	added	on	top	of	the	resolving	gel.	A	10	well	comb	was	inserted	into	the	stacking	gel	and	the	gel	was	left	to	set	for	20	minutes.		
Table	5	Components	of	the	polyacrylamide	resolving	and	stacking	gels.	Component	 7.5%	Resolving	gel	 10%	Resolving	gel	 15%	Resolving	gel	 4%	Stacking	gel	
Molecular	
weight	of	
protein	
40-200	kDa	 20-100	kDa	 8-50	kDa	 	
dH2O	 4.8	ml	 4	ml	 2.3	ml	 6.1	ml	
30	%	
Acrylamide	
2.5	ml	 3.3	ml	 5	ml	 1.3	ml	
1.5	M	TRIS	
pH	8.8	 2.5	ml	 2.5	ml	 2.5	ml	 	
0.5	M	TRIS	
pH	6.8	 	 	 	 2.5	ml	
10%	SDS	 100	µl	 100	µl	 100	µl	 100	µl	
10%	APS	 100	µl	 100	µl	 100	µl	 50	µl	
TEMED	 6	µl	 6	µl	 6	µl	 10	µl	
SDS:	 sodium	 dodecyl	 sulphate;	 APS:	 ammonium	 persulphate;	 TEMED:	
tetramethylethylenediamine.	Percentages	are	w/v.	
2.5.7 Gel	electrophoresis	The	 comb	was	 removed	 and	 the	 gel	 was	 placed	 into	 an	 electrophoresis	 tank	(Mini-PROTEAN,	 Bio-Rad	 Laboratories,	 UK)	 and	 submerged	 in	 running	 buffer	(25	mM	TRIS	Base,	192	mM	Glycine,	0.1%	w/v	SDS,	pH	8.3).	Protein	molecular	weight	 marker	 (3	µl;	 Spectra	 multicolour	 broad	 range	 protein	 ladder,	ThermoFisher	Scientific,	UK)	was	loaded	into	the	first	well	of	each	gel	and	20	µg	of	prepared	protein	sample	(section	2.5.4)	was	loaded	into	the	remaining	wells.	An	electrical	field	was	applied	to	the	gel	causing	the	negative	charged	proteins	to	migrate	towards	the	anode.	The	gel	was	run	for	approximately	45	minutes	at	180V	or	until	the	dye	front	had	reached	the	bottom	of	the	gel.		
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Figure	6	 Assembly	of	Western	blot	 transfer	 apparatus.	The	membrane	 is	placed	
between	the	gel	and	the	positive	anode	to	allow	the	negative	charged	proteins	to	
transfer	from	the	gel	to	the	membrane	towards	the	anode	as	indicated.		
2.5.8 Transfer	of	proteins	to	nitrocellulose	membrane	Once	separated,	the	proteins	were	transferred	on	to	a	nitrocellulose	membrane.	The	 gel	 was	 carefully	 removed	 from	 the	 glass	 plates,	 the	 stacking	 gel	 was	discarded	and	the	resolving	gel	was	placed	into	a	transfer	cassette.	The	cassette	was	composed	of	foam	pads,	filter	paper	and	membrane	which	had	all	been	pre-soaked	 in	 transfer	 buffer	 (25	 mM	 TRIS	 Base,	 192	 mM	 Glycine,	 20%	 v/v	methanol,	pH	8).	The	cassette	was	placed	into	a	wet	electroblotting	tank	(Mini-PROTEAN,	Bio-Rad	Laboratories,	UK)	with	the	membrane	located	between	the	gel	and	positive	electrode,	thus	when	an	electrical	 field	 is	applied	the	negative	charged	proteins	transfer	from	the	gel	to	the	membrane,	as	shown	in	Figure	6.	An	 ice	block	was	added	 to	 the	 tank	which	was	 filled	with	 transfer	buffer.	The	proteins	were	transferred	for	1	hour	at	100V.	Once	transferred,	the	membrane	was	removed	from	the	cassette	and	submerged	in	0.1	%	w/v	Ponceau	S	(made	up	in	5	%	v/v	acetic	acid	in	distilled	water)	stain	to	visualise	the	protein	bands,	ensure	efficient	transfer	and	equal	protein	loading.	The	Ponceau	S	was	washed	off	 with	 tris	 buffered	 saline	 (TBS)-Tween	 (0.05	%	 v/v)	 comprised	 of	 Trizma	base	(10	mM),	NaCl	 (100mM)	and	Tween	20	(0.05	%	v/v)	and	 the	membrane	was	blocked	in	5%	non-fat	dried	milk	(Marvel)	in	TBS-Tween	(0.05	%	v/v)	for	1	hour	 with	 agitation	 at	 room	 temperature.	 Blocking	 prevents	 antibodies	 from	binding	non-specifically	to	the	membrane.	
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2.5.9 Incubation	with	antibodies	The	membrane	was	removed	from	the	blocking	solution	and	incubated	in	5	ml	of	primary	antibody	(Table	6)	(diluted	in	1%	Marvel/TBS-Tween)	overnight	at	room	temperature	on	a	roller	mixer.	The	membrane	was	washed	in	TBS-Tween	(3	X	5	minutes)	to	remove	any	unbound	antibody	before	being	incubated	in	5	ml	of	 horseradish	 peroxidase	 (HRP)-conjugated	 secondary	 antibody	 (Table	 6)	(diluted	in	1%	Marvel/TBS-Tween)	for	1	hour	at	room	temperature	on	a	roller	mixer	(MX-T6-S,	Camlab,	UK).	The	membrane	was	washed	in	TBS-Tween	(5	X	5	minutes)	to	remove	any	unbound	antibody	before	protein	detection.		
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Table	 6	 Primary	 antibodies	 used	 for	Western	 blotting	 along	with	 their	 corresponding	 dilution,	 source,	 product	 number,	 host	 species,	
secondary	antibody	and	predicted	molecular	weight.	
Target	 Dilution	 Species	 Product	
Number	
Source	 Secondary	Antibody	 Protein	Size	
BCL3	 1:1000	 Rabbit	(pAb)	 sc-185	 SCBT	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 60	kDa	
CLU	 1:1000	 Mouse	 sc-5289	 SCBT	 HRP-conjugated	anti-Mouse	diluted	1:10000	 70	kDa	&	40	kDa	
GABBR2	 1:1000	 Rabbit	(mAb)	 ab75838	 Abcam	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 106	kDa	*	
GILZ/	
TSC22D3	
1:1000	 Mouse	(mAb)	 sc-133215	 SCBT	 HRP-conjugated	anti-Mouse	diluted	1:10000	 18	kDa	
GRB2¶	 1:1000	 Mouse	 	 SCBT	 HRP-conjugated	anti-Mouse	diluted	1:10000	 30	kDa	
p50	 1:1000	 Rabbit	(pAb)	 sc-7178	 SCBT	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 50	kDa	&	100	kDa	
p52	 1:1000	 Rabbit	(pAb)	 sc-298	 SCBT	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 52	kDa	&	100	kDa	
p105/	
p50	
1:1000	 Mouse	(mAb)	 NBP2-22178	 NB	 HRP-conjugated	anti-Mouse	diluted	1:10000	 50	kDa	&	100	kDa	
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Target	 Dilution	 Species	 Product	
Number	
Source	 Secondary	Antibody	 Protein	Size	
SP-1¶	 1:1000	 Rabbit	 	 SCBT	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 100	kDa	
β-actin	 1:2000	 Rabbit	(mAb)	 A5060	 Sigma-Aldrich,	UK	 HRP-conjugated	anti-Rabbit	diluted	1:5000	 40	kDA	
δ-catenin	 1:1000	 Mouse	(mAb)	 sc-81793	 SCBT	 HRP-conjugated	anti-Mouse	diluted	1:10000	 133	kDa	
SCBT:	Santa	Cruz	Biotechnology,	Inc.	NB:	Novus	Biologicals,	UK,	pAb:	Polyclonal	antibody,	mAb:	Monoclonal	antibody,	HRP:	Horseradish	
peroxidase.	 *GABBR2	predicted	molecular	weight	 is	106	kDa,	but	 the	observed	protein	weight	 in	 this	project	 is	80	kDa	supporting	 the	
findings	 from	Kuriyama	 et	 al.296.	 ¶	 Kindly	 provided	 by	 Dr	 Glorianne	 Lazaro,	 School	 of	 Pharmacy	 and	 Pharmaceutical	 Sciences,	 Cardiff	
University.	
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2.5.10 Protein	detection	The	 appropriate	 ECL	 reagent	 (100	 µl;	 SuperSignal	West	 Dura	 or	 SuperSignal	West	Femto	chemiluminescent	detection	reagent,	ThermoFisher	Scientific,	UK)	was	applied	 to	 the	membrane	 following	 the	manufactures	 instructions,	before	being	placed	into	the	G:BOX	for	detection.	Densitometry	analysis	was	performed	using	GeneSys	 software.	Raw	densitometry	 values	were	normalised	 to	β-actin	loading	control.	
2.6 Functional	studies	of	high	priority	genes	
2.6.1 siRNA	transfection	siRNA	 is	 a	 sequence-specific,	 short	 double-stranded	 RNA	 able	 to	 destruct	complementary	mRNA,	 to	 induce	knockdown	of	 target	gene	expression.	siRNA	is	 transported	 into	 the	 cell	 via	 lipid	 carriers	 and	 once	 in	 the	 cytoplasm,	 the	siRNA	 is	 incorporated	 into	 a	 protein	 complex	 called	 RNA-induced	 silencing	complex	 (RISC)	 as	 shown	 in	 Figure	 7297.	 Subsequently,	 RISC	 unwinds	 the	double-stranded	 siRNA	 and	 cleaves	 the	 sense	 strand	 to	 generate	 an	 activated	RISC	 complex	 containing	 the	 antisense	 strand	 of	 the	 siRNA298.	 The	 antisense	strand	directs	the	RISC	to	complementary	mRNA	and	once	bound,	the	antisense-RISC	 complex	 cleaves	 the	 target	 mRNA	 resulting	 in	 gene	 silencing299.	 The	activated	 RISC-siRNA	 complex	 is	 then	 recycled	 for	 continued	 destruction	 of	identical	 mRNA	 targets	 to	 further	 propagate	 gene	 silencing300.	 However,	 this	gene	silencing	is	transient,	only	lasting	approximately	4	days	in	rapidly	dividing	cells.	 siRNA	 becomes	 diluted	 due	 to	 cell	 division	 and	 thus	 requires	 repeated	administration	to	achieve	a	persistent	knockdown	effect301.		
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Figure	 7	 Mechanism	 of	 siRNA-mediated	 gene	 silencing.	 Once	 in	 the	 cytoplasm,	
double	 stranded	 small	 interfering	 RNA	 (siRNA)	 is	 incorporated	 into	 the	
RNA-induced	 silencing	 complex	 (RISC).	The	 sense	 strand	 is	 cleaved,	 resulting	 in	
an	 activated	 RISC-siRNA	 complex	 containing	 the	 antisense	 strand.	The	activated	
RISC	complex	seeks	out,	binds	to	and	cleaves	the	complementary	RNA,	leading	to	
the	knockdown	of	the	target	gene.	The	activated	RISC	complex	is	then	recycled	for	
continued	 destruction	 of	 identical	 mRNA	 targets.	 Adapted	 from	 Whitehead	 et	
al.457.	
In	vitro	siRNA	transfection	was	utilised	in	this	study	to	transiently	suppress	the	high	priority	genes	BCL3	and	CLU	to	allow	investigation	of	cell	growth,	cell	cycle	distribution	 and	 apoptosis	 to	 determine	 whether	 such	 knockdown	 promoted	the	 survival	 of	 antihormone-responsive	 and	 –resistant	 cells	 and	 ultimately	contributed	 to	 the	 development	 of	 resistance.	 Cells	 were	 seeded	 into	 60	mm	dishes	(3	x	105	cells)	in	experimental	media	(see	section	2.1.2)	and	grown	until	approximately	 60%	 confluency	 was	 reached	 before	 being	 transferred	 into	antibiotic-free	 experimental	 medium	 for	 1	 hour	 prior	 to	 siRNA	 transfection.	Transfections	 were	 performed	 according	 to	 the	 manufacturer’s	 instructions	
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(Dharmacon	 RNA	 Technologies,	 Lafayette,	 CO,	 USA).	 siRNA	 (Table	 7)	 were	diluted	to	a	working	stock	concentration	of	20	µM	in	sterile	Dharmacon	RNase	free	 1	 x	 siRNA	 buffer.	 The	 siRNA	 were	 then	 mixed	 with	 DharmaFECT	 1	transfection	reagent	(Dharmacon,	GE	Healthcare,	UK)	at	a	ratio	of	20	µl	siRNA:	1	µl	 transfection	 reagent	 and	 incubated	 at	 room	 temperature	 for	 20	 minutes,	allowing	 the	 formation	 of	 siRNA-containing	 micelles.	 The	 cell	 medium	 was	discarded	 and	 replaced	 with	 fresh	 antibiotic-free	 experimental	 medium	 to	which	 the	 siRNA	 transfection	 reagent	 mix	 was	 added	 to	 give	 a	 final	 siRNA	concentration	of	 100	nM	per	dish.	 Control	 experiments	 comprised	of	medium	only,	 DharmaFECT	 1	 transfection	 reagent	 only	 and	 transfection	 with	 a	 non-targeting	scrambled	control	siRNA	(100	nM	per	dish).	Cells	were	incubated	for	4	days	 prior	 (unless	 stated	 otherwise)	 to	 RNA	 and	 protein	 lysis	 for	 subsequent	RT-PCR	 and	Western	 blot	 analysis	 (as	 described	 in	 sections	 2.2,	 2.4	 and	 2.5).	Fulvestrant	(100	nM)	was	added	to	MCF-7	and	T47D	cells	48	hours	post	siRNA	transfection	for	the	remaining	2	day	incubation	period.		
Table	7	Target	siRNA,	source	and	product	number.	
Target	siRNA	 Source	 Product	Number	
ON-TARGETplus	
Human	BCL3	
Dharmacon,	GE	Healthcare,	UK	 L-003874-00-0020	
ON-TARGETplus	
Human	CLU	
Dharmacon,	GE	Healthcare,	UK	 L-019513-00-0010	
ON-TARGETplus	Non-
targeting	(control)	
Dharmacon,	GE	Healthcare,	UK	 D-001810-10-20	
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2.6.2 Flow	cytometry	Flow	cytometry	is	a	laser-based	technique	that	allows	rapid	analysis	of	multiple	characteristics	of	single	cells,	including	cell	size,	DNA	or	RNA	content	and	a	wide	range	of	membrane-bound	and	intracellular	proteins.	Briefly,	a	cell	suspension	(containing	fluorochrome-labelled	target	proteins)	is	injected	into	the	flow	cell	and	 drawn	 into	 a	 stream	 of	 single	 cells	 created	 by	 the	 surrounding	 sheath	 of	isotonic	fluid	(as	shown	in	Figure	8).	Upon	arrival	at	the	interrogation	point,	a	laser	beam	intersects	each	cell	individually.	Scattered	laser	light	and	fluorescent	emissions	 are	 collected	 by	 several	 detectors.	 The	 forward	 scatter	 channel	collects	 light	 scattered	 in	a	 forward	direction	and	 is	 indicative	of	 cell	 size	and	the	side	scatter	light,	detected	by	the	side	scatter	channel,	relates	to	the	internal	structure	(granularity)	of	the	cell.	Fluorescent	emissions	(of	known	wavelength	from	excited	fluorochromes)	are	directed	through	a	series	of	filters	according	to	their	wavelength	 towards	 the	appropriate	detector.	The	detectors	generate	an	electrical	signal	that	is	sent	to	the	computer	for	analysis.		
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2.6.2.1 Apoptosis	assay	An	 Annexin	 V-FITC	 and	 propidium	 iodide	 (PI)	 apoptosis	 detection	 kit	(eBioscience	 Ltd,	 UK)	 was	 used	 to	 examine	 apoptosis.	 Briefly,	 upon	 the	acquisition	 of	 apoptosis,	 cells	 lose	 membrane	 phospholipid	 asymmetry	 and	phosphatidylserine	 (PS)	 is	 translocated	 from	 the	 inner	 to	 the	outer	 surface	of	the	plasma	membrane.	Annexin	V	is	a	calcium-dependent	phospholipid-binding	protein	 that	 has	 a	 high	 affinity	 for	 PS.	 Thus,	 annexin	 V	 labelled	 with	 a	fluorochrome	 (e.g.	FITC)	binds	PS	exposed	on	 the	outer	 surface	of	 the	plasma	membrane	which	can	be	detected	by	flow	cytometry.	Counterstaining	with	the	nucleic	acid	binding	dye	PI	allows	the	discrimination	of	early	apoptotic	and	late	apoptotic/dead	cells.	PI	is	impermeant	to	viable	cells,	however	during	late	stage	apoptosis	the	loss	of	membrane	integrity	allows	the	uptake	of	PI	which	binds	to	the	nucleic	acids	and	stains	dead	cells	with	red	fluorescence	which	is	detected	by	flow	cytometry.	
Figure	 8	 Flow	 cytometer.	 Cells	 injected	 into	 the	 flow	 cell	 are	 hydrodynamically	
focussed	by	the	surrounding	sheath	fluid	to	generate	a	stream	of	single	cells.	The	
laser	beam	interrogates	each	cell	individually	and	a	series	of	detectors	collect	the	
scattered	light	and	fluorescence	emissions	 to	generate	an	electrical	signal	which	
is	sent	to	the	computer	for	analysis.	FSC;	forward	scatter	channel,	SSC:	side	scatter	
channel.		
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The	 adherent	 cells	 were	 collected	 by	 trypsinisation	 (see	 section	 2.1.1)	 and	combined	 with	 the	 non-adherent	 cells	 present	 in	 the	 medium	 prior	 to	centrifugation	 for	 5	 minutes	 at	 1000	 rpm.	 The	 cell	 pellet	 (containing	approximately	 5	 x	 105	 cells)	 was	 re-suspended	 in	 1	 ml	 of	 binding	 buffer	(Annexin	 V-FITC	 apoptosis	 detection	 kit,	 eBioscience	 Ltd,	 UK)	 and	 passed	through	a	25G	needle	and	syringe	to	ensure	a	single	cell	suspension.	The	cells	were	centrifuged	for	5	minutes	at	1000	rpm	prior	to	a	second	wash	in	binding	buffer	to	remove	any	residual	trypsin	that	may	inhibit	annexin	V	staining.	The	cell	pellet	was	re-suspended	in	200	µl	of	binding	buffer.	Annexin	V-FITC	(5	µl;	Annexin	V-FITC	apoptosis	detection	kit,	eBioscience	Ltd,	UK)	was	added	to	185	µl	 of	 the	 cell	 suspension	 and	 incubated	 for	 10	minutes	 at	 room	 temperature	prior	 to	 the	 addition	 of	 10	 µl	 of	 PI	 (20	 µg/ml;	 Annexin	 V-FITC	 apoptosis	detection	kit,	eBioscience	Ltd,	UK).	The	samples	(20,000	events)	were	analysed	by	an	Accuri	C6	flow	cytometer	and	CFlow	Plus	software	(BD,	UK).	Forward	and	side	 scatter	 plots	were	 used	 for	 gating	 cells,	 excluding	 debris	 and	 identifying	any	changes	in	the	scatter	properties	of	the	cells	(as	shown	in	Figure	9A).	This	gate	 was	 applied	 to	 PI	 versus	 annexin	 V-FITC	 plots	 with	 quadrant	 gates	 to	determine	 the	 populations	 corresponding	 to	 viable	 (annexin	 V-/PI-),	 early	
	
Figure	9	Cytometry	gating	for	apoptosis.	Forward	scatter	channel	–	area	(FSC-A)	versus	
side	scatter	channel	–	area	(SSC-A)	plots	were	used	to	gate	the	cells	and	exclude	debris	
(A).	 This	 gate	 was	 applied	 to	 annexin	 V-FITC	 –	 area	 (annexin	 V-FITC-A)	 versus	
propidium	iodide	–	area	(PI-A)	plots	 (B).	The	quadrant	gates	show	the	populations	of	
cells	corresponding	 to	viable	 (Annexin	V-/PI-;	Q2-LL),	early	apoptotic	 (annexin	V+/PI-;	
Q2-LR)	and	late	apoptotic/dead	(annexin	V+/PI+;	Q2-UR)	cells.	Annexin	V-/PI+	cells	are	
also	gated	(Q2-UL).	
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apoptotic	 (Annexin	 V+/PI-)	 and	 late	 apoptotic/dead	 (Annexin	 V+/PI+)	 cells	(Figure	9B).		Positive	 control	 cells	 were	 treated	 with	 the	 apoptosis	 inducer	 thapsigargin	(1	µM	diluted	in	dimethyl	sulfoxide)	48	hours	prior	to	analysis.	Thapsigargin	is	an	 inhibitor	 of	 the	 sarcoendoplasmic	 reticulum	 calcium	 ATPase	 and	 as	 such	blocks	 the	 ability	 of	 these	pumps	 to	 transfer	 calcium	 from	 the	 cytoplasm	 into	the	endoplasmic	reticulum.	The	endoplasmic	reticulum	calcium	stores	become	depleted	 and	 in	 turn	 induces	 endoplasmic	 reticulum	 stress	 which	 ultimately	leads	to	cell	death.	
2.6.2.2 Cell	cycle	distribution	Cell	 cycle	 was	 monitored	 by	 measuring	 DNA	 content	 using	 the	 DNA-binding	fluorescent	dye	PI	which	is	detected	by	flow	cytometry.	Analysis	of	DNA	content	reveals	the	percentage	of	cells	in	the	G1,	S	and	G2/M	phases	of	the	cell	cycle	(as	detailed	 in	 Figure	 10).	 Initially,	 cells	 are	 fixed/permeabilised	 with	 ethanol	 to	allow	entry	of	PI.	However,	since	PI	also	stains	double	stranded	RNA,	the	cells	are	pre-treated	with	RNase	for	optimal	DNA	resolution	before	staining	with	PI.	The	 cell	 medium	 was	 removed	 and	 the	 cells	 (approximately	 1	 x	 106)	 were	harvested	by	trypsination	(detailed	in	2.1.1).	The	cell	pellet	was	washed	by	re-suspending	in	5	ml	of	PBS	followed	by	centrifugation	for	5	minutes	at	1000	rpm.	The	 supernatant	was	 discarded	 and	 the	 cell	 pellet	was	washed	 a	 further	 two	times.	The	cell	pellet	was	re-suspended	in	1ml	of	PBS	and	transferred	to	a	5	ml	polypropylene	tube.	Cold	absolute	ethanol	(1	ml)	was	added	to	the	cells	which	were	 then	 passed	 through	 a	 25G	 needle	 and	 syringe	 to	 ensure	 a	 single	 cell	suspension	and	prevent	cell	clumping.	The	cells	were	fixed	for	at	least	24	hours	at	 -20°C.	 The	 cells	 were	 then	 washed	 twice	 in	 5	 ml	 of	 PBS	 followed	 by	centrifugation	at	2000	rpm	for	5	minutes.	The	cell	pellet	was	re-suspended	in	50	µl	of	RNase	A	stock	solution	(10	µg/ml)	and	incubated	at	37°C	for	45	minutes.	PI	staining	solution	(300	µl	of	50	µg/ml	PI	in	PBS)	was	next	added	and	the	samples	(50,000	events)	were	analysed	by	an	Accuri	C6	flow	cytometer	and	CFlow	Plus	software	(BD,	UK).	Cell	gating	to	exclude	cell	doublets	and	debris	was	applied	to	the	 PI	 histogram	 plot	 (Figure	 11).	 The	 percentage	 of	 cells	 in	 each	 cell	 cycle	phase	was	determined	by	gating	each	phase	individually.	
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Figure	10	Relationship	between	 the	 cell	 cycle	 and	 the	DNA	 content	 represented	by	 a	
histogram.	 (A)	 Phases	 of	 the	 cell	 cycle:	 at	 G1,	 the	 interval	 between	 mitosis	 and	
initiation	of	DNA	replication,	 the	cells	are	diploid	(2n).	As	 the	cells	enter	 the	S	phase,	
DNA	 replication	 begins	 and	 the	 DNA	 content	 increases	 from	 2n	 to	 4n.	 DNA	 content	
remains	 at	 4n	 in	 the	 G2	 and	 M	 phase	 decreasing	 to	 2n	 after	 cytokinesis.	 (B)	
Demonstrative	 histogram	 of	 cell	 number	 versus	 DNA	 content.	 DNA	 content	 is	
determined	 by	 the	 fluorescence	 intensity	 of	 propidium	 iodide-labelled	DNA	 detected	
by	 flow	 cytometry.	 The	 distribution	 shows	 two	 peaks	 equivalent	 to	 cells	 with	 DNA	
contents	of	2n	and	4n;	these	cells	are	in	G1	and	G2/M	phase	of	the	cycle,	respectively.	
The	cells	in	S	phase	have	DNA	contents	between	2n	and	4n	and	are	distributed	between	
these	two	peaks.	
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2.6.3 Cell	counting	Cells	were	seeded	into	24	well	plates	at	a	density	of	3	x	104	cells	per	well	in	1	ml	of	experimental	media	(detailed	in	2.1.2).	Once	approximately	60%	confluencey	was	reached,	siRNA	(100	nM)	±	fulvestrant	(100	nM)	(as	detailed	in	2.6.1)	were	added	in	triplicate	to	antihormone	responsive	and	resistant	cell	lines.	The	cells	were	counted	following	four	days	of	incubation.	The	medium	was	removed	and	the	 cells	 were	 washed	 three	 times	 with	 1	 ml	 of	 tissue	 culture	 grade	 PBS.	Trypsin/EDTA	 (250	 µl)	 was	 added	 to	 each	 well	 and	 once	 the	 cells	 had	completely	 detached	 (approximately	 3	 to	 5	 minutes	 in	 the	 37°C/5%	 CO2	incubator),	750	µl	of	appropriate	medium	was	added	to	each	well	to	neutralise	the	trypsin/EDTA	solution.	The	cells	were	passed	through	a	sterile	25G	syringe	
Figure	11	Cytometry	gating	for	cell	cycle	phases.	Side	scatter	channel	–	area	(SSC-
A)	versus	forward	scatter	channel	–	area	(FSC-A),	FSC-height	(FSC-H)	versus	FSC-A	
and	propidium	iodide	–	area	(PI-A)	versus	FSC-A	plots	were	used	to	gate	the	cells	
and	exclude	debris	and	cell	doublets	(A).	Histogram	plot	of	cell	count	versus	PI-A	
(C)	 from	 the	 gated	 cells	 shows	 the	 population	 of	 cells	 in	 each	 stage	 of	 the	 cell	
cycle.	The	percentage	of	 cells	 in	each	cell	 cycle	phase	was	determined	by	 gating	
each	phase	individually	(B).	
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needle	twice	to	ensure	a	single	cell	suspension.	The	cell	number	was	measured	by	an	automated	cell	counter	(see	section	2.1.2).		
2.6.4 Immunofluorescence		Cells	 were	 seeded	 into	 6	 well	 plates	 containing	 0.13-0.17	 mm	 thick	 glass	coverslips	(VWR	microscope	cover	glasses	22	x	22	mm,	No.1,	VWR	International	Ltd,	UK)	at	a	density	between	1.5	–	2	x	105	/	well	 in	1.5	ml	media	(detailed	in	2.1.2).	MCF-7	 and	T47D	 cells	were	 allowed	 to	 adhere	 to	 the	 coverslips	 for	 24	hours	prior	 to	 the	addition	of	 control	and	antihormone	 treatments	 for	7	days.	The	 resistant	 and	 wild-type	 control	 cells	 were	 allowed	 to	 grow	 until	 they	reached	 approximately	 60-70%	 confluency.	 After	 incubation,	 the	 media	 was	removed	and	the	cells	were	fixed	with	3.7%	formaldehyde	(diluted	in	PBS)	for	15	 minutes.	 Cells	 were	 then	 washed	 with	 PBS	 two	 times	 before	 being	permeabilised	by	incubation	in	PBS	containing	1%	BSA	and	0.4%	saponin	for	15	minutes.	 Cells	 were	 blocked	 in	 10%	 normal	 goat	 serum	 (Dako	 normal	 goat	serum	X0907,	Dako	UK	Ltd)	(diluted	in	1%	BSA	and	0.4%	saponin	in	PBS)	for	15	minutes	to	prevent	non-specific	antibody	binding.	The	cells	were	then	incubated	in	two	primary	antibodies	simultaneously,	one	from	mouse	and	the	other	from	rabbit	host	species,	(diluted	in	PBS	containing	1%	BSA	and	0.4%	saponin;	Table	8)	 for	 1	 hour.	 Cells	 were	 washed	 three	 times	 with	 PBS	 prior	 to	 30	 minute	incubation	 in	 the	 dark	 with	 fluorophore-conjugated	 secondary	 antibodies	(Table	 8)	 diluted	 1:1000	 in	 PBS	 containing	 1%	 BSA	 and	 0.4%	 saponin.	Coverslips	were	drained	and	mounted	onto	glass	slides	(SuperFrost	Plus	glass	microscope	 slides,	 Menzel-Glӓser,	 Germany	 supplied	 by	 Thermo	 Fisher,	 UK)	using	 Vectashield	 mounting	 medium	 containing	 DAPI	 (4’,	 6-diamidino-2-phenylindole)	 nuclear	 counterstain.	 The	 cells	 were	 viewed	 on	 a	 Leica	fluorescent	microscope	(Leica	DMil,	Leica	Microsystemt	Ltd,	Milton	Keynes,	UK)	at	x63	magnification	under	an	oil	immersion	(Zeiss	immersion	oil,	Thermofisher	Scientific,	UK)	and	analysed	by	OpenLab	software	(PerkinElmer,	UK).	
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Table	 8	 Primary	 and	 secondary	 antibodies	 used	 for	 immunofluorescence	 with	
their	 corresponding	 dilution,	 conjugate	 where	 applicable,	 species,	 source	 and	
product	number	Target	 Dilution	 Conjugate	 Species	 Source	 Product	Number	BCL3	 1:250	 	 Rabbit		 SCBT	 sc-185	CLU	 1:250	 	 Mouse	 SCBT	 sc-5289	p50	 1:250	 	 Rabbit	 SCBT	 sc-7178	p50	 1:500	 	 Mouse	 NB	 NBP2-22178	Anti-rabbit	IgG	 1:1000	 Alexa	Fluor	488	 Goat	 Thermofisher	Scientific,	UK	 A-11034	Anti-mouse	IgG	 1:1000	 Alexa	Fluor	594	 Goat	 Thermofisher	Scientific,	UK	 A-11032	
SCBT:	Santa	Cruz	Biotechnology,	NB:	Novus	Biologicals.		
2.6.5 Immunoprecipitation		Immunoprecipitation	is	a	method	used	to	purify	a	protein	of	interest	or	group	of	proteins	 from	 a	 complex	 mixture	 using	 a	 specific	 antibody	 immobilised	 to	 a	solid	support.	Within	this	project,	immunoprecipitation	was	used	to	investigate	proteins	 interacting	 with	 the	 protein	 of	 interest.	 Briefly,	 an	 antibody	 is	incubated	with	protein	cell	lysate	to	allow	an	immune	complex	to	form	with	the	antigen	it	recognises.	The	antibody/antigen	complex	is	then	captured	on	a	solid	support	 (e.g.	 agarose)	with	 immobilised	 Protein	 A	 (IgG	 binding	 protein).	 Any	proteins	 not	 bound	 by	 the	 Protein	 A	 are	washed	 away	 and	 the	 antigen	 along	with	 any	 proteins	 bound	 to	 it	 is	 eluted.	 This	 protein	 complex	 can	 then	 be	analysed	by	SDS-PAGE	and	Western	blotting.		Protein	 lysates	 (500	 µg)	 were	 diluted	 in	 500	 µl	 of	 ice	 cold	 lysis	 buffer	 (see	section	2.5.1)	containing	cocktail	protease	inhibitor	and	1	mM	of	PMSF	diluted	in	 isopropanol	 and	 incubated	with	 1	 µg	 of	 primary	 antibody	 for	 1	 hour	with	rotation	at	4°C	 to	allow	 formation	of	antibody/antigen	complexes.	Meanwhile,	protein	A	agarose	beads	were	washed	and	prepared	 for	 immunoprecipitation.	The	beads	(30	µl)	were	aliquoted	into	eppendorf	tubes	and	resuspended	in	750	µl	of	ice	cold	lysis	buffer	then	centrifuged	for	1	minute	at	10,000	rpm	at	4°C.	The	
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supernatant	was	 decanted	 and	 this	wash	 step	was	 repeated	 two	more	 times.	After	the	final	wash	the	supernatant	was	removed	and	the	bead	pellet	kept	on	ice.		The	antibody/antigen	complexes	were	added	to	30	µl	of	the	prepared	beads	and	incubated	for	2	hours	with	rotation	at	4°C,	to	allow	the	complexes	to	bind	to	the	beads	via	Protein	A,	prior	to	storage	overnight	at	-20°C.	The	samples	were	then	centrifuged	 at	 10,000	 rpm	 for	 2	 minutes	 at	 4°C	 and	 the	 supernatant	 was	carefully	removed.	The	bead	pellet	was	washed	three	times	by	adding	750	µl	of	ice	 cold	 lysis	 buffer,	 vortexed	 briefly,	 allowed	 to	 stand	 for	 5	 minutes	 on	 ice,	followed	by	centrifugation	as	above.	After	 the	 final	wash,	 the	supernatant	was	removed	and	the	pellet	was	resuspended	in	60	µl	of	2	X	Lamelli	sample	loading	buffer	 (see	 section	 2.5.4,	 except	 supplemented	 with	 3.08	 %	 w/v	 DTT)	 and	vortexed	 prior	 to	 incubation	 at	 70°C	 for	 15	 minutes	 to	 release	 the	 immune	complexes	from	the	beads.	The	samples	were	vortexed	again	and	centrifuged	at	13,000	rpm	for	2	minutes.	The	supernatant	containing	the	immunoprecipitated	proteins	 was	 collected	 and	 separated	 by	 SDS-PAGE	 followed	 by	 Western	blotting.	
2.6.6 Statistical	analysis	Data	were	analysed	using	GraphPad	Prism	(GraphPad	Software,	Inc.	USA).	The	specific	statistical	analyses	utilised	are	detailed	in	each	results	Chapter.	Data	are	expressed	 as	 mean	 ±	 SEM	 and	 a	 p	 value	 	 <0.05	 was	 considered	 statistically	significant.		
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3 Results	I:	Identification	and	validation	of	antihormone-induced	pro-survival	genes	in	MCF-7	cells	
3.1 	Introduction	Antihormones	 are	 the	 mainstay	 therapy	 for	 ER+	 breast	 cancer	 and	 have	contributed	 to	a	substantial	decrease	 in	mortality	over	recent	decades.	However,	resistance	remains	a	significant	clinical	problem,	with	40%	of	such	tumours	in	the	adjuvant	 setting	 and	 virtually	 all	 patients	 with	 advanced	 disease,	 acquiring	resistance	 to	 these	 therapies.	 Surprisingly,	 the	 majority	 of	 oestrogen-regulated	genes	in	human	breast	cancer	cells	are	repressed	and	many	of	these	genes	act	as	growth	 and/or	 transcriptional	 repressors38.	 Thus,	 the	 benefit	 of	 antihormone	therapy	 arises	 from	 their	 ability	 to	 induce	 the	 expression	 of	 these	 negative	regulators	 of	 cell	 proliferation.	 Indeed,	 the	 main	 mechanism	 of	 action	 of	antihormones	is	to	 inhibit	cell	proliferation,	however	they	are	unable	to	promote	significant	levels	of	cell	death216.	Paradoxically,	more	recent	research	has	revealed	that	oestrogens	 can	 suppress,	 and	antihormones	 induce,	 genes	 that	promote	 cell	proliferation	and	survival197,216,259.	Furthermore,	antihormones	have	the	ability	to	rapidly	 induce	 “compensatory”	 signal	 transduction	 pathways	 to	 promote	 cell	survival302.	 Critically,	 such	 “reprogramming”	 of	 intracellular	 signalling	 networks,	induced	by	antihormones,	may	allow	a	cohort	of	cells	to	escape	the	initial	growth	inhibitory	 actions	 of	 these	 agents	 and	 ultimately	 drive	 acquired	 resistant	 cell	growth.		Clearly,	 the	 ultimate	 marker	 of	 antihormone	 resistance	 is	 the	 loss	 of	 the	 drug	target	 i.e.	 ER303.	 However,	 there	 are	 currently	 very	 few	 markers	 predicting	 the	degree	 and	 duration	 of	 patient	 response	 and	 the	 acquisition	 of	 resistance.	 Such	markers	 have	 been	 identified	 by	 comparing	 endocrine	 resistant	 cell	 models	 to	their	wild	type	counterparts.	For	example,	increased	expression	of	EGFR	and	HER2	receptors	 has	 been	 demonstrated	 in	 tamoxifen-resistant	 cells	 versus	 tamoxifen-responsive	 wild	 type	 MCF-7	 cells185.	 Furthermore,	 increased	 EGFR/HER2	heterodimerisation	 and	 receptor	 phosphorylation	 and	 consequently	 increased	
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activation	 of	 downstream	 kinases	 ERK	 1/2	 MAP	 kinase	 and	 AKT,	 previously	implicated	 in	 cell	 proliferation	 and	 survival,	 has	 been	 reported	 in	 these	tamoxifen-resistant	cells	compared	to	wild	type185,263.	In	support	of	these	findings,	Miller	 et	 al.	 have	 also	 reported	 increased	 activity	 of	 AKT	 signalling	 in	 oestrogen	deprivation-resistant	cell	lines	versus	wild	type296.	Although	several	studies	have	identified	alterations	in	signalling	pathways	utilised	by	 endocrine	 resistant	 cell	 models	 compared	 to	 endocrine	 sensitive	 wild	 type	counterparts,	 more	 recent	 studies	 addressing	 the	 temporal	 changes	 in	 the	genotype/phenotype	 directly	 associated	 with	 the	 acquisition	 of	 resistance	 are	emerging.	 Indeed,	 the	 pro-proliferative	 genes,	 EGFR	 and	 HER2,	 have	 been	established	as	oestrogen-suppressed	and	antihormone-induced	 in	a	panel	of	ER+	breast	 cancer	 cell	 lines.	 Short-term	 tamoxifen	 treatment	 has	 been	 shown	 to	increase	EGFR	and	HER2	expression	in	vitro	and	in	vivo	MCF-7	cell	models	of	ER+	breast	 cancer,	 with	 subsequent	 downstream	 activity	 of	 cell	 survival	 and	proliferation	pathways216,217.	Such	signalling	may	allow	cells	 to	escape	 inhibition,	thus	 supporting	 the	 partial	 inhibitory	 effects	 on	 proliferation	 and	 minimal	 cell	death	 promoted	 by	 this	 antihormone.	 Indeed,	 targeting	 of	 these	 receptors	 in	conjunction	 with	 tamoxifen	 suppressed	 downstream	 residual	 kinase	 signalling	activity,	greatly	enhanced	the	anti-tumour	activity	of	this	antihormone	and	delayed	the	acquisition	of	resistance216,217.	Furthermore,	increased	expression	of	EGFR	and	HER2	and	substantial	downstream	kinase	activity	was	maintained	through	to	the	emergence	of	resistance216,217,	suggesting	that	early	 tamoxifen-induced	EGFR	and	HER2	 expression	 limits	 the	 anti-tumour	 response	 and	 provides	 protective	mechanisms	 to	a	 cohort	of	 cells	 from	which	 resistance	 subsequently	emerges.	 In	addition	to	the	well-characterised	EGFR	and	HER2	genes,	antihormones	have	been	shown	 to	 induce	 expression	 of	 pro-invasive	 genes	 (RhoE	 and	 δ-catenin),	 with	expression	maintained	through	to	the	acquisition	of	resistance304.	Such	genes	may	contribute	to	the	small	inductive	effect	of	invasiveness	observed	in	MCF-7	cells	in	the	presence	of	antioestrogens305.		There	 is	now	considerable	evidence	 implicating	 the	role	of	antihormone-induced	pro-proliferative	 genes	 in	 endocrine	 resistance,	 however	 the	 role	 played	 by	antihormone-induced	pro-survival	genes	remains	largely	unexplored.	Importantly,	
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identification	 of	 early	 antihormone-induced	pro-survival	 genes	may	 reveal	 novel	biomarkers	 predictive	 of	 response	 and	 underlying	 mechanisms	 involved	 in	resistance,	which	may	lead	to	the	identification	of	potential	therapeutic	targets	to	improve	 antihormone	 response	 and	 prevent	 the	 establishment	 of	 the	 resistant	phenotype.	Thus,	the	purpose	of	the	work	described	in	this	thesis	is	to	identify	and	characterise	 antihormone-induced	 pro-survival	 genes	 involved	 in	 limiting	response	and	promoting	the	acquisition	of	resistance.	Tamoxifen,	 fulvestrant	and	oestrogen	deprivation	treatments	were	examined	to	determine	whether	common	resistant-promoting	 genes	 are	 induced	 by	 all	 three	 clinically	 used	 treatments.	Furthermore,	 4	 ER+	 breast	 cancer	 cell	 lines	 (HER2-:	 MCF-7	 and	 T47D;	 HER2+:	BT474	and	MDA-MB-361)	were	utilised	to	consider	an	aspect	of	heterogeneity	that	exists	 in	ER+	breast	cancer	and	also	 to	determine	whether	antihormone-induced	mechanisms	of	acquired	hormone-independent	growth	are	common	across	several	cell	lines	and	molecular	subtypes	including	HER2-	and	HER2+	disease.	In	this	Chapter,	microarray	gene	expression	profiling	has	been	utilised	to	identify	antihormone-induced	 pro-survival	 genes	 in	 MCF-7	 cells	 during	 response	 with	increased	expression	maintained	in	to	cell	models	of	endocrine	resistance.		It	was	hypothesised	 that	 antihormone-induced	 expression	 of	 these	 pro-survival	 genes	early	 during	 response	may	 limit	 the	 pro-apoptotic	 actions	 of	 antihormones	 and	allow	 a	 cohort	 of	 cells	 to	 evade	 the	 growth	 inhibitory	 actions	 of	 these	 agents,	resulting	 in	 anti-tumour	 responses	 of	 finite	 duration	 and	 ultimately	 the	development	 of	 resistance.	 Microarray	 technologies	 allow	 thousands	 of	 mRNA	transcripts	 to	 be	 examined	 simultaneously,	 creating	 a	 genome-wide	 gene	expression	 profile.	 Such	 profiling	 has	 proved	 very	 successful	 in	 breast	 cancer	research.	 Indeed,	 microarray	 studies	 identified	 the	 heterogeneity	 that	 exists	 in	breast	 cancer	 and	 demonstrated	 that	 breast	 cancer	 is	 a	 collection	 of	 distinct	diseases	 affecting	 the	 same	 anatomical	 site277.	 Furthermore,	 microarray	 gene	expression	 profiling	 has	 been	 utilised	 in	 breast	 cancer	 studies	 to	 investigate	overexpressed	 genes	 that	 may	 be	 involved	 in	 disease	 progression306,	 gene	signatures	predictive	of	clinical	outcome283,307	and	tumour	aggressiveness308.	Such	studies	have	 led	to	the	development	of	commercially	available	genomic	assays	to	predict	 clinical	 outcome	 in	 breast	 cancer	 patients.	 For	 example,	 the	OncotypeDX	
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assay	 measures	 the	 expression	 of	 a	 21-gene	 panel,	 consisting	 of	 ER,	 HER2,	ER-regulated	genes	and	several	proliferative	genes,	 to	estimate	the	probability	of	recurrence	 at	 10	 years	 and	 to	 stratify	 patients	 into	 low-,	 intermediate-	 and	high-risk	cohorts280.	Furthermore,	studies	have	demonstrated	that	patients	in	the	high-risk	category	are	likely	to	respond	to	adjuvant	chemotherapy	combined	with	endocrine	 treatment.	 Since	 the	 majority	 of	 patients	 with	 early	 breast	 cancer	receive	adjuvant	chemotherapy,	 this	assay	would	prevent	those	patients	who	are	likely	to	obtain	low/no	benefit	from	receiving	unnecessary	treatment	and	critically	being	affected	by	its	toxicity281.		However,	such	assays	provide	only	prognostic	data	and	fail	to	identify	therapeutic	targets	that	may	improve	response.	Furthermore,	there	are	no	gene	signatures	to	distinguish	endocrine	sensitive	from	resistant	patients	or	signatures	predictive	of	antihormone	 response.	 A	 limited	 number	 of	 studies	 have	 employed	 global	 gene	expression	 profiling	 combined	 with	 antihormone	 therapy	 during	 response	 to	potentially	identify	drug-induced	molecular	signatures	that	serve	to	limit	response	and	 ultimately	 are	 involved	 in	 the	 acquisition	 of	 resistance.	 Cappelletti	 et	 al.	utilised	microarrays	to	define	a	gene	expression	profile	associated	with	toremifene	response	in	ER+	breast	cancer	patients	and	to	identify	potential	genes	modulated	by	 neo-adjuvant	 toremifene	 treatment	 which	 may	 be	 involved	 in	 antihormone	resistance	 mechanisms309.	 Indeed,	 this	 study	 identified	 a	 53-gene	 signature	significantly	related	to	treatment	response	and	more	importantly	identified	genes	(including	 MAPK6	 and	 MMP2)	 modulated	 by	 toremifene	 treatment	 in	non-responding	patients	which	are	likely	to	be	involved	in	resistance.	The	aims	of	this	Chapter	were	to	(i)	recapitulate	in	part	the	study	by	Cappelletti	et	al.	and	utilise	microarray	gene	expression	profiling	to	examine	whether	any	genes	with	 known	 pro-survival	 ontology	 are	 induced	 in	 response	 to	 a	 range	 of	antihormones	in	ER+	MCF-7	cell	lines,	(ii)	identify	those	genes	that	are	common	to	all	 antihormones	 and	 (iii)	 examine	 whether	 these	 genes	 are	 also	 expressed	 at	increased	 levels	 in	 endocrine-resistant	 MCF-7	 cell	 lines	 to	 potentially	 implicate	such	genes	in	the	development	of	resistance.	It	was	hoped	that	novel	drug-induced	genes	 that	 may	 subsequently	 limit	 response	 and	 contribute	 to	 the	 adverse	
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resistant	phenotype	could	be	revealed	and	ultimately	 lead	to	the	 identification	of	novel	therapeutic	options	for	such	patients.		
3.2 	Methods	
3.2.1 Microarray	analysis	Microarray	gene	expression	profiling,	 as	described	 in	 section	2.2,	was	completed	for	 10	day	 antihormone-treated	 (tamoxifen,	 falsodex	 and	 oestrogen	deprivation)	MCF-7	 cells,	 in	 addition	 to	 the	 associated	 MCF-7	 cell	 models	 of	 acquired	(short-term)	 endocrine	 resistance	 (TAMR,	 FASR	 and	 XR),	 versus	 E2-treated	 and	wild	type	control,	respectively.	The	cell	culture	methods	and	the	generation	of	the	resistant	cell	lines	are	detailed	in	section	2.1.		The	 resultant	 triplicate	 data	 were	 uploaded	 on	 to	 the	 online	 bioinformatics	software	 GeneSifter	 where	 the	 data	 were	 first	 median	 normalised	 and	 log	transformed	prior	to	analysis.	Heatmaps	and	log2-expression	intensity	plots	were	constructed	 to	 allow	 individual	 gene	 expression	 changes	 to	be	 investigated.	This	GeneSifter-assembled	 array	 resource	 was	 interrogated	 to	 identify	 robust	antihormone-induced	 expression	 of	 pro-survival	 genes	 (n=248;	 assembled	 using	ontology	 and	 website	 resources;	 Appendix	 Table	 15)	 during	 drug	 response	 and	was	 extended	 into	 cell	 models	 of	 antihormone-resistance	 to	 determine	whether	expression	of	such	genes	was	maintained	and	hence	may	contribute	substantially	to	the	emergence	of	resistance.	In	the	majority	of	cases,	each	gene	was	represented	by	more	than	one	probe	on	the	Affymetrix	gene	chip.	All	of	the	probes	for	the	genes	of	 interest	 were	 analysed	 to	 determine	 whether	 a	 consistent	 expression	 profile	was	achieved	across	all	probes	for	a	given	gene,	providing	further	confidence	that	any	antihormone-induced	change	in	expression	was	robust.	Particular	importance	was	 placed	 on	 the	 optimal	 ‘jetset’	 probe	 (detailed	 in	 section	 2.2.7).	 ANOVA	 and	post-hoc	 Tukey	 tests	 were	 used	 to	 analyse	 the	 differences	 between	 means.	 A	p	value	<0.05	was	considered	statistically	significant.	
3.2.2 RT-PCR	RT-PCR	(as	described	in	section	2.4)	was	performed	on	triplicate	RNA	from	10	day	E2-	and	antihormone-treated	MCF-7	cells	(cultured	under	the	same	conditions	as	
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those	used	 to	generate	 the	 samples	 for	microarray	gene	expression	profiling),	 to	verify	the	Affymetrix	expression	profiles	of	the	genes	of	interest.		
3.2.3 Ontological	investigation	of	the	genes	of	interest	identified	by	
microarray	analysis	Ontological	 studies	 were	 performed	 on	 the	 genes	 of	 interest	 to	 identify	 any	reported	 associations	with	 cancer,	 antihormone-response	 and	 –resistance	 in	 the	literature.	 Searches	 in	 Pubmed	 using	 the	 gene	 name/acronym	 combined	 with	keywords	 such	 as	 ‘breast	 cancer,’	 	 ‘antihormone,’	 ‘resistance’	 and	 ‘survival’	were	performed	to	generate	the	ontological	information	for	each	gene.	For	one	gene	in	particular,	such	studies	identified	genes/proteins	essential	for	the	function	of	this	gene	and	subsequently,	heatmaps	and	log2	profiles	were	generated	to	examine	the	profile	 of	 these	 essential	 genes	 in	 antihormone-treated	 MCF-7	 cells	 and	 the	resistant	cell	models.	
3.2.4 Western	blotting	The	 expression	 of	 the	 genes	 of	 interest	 was	 examined	 at	 the	 protein	 level	 by	Western	blotting.	Western	blotting	(as	described	in	section	2.5)	was	performed	on	triplicate	protein	 samples	 from	10	day	E2-	and	antihormone-treated	MCF-7	cells	(cultured	 under	 the	 same	 conditions	 as	 those	 used	 to	 generate	 the	 samples	 for	microarray	gene	expression	profiling	and	subsequent	RT-PCR).	
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3.3 Results	
3.3.1 Validation	of	antihormone-induced	repression	of	E2-regulated	genes	
and	subsequent	decrease	in	MCF-7	cell	proliferation	following	
short-term	treatment	The	 short-term	 effects	 of	 antihormones	 on	 E2-regulated	 genes	 and	 the	proliferation	of	hormone-responsive	MCF-7	 cells	have	previously	been	examined	within	the	group.	Indeed,	10	day	oestrogen	deprivation,	tamoxifen	and	fulvestrant	treatment	 of	 MCF-7	 cells,	 cultured	 under	 the	 same	 conditions	 as	 those	 used	 to	generate	the	gene	expression	profiles	 in	this	thesis,	resulted	in	a	depletion	of	the	E2-regulated	genes,	pS2	and	amphiregulin310;	thus	verifying	the	cells	as	hormone	responsive.	 Moreover,	 the	 group	 has	 previously	 shown	 that	 short-term	antihormone	 treatment	 exerts	 significant	 anti-proliferative	 effects,	 but	 promotes	only	 minimal	 cell	 death.	 Indeed,	 tamoxifen	 has	 been	 demonstrated	 to	 decrease	MCF-7	cell	growth	from	as	early	as	week	one,	which	reached	statistical	significance	(reducing	 by	 55%)	 by	 week	 two216.	 Concomitant	 decreases	 in	 the	 Ki67/MIB1	proliferation	marker	 and	 the	 percentage	 of	 cells	 in	 the	 S	 phase	 of	 the	 cell	 cycle,	with	an	 increase	 in	G0/G1	arrest	were	observed.	A	modest	 increase	 in	apoptosis	with	partial	suppression	of	the	cell	survival	protein,	BCL-2,	was	apparent	at	week	four	 of	 tamoxifen	 treatment216.	 In	 support	 of	 our	 studies,	 others	 have	 also	demonstrated	 tamoxifen-induced	anti-proliferative	effects	 in	MCF-7	cells	 from	as	early	 as	 24	 hours,	 together	 with	 marked	 accumulation	 of	 cells	 in	 G1	 and	 a	depletion	of	cells	in	the	S	phase	of	the	cell	cycle311,312.		Similarly,	 our	 group	 have	 previously	 demonstrated	 a	 statistically	 significant	decrease	 in	 MCF-7	 cell	 growth	 following	 seven	 days	 of	 fulvestrant	 treatment,	parallel	with	a	decrease	in	ER	protein	expression	and	associated	reductions	in	PR	mRNA	 and	 cyclin	 D1	 protein	 expression,	 indicative	 of	 a	 reduction	 in	 ER	transcriptional	activity262.	A	statistically	significant	decrease	in	MCF-7	cell	growth	following	 fulvestrant	 treatment	 has	 been	 reported	 from	as	 early	 as	 day	 three313.	Likewise,	 oestrogen	 deprived	 cells	 express	 lower	 protein	 levels	 of	 cyclin	 D1	compared	to	E2-treated	cells,	coincident	with	a	decrease	in	cell	proliferation	from	as	 early	 as	 30	 hours	 of	 treatment314.	 Together,	 these	 findings	 confirm	
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antihormone-induced	 repression	 of	 E2-regulated	 genes	 in	 MCF-7	 cells	 and	downstream	 repression	 of	 cell	 proliferation	 and	 regulation	 of	 cell	 cycle	 kinetics,	following	short-term	treatment.	
3.3.2 Confirmation	of	antihormone-induced	HER2	expression	using	the	
microarray	datasets	Initially,	to	validate	and	assess	the	quality	of	the	array	data,	expression	of	known	antihormone-induced	 gene,	 HER2,	 was	 examined.	 As	 predicted,	 the	 heatmap	presented	in	Figure	12A	shows	that	HER2	expression	was	statistically	significantly	(p	<0.05)	 induced	by	fulvestrant	and	oestrogen	deprivation	treatments,	with	fold	changes	>1.5,	versus	E2-treated	control	(Figure	12A,	B	&	C).	Tamoxifen	induced	a	small,	 non-significant,	 increase	 in	 HER2	 expression	 compared	 to	 E2-treated	control	(Figure	12A,	B	&	C).	
		 84	
	E2	 TAM	ED	
	 E2-
control	
ED	 TAM	 FAS	
Fold	change	 	 2.44	 1.44	 2.64		
A	
C	
Figure	12	Heatmap	(A)	and	log2	intensity	plot	(B)	displaying	the	normalised	(mean	of	
three	 independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 HER2	 (jetset	 probe	 ID:	
216836_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	 deprivation	 (ED),	 tamoxifen	 (TAM;	 10-7	M)	 and	 fulvestrant	 (FAS;	 10-7	 M).	
Red	denotes	 an	 increase	 in	 gene	expression	 compared	 to	 control	 (shown	 in	black).	
(C)	 Table	 displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 from	 the	
triplicate	samples.	*	p	<0.05	compared	to	E2-control.		
FAS	
B	
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3.3.3 Identification	of	pro-survival	genes	up	regulated	with	antihormone	
treatment	and	maintained	into	the	development	of	resistance	Following	 the	 validation	 of	 the	 quality	 of	 the	 array	 expression	 data	 and	confirmation	 that	 antihormones	were	 deregulating	 known	oestrogen-suppressed	genes	in	MCF-7	cells,	 the	expression	data	were	further	interrogated	to	determine	whether	pro-survival	genes	were	induced	by	antihormones	during	response,	with	expression	maintained	 into	 the	 acquisition	 of	 resistance.	 The	 pro-survival	 genes		(n=248)	were	subjected	to	a	stringent	filtering	process	to	maximise	identification	of	the	most	robust	antihormone-induced	proteins	(Figure	13).	Firstly,	the	heatmap	tool	 was	 utilised	 to	 identify	 genes	 up	 regulated	 by	 at	 least	 one	 antihormone	treatment	during	response,	with	increased	expression	also	reported	in	at	least	one	antihormone-resistant	 cell	 model	 (Appendix	 Table	 16).	 Additionally,	 all	 of	 the	probes	representing	each	gene	were	examined	 to	ensure	a	consistent	expression	profile	 was	 displayed.	 To	 filter	 the	 genes	 further,	 the	 detection	 calls	 were	 next	studied.	 The	detection	 call	 algorithms	 indicate	whether	 the	 expression	of	 a	 gene	transcript	 is	 reliably	 detected	 (as	 described	 in	 section	 2.2.7).	 Genes	 with	 a	‘marginal’	 or	 ‘present’	 detection	 call	 (signifying	 partial	 and	 reliable	 detection	 of	gene	expression	respectively)	in	at	least	one	antihormone	treatment	and	resistant	cell	line	were	selected	for	further	study.	Genes	exhibiting	an	‘absent’	detection	call,	indicating	unreliable	detection	of	expression,	were	dismissed	from	further	study.		Next,	the	heatmaps	of	the	remaining	genes	were	considered	to	ensure	that	the	up	regulation	induced	by	antihormones	was	maintained	into	the	associated	resistant	model	(e.g.	 induced	by	tamoxifen	during	response	with	maintained	expression	 in	TAMR	 cells).	 The	 remaining	 92	 genes	 (Appendix	 Table	 17)	 were	 exposed	 to	 an	ANOVA	and	post-hoc	tukey	statistical	test	to	identify	those	significantly	(p	<0.05)	up	 regulated	 by	 at	 least	 one	 antihormone	 treatment	 during	 response,	 to	 further	maximise	 the	 chances	 of	 determining	 robust	 induced	 expression	 changes	 with	antihormone	treatment	(n=17,	Appendix	Table	18).	Finally,	the	fold	change	tool	in	GeneSifter	 was	 utilised	 to	 identify	 genes	 with	 a	 greater	 than	 1.5	 fold	 change	induction	during	antihormone	treatment	versus	E2-treated	control.	Together,	this	stringent	filtering	process	identified	14	genes	significantly	up	regulated	by	at	least	one	 antihormone	 treatment	 during	 response,	 with	 expression	 maintained	 into	
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antihormone	 resistance.	 The	 magnitude	 of	 antihormone-induced	 expression	during	 response	 and	 expression	 in	 resistant	 cell	 models	 versus	 wild-type	 is	illustrated	by	the	heatmaps	shown	in	Figure	14	and	Figure	15.	Figure	16	to	Figure	30	further	illustrate	the	corresponding	intensity	profiles,	associated	detection	calls	and	fold	change	inductions	for	each	of	the	14	genes	identified.	The	optimal	‘jetset’	probe	was	used	to	generate	the	heatmap	and	intensity	profiles.		The	 Affymetrix	 expression	 profiles	 of	 the	 14	 high	 priority	 genes	 identified,	 and	hypothesised	 to	 contribute	 to	 the	 development	 of	 antihormone	 resistance,	were	verified	in	MCF-7	cells	during	antihormone	response	by	RT-PCR.	The	PCR	results	are	illustrated	alongside	the	intensity	profiles	in	Figure	16	to	Figure	30.		
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Survival	genes	(n=248)
Upregulated	by	at	least	one	
antihormone	treatment	and	in	at	
least	one	antihormone-resistant	
cell	line	(n=163)
Marginal	or	present	detection	call	
in	at	least	one	antihormone	
treatment	and	resistant	cell	line	
(n=96)
Upregulated	by	antihormone	
treatment	and	maintained	into	
appropriate	resistant	setting	(e.g.	
Tamoxifen	and	TAMR)	(n=92)
Significant	(ANOVA	and	post-hoc	
tukey)	in	at	least	one	
antihormone	treatment	versus	
control	(n=17)
Expression	fold	change	>1.5	with	
at	least	one	antihormone	
treatment	(n=14)
Figure	 13	 Flow	 diagram	 illustrating	 the	 filtering	 stages	 used	 within	 this	 project	 to	 identify	 the	 high	 priority	 genes	 to	 take	 forward	 for	
further	investigation.	
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Figure	14	Heatmap	displaying	 the	 change	 in	 expression	of	 the	14	 genes	of	 interest	
following	 10	 day	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	 deprivation	 (ED),	
tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M)	 treatment	in	MCF-7	cells.	Red	
denotes	an	increase	in	gene	expression	compared	to	control	(shown	in	black).	
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Figure	15	Heatmaps	displaying	 the	change	 in	expression	of	 the	14	genes	of	 interest	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	(FASR)	and	oestrogen	deprivation-resistant	(XR)	cells	versus	MCF-7	cells.		Red	denotes	an	increase,	and	green	denotes	a	
decrease,	in	gene	expression	compared	to	control	(shown	in	black).	
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3.3.3.1 Gamma-aminobutyric	acid	B	receptor,	2	(GABBR2)	The	G-protein-coupled	GABBR2	was	 identified	as	 the	gene	with	 the	greatest	 fold	change	induced	by	all	antihormones	compared	to	E2-treated	control	as	illustrated	in	Figure	16A.	Following	10	day	antihormone	treatment,	GABBR2	expression	was	significantly	(p	<0.05)	up	regulated	by	all	 treatments,	with	the	greatest	 induction	mediated	by	 fulvestrant,	which	 showed	almost	 a	 95	 fold	 induction	 (Figure	16A).	The	 detection	 calls	were	 present	 following	 antihormone	 treatment,	 indicative	 of	reliable	 gene	 expression	whereas	 the	 log2	 expression	 of	 E2-treated	MCF-7	 cells	was	below	0,	suggesting	extremely	low/no	gene	expression	(Figure	16B).		GABBR2	 expression	was	maintained	 through	 to	 resistance,	 demonstrated	 by	 the	present	 detection	 calls	 in	 the	 TAMR,	 FASR	 and	 XR	 cells	 (Figure	 16C).	 GABBR2	expression	was	also	significantly	(p	<0.05)	up	regulated	in	the	three	resistant	cell	models	versus	MCF-7	control,	with	the	greatest	induction	apparent	in	the	XR	cells,	which	showed	almost	a	6	fold	induction	(Figure	16C).	The	Affymetrix	profile	of	GABBR2	during	antihormone	response	was	next	verified	by	RT-PCR.	In	agreement	with	the	microarray	data,	GABBR2	RNA	expression	was	induced	by	tamoxifen,	fulvestrant	and	oestrogen	deprivation	treatments	compared	to	E2-treated	control	and	actin	levels	remained	constant	(Figure	16D).	Fulvestrant	induced	the	greatest	up	regulation	of	GABBR2	expression	(Figure	16D),	mimicking	the	 log2	expression	 intensity	plot	 and	 fold	 change	 reported	 from	 the	microarray	data	 (Figure	 16A	 and	 B).	 Furthermore,	 the	 microarray	 detection	 calls	 reported	‘absent’	 for	E2-	and	’present’	 for	antihormone-treated	cells,	which	were	mirrored	by	the	absent	and	present	mRNA	expression	of	GABBR2	detected	by	PCR.	
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Figure	 16	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 GABBR2	 (jetset	 probe	 ID:	
209990_s_at)	 in	MCF-7	cells	 treated	 for	10	days	with	oestradiol	 (E2	 control;	10-9	M),	
oestrogen	deprivation	(ED),	tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M).	(B)	
Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	
from	the	triplicate	samples.	(C)	Table	displaying	the	fold	change	increase	in	GABBR2	
gene	expression,	 detection	calls	and	displaying	whether	 the	change	 in	expression	 is	
statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	
and	oestrogen	deprivation-resistant	(XR)	cell	models	compared	to	MCF-7	control.	(D)	
PCR	images	from	three	independent	experiments	showing	GABBR2	and	β-actin	mRNA	
expression	in	MCF-7	cells	treated	with	E2,	TAM,	FAS	and	ED	for	10	days.	P:	present;	A:	
absent;	*	p	<0.05	compared	to	E2-control;	ü:	p	<0.05	compared	to	MCF-7	control.		
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3.3.3.2 Catenin	(Cadherin-associated	protein),	delta	2	(CTNND2)		The	log2	intensity	plot	and	corresponding	fold	change	and	detection	calls	(Figure	17A	and	B)	revealed	significant	(p	<0.05)	up	regulation	of	δ-catenin,	CTNND2,	gene	expression	 (greater	 than	 1.5	 fold	 change)	 by	 all	 three	 antihormone	 treatments	compared	to	E2-treated	control.	Fulvestrant	promoted	the	greatest	up	regulation	of	 CTNND2	 expression,	 showing	 approximately	 9	 fold	 induction	 in	 expression	(Figure	 17B).	 This	 profile	 was	 mirrored	 by	 absent	 expression	 of	 CTNND2	 in	E2-treated	 cells	 versus	 present	 detection	 calls	 in	 tamoxifen-	 and	fulvestrant-treated	cells	and	predominantly	absent	calls	in	the	oestrogen	deprived	cells	(Figure	17B).		CTNND2	 expression	 was	 maintained	 through	 to	 antihormone	 resistance.	Specifically,	 CTNND2	 expression	 was	 significantly	 (p	 <0.05)	 increased,	 together	with	 present	 detection	 calls,	 in	 FASR	 cells	 versus	 MCF-7	 control	 (Figure	 17C).	Similarly,	 CTNND2	 expression	 was	 up	 regulated	 in	 TAMR	 and	 XR	 cells	 versus	control.	Predominantly	absent	detection	calls	were	recorded	in	the	TAMR	and	XR	cell	lines	(Figure	17C).		PCR	 verification	 revealed	 induction	 of	 CTNND2	 mRNA	 expression	 by	 all	 three	antihormone	treatments	compared	to	E2-treated	control	(Figure	17D).	Actin	levels	remained	 constant	 following	 all	 treatments.	 This	 again	 nicely	 paralleled	 the	microarray	profile.			
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Figure	 17	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 CTNND2	 (jetset	 probe	 ID:	
209618_at)	 in	MCF-7	 cells	 treated	 for	10	days	with	oestradiol	 (E2	 control;	 10-9	M),	
oestrogen	deprivation	 (ED),	 tamoxifen	 (TAM;	10-7	M)	and	 fulvestrant	 (FAS;	10-7	M).	
(B)	Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	
calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	
CTNND2	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	 change	 in	
expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	(FASR)	and	oestrogen	deprivation-resistant	 (XR)	cell	models	compared	to	
MCF-7	 control.	 (D)	 PCR	 images	 from	 three	 independent	 experiments	 showing	
CTNND2	and	β-actin	mRNA	expression	in	MCF-7	cells	treated	with	E2,	TAM,	FAS	and	
ED	 for	10	days.	P:	present;	A:	absent;	 *	p	<0.05	compared	to	E2-control;	ü:	p	<0.05	
compared	to	MCF-7	control.	
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3.3.3.3 Clusterin	(CLU)	The	 log2	 expression	 plot	 revealed	 significant	 (p	 <0.05)	 up	 regulation	 of	 CLU	 (a	multifunctional	 glycoprotein)	 expression	 by	 all	 three	 antihormone	 treatments	versus	 E2-treated	 control	 (Figure	 18A).	 Predominantly	 present	 detection	 calls	were	 reported	 in	 the	 antihormone-treated	 cells,	 indicating	 reliable	 detection	 of	CLU	 gene	 expression	 (Figure	 18B).	However,	 an	 absent	 call	was	 recorded	 in	 the	E2-treated	control	cells,	together	with	a	negative	log2	expression	value,	suggesting	relatively	low/no	expression	of	this	gene	following	this	treatment	(Figure	18A	and	B).	Similarly,	CLU	expression	was	up	regulated	in	the	three	antihormone-resistant	cell	lines	(fold	change	>	1.5),	with	significant	up	regulation	in	FASR	cells,	compared	to	MCF-7	 control	 cells	 (Figure	 18C).	 Predominantly,	 present	 detection	 calls	 were	reported	 in	 the	 FASR	 and	XR	 cells,	with	 absent	 calls	 reported	 in	 the	TAMR	 cells	(Figure	18C).	Although	 the	 microarray	 data	 indicated	 up	 regulation	 of	 CLU	 expression	 by	 all	three	 antihormone	 treatments,	 PCR	was	 only	 able	 to	 validate	 gene	 induction	 by	tamoxifen	and	fulvestrant.	CLU	mRNA	expression	following	oestrogen	deprivation	treatment	 was	 comparable	 to	 the	 expression	 observed	 following	 E2	 treatment	(Figure	18D).	Actin	levels	remained	constant	following	each	treatment.	
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Figure	 18	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	replicates	±	SEM)	gene	expression	of	CLU	(jetset	probe	ID:	222043_at)	
in	 MCF-7	 cells	 treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	
deprivation	 (ED),	 tamoxifen	 (TAM;	10-7	M)	 and	 fulvestrant	 (FAS;	10-7	M).	 (B)	Table	
displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	
from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	 CLU	
gene	expression,	detection	calls	and	displaying	whether	the	change	in	expression	is	
statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	
and	 oestrogen	 deprivation-resistant	 (XR)	 cell	 models	 compared	 to	 MCF-7	 control.	
(D)	 PCR	 images	 from	 three	 independent	 experiments	 showing	 CLU	 and	 β-actin	
mRNA	 expression	 in	MCF-7	 cells	 treated	with	 E2,	TAM,	 FAS	 and	 ED	 for	10	 days.	P:	
present;	A:	absent;	*	p	<0.05	compared	to	E2-control;	ü:	p	<0.05	compared	to	MCF-7	
control.		
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3.3.3.4 Chemokine	receptor	4	(CXCR4)	All	 three	antihormones	 induced	up	 regulation	of	 the	 chemokine	 receptor,	CXCR4	(fold	change	greater	than	1.5),	which	was	significant	(p	<0.05)	with	fulvestrant	and	oestrogen	deprivation	 treatments,	 versus	E2-treated	 control	 (Figure	19A	and	B).	Present	 detection	 calls	 were	 recorded	 in	 the	 antihormone-	 and	 E2-treated	 cells	(Figure	19B).	In	 the	 antihormone-resistant	 cells,	 CXCR4	 expression	was	 significantly	 (p	 <0.05)	up	regulated	 in	XR	and	FASR	cells	 (by	41	and	3	 fold,	 respectively)	versus	MCF-7	control	cells	(Figure	19C).	Present	detection	calls	were	also	reported	in	these	cell	lines.	 However,	 CXCR4	 expression	 was	 down	 regulated	 in	 TAMR	 cells,	 together	with	 predominantly	 absent	 detection	 calls,	 compared	 to	 MCF-7	 control	 cells	(Figure	19C).			In	 response	 to	 all	 three	 antihormones,	 CXCR4	 mRNA	 expression	 was	 clearly	induced	 (Figure	19D)	which	 is	 in	 agreement	with	 the	microarray	profile	 (Figure	19).	Actin	levels	remained	relatively	constant	following	each	treatment.	
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Figure	 19	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 CXCR4	 (jetset	 probe	 ID:	
217028_at)	 in	MCF-7	 cells	 treated	 for	10	days	with	oestradiol	 (E2	 control;	 10-9	M),	
oestrogen	deprivation	(ED),	 tamoxifen	 (TAM;	10-7	M)	and	 fulvestrant	 (FAS;	10-7	M).	
(B)	Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	
calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	
CXCR4	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	 change	 in	
expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	(FASR)	and	oestrogen	deprivation-resistant	 (XR)	cell	models	compared	to	
MCF-7	control.	(D)	PCR	images	from	three	independent	experiments	showing	CXCR4	
and	β-actin	mRNA	expression	 in	MCF-7	 cells	 treated	with	E2,	TAM,	 FAS	 and	ED	 for	
10	days.	 P:	 present;	 A:	 absent;	 *	 p	 <0.05	 compared	 to	 E2-control;	 ***	 suppressed	
versus	control;	ü:	p	<0.05	compared	to	MCF-7	control.		
D	 E2 TAM FAS ED 
E2 TAM FAS ED 
E2 TAM FAS ED 
CXCR4 
β-actin 
CXCR4 
β-actin 
CXCR4 
β-actin 
		 102	
3.3.3.5 TSC22	domain	family,	member	3	(TSC22D3)	The	log2	intensity	plot	revealed	significant	(p	<0.05)	induction	in	expression	of	a	gene	encoding	a	glucocorticoid-induced	leucine	zipper	protein,	TSC22D3,	following	10	 day	 oestrogen	 deprivation,	 tamoxifen	 and	 fulvestrant	 treatment	 compared	 to	E2-treated	 control	 (Figure	 20A).	 This	 profile	was	 parallel	 to	 the	 log2	 expression	values	 that	 showed	 predominantly	 absent	 expression	 of	 TSC22D3	 in	 E2-treated	control	 cells	 and	 present	 expression	 calls	 in	 antihormone-treated	 cells	 implying	reliable	detection	of	gene	expression	(Figure	20B).		TSC22D3	 was	 also	 up	 regulated	 in	 FASR	 and	 XR	 cells,	 which	 was	 significant	(p	<0.05)	 in	 the	 latter,	 compared	 to	 MCF-7	 control	 (Figure	 20C).	 Additionally,	present	 detection	 calls	 were	 reported	 in	 these	 cell	 lines.	 Similar	 to	 CXCR4	expression,	 TSC22D3	 was	 also	 down	 regulated	 in	 TAMR	 cells,	 with	 absent	detection	calls	reported,	compared	to	MCF-7	control	(Figure	20C).	In	 agreement	 with	 the	 microarray	 profile,	 the	 PCR	 data	 demonstrated	 up	regulation	of	TSC22D3	expression	by	all	three	antihormone	treatments	compared	to	 E2-treated	 control	 (Figure	 20D).	 Actin	 levels	 remained	 relatively	 constant	following	each	treatment.		
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Figure	 20	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 TSC22D3	 (jetset	 probe	 ID:	
208763_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	deprivation	(ED),	 tamoxifen	 (TAM;	10-7	M)	and	 fulvestrant	 (FAS;	10-7	M).	
(B)	Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	
calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	
TSC22D3	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	 change	 in	
expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	(FASR)	and	oestrogen	deprivation-resistant	 (XR)	cell	models	compared	 to	
MCF-7	 control.	 (D)	 PCR	 images	 from	 three	 independent	 experiments	 showing	
TSC22D3	and	β-actin	mRNA	expression	in	MCF-7	cells	treated	with	E2,	TAM,	FAS	and	
ED	 for	 10	 days.	 P:	 present;	 A:	 absent;	 *	 p	 <0.05	 compared	 to	 E2-control;	
***	suppressed	versus	control;	ü:	p	<0.05	compared	to	MCF-7	control.		
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3.3.3.6 B	cell	lymphoma	3	(BCL3)	Similar	to	TSC22D3	expression,	BCL3	gene	expression,	which	transcribes	a	protein	involved	 in	 the	 regulation	 of	 NF-κB	 activity,	 was	 also	 significantly	 (p	 <0.05)	induced	 by	 all	 three	 antihormone	 treatments	 (Figure	 21A).	 All	 detection	 calls	identified	 the	 gene	 as	 being	 present	 in	 antihormone-treated	 cells	 indicating	reliable	detection	of	BCL3	gene	expression.	However,	the	log2	expression	values	of	BCL3	in	E2-treated	cells	failed	to	rise	above	0	and	a	predominantly	absent	call	was	recorded	 suggesting	 relatively	 low/no	 expression	 of	 this	 gene	 following	 this	treatment	(Figure	21B).	In	resistance,	BCL3	expression	was	significantly	(p	<0.05)	up	 regulated	 in	 all	 three	 antihormone-resistant	 cell	 lines,	 together	 with	 present	detection	calls	recorded,	versus	MCF-7	control	cells	(Figure	21C).	In	 agreement	 with	 the	 log2-expression	 intensity	 plot	 generated	 from	 the	microarray	 data,	 PCR	 revealed	 up	 regulation	 of	 BCL3	 expression	 across	 all	antihormone	 treatments	with	 little	expression	detected	 in	 the	E2-treated	control	cells	while	actin	levels	remained	constant	(Figure	21D).	This	profile	mimicked	the	detection	calls	from	the	microarray	analysis	(Figure	21B).		
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Figure	 21	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 BCL3	 (jetset	 probe	 ID:	
204908_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	deprivation	 (ED),	 tamoxifen	 (TAM;	10-7	M)	 and	 fulvestrant	 (FAS;	10-7	M).	
(B)	Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	
calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	
BCL3	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	 change	 in	
expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	 (FASR)	and	oestrogen	deprivation-resistant	 (XR)	cell	models	compared	to	
MCF-7	 control.	 (D)	PCR	 images	 from	 three	 independent	experiments	showing	BCL3	
and	β-actin	mRNA	expression	 in	MCF-7	 cells	 treated	with	E2,	TAM,	 FAS	and	ED	 for	
10	days.	 P:	 present;	 A:	 absent;	 *	 p	 <0.05	 compared	 to	 E2-control;	 ü:	 p	 <0.05	
compared	to	MCF-7	control.	
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3.3.3.7 BCL2-associated	anthanogene	(BAG1)	The	 log2	 intensity	 profile	 demonstrated	 significant	 (p	 <0.05)	 induction	 of	 BAG1	gene	 expression	 following	 oestrogen	 deprivation	 and	 fulvestrant	 treatment	with	slightly	less	induction	mediated	by	tamoxifen	treatment	(Figure	22A).	All	detection	calls	 indicated	 that	 the	 gene	was	 present	 following	 the	 four	 treatments	 and	 the	error	 bars	 were	 small	 (with	 the	 exception	 of	 tamoxifen),	 implying	 reproducible	detection	of	gene	expression	in	all	samples	(Figure	22B).	BAG1	 expression	was	maintained	 through	 to	 resistance,	 represented	 by	 present	detection	calls	 in	 the	three	antihormone-resistant	cells	(Figure	22C).	 In	 the	FASR	and	XR	cell	 lines,	BAG1	expression	was	significantly	up	regulated,	whereas	in	the	TAMR	cells	BAG1	expression	was	decreased,	versus	MCF-7	control	(Figure	22C).	Antihormone-induced	 up	 regulation	 of	 BAG1	 expression	 reported	 by	 the	microarray	data,	was	not	successfully	verified	by	PCR	(Figure	22D).	Indeed,	similar	to	actin	expression,	BAG1	mRNA	expression	was	relatively	equal	following	all	four	treatments.				
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Figure	 22	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	replicates	±	SEM)	gene	expression	of	BAG1	(jetset	probe	ID:	202387_at)	
in	 MCF-7	 cells	 treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	
deprivation	 (ED),	 tamoxifen	 (TAM;	10-7	M)	 and	 fulvestrant	 (FAS;	10-7	M).	 (B)	Table	
displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	
from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	 BCL3	
gene	expression,	detection	calls	and	displaying	whether	the	change	in	expression	is	
statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	
and	 oestrogen	 deprivation-resistant	 (XR)	 cell	 models	 compared	 to	 MCF-7	 control.	
(D)	 PCR	 images	 from	 three	 independent	 experiments	 showing	 BAG1	 and	 β-actin	
mRNA	 expression	 in	 MCF-7	 cells	 treated	 with	 E2,	 TAM,	 FAS	 and	 ED	 for	 10	 days.	
P:	present;	 *	 p	 <0.05	 compared	 to	 E2-control;	 ***	 suppressed	 versus	 control;	
ü:	p	<0.05	compared	to	MCF-7	control.			
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3.3.3.8 Insulin-like	growth	factor	binding	protein	5	(IGFBP5)	Although	 all	 antihormone	 treatments	 promoted	 up	 regulation	 of	 IGFBP5	 gene	expression,	which	encodes	an	IGFR	binding	protein,	only	tamoxifen	and	oestrogen	deprivation	treatments	induced	up	regulation	with	a	fold	change	greater	than	1.5,	with	 the	 latter	 additionally	 reaching	 significance	 (p	<0.05)	 (Figure	23A).	Present	detection	 calls	 across	 all	 four	 treatments	 were	 also	 reported,	 thus	 indicating	reliable	gene	expression	(Figure	23B).	IGFBP5	 expression	 was	 maintained	 through	 to	 the	 acquisition	 of	 resistance,	 as	demonstrated	 by	 the	 present	 detection	 calls	 reported	 in	 the	 three	antihormone-resistant	 cells	 (Figure	23C).	 In	 the	TAMR	and	XR	 cell	 lines,	 IGFBP5	was	up	regulated	with	a	fold	change	greater	than	1.5,	with	the	latter	also	reaching	significance	(p	<0.05)	(Figure	23C).	In	the	FASR	cells,	IGFBP5	expression	was	down	regulated	compared	to	MCF-7	control	(Figure	23C).	Subsequent	PCR	verification	of	 IGFBP5	expression	during	 antihormone	 response	continued	to	fail,	with	no	mRNA	detected	in	MCF-7	cells	irrespective	of	treatment	(Figure	 23D).	 Equal	 mRNA	 expression	 of	 actin	 was	 demonstrated	 following	 the	four	treatments.		
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Figure	 23	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 IGFBP5	 (jetset	 probe	 ID:	
211959_at)	 in	MCF-7	 cells	 treated	 for	10	days	with	oestradiol	 (E2	 control;	 10-9	M),	
oestrogen	deprivation	(ED),	 tamoxifen	 (TAM;	10-7	M)	and	 fulvestrant	 (FAS;	10-7	M).	
(B)	Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	
calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	
IGFBP5	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	 change	 in	
expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-
resistant	(FASR)	and	oestrogen	deprivation-resistant	 (XR)	cell	models	compared	to	
MCF-7	 control.	 (D)	 PCR	 images	 from	 three	 independent	 experiments	 showing	
IGFBP5	and	β-actin	mRNA	expression	in	MCF-7	cells	 treated	with	E2,	TAM,	FAS	and	
ED	for	10	days.	P:	present;	*	p	<0.05	compared	to	E2-control;	***	suppressed	versus	
control;	ü:	p	<0.05	compared	to	MCF-7	control.	
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3.3.3.9 BCL2	like	1	(BCL2L1)	The	 log2	 intensity	 profile	 demonstrated	 that	 all	 three	 antihormone	 treatments	induced	 up	 regulation	 of	 BCL2L1	 expression	 compared	 to	 E2-treated	 control	(Figure	 24A).	 BCL2L1	 encodes	 a	 protein	 belonging	 to	 the	 BCL2	 protein	 family.	Oestrogen	deprivation	and	fulvestrant	treatments	promoted	the	greatest	induction	of	 gene	 expression	 (fold	 change	 greater	 than	 1.5)	 with	 the	 latter	 also	 reaching	significance	 (p	 <0.05).	 Tamoxifen	 promoted	 a	 lesser	 degree	 of	 up	 regulation	 of	gene	expression	compared	to	the	other	antihormonal	treatments,	characterised	by	a	 1.36	 fold	 induction.	 The	 log2	 expression	 values	 were	 all	 above	 0	 and	 present	detection	calls	were	reported	for	all	four	treatments	(Figure	24B).	BCL2L1	 was	 also	 up	 regulated	 in	 the	 three	 antihormone-resistant	 cell	 models,	together	with	present	detection	calls	reported,	versus	MCF-7	control	(Figure	24C).	The	greatest	up	regulation	was	apparent	in	the	FASR	cells,	characterised	by	a	2.51	fold	induction.	In	 agreement	 with	 the	 microarray	 profile,	 tamoxifen,	 fulvestrant	 and	 oestrogen	deprivation	 treatments	 induced	 up	 regulation	 of	 BCL2L1	 mRNA	 expression	compared	 to	E2-treated	control	as	determined	by	PCR	(Figure	24D	and	E).	Actin	levels	 remained	constant	 following	 the	 four	 treatments.	Furthermore,	 fulvestrant	induced	the	greatest	up	regulation	of	expression,	which	mimicked	the	microarray	profile.	 Additionally,	 the	 microarray	 data	 reported	 ‘present’	 detection	 calls	(suggesting	reliable	detection	of	gene	expression)	across	all	 four	 treatments.	The	PCR	 profile	 mirrored	 the	 detection	 calls,	 with	 mRNA	 expression	 detected	 in	 all	treatments,	 although	BCL2L1	expression	was	minimal	 in	E2-treated	cells	 (Figure	24D).		
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Figure	24	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	±	SEM)	gene	expression	of	BCL2L1	(jetset	probe	ID:	212312_at)	in	MCF-7	cells	
treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	 deprivation	 (ED),	
tamoxifen	 (TAM;	 10-7	 M)	 and	 fulvestrant	 (FAS;	 10-7	 M).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	 from	 the	 triplicate	
samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	 BCL2L1	 gene	 expression,	
detection	calls	and	displaying	whether	the	change	in	expression	is	statistically	significant	
in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	 and	oestrogen	deprivation-
resistant	 (XR)	 cell	 models	 compared	 to	 MCF-7	 control.	 (D)	 PCR	 images	 from	 three	
independent	experiments	showing	BCL2L1	and	β-actin	mRNA	expression	in	MCF-7	cells	
treated	 with	 E2,	 TAM,	 FAS	 and	 ED	 for	 10	 days.	 P:	 present;	 *	 p	 <0.05	 compared	 to	
E2-control.		
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3.3.3.10 	Presenilin	1	(PSEN1)	The	log2	intensity	plot	and	associated	fold	changes	showed	antihormone-induced	up	regulation	of	PSEN1	expression,	which	encodes	a	presenilin	protein,	compared	to	 E2-treated	 control	 (Figure	 25A).	 Oestrogen	 deprivation	 and	 fulvestrant	promoted	significant	(p	<0.05)	up	regulation	of	gene	expression,	whilst	tamoxifen	promoted	 only	minimal	 induction	 represented	 by	 a	 1.38	 fold	 change.	 The	 error	bars	 were	 small	 and	 present	 detection	 calls	 were	 reported	 in	 all	 treatments,	implying	reproducible	detection	of	expression	in	all	samples	(Figure	25B).	PSEN1	 expression	 was	 maintained	 through	 to	 the	 acquisition	 of	 resistance,	represented	by	 the	present	detection	 calls	 reported	 (Figure	25C).	PSEN1	was	up	regulated	in	the	TAMR	and	XR	cell	lines,	and	down	regulated	in	the	FASR	cell	line,	versus	MCF-7	control	(Figure	25C).	The	 PCR	 of	 PSEN1	 revealed	 antihormone-induced	 up	 regulation	 of	 expression	compared	to	E2-control	(Figure	25D),	which	is	in	agreement	with	the	microarray	data.	 In	accordance	with	 the	 ‘present’	detection	calls	 identified	 in	 the	microarray	data,	 mRNA	 expression	 of	 PSEN1	 was	 apparent	 following	 all	 four	 treatments	(Figure	25D).	Actin	expression	remained	constant	following	all	four	treatments.		
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Figure	25	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	±	SEM)	gene	expression	of	PSEN1	(jetset	probe	ID:	203460_s_at)	in	MCF-7	cells	
treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	 deprivation	 (ED),	
tamoxifen	 (TAM;	 10-7	 M)	 and	 fulvestrant	 (FAS;	 10-7	 M).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	 from	 the	 triplicate	
samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	 PSEN1	 gene	 expression,	
detection	calls	and	displaying	whether	the	change	in	expression	is	statistically	significant	
in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	and	oestrogen	deprivation-
resistant	 (XR)	 cell	 models	 compared	 to	 MCF-7	 control.	 (D)	 PCR	 images	 from	 three	
independent	 experiments	 showing	 PSEN1	 and	 β-actin	mRNA	 expression	 in	MCF-7	 cells	
treated	 with	 E2,	 TAM,	 FAS	 and	 ED	 for	 10	 days.	 P:	 present;	 *	 p	 <0.05	 compared	 to	
E2-control;	***	suppressed	versus	control.			
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3.3.3.11 	ELKS/RAB6-interacting/CAST	family	member	1	(ERC1)	The	 log2	 intensity	plot	demonstrated	significant	 (p	<0.05)	up	regulation	of	ERC1	gene	expression	(which	encodes	a	protein	belonging	to	the	family	of	RIM-binding	proteins)	by	fulvestrant	and	oestrogen	deprivation	treatments	versus	control,	with	the	 latter	 promoting	 the	 greatest	 induction	 represented	 by	 an	 almost	 1.7	 fold	change	 (Figure	 26A).	 Tamoxifen	 promoted	 up	 regulation	 of	 gene	 expression	 but	this	 induction	 did	 not	 reach	 statistical	 significance.	 The	 log2	 expression	 values	were	all	above	0	and	present	detection	calls	were	reported	for	all	four	treatments	(Figure	26B).	ERC1	expression	was	up	regulated	in	TAMR	and	FASR	cells	and	down	regulated	in	XR	cells	versus	MCF-7	control	(Figure	26C).	Predominantly	absent	detection	calls	were	 reported	 in	 the	 TAMR	 and	 XR	 cell	 lines,	 whereas	 predominantly	marginal	calls	were	reported	in	the	FASR	cells	(Figure	26C).	According	 to	 the	 PCR	 data,	 tamoxifen	 and	 fulvestrant	 induced	 up	 regulation	 of	ERC1	 expression	 compared	 to	 control	 (Figure	 26D).	 However,	 oestrogen	deprivation-	and	E2-treated	cells	exhibited	comparable	ERC1	expression.	This	was	in	partial	disagreement	with	 the	microarray	profile,	which	demonstrated	 that	all	three	 antihormones	 promoted	 up	 regulation	 of	 ERC1	 gene	 expression,	 with	 the	greatest	 induction	mediated	by	oestrogen	deprivation	treatment	(Figure	26A	and	B).	Actin	levels	remained	constant	following	all	four	treatments.		
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Figure	 26	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 ERC1	 (jetset	 probe	 ID:	
215606_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	deprivation	(ED),	tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M).	
(B)	 Table	 displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	
detection	 calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	
increase	 in	 ERC1	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	
change	 in	 expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	
fulvestrant-resistant	 (FASR)	 and	oestrogen	 deprivation-resistant	 (XR)	 cell	models	
compared	 to	MCF-7	control.	 (D)	PCR	 images	 from	 three	 independent	experiments	
showing	ERC1	 and	β-actin	mRNA	 expression	 in	MCF-7	 cells	 treated	with	E2,	TAM,	
FAS	and	ED	for	10	days.	P:	present;	M:	marginal;	A:	absent;	*	p	<0.05	and	**	p	<0.01	
compared	to	E2-control;	***	suppressed	versus	control.		
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3.3.3.12 	Dimethylarginine	dimethylaminohydrolase	2	(DDAH2)	The	log2	intensity	profile	demonstrated	up	regulation	of	DDAH2	gene	expression	following	 10	 day	 oestrogen	 deprivation	 and	 fulvestrant	 treatment	 compared	 to	E2-treated	 control	 with	 fold	 change	 inductions	 greater	 than	 1.5	 (Figure	 27A).	DDAH2	 encodes	 a	 dimethylarginine	 dimethylaminohydrolase,	which	 functions	 in	nitric	 oxide	 generation315.	 Tamoxifen	 promoted	 only	 minimal	 induction	 of	 gene	expression.	 All	 detection	 calls	 were	 reported	 as	 present,	 implying	 reliable	detection	 of	 gene	 expression	 (Figure	 27B).	 DDAH2	 expression	 was	 maintained	through	 to	 the	 development	 of	 resistance,	 as	 demonstrated	 by	 the	 present	detection	calls	reported	in	the	three	antihormone-resistant	cell	lines	(Figure	27C).	DDAH2	was	up	regulated	in	the	FASR	cells	and	down	regulated	in	the	TAMR	and	XR	cells	versus	MCF-7	control.	However,	 it	 is	 apparent	 that	 the	 jetset	 probe	 did	 not	 detect	 significant	 up	regulation	of	DDAH2	by	any	antihormone	treatment.	In	accordance	with	the	initial	filtering	 stages	 applied	 to	 the	microarray	 data	 (i.e.	 significant	 induction	 of	 gene	expression	 by	 at	 least	 one	 antihormone	 treatment;	 Figure	 13),	 identification	 of	DDAH2	arose	from	a	non-jetset	gene	probe	(215537_x_at).	Indeed,	this	gene	probe	exhibited	 a	 very	 similar	 antihormone-induced	 profile	 to	 the	 jetset	 probe,	 with	significant	 (p	 <0.05)	 induction	 of	 DDAH2	 expression	 following	 oestrogen	deprivation	 treatment	 (Figure	 28A).	 Additionally,	 in	 agreement	 with	 the	 jetset	probe,	 predominantly	 present	 detection	 calls	 were	 reported	 following	 E2	 and	antihormone	 treatments	 (Figure	 28B).	 In	 resistance,	 DDAH2	 expression	 was	significantly	(p	<0.05)	up	regulated	in	FASR	cells,	together	with	present	detection	calls,	versus	MCF-7	control	(Figure	28C).	In	XR	cells,	DDAH2	was	also	up	regulated	yet	 to	 a	 lesser	 degree	 than	 in	 FASR	 cells,	 along	 with	 present	 detection	 calls	reported	 (Figure	 28C).	 In	 TAMR	 cells,	 DDAH2	was	 significantly	 (p	 <0.05)	 down	regulated,	with	absent	calls	reported,	compared	to	MCF-7	control	(Figure	28C).	Although	 the	 microarray	 data	 revealed	 antihormone-induced	 up	 regulation	 of	DDAH2	 gene	 expression,	 particularly	 following	 oestrogen	 deprivation	 and	fulvestrant	treatments,	 this	profile	was	not	verified	by	PCR	(Figure	28D).	 Indeed,	PCR	revealed	comparable	expression	of	DDAH2	following	all	 four	treatments	and	actin	 levels	 remained	 constant.	 In	 accordance	 with	 the	 ‘present’	 detection	 calls	
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reported	 from	 the	 microarray	 data,	 DDAH2	 mRNA	 expression	 was	 apparent	following	all	four	treatments	(Figure	28D).		
	E2	 TAM	ED	
	 E2-
control	
ED	 TAM	 FAS	
Fold	change	 	 1.61	 1.04	 1.51	
Detection	call	 PPP	 PPP	 PPP	 PPP	
A	
B	
Figure	 27	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 DDAH2	 (jetset	 probe	 ID:	
214909_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	deprivation	(ED),	tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M).	
(B)	 Table	 displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	
detection	 calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	
increase	 in	 DDAH2	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	
change	 in	 expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	
fulvestrant-resistant	 (FASR)	 and	oestrogen	deprivation-resistant	 (XR)	 cell	models	
compared	to	MCF-7	control.	P:	present;	***	suppressed	versus	control.			
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Figure	 28	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	replicates	±	SEM)	 gene	expression	of	DDAH2	(probe	 ID:	215537_x_at)	
in	 MCF-7	 cells	 treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	
deprivation	(ED),	 tamoxifen	 (TAM;	10-7	M)	and	 fulvestrant	 (FAS;	10-7	M).	 (B)	Table	
displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	
from	the	triplicate	samples.	(C)	Table	displaying	the	fold	change	increase	in	DDAH2	
gene	expression,	detection	calls	and	displaying	whether	the	change	in	expression	is	
statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	
and	 oestrogen	 deprivation-resistant	 (XR)	 cell	 models	 compared	 to	 MCF-7	 control.	
(D)	PCR	 images	 from	 three	 independent	 experiments	 showing	DDAH2	and	β-actin	
mRNA	 expression	 in	 MCF-7	 cells	 treated	 with	 E2,	 TAM,	 FAS	 and	 ED	 for	 10	 days.	
P:	present;	M:	marginal;	A:	absent;	*	p	<0.05	compared	to	E2-control;	***	suppressed	
versus	control;	ü:	p	<0.05	compared	to	MCF-7	control.		
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3.3.3.13 	AKT1	The	 log2	 intensity	 plot	 demonstrated	 significant	 (p	 <0.05)	 induction	 of	 AKT1	expression,	which	encodes	a	serine-threonine	protein	kinase,	following	oestrogen	deprivation	 therapy	 compared	 to	 E2-treated	 control	 (Figure	 29A).	 Fulvestrant	promoted	 some	 induction	 of	 gene	 expression	 (fold	 change	 less	 than	 1.5)	 whilst	tamoxifen	promoted	very	 little,	 if	 any,	 induction	compared	 to	E2-treated	control.	All	 detection	 calls	 were	 recorded	 as	 present,	 suggesting	 reliable	 detection	 of	expression	 (Figure	 29B).	 In	 resistance,	 AKT1	 expression	 was	 significantly	(p	<0.05)	up	regulated	 in	all	 three	antihormone-resistant	cell	 lines,	 together	with	present	detection	calls	reported,	versus	MCF-7	control	(Figure	29C).	The	PCR	data	revealed	a	small	induction	of	AKT1	expression	following	fulvestrant	and	tamoxifen	treatment	(Figure	29D).	Oestrogen	deprivation	failed	to	 induce	up	regulation	of	AKT1	expression	compared	to	E2-treated	control.	Indeed	the	mRNA	expression	 of	 AKT1	 was	 comparable	 in	 these	 two	 samples	 (Figure	 29D).	 Actin	levels	remained	constant.	However,	 the	AKT1	mRNA	profile	was	 in	disagreement	with	the	microarray	profile,	where	oestrogen	deprivation	treatment	was	shown	to	induce	the	greatest	and	significant	induction	of	AKT1	gene	expression	compared	to	E2-treated	control	(Figure	29A).			
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Figure	 29	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 AKT1	 (jetset	 probe	 ID:	
207163_s_at)	in	MCF-7	cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	
oestrogen	deprivation	(ED),	 tamoxifen	(TAM;	10-7	M)	and	fulvestrant	 (FAS;	10-7	M).	
(B)	 Table	 displaying	 the	 corresponding	 fold	 change	 in	 gene	 expression	 and	
detection	 calls	 from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	
increase	 in	 AKT1	 gene	 expression,	 detection	 calls	 and	 displaying	 whether	 the	
change	 in	 expression	 is	 statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	
fulvestrant-resistant	 (FASR)	 and	 oestrogen	 deprivation-resistant	 (XR)	 cell	 models	
compared	 to	MCF-7	 control.	 (D)	PCR	 images	 from	 three	 independent	 experiments	
showing	 AKT1	and	 β-actin	mRNA	expression	 in	MCF-7	 cells	 treated	with	 E2,	 TAM,	
FAS	and	ED	 for	10	days.	P:	 present;	 *	 p	<0.05	 compared	 to	 E2-control;	ü:	 p	 <0.05	
compared	to	MCF-7	control.		
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3.3.3.14 	Hepatitis	B	virus	X-interacting	protein	(HBXIP)	Oestrogen	deprivation	 induced	significant	 (p	<0.05)	up	regulation	of	HBXIP	gene	expression	 as	 demonstrated	 by	 the	 log2	 intensity	 plot	 versus	 E2-treated	 control	(Figure	30A).	HBXIP	was	originally	identified	through	its	interaction	with	hepatitis	B	 virus	 X	 protein316.	 Fulvestrant	 induced	 some	 expression	 of	 HBXIP,	 whilst	tamoxifen	promoted	very	little,	if	any,	expression	compared	to	E2-treated	control.	HBXIP	 expression	 was	 present	 in	 all	 treatments,	 including	 the	 control,	 as	demonstrated	by	the	present	detection	calls	(Figure	30B).	Present	detection	calls	were	maintained	through	to	the	acquisition	of	resistance	to	all	three	antihormones	(Figure	30C).	HBXIP	expression	was	up	regulated	in	FASR	and	XR	cells,	and	down	regulated	in	TAMR	cells,	compared	to	MCF-7	control	(Figure	30C).	Although	 the	 microarray	 data	 revealed	 antihormone-induced	 up	 regulation	 of	HBXIP	 gene	 expression,	 particularly	 by	 oestrogen	 deprivation	 and	 fulvestrant	treatments,	this	profile	was	not	verified	by	PCR	(Figure	30D).	Indeed,	PCR	revealed	comparable	 expression	 of	 HBXIP	 following	 E2	 and	 the	 three	 antihormone	treatments	(Figure	30D).	Actin	levels	remained	constant.		
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	E2	 TAM	ED	
	 E2-
control	
ED	 TAM	 FAS	
Fold	change	 	 1.51	 1.03	 1.26	
Detection	call	 PPP	 PPP	 PPP	 PPP	
A	
B	
FAS	
*	
	 TAMR	 FASR	 XR	
Fold	change	 1.37***	 1.17	 1.25	
Detection	call	 PPP	 PPP	 PPP	
P	<0.05	 	 	 		
C	
Continued	on	next	page	
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Figure	 30	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 HBXIP	 (jetset	 probe	 ID:	
202299_s_at)	 in	MCF-7	 cells	 treated	 for	10	days	with	oestradiol	 (E2	control;	10-9	M),	
oestrogen	deprivation	(ED),	tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M).	(B)	
Table	displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	
from	 the	 triplicate	 samples.	 (C)	 Table	 displaying	 the	 fold	 change	 increase	 in	 HBXIP	
gene	expression,	 detection	 calls	 and	displaying	whether	 the	 change	 in	 expression	 is	
statistically	 significant	 in	 tamoxifen-resistant	 (TAMR),	 fulvestrant-resistant	 (FASR)	
and	oestrogen	deprivation-resistant	(XR)	cell	models	compared	to	MCF-7	control.	(D)	
PCR	 images	 from	 three	 independent	experiments	showing	HBXIP	and	β-actin	mRNA	
expressio	 in	 MCF-7	 cells	 treated	with	 E2,	 TAM,	 FAS	 and	 ED	 for	 10	 days.	 P:	 present;	
*	p	<0.05	compared	to	E2-control;	***	suppressed	versus	control.			
D	
HBXIP 
β-actin 
E2 TAM FAS ED 
E2 TAM FAS ED 
E2 TAM FAS ED HBXIP 
β-actin 
HBXIP 
β-actin 
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3.3.4 Identification	of	genes	significantly	induced	by	all	three	antihormone	
treatments	versus	control	Following	 extensive	 analysis	 of	 microarray	 gene	 expression	 profiles	 combined	with	 a	 stringent	 filtering	 strategy,	 supported	 by	 PCR	 verification,	14	antihormone-induced	 genes	 were	 identified	 with	 increased	 expression	maintained	 into	 resistance.	 It	 was	 hypothesised	 that	 these	 genes	 could	 allow	 a	cohort	 of	 breast	 cancer	 cells	 to	 survive	 the	 growth	 inhibitory	 actions	 of	antihormones	 and	 ultimately	 contribute	 substantially	 to	 the	 development	 of	resistance.	 To	 prioritise	 these	 genes	 further,	 those	 identified	 by	 the	 microarray	data	 to	 be	 significantly	 induced	 by	 all	 three	 antihormone	 treatments	 were	considered	 for	 further	 investigation.	 The	 Venn	 diagram	 shown	 in	 Figure	 31,	constructed	from	the	microarray	data,	identifies	5	genes	(GABBR2,	CTNND2,	CLU,	TSC22D3	 and	BCL3),	which	were	 significantly	 induced	 by	 all	 three	 antihormone	treatments.	The	rationale	was	that	continued	study	of	these	genes	may	ultimately	lead	to	the	identification	of	a	resistance	mechanism	common	to	three	antihormone	therapies	 used	 clinically.	 Furthermore,	 such	 studies	 may	 identify	 a	 potential	therapeutic	target	or	novel	biomarker	of	resistance	exhibited	by	a	large	cohort	of	patients.	 Interestingly,	 as	 illustrated	 in	 the	 Venn	 diagram,	 not	 one	 gene	 was	significantly	induced	by	tamoxifen	only.		
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3.3.5 Ontological	investigation	of	the	potential	antihormone-induced	
pro-survival	genes	Ontological	 studies	were	also	performed	on	 the	5	genes	of	 interest	 to	determine	their:	1. Function	2. Association	with	breast	cancer	and	antihormone	response	and	resistance	3. Association	with	other	cancers	4. Known	 or	 potential	 pro-survival	 role	 which	may	 ultimately	 contribute	 to	the	emergence	of	antihormone	resistance	This	information	is	collated	in	Table	9	to	Table	13.		
Figure	 31	 Venn	 diagram	 of	 the	 14	 genes	 significantly	 upregulated	 by	 10	 day	
antihormone	 treatment	 versus	E2-treated	 control.	 ED:	 oestrogen	deprivation;	TAM:	
tamoxifen;	FAS:	fulvestrant.	
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3.3.5.1 	GABBR2	
Table	 9	 Summary	 of	 the	 function	 of	 GABBR2	 including	 its	 previously	 reported	
association	with	breast	and	other	cancers	and	potential	pro-survival	role.	
		
Gene	name	 Gamma-aminobutyeic	acid	type	B	receptor,	2	Function	 Gamma-aminobutyric	 acid	 (GABA)	 B	 receptors	 belong	 to	 the	 C	family	 of	 G-protein	 coupled	 receptors	 (GPCRs).	 GABA-mediated	activation	 of	 these	 receptors	 inhibits	 neuronal	 activity	 by	activating	 G	 proteins	 and	 their	 downstream	 effectors.	 GABA	 B	receptors	 are	 heterodimers	 composed	 of	 GABBR1	 and	GABBR2	subunits,	 both	 of	which	 are	 believed	 to	 be	 required	 for	 normal	receptor	function317.		Associations	with	breast	cancer	
GABA	is	synthesised	predominantly	from	glutamate	by	glutamate	decarboxylase	 (GAD).	 Both	 GABA	 content	 and	 GAD	 activity	 are	increased	in	breast	tumour	tissue	compared	to	normal	tissue318.	Furthermore,	activation	of	GABA	B	receptors	has	been	shown	to	promote	breast	cancer	cell	invasion	and	metastasis	by	promoting	phosphorylation	 of	 ERK	 1/2	 and	 subsequently	 increasing	 the	expression	 of	 matrix	 metalloproteinase-2	 (MMP-2)319.	 MMP-2	positivity	 is	 associated	 with	 progression	 of	 breast	 cancer	 and	poorer	patient	outlook320.	Associations	with	other	cancers	
Increased	GABA	content	and	GAD	activity	have	also	been	shown	in	 colon321,	 stomach322,	 thyroid323	 and	 ovarian	 cancers324.	 In	prostate	cancer,	activation	of	GABA	B	receptors	has	been	shown	to	 increase	 the	 invasive	 ability	 of	 tumour	 cells	 by	 promoting	MMP-3	production325.	Pro-survival	role	 GABA	 B	 receptors	 in	 neuronal	 cells	 have	 been	 shown	 to	transactivate	 IGF-1R	 to	 induce	 AKT	 phosphorylation	 and	downstream	 survival	 signalling	 to	 protect	 neurons	 from	apoptosis326.		
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As	described	in	Table	9,	GABA	B	receptors	are	heterodimers	comprised	of	GABBR1	and	GABBR2	subunits	and	both	of	which	are	 reported	 to	be	 required	 for	normal	receptor	 function.	 Thus,	 expression	 of	 GABBR1	 in	 parallel	 with	 GABBR2	 may	indirectly	suggest	receptor	dimerisation	and	normal	function.	Using	the	jetset	gene	probe	(205890_s_at)	for	GABBR1,	the	microarray	expression	level	of	this	gene	was	analysed	 in	 MCF-7	 cells	 following	 antihormone	 treatment	 and	 in	 the	antihormone-resistant	 cell	 models.	 The	 heatmap	 shown	 in	 Figure	 32A	 suggests	that	 10	 day	 fulvestrant	 treatment	 down	 regulated	 GABBR1	 expression,	 whereas	oestrogen	deprivation	and	tamoxifen	had	no	effect	on	gene	expression	compared	to	 E2-treated	 control.	 The	 log2	 expression	 values	 failed	 to	 reach	 0,	 indicative	 of	very	 low	gene	expression	(Figure	32B).	 In	antihormone-resistance,	 the	heatmaps	shown	 in	 Figure	33A	 suggests	 that	GABBR1	expression	 is	 up	 regulated	 in	TAMR	cells,	 with	 very	 little	 change	 in	 expression	 apparent	 in	 the	 XR	 and	 FASR	 cells,	compared	to	MCF-7	control.	However,	the	log2	expression	values	failed	to	reach	0,	indicative	of	very	low	gene	expression	(Figure	33B).	
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Figure	32	(A)	Heatmap	displaying	the	change	in	expression	of	GABBR1	(jetset	probe	
ID:	 205890_s_at)	 following	 10	day	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	
deprivation	(ED),	tamoxifen	(TAM;	10-7	M)	and	fulvestrant	(FAS;	10-7	M)	treatment	in	
MCF-7	 cells.	 Red	 denotes	 an	 increase,	 and	 green	 denotes	 a	 decrease,	 in	 gene	
expression	 compared	 to	 control	 (shown	 in	black).	 (B)	Corresponding	 log2	 intensity	
plot	 displaying	 the	 normalised	 (mean	 of	 three	 independent	 replicates	 ±	 SEM)	 gene	
expression	of	GABBR1.			
		
	
	
Figure	 33	 (A)	 Heatmaps	 displaying	 the	 change	 in	 expression	 of	 GABBR1	 (jetset	 probe	 ID:	 205890_s_at)	 in	 tamoxifen-resistant	 (TAMR),	
fulvestrant-resistant	(FASR)	and	oestrogen	deprivation-resistant	(XR)	cells	versus	MCF-7	cells.	Red	denotes	an	increase	in	gene	expression	
compared	 to	 control	 (shown	 in	 black).	 (B)	 Corresponding	 log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	 independent	
replicates	±	SEM)	gene	expression	of	GABBR1.	
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Furthermore,	GABA,	 the	 ligand	 for	 the	receptor	must	be	produced	by	the	cells	 to	promote	receptor	activation.	GABA	is	synthesised	from	glutamate	by	GAD	enzyme.	Thus	 it	was	 hypothesised	 that	 increased	 GAD	 expression	may	 indirectly	 suggest	increased	 GABA	 levels.	 The	 expression	 of	 the	 two	 isoforms	 of	 GAD,	 GAD1	 and	GAD2,	 (using	 the	 jetset	 probes	 206669_at	 and	 216651_s_at,	 respectively)	 were	next	analysed	in	antihormone-treated	MCF-7	cells.	The	heatmaps	shown	in	Figure	34A	 reveal	 that	 oestrogen	deprivation	 treatment	 induced	up	 regulation	 of	 GAD2	expression,	whereas	 tamoxifen	and	 fulvestrant	promoted	down	regulation	of	 the	gene	compared	to	E2-treated	control.	GAD1	expression	was	down	regulated	by	all	three	 antihormone	 treatments,	 with	 the	 greatest	 down	 regulation	 induced	 by	oestrogen	 deprivation	 and	 fulvestrant	 treatments	 compared	 to	 the	 control.	 The	log2	 intensity	 profiles	 (Figure	 34B	 and	 C)	 mirror	 the	 heatmaps.	 However,	 the	majority	of	log2	expression	values	did	not	reach	above	0	suggesting	very	little	gene	expression.	Following	 the	 acquisition	 of	 resistance,	 GAD1	 and,	 to	 a	 lesser	 degree,	 GAD2	expression	were	up	 regulated	 in	TAMR	 cells	 versus	MCF-7	 control	 (Figure	35A).	Furthermore,	 the	 log2	 intensity	 plot	 revealed	 expression	 values	 above	 0,	suggesting	reliable	gene	expression	(Figure	35B	&	C).	In	contrast,	GAD1	expression	was	 down	 regulated	 in	 FASR	 and	 XR	 cells,	 with	 very	 little	 change	 in	 GAD2	expression	 apparent,	 compared	 to	MCF-7	 control	 (Figure	 35A).	 Additionally,	 the	log2	 intensity	 plots	 demonstrated	 expression	 levels	 below	 0,	 indicative	 of	 very	little	gene	expression	(Figure	35B	&	C).	
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Figure	34	(A)	Heatmap	displaying	the	change	in	expression	of	GAD2	(jetset	probe	
ID:	 216651_s_at)	 and	 GAD1	 (jetset	 probe	 ID:	 206669_at)	 following	 10	 day	
oestradiol	(E2	control;	10-9	M),	oestrogen	deprivation	(ED),	tamoxifen	(TAM;	10-7	
M)	 and	 fulvestrant	 (FAS;	 10-7	 M)	 treatment	 in	 MCF-7	 cells.	 Red	 denotes	 an	
increase,	and	green	denotes	a	decrease,	 in	gene	expression	compared	to	control	
(shown	 in	 black).	 Corresponding	 log2	 intensity	 plot	 displaying	 the	 normalised	
(mean	of	 three	 independent	replicates	±	 SEM)	 gene	expression	of	GAD2	 (B)	and	
GAD1	(C).	
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Figure	35	(A)	Heatmap	displaying	the	change	in	expression	of	GAD2	(jetset	probe	ID:	216651_s_at)	and	GAD1	(jetset	probe	ID:	
206669_at)	in	tamoxifen-resistant	(TAMR),	fulvestrant-resistant	(FASR)	and	oestrogen	deprivation-resistant	(XR)	cells	versus	
MCF-7	cells.	Red	denotes	an	increase,	and	green	denotes	a	decrease,	in	gene	expression	compared	to	control	(shown	in	black).		
Corresponding	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	replicates	±	SEM)	gene	expression	of	
GAD1	(B)	and	GAD2	(C).	
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3.3.5.2 CTNND2	
Table	 10	 Summary	 of	 the	 function	 of	 CTNND2,	 including	 previous	 associations	 of	
CTNND2	with	breast	and	other	cancers	and	its	potential	pro-survival	role.	
	Interestingly,	 as	 described	 in	 Table	 10,	 CTNND2-induced	 E-cadherin	 processing	and	 anti-apoptotic	 functions	 in	 prostate	 cancer	 cells	 has	 been	 shown	 to	 be	mediated	by	PSEN1	and	BCL2L1	genes,	respectively.	In	support	of	this,	microarray	studies	and	subsequent	PCR	verification	performed	previously	within	this	project	identified	increased	expression	of	both	PSEN1	and	BCL2L1	in	MCF-7	cells	treated	with	 antihormones	 and	 expression	 was	 maintained	 into	 the	 development	 of	resistance.	
Gene	name	 Catenin	(Cadherin-associated	protein),	delta	2	Function	 CTNND2	 is	 an	 adhesive	 junction	 protein	 of	 the	β-catenin/armadillo	 superfamily,	 abundantly	 expressed	 in	neuronal	 cells.	 It	 plays	 a	 role	 in	 promoting	 disruption	 of	E-cadherin	based	adherens	junctions	to	promote	cell	spreading.	Associations	with	breast	cancer	
Until	 a	 recent	 study	 by	 Zhang	 et	 al.327	 CTNND2	 expression	 had	not	 been	 previously	 reported	 in	 breast	 cancer.	 Zhang	 et	 al.	reported	 increased	 expression	 of	 CTNND2	 in	 breast	 cancer	tissues	 which	 was	 associated	 with	 increased	 malignancy	 and	poor	prognosis327.	In	breast	cancer	cell	lines,	CTNDD2	expression	promoted	invasion	and	cell	cycle	progression327.	Associations	with	other	cancers	
CTNND2	is	strongly	expressed	in	several	cancers,	including	lung,	ovarian,	prostate	and	oesophageal328–331.	Increased	expression	of	CTNND2	in	prostate	cancer	promotes	cell	growth	and	survival	by	up	 regulating	 expression	 of	 cyclin	D1	 and	BCL2L1	 genes	which	are	 involved	 in	promoting	cell	 cycle	progression	and	protecting	cells	 from	 apoptosis,	 respectively332.	 Furthermore,	CTNND2-induced	E-cadherin	processing	 in	prostate	cancer	cells	has	been	shown	to	be	mediated	by	PSEN1333.	Pro-survival	role	 CTNND2	 has	 been	 shown	 to	 up	 regulate	 survival	 proteins	 in	prostate	cancer	cells	to	provide	protection	from	apoptosis332.	
		 143	
3.3.5.3 CLU	
Table	11	 Summary	of	 CLU	 function,	 including	 its	 reported	 association	with	breast	
and	other	cancers	and	pro-survival	role.	Gene	name	 Clusterin	Function	 CLU	is	a	ubiquitously	expressed	glycoprotein	involved	in	several	physiological	 processes	 including	 lipid	 transportation,	complement	 regulation	 and	 apoptosis.	 CLU	 has	 also	 been	implicated	 in	 pathological	 disorders	 such	 as	 neurodegenerative	diseases,	 ischemia	 and	 cancer334.	 As	 a	 result	 of	 alternative	splicing,	 CLU	 has	 two	 main	 isoforms	 with	 distinct	 biologic	activities.	The	cytoplasmic	secreted	 form	promotes	cell	 survival	whereas	the	nuclear	form	is	associated	with	cell	death.		Associations	with	breast	cancer	
CLU	 has	 been	 largely	 explored	 in	 breast	 cancer	 where	 its	elevated	expression	 is	 associated	with	 invasion,	metastasis,	 cell	survival	 and	 ultimately	 poor	 patient	 survival335,336.	 Indeed,	secretory	CLU	 (CLU-S)	expression	 in	breast	 cancer	 cells	plays	a	significant	 role	 in	 promoting	 tumour	 growth	 by	 inhibiting	apoptosis,	resulting	in	cell	survival	whilst	also	allowing	the	cells	to	survive	the	multiple	stages	of	metastasis	337.			More	 recent	 research	 is	 focusing	 on	 a	 possible	 role	 for	 CLU	during	antihormone	response	and	resistance.	 Indeed,	 tamoxifen	treatment	has	been	shown	to	increase	CLU	expression	in	MCF-7	cells	 correlated	 with	 an	 increase	 in	 cell	 viability338,339.	Furthermore,	tamoxifen	combined	with	antibodies	targeting	CLU	produced	 a	 greater	 and	 significant	 effect	 on	 cytotoxicity	compared	 to	 tamoxifen	 alone.	 Moreover,	 CLU	 has	 also	 been	shown	to	promote	the	growth	of	antihormone-resistant	cells	and	CLU	down	regulation	restored	the	sensitivity	of	these	cells	to	the	antioestrogen	toremifene338.	Associations	with	other	cancers	
Increased	expression	of	 the	CLU-S	has	been	reported	 in	several	cancers,	including	lung,	bladder	and	kidney,	where	it	is	found	to	play	a	significant	role	in	disease	progression.		
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In	 hormone-dependent	 prostate	 cancer,	 CLU-S	 expression	increases	 with	 androgen	 withdrawal	 therapy,	 thus	 identifying	CLU-S	as	 a	potential	 anticancer	 target.	Antisense-induced	down	regulation	 of	 secretory	 CLU	 expression	 in	 prostate	 cancer	enhances	 tumour	 regression	 and	 the	 cytotoxicity	 of	 several	chemotherapeutic	 agents	 (reviewed	 by	 Miyake	 et	 al.340).	Consistent	 with	 prostate	 cancer,	 inhibition	 of	 CLU	 expression	also	chemosensitises	several	other	cancers	including	bladder	and	lung.		An	 antisense	 inhibitor	 of	 CLU,	 OGX-011,	 is	 currently	 in	 clinical	development.	 Phase	 I	 and	 II	 trials	 in	 prostate	 cancer	 patients	demonstrated	 that	 OGX-011	 is	 well	 tolerated	 and	 produces	significant	 suppression	 of	 CLU	 in	 tumour	 tissues.	 In	 advanced	lung	 and	 breast	 cancers,	 phase	 II	 trials	 of	 OGX-011	 combined	with	chemotherapy	produced	positive	results	in	terms	of	overall	survival341,342.	 Several	 Phase	 III	 trials	 evaluating	 OGX-011	 in	combination	with	chemotherapy	 in	prostate	cancer	patients	are	underway	(reviewed	by	Zielinski	&	Chi343).	Pro-survival	role	 The	 anti-apoptotic/pro-survival	 actions	 of	 CLU	 have	 been	described	to	function	through	a	variety	of	mechanisms.	CLU	has	been	 reported	 to	 bind	 to	 the	 pro-apoptotic	 protein	 Bax	 thus	interfering	 with	 its	 activation	 in	 the	 mitochondria	 and	preventing	 apoptosis344.	 Moreover,	 CLU-S	 has	 been	 shown	 to	regulate	ERK1/2	activity	in	several	cancers,	including	pancreatic,	lung	 and	 osteosarcoma345–347.	 ERK1/2	 signalling	 has	 been	identified	 as	 a	 potential	 survival	 pathway	 in	 cancer.	Furthermore,	 in	prostate	cancer	cells,	CLU-S	has	been	shown	to	up	 regulate	 AKT	 phosphorylation	 and	 downstream	 survival	signalling,	 as	 well	 as	 promote	 nuclear	 translocation	 of	 NF-κB,	thus	increasing	its	transcriptional	activation	of	genes	implicated	in	cell	survival	and	proliferation348,349.	
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3.3.5.4 TSC22D3	
Table	12	Summary	of	TSC22D3	function	including	previously	reported	associations	
with	breast	and	other	cancers	and	potential	pro-survival	role.	
	
Gene	name	 TSC22	domain	family,	member	3	Function	 TSC22D3	 is	 a	 ubiquitous	 glucocorticoid-induced	 leucine	 zipper	protein,	 which	 mediates	 several	 anti-inflammatory	 and	immunomodulatory	 functions	 of	 glucocorticoids.	 TSC22D3	 has	been	 largely	 studied	 in	 T	 lymphocytes	 where	 it	 mediates	 a	number	 of	 glucocorticoid	 effects,	 such	 as	 T	 cell	 activation,	apoptosis	 and	 proliferation	 (as	 reviewed	 by	 Ayroldi	 &	Riccardi350).	Associations	with	breast	cancer	
There	 is	 only	 one	 study	 demonstrating	 an	 association	 between	TSC22D3	 and	 breast	 cancer	 whereby	 tamoxifen	 up	 regulated	TSC22D3	 expression	 in	 MCF-7	 cells,	 which	 was	 reversed	 with	oestrogen	treatment351.	In	contrast,	oestrogen	has	been	shown	to	up	 regulate	 TSC22D3	 expression	 in	 HeLa	 cervical	 cancer	 cells	indicating	that	cell	type	specific	factors	are	likely	to	be	involved	in	 the	 oestrogen	 regulation	 of	 the	 gene	 and	 its	 functions	 are	likely	 to	 differ	 according	 to	 the	 cellular	 milieu351.	 However,	 its	function	in	breast	cancer	remains	unexplored.	Associations	with	other	cancers	
TSC22D3	has	been	reported	in	multiple	myeloma,	lymphoblastic	leukaemia	and	ovarian	cancer352–354.	In	ovarian	cancer,	TSC22D3	activates	 AKT	 signalling,	 enhances	 cyclin	 D1	 expression	 and	down	 regulates	 p21	 expression	 to	 promote	 tumour	progression354.		Pro-survival	role	 TSC22D3	 has	 been	 shown	 to	 promote	 apoptosis	 in	 neutrophils	and	 chronic	 myeloid	 leukaemia	 cells	 but	 protects	 T	 cells	 from	activation-induced	 cell	 death355–357.	 The	 pro-survival	 role	 of	TSC22D3	 is	 likely	 to	 differ	 according	 to	 cell	 type.	 There	 are	 no	studies	 describing	 a	 pro-survival	 role	 of	 this	 protein	 in	 breast	cancer.			
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3.3.5.5 BCL3	
Table	13	Summary	of	BCL3	function	including	previously	reported	associations	with	
breast	and	other	cancers	and	potential	pro-survival	role.	Gene	name	 B	cell	lymphoma	3	Function	 BCL3	is	an	atypical	member	of	the	inhibitor	of	κB	(IκB)	family	of	proteins.	 Typically,	 IκB	 proteins	 function	 by	 binding	 and	sequestering	 NF-κB	 dimers	 in	 the	 cytoplasm,	 blocking	 nuclear	translocations,	thus	preventing	transcription	of	a	large	number	of	genes	 involved	 in	 cell	 survival	 and	 proliferation358.	 However,	BCL3	 is	 a	 nuclear	 protein	 with	 both	 transactivation	 and	transrepressor	functions	mediated	by	its	association	with	NF-κB	p50	 and	 p52	 homodimers359.	 Physiologically,	 BCL3	 is	 required	for	T-cell	dependent	immunity	and	B	cell	survival.	Associations	with	breast	cancer	
BCL3	 is	 overexpressed	 in	 breast	 cancer	 tissue	 and	 cell	 lines,	however	 its	 precise	 function	 in	 tumourigenesis	 is	 largely	unknown360.	Studies	in	cell	lines	suggest	that	BCL3	stimulates	cell	proliferation	 and	 survival.	 Indeed,	 Westerheide	 et	 al.	demonstrated	 in	 breast	 cancer	 cell	 lines	 that	 BCL3,	 acting	 as	 a	coactivator	of	p50	dimers,	 stimulates	 transcription	of	 the	 cyclin	D1	gene	thus	potentiating	G1	to	S	phase	cell	cycle	transition361	 .	Furthermore,	 BCL3	 has	 been	 shown	 to	 promote	 metastasis	 of	HER2+	breast	tumours	without	effect	on	cell	growth362.		Regarding	a	role	for	BCL3	in	antihormone	failure	and	promoting	endocrine	 resistance,	 Pratt	 et	 al.	 have	 shown	 that	 oestrogen	withdrawal	 increases	 BCL3	 expression	 and	 NF-κB	 activity	 in	MCF-7	 cells	 in	 parallel	 with	 enhanced	 tumour	 growth363.	Furthermore,	 BCL3	 expression	 and	 NF-κB	 activity	 (dominantly	p50	 dimers)	 was	 enhanced	 further	 in	 ER+,	oestrogen-independent	 cells	 (model	of	 resistance)	derived	 from	MCF-7	cells,	suggesting	that	both	BCL3	and	NF-κB	activities	may	allow	a	cohort	of	cells	to	grow	and	survive	oestrogen	withdrawal,	thus	establishing	a	hormone-independent	phenotype.	
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	Interestingly,	 CLU	 and	 BCL3	 may	 work	 together	 to	 promote	 cell	 survival.	 As	mentioned	 in	Table	11,	CLU	has	been	shown	to	promote	nuclear	 translocation	of	NF-κB349,	which	may	include	p50	dimers.	Nuclear	BCL3	may	activate	these	dimers	to	promote	downstream	transcription	of	genes	involved	in	cell	survival.	Together,	as	demonstrated	in	Table	9-Table	13,	 increased	expression	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	in	breast	cancer	has	been	previously	reported	to	 be	 involved	 in	 disease	 progression	 and	 poorer	 patient	 outlook.	 Furthermore,	with	regard	to	a	role	in	limiting	antihormone	response	and	promoting	resistance,	the	 ontological	 studies	 (Table	 9	 to	 Table	 13)	 revealed	 that	 tamoxifen	 has	 been	shown	 to	 induce	 TSC2DD3	 and	 CLU	 expression	 and	 oestrogen	 deprivation	treatment	has	been	shown	to	promote	BCL3	expression338,351,363.		
Associations	with	other	cancers	
BCL3	was	 first	 identified	 in	 chronic	 lymphocytic	 leukaemia	 but	has	 since	 been	 shown	 to	 be	 overexpressed	 in	 several	 cancers,	including	 nasopharyngeal,	 endometrial	 and	 colorectal364–366.	 In	nasopharyngeal	 carcinomas,	 BCL3	 and	 p50	 homodimers	 are	complexed	 in	 the	 nucleus	 and	 these	 complexes	 are	 reported	 to	bind	 to	 the	 promoter	 of	 EGFR,	 potentially	 inducing	transcriptional	 up	 regulation	 of	 this	 oncogene	 and	 playing	 a	crucial	 role	 in	 its	 overexpression364.	 Similarly,	 in	 metastatic	colorectal	cancer,	nuclear	expression	of	BCL3	together	with	p50	was	negatively	associated	with	patient	survival366.	Pro-survival	role	 Several	studies	have	reported	a	survival	role	for	BCL3	in	a	variety	of	cell	types.	Interestingly,	in	response	to	DNA	damage,	BCL3	up	regulation	 has	 been	 shown	 to	 inhibit	 activation	 of	 the	 tumour	suppressor	p53	in	breast	cancer	cells,	consequently	suppressing	cell	cycle	arrest	and	apoptosis,	ultimately	promoting	cell	growth	and	survival.	The	major	proposed	mechanism	in	this	circuit	is	the	ability	 of	 BCL3	 to	 induce	 up	 regulation	 of	 HDM2,	 the	 main	negative	regulator	of	p53367.	Furthermore,	BCL3	has	been	shown	to	 bind	 CtBP1	 and	 prevent	 its	 apoptotic	 responses,	 ultimately	resulting	in	survival368.	
		 148	
3.3.6 Verification	of	the	5	genes	of	interest	at	the	protein	level	by	Western	
blotting	The	expression	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	was	next	examined	at	the	protein	level	by	Western	blotting	(shown	in	Figure	36	to	Figure	40).		
3.3.6.1 GABBR2	In	 agreement	with	 previous	microarray	 and	PCR	data,	Western	 blotting	 analysis	revealed	up	regulation	of	GABBR2	expression	following	tamoxifen,	fulvestrant	and	oestrogen	 deprivation	 treatments	 compared	 to	 E2-treated	 control	 (Figure	 36).	GABBR2	expression	was	relatively	consistent	with	all	antihormone	treatments	and	very	little	protein	expression	was	apparent	in	the	E2-treated	control.	Actin	levels	were	similar	following	all	treatments.			
		 149	
		
Figure	 36	 Western	 blot	 images	 from	 three	 independent	 experiments	 showing	
GABBR2	 and	 β-actin	 protein	 expression	 in	 MCF-7	 cells	 treated	 with	 oestradiol	 (E2	
control;	 10-9	 M),	 tamoxifen	 (TAM;	 10-7	 M),	 fulvestrant	 (FAS;	 10-7	 M)	 and	 oestrogen	
deprivation	(ED)	for	10	days.		
GABBR2 
β-actin 
E2 TAM FAS ED 
E2 TAM FAS ED 
E2 TAM FAS ED GABBR2 
β-actin 
GABBR2 
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3.3.6.2 CTNND2	Unfortunately,	 CTNND2	 expression	 could	 not	 be	 verified	 at	 the	 protein	 level	(Figure	37).	This	was	likely	due	to	the	poor	specificity	of	the	antibody	and	the	lack	of	available	antibodies.			
Figure	 37	 Western	 blot	 images	 from	 three	 independent	 experiments	 showing	
CTNND2	 and	 β-actin	 protein	 expression	 in	 MCF-7	 cells	 treated	 with	 oestradiol	 (E2	
control;	 10-9	 M),	 tamoxifen	 (TAM;	 10-7	 M),	 fulvestrant	 (FAS;	 10-7	 M)	 and	 oestrogen	
deprivation	(ED)	for	10	days.	
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3.3.6.3 CLU	As	determined	from	the	ontological	studies	(Table	11),	two	isoforms	of	CLU	exist.	The	 nuclear	 isoform	 is	 associated	with	 promoting	 cell	 death	whereas	 the	 CLU-S	form	 is	 associated	with	 cell	 survival369,370.	 Since	 this	 project	 is	 interested	 in	 the	survival	 role	 of	 CLU,	 CLU-S	was	 analysed	 by	Western	 blotting.	 CLU-S	 exists	 as	 a	precursor	 (approximately	 60	 kDa)	 which	 is	 cleaved	 into	 α-	 and	 β-subunits	 that	dimerise	 to	 form	 the	 mature	 secretory	 CLU	 form,	 with	 an	 apparent	 molecular	weight	of	75-80	kDa371.		However,	under	reducing	SDS-PAGE	conditions,	the	α-	and	β-subunits	appear	as	36-39	kDa	and	34-36	kDa	bands,	respectively.	Western	 analysis	 (specific	 for	 CLUα)	 revealed	 up	 regulation	 of	 CLU-S	 following	tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 treatment	 (Figure	 38).	 Two	bands	appeared	on	the	blot	at	60	kDa	and	40	kDa	representing	the	CLU	precursor	and	 α-subunit,	 respectively.	 All	 three	 antihormone	 treatments	 induced	 protein	expression	 of	 CLU	 precursor	 and	 CLUα,	 which	 mimics	 the	 microarray	 profile.	Protein	expression	was	minimal	 following	E2	 treatment	 (Figure	38).	Actin	 levels	remained	constant	following	all	treatments.	
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Figure	38	Western	blot	 images	 from	three	 independent	experiments	showing	CLU	
precursor,	 CLUα	 and	 β-actin	 protein	 expression	 in	 MCF-7	 cells	 treated	 with	
oestradiol	 (E2	 control;	 10-9	M),	 tamoxifen	 (TAM;	10-7	M),	 fulvestrant	 (FAS;	10-7	M)	
and	oestrogen	deprivation	(ED)	for	10	days.		
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3.3.6.4 TSC22D3	In	 agreement	 with	 previous	 microarray	 and	 PCR	 data,	 Western	 blot	 analysis	demonstrated	 up	 regulation	 of	 TSC22D3	 expression	 by	 all	 three	 antihormone	treatments	 (Figure	 39).	 Actin	 levels	 remained	 constant	 following	 all	 four	treatments.			
Figure	 39	 Western	 blot	 images	 from	 three	 independent	 experiments	 showing	
TSC22D3	 and	 β-actin	 protein	 expression	 in	 MCF-7	 cells	 treated	with	 oestradiol	 (E2	
control;	 10-9	 M),	 tamoxifen	 (TAM;	 10-7	 M),	 fulvestrant	 (FAS;	 10-7	 M)	 and	 oestrogen	
deprivation	(ED)	for	10	days.			
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3.3.6.5 BCL3	In	 agreement	 with	 the	 microarray	 and	 subsequent	 PCR	 data,	 BCL3	 protein	expression	 was	 up	 regulated	 by	 all	 three	 antihormone	 treatments	 compared	 to	E2-treated	 control	 (Figure	 40).	 BCL3	 was	 expressed	 at	 low	 levels	 in	 E2-treated	control	cells	and	actin	levels	remained	constant	following	all	four	treatments.			
	
Figure	40	Western	blot	images	from	three	independent	experiments	showing	BCL3	
and	 β-actin	 protein	 expression	 in	 MCF-7	 cells	 treated	 with	 oestradiol	 (E2	
control;	10-9	M),	 tamoxifen	 (TAM;	 10-7	M),	 fulvestrant	 (FAS;	 10-7	M)	 and	 oestrogen	
deprivation	(ED)	for	10	days.		
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3.4 Discussion	In	 this	 Chapter	 a	 filtering	 process	was	 performed	 to	 identify	 pro-survival	 genes	significantly	 induced	by	10	day	antihormone	treatment	(fold	change	greater	than	1.5,	 combined	 with	 present	 detection	 calls)	 in	 MCF-7	 cells,	 with	 expression	maintained	 into	 the	acquisition	of	 resistance.	Following	extensive	analysis	of	 the	microarray	 gene	 expression	data,	 14	 genes	were	 identified	 as	 being	 significantly	induced	by	at	 least	one	antihormone	treatment	during	response,	with	expression	maintained	 into	 the	 development	 of	 resistance.	 It	 was	 hypothesised	 that	 these	antihormone-induced	 pro-survival	 genes	 could	 allow	 a	 cohort	 of	 breast	 cancer	cells	to	evade	the	growth	inhibitory	actions	of	these	agents	early	during	response,	ultimately	 driving	 acquired	 resistant	 growth,	 thus	 resulting	 in	 poorer	 patient	outcome.	 Furthermore,	 targeting	 of	 these	 genes	 alongside	 antihormones	 during	response	 may	 enhance	 the	 anti-proliferative	 actions	 exerted	 by	 these	 therapies	and	 prevent	 or	 delay	 the	 development	 of	 resistance.	 Additionally,	 targeting	 of	these	genes	during	resistance	may	potentially	reverse	this	adverse	phenotype	and	re-sensitise	the	cells	to	antihormone	treatments.	Alternatively,	expression	of	these	pro-survival	 genes	 during	 initial	 antihormone	 response	 may	 provide	 early	predictive	 markers	 of	 limited	 response	 and	 subsequently	 the	 acquisition	 of	resistance.		The	majority	of	the	microarray	profiles	of	the	14	genes	were	successfully	verified	by	RT-PCR,	with	the	exception	of	BAG1,	DDAH2	and	HBXIP,	which	showed	similar	levels	 of	 mRNA	 expression	 following	 E2-control	 and	 antihormone	 treatments.	Additionally,	 RT-PCR	 verification	 of	 IGFBP5	 continued	 to	 fail,	 with	 no	 mRNA	expression	 detected.	 This	 was	 likely	 due	 to	 the	 PCR	 primers	 recognising	 an	alternative	 region	 of	 mRNA	 to	 that	 recognised	 by	 the	 probes	 on	 the	 Affymetrix	gene	chip.		To	 prioritise	 the	 genes	 further,	 those	 identified	 by	 microarray	 gene	 expression	profiling	to	be	significantly	induced	by	all	three	antihormone	treatments,	with	PCR	verification,	were	considered	for	further	investigation.	These	genes	included	BCL3,	GABBR2,	CTNND2,	CLU	and	TSC22D3.	It	was	hoped	that	a	common	mechanism	of	resistance	to	all	three	clinically-used	antihormone	treatments	could	be	identified.	Such	 genes	 may	 ultimately	 provide	 a	 novel	 biomarker	 indicative	 of	 treatment	
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response	or	a	therapeutic	 target	common	to	resistance	to	all	 three	antihormones	and	 thus	 offering	 a	 therapeutic	 option	 to	 a	 significant	 cohort	 of	 breast	 cancer	patients.	 Ontological	 investigation	 confirmed	 tumour-promoting	 functions	 for	these	 genes	 and	 Western	 blot	 analysis	 (except	 for	 CTNND2)	 revealed	antihormone-induced	 expression	 at	 the	 protein	 level	 in	 MCF-7	 cells	 as	 well	 as	absent	expression	following	E2-control	treatment.		Increased	expression	of	BCL3	has	been	demonstrated	in	breast	cancer	tissue	and	cell	lines,	however	its	precise	role	remains	largely	unknown360.	BCL3	is	an	atypical	member	 of	 the	 IκB	 family	 of	 proteins	 and	 its	 function	 as	 a	 transactivator	 and	transrepressor	 of	 NF-κB	 p50	 and	 p52	 homodimers	 has	 been	 well	 established.	Indeed,	the	majority	of	studies	exploring	the	role	of	BCL3	in	cancer	have	examined	its	association	with	p50	and	p52	and	consequently	 the	activation	of	downstream	NF-κB-regulated	 genes.	 NF-κB	 regulates	 a	 wide	 variety	 of	 genes	 involved	 in	inflammation,	 immunity,	 cell	 growth	and	apoptosis372.	 In	breast	 cancer	cell	 lines,	BCL3	 has	 been	 shown	 to	 act	 as	 a	 coactivator	 of	 p50	 dimers	 to	 stimulate	transcription	 of	 the	 cyclin	 D1	 gene,	 subsequently	 promoting	 G1	 to	 S	 phase	 cell	cycle	transition	and	cell	cycle	progression361.			Short-term	tamoxifen,	fulvestrant	and	oestrogen	deprivation	treatments	have	been	shown	in	this	study	to	induce	up	regulation	of	BCL3	mRNA	and	protein	expression	in	 MCF-7	 cells,	 with	 increased	 expression	 maintained	 into	 the	 emergence	 of	resistant	 growth.	 In	 agreement	 with	 these	 findings,	 Pratt	 et	 al.	 demonstrated	increased	expression	of	BCL3	in	MCF-7	cells	following	oestrogen	withdrawal,	with	parallel	increases	in	NF-κB	activity	(consisting	primarily	of	p50	homodimers)	and	enhanced	 tumour	 growth363.	 These	 actions	 may	 be	 due	 in	 part	 to	 the	 reported	ability	of	BCL3-p50/p52	complexes	to	induce	cyclin	D1361,373	expression	as	well	as	promote	AP-1-mediated	 transactivation	and	cell	proliferation374.	Moreover,	BCL3	and	 NF-κB	 activity	 was	 enhanced	 further	 in	 ER+	 oestrogen-independent	 cells	derived	from	MCF-7	cells.	The	findings	presented	 in	the	current	study,	as	well	as	those	 reported	 previously,	 strongly	 suggest	 that	 early	 induction	 of	 BCL3	 by	antihormones	during	 response	 likely	 contributes	 to	 the	 ability	of	 cells	 exhibiting	increase	BCL3-p50/p52	complexes	to	grow	and	survive	the	antihormone	challenge	to	establish	the	hormone-independent	cohort.		
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Several	 studies	 have	 reported	 a	 pro-survival	 for	 BCL3.	 In	 MCF-7	 cells,	 BCL3	expression	has	been	reported	to	increase	following	DNA	damage,	with	constitutive	expression	of	BCL3	promoting	suppression	of	DNA-damage-induced	cell	death	via	inhibiting	 the	 expression	 of	 the	 tumour	 suppressor	 gene	 p53367.	 Consequently,	such	 inhibition	 results	 in	 the	 suppression	of	 apoptosis	 and	ultimately	 stimulates	cell	survival.	The	dominant	mechanism	reported	by	which	this	inhibition	occurs	is	via	 the	 ability	 of	 BCL3	 to	 induce	 up	 regulation	 of	 the	 p53	 inhibitor	 Hdm2367.	Furthermore,	BCL3	has	been	shown	to	bind	to	the	anti-apoptotic	protein	CtBP1	to	promote	 cell	 survival368.	 CtBP1	 exerts	 its	 anti-apoptotic	 function	 by	transcriptionally	repressing	pro-apoptotic	genes.	In	response	to	apoptotic	stimuli,	CtBP1	 is	degraded	which	 results	 in	derepression	of	pro-apoptotic	genes	 to	allow	apoptosis	to	proceed375.	However,	BCL3	has	been	shown	to	bind	to	CtBP1,	blocking	its	 ubiquitination	 thus	 leading	 to	 its	 stabilisation.	 Consequently,	 CtBP1-mediated	repression	 of	 pro-apoptotic	 genes	 is	 sustained	 and	 cells	 become	 resistant	 to	apoptotic	 stimuli,	 ultimately	 promoting	 cell	 survival368.	 Moreover,	 a	 positive	correlation	 between	 increased	 BCL3	 and	 CtBP1	 proteins	 levels	 has	 been	demonstrated	in	breast	cancer	cell	lines	and	tissues368.		Of	the	5	pro-survival	genes	identified,	CLU	has	been	explored	the	most	with	regard	to	 breast	 cancer	 and	 endocrine	 resistance.	 CLU	 is	 a	 ubiquitously	 expressed	glycoprotein	 implicated	 in	 several	 physiological	 processes,	 including	 lipid	transport,	 complement	 cascade	 and	 programmed	 cell	 death.	 As	 a	 result	 of	alternative	 splicing,	 CLU	 has	 two	 main	 isoforms,	 both	 exhibiting	 opposing	biological	functions.	The	CLU-S	form	starts	as	an	approximately	60	kDa	precursor	peptide	 which	 is	 cleaved	 and	 glycosylated	 to	 generate	 an	 α	 and	 β	 chain,	 each	approximately	40	kDa,	which	heterodimerise	and	ultimately	become	the	secreted	form370.	 CLU-S	 is	 believed	 to	 be	 cytoprotective	 and	 involved	 in	 the	 clearance	 of	cellular	debris	and	promotion	of	phagocytosis376,377.	 In	contrast,	 the	nuclear	form	is	 first	 translated	 into	 an	 inactive	 49	 kDa	 form	 which	 is	 post-translationally	modified	to	an	active	55	kDa	form	which	accumulates	in	the	nucleus	and	promotes	cell	death369,378,379.		Increased	 expression	 of	 CLU-S	 has	 been	 reported	 in	 several	 cancers,	 including	gastric,	ovarian	and	breast	where	it	is	found	to	play	a	significant	role	in	metastasis,	
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invasion	 and	 cell	 survival,	 ultimately	 contributing	 to	 poor	 patient	outlook336,337,380,381.	Furthermore,	short-term	tamoxifen,	fulvestrant	and	oestrogen	deprivation	 treatments	 have	 been	 shown	 here	 to	 significantly	 up	 regulate	 CLU	expression	 in	MCF-7	 cells	 during	 response,	with	 expression	maintained	 into	 the	acquisition	of	 resistance.	Although	 the	microarray	 gene	probes	 and	PCR	primers	did	 not	 specifically	 target	 CLU-S,	 the	 antibody	 used	 in	 the	Western	 analysis	was	CLU-S-specific	 and	 a	 previous	 study	 has	 identified	 CLU-S	 as	 the	 most	 abundant	form	 in	 MCF-7	 cells295.	 Together	 this	 strongly	 suggests	 that	 the	 anti-apoptotic	CLU-S	 form	 is	 induced	 by	 antihormones.	 In	 agreement	 with	 these	 findings,	Toffanin	et	al.	have	demonstrated	 increased	expression	of	CLU-S	 following	3	day	treatment	 with	 the	 SERMs	 tamoxifen	 and	 toremifene	 in	 ER+	 breast	 cancer	 cell	lines,	 including	MCF-7	cells338.	Moreover,	Redondo	et	al.	demonstrated	 increased	CLU	expression	 as	 early	 as	24	hours	post-tamoxifen	 treatment	 in	MCF-7	 cells339.	Additionally,	 a	 combination	 of	 tamoxifen	 and	 antibodies	 targeting	 CLU	 inhibited	CLU	 expression	 together	 with	 inducing	 a	 decrease	 in	 cell	 viability.	 This	combination	treatment	had	a	greater	effect	on	cytotoxicity	compared	to	tamoxifen	alone339.	 These	 findings	 strongly	 suggest	 a	 cytoprotective	 role	 for	 CLU	 in	 breast	cancer	cells	which	may	limit	the	anti-tumour	actions	of	antihormones	to	promote	resistant	 growth,	 and	 also	 illustrates	 the	 potential	 for	 anti-CLU	 therapy	 in	 the	treatment	of	breast	cancer.	Furthermore,	increased	levels	of	CLU	have	been	shown	in	T47D	cells	deemed	resistant	to	antihormones,	with	CLU	expression	involved	in	promoting	resistant	cell	growth.	Down	regulation	of	CLU	re-sensitised	these	cells	to	 toremifene338.	 However	 there	 are	 no	 studies	 showing	 an	 association	 between	CLU	expression	and	limited	response	to	fulvestrant	and	oestrogen	deprivation/AIs.			Several	 studies	 have	 reported	 a	 pro-survival	 role	 for	 CLU-S	 via	 interacting	with,	and	 modulating,	 several	 key	 signalling	 pathways	 involved	 in	 carcinogenesis.	 In	prostate	 cancer	 cells,	 CLU-S	 has	 been	 demonstrated	 to	 increase	 AKT	phosphorylation	and	promote	downstream	survival	signalling348.	Additionally,	also	in	 prostate	 cancer,	 CLU-S	 has	 been	 shown	 to	 enhance	 nuclear	 translocation	 of	NF-κB	 subsequently	 increasing	 transactivation	 of	 NF-κB–regulated	 genes	implicated	 in	cell	survival	and	proliferation349.	Furthermore,	several	studies	have	shown	 that	 ERK	 1/2	 (members	 of	 the	 MAPK	 super	 family,	 involved	 in	 cell	
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proliferation	 and	 apoptosis)	 is	 regulated	 by	 CLU-S	 in	 several	 cancers,	 including	pancreatic,	 lung	 and	 osteosarcoma345–347.	 These	 pathways	 have	 all	 been	 heavily	implicated	 in	 breast	 cancer	 and	 indeed	 endocrine	 resistance,	 thus	 it	 is	 strongly	possible	that	antihormone-induced	CLU-S	 interacts	and	regulates	these	pathways	to	establish	a	mechanism	to	combat	antihormone	challenge	and	promote	resistant	cell	 growth.	 An	 antisense	 inhibitor	 of	 CLU,	 OGX-011,	 is	 currently	 in	 clinical	development.	Phase	I	and	II	clinical	trials	have	demonstrated	that	OGX-011	is	well	tolerated	 and	 is	 successfully	 delivered	 to	 malignant	 tissues	 with	 significant	inhibition	of	CLU	expression.	A	phase	II	study	demonstrated	a	survival	advantage	of	OGX-011	combined	with	docetaxel	in	patients	with	advanced	prostate	cancer382.	This	 led	 to	 the	 development	 of	 phase	 III	 trials	 which	 are	 currently	 underway,	examining	OGX-011	in	combination	with	chemotherapy	in	patients	with	metastatic	prostate	cancer.	If	successful,	these	studies	will	validate	OGX-011	as	a	new	option	for	metastatic	prostate	cancer	patients343.	These	studies	may	endorse	a	new	class	of	targets	and	targeted	therapy	approach	for	cancer.	In	breast	cancer,	combination	of	 OGX-011	 and	 antihormone	 therapy	 may	 delay/prevent	 the	 development	 of	resistance	 or	 in	 endocrine	 resistant	 tumours	OGX-011	may	 reverse	 the	 resistant	phenotype	and	re-sensitise	breast	cancer	cells	to	antihormones.		Increased	 GABA	 B	 receptor	 expression	 has	 been	 reported	 in	 several	 cancers,	including	gastric,	 thyroid	and	breast317.	However,	 the	role	of	 this	receptor	and	 in	particular	 the	 GABBR2	 subunit	 in	 cancer	 remains	 largely	 unexplored.	 Increased	expression	 of	 GABA	 B	 receptor	 and	 the	 GABA	 synthesising	 enzymes,	 GAD1	 and	GAD2,	 in	 breast	 cancer	 cells	 has	 been	 demonstrated	 suggesting	 the	 existence	 of	GABAergic	 signalling	 within	 these	 cells318.	 Furthermore,	 activation	 of	 GABA	 B	receptors	 promotes	 breast	 cancer	 cell	 invasion	 and	 metastasis	 by	 increasing	phosphorylated	 ERK	 1/2	 levels	 and	 subsequently	 increasing	 the	 expression	 of	MMP-2319.	Similarly,	increased	GABA	B	receptor	signalling	in	prostate	cancer	cells	has	been	shown	to	enhance	the	metastatic	and	invasive	capacity	of	the	cells,	again	by	promoting	expression	of	MMPs,	in	particular	MMP-3325.	MMPs	play	vital	roles	in	degrading	 the	 extracellular	 matrix,	 thus	 enabling	 tumour	 cells	 to	 penetrate	 the	basement	membrane,	enter	the	circulation	and	invade	target	organs319.	MMP-2	has	been	shown	to	play	a	role	in	metastasis	of	breast	cancer	to	the	brain	and	as	such	its	
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expression	 is	 associated	 with	 disease	 progression	 and	 poorer	 patient	outlook320,383.	In	contrast,	studies	in	pancreatic	and	lung	cancer	have	implicated	a	growth	inhibitory	role	for	GABA	B	receptor	activation384,385.	However,	 GABBR2	 has	 never	 previously	 been	 associated	 with	 limiting	antihormone	 response	 in	 breast	 cancer	 and	 promoting	 the	 development	 of	resistance.	 GABBR2	 expression	 increases	 in	MCF-7	 cells	 treated	 short-term	with	tamoxifen,	fulvestrant	and	oestrogen	deprivation	(to	mimic	the	actions	of	AIs)	and	its	expression	is	maintained	into	the	resistant	setting	as	shown	in	TAMR,	FASR	and	XR	cells.	These	 findings	demonstrate	 that	antihormones	 induce	the	expression	of	GABBR2	early	during	response,	with	increased	expression	maintained	through	to	the	 acquisition	 of	 resistance,	 and	 together	 with	 the	 above-mentioned	tumour-promoting	functions	reported	for	GABA	B	receptor,	suggest	that	this	gene	may	contribute	substantially	to	the	emergence	of	endocrine	resistance.		GABA	B	receptors	are	heterodimeric	GPCRs	comprised	of	GABBR1	(which	contains	the	 ligand-binding	 domain)	 and	 GABBR2	 (which	 is	 coupled	 to	 G	 proteins	 to	regulate	 activity)	 subunits,	 both	 of	 which	 are	 required	 for	 normal	 receptor	function.	 Therefore,	 the	 expression	 of	 GABBR1	 was	 also	 investigated	 during	antihormone	response	and	resistance	to	determine	whether	it	is	present	together	with	 GABBR2,	 thus	 rendering	 the	 receptor	 fully	 active.	 GABBR1	 expression	was	analysed	 in	 the	 microarray	 gene	 expression	 dataset	 of	 MCF-7	 cells	 treated	 for	10	days	with	 antihormones	 and	 in	 the	 endocrine-resistant	 cell	models.	 The	 data	suggested	absent	expression	of	this	protein	following	E2-control	and	antihormone	treatments	 in	 MCF-7	 cells,	 characterised	 by	 log2	 intensity	 values	 below	 0	 and	down	 regulation	 of	 expression	mediated	 by	 fulvestrant	 treatment.	 Following	 the	acquisition	 of	 resistance,	 the	 microarray	 data	 demonstrated	 up	 regulation	 of	GABBR1	 in	TAMR	cells,	with	no	change	 in	gene	expression	apparent	 in	 the	FASR	and	XR	cells	compared	to	MCF-7	control.	However,	the	log2	intensity	values	were	below	0	 in	 the	three	antihormone-resistant	cell	 lines,	 indicative	of	very	 low	gene	expression.	Moreover,	GAD1	and	GAD2	are	 the	key	enzymes	 involved	 in	 the	 synthesis	of	 the	ligand,	GABA.	Thus,	 their	expression	was	next	 investigated	to	determine	whether	
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GABA	 is	 produced	 by	 the	 cells	 and	 therefore	 able	 to	 activate	 GABA	 B	 receptor	signalling.	Analysis	of	GAD1	and	GAD2	in	the	microarray	dataset	revealed	absent	expression	 in	 MCF-7	 cells	 regardless	 of	 treatment,	 characterised	 by	 log2	expression	values	below	0.	Furthermore,	antihormones	 induced	down	regulation	of	GAD1	expression	compared	 to	E2-control.	Similarly,	 tamoxifen	and	 fulvestrant	promoted	 down	 regulation	 of	 GAD2	 expression	 whilst	 oestrogen	 deprivation	increased	 its	 expression	 compared	 to	 control.	 In	 contrast,	 GAD1	 and	 GAD2	expression	were	up	regulated	 in	TAMR	cells	versus	MCF-7	control,	 together	with	log2	 intensity	 values	 above	 0,	 strongly	 suggesting	 reliable	 gene	 expression.	However,	 in	 the	FASR	and	XR	cell	models,	GAD1	was	down	regulated,	 and	GAD2	expression	 was	 unchanged,	 compared	 to	 MCF-7	 control,	 together	 with	 log2	expression	values	below	0,	representative	of	very	low	gene	expression.	The	 microarray	 data	 suggested	 very	 low	 expression	 of	 GABBR1	 in	 MCF-7	 cells	during	 antihormone	 response,	 with	 low	 expression	 maintained	 through	 to	 the	acquisition	 of	 resistance.	 Similarly,	 low	 expression	 of	 GAD1	 and	 GAD2	 were	reported	in	antihormone-treated	MCF-7	cells	and	antihormone-resistant	FASR	and	XR	cells.	Together,	these	findings	imply	no	GABBR2	activation	during	antihormone	response	and	following	the	development	of	resistance	to	fulvestrant	and	oestrogen	deprivation.	 However,	 the	 microarray	 data	 suggest	 that	 the	 ligand,	 GABA,	 is	synthesised	in	TAMR	cells,	characterised	by	the	presence	of	GAD1	and	GAD2	genes.	Even	 though	 the	microarray	 findings	 suggest	 low	 expression	 of	 GABBR1	 during	antihormone-response	 and	 –resistance	 (necessary	 for	 normal	 GABA	 B	 receptor	function),	 antihormone-induced	expression	of	GABBR2	at	 the	mRNA	and	protein	level,	with	expression	detected	in	resistance	by	microarray,	plus	ontology	strongly	suggesting	a	role	in	disease	progression,	warrants	further	study	of	GABBR2.	However,	 in	 contrast	 to	 the	microarray	 data	 reported	 in	 this	 study,	 Zhang	 et	 al.		have	demonstrated	expression	of	GABBR1	and	GAD1/2	proteins	 in	breast	cancer	cell	 lines,	 including	 MCF-7	 cells,	 and	 in	 normal	 and	 cancerous	 breast	 tissue319.	Additionally,	 the	 GABA	 B	 receptor	 agonist	 baclofen	 promoted	 cell	 invasion	 and	migration	 in	 vitro	 and	 metastasis	 in	 vivo,	 mediated	 via	 enhanced	 ERK	 1/2	signalling	and	MMP-2	production.	This	suggests	that	GABAB	receptors	(comprising	
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GABBR1	and	GABBR2	subunits)	are	functional	and	activated	in	breast	cancer,	with	such	activation	involved	in	promoting	disease	progression.		The	 function	 of	 GABBR2	 in	 breast	 cancer	 is	 largely	 unknown	 and	 a	 pro-survival	role	 is	 particularly	 unreported.	 However,	 GABBR2	 activation	 has	 been	 shown	 to	promote	 survival	 of	 neuronal	 cells	 and	 to	 inhibit	 apoptosis	 by	 transactivating	IGF-1R326.	 The	 importance	 of	 IGF-1R	 signalling	 in	 promoting	 breast	 cancer	 cell	survival	 is	well	 established	with	 increased	 signalling	 also	 playing	 a	 role	 in	 drug	resistance	 (as	 previously	 discussed	 in	 section	 1.7.4.1)198.	 Specifically,	 increased	signalling	 via	 the	 IGF-1R	 pathway	 has	 been	 associated	 with	 the	 acquisition	 of	resistance	 to	 gefitinib	 (EGFR	 inhibitor),	 herceptin	 (HER2	 inhibitor)	 and	tamoxifen198,222,386.	Increased	 expression	 of	 CTNND2	 has	 been	 observed	 in	 several	 human	 cancers	including	 ovarian,	 prostate	 and	 oesophageal,	 and	 is	 associated	 with	 enhanced	malignancy	 and	 poor	 prognosis329,331,332.	 The	 role	 of	 CTNND2	 has	 been	 largely	studied	 in	 prostate	 cancer.	 Indeed,	 CTNND2	 disrupts	 E-cadherin-based	 cell-cell	junctions	(which	are	pivotal	in	maintaining	epithelial	tissue	integrity)	to	promote	cell	 migration,	 increases	 the	 expression	 of	 cyclin	 D1	 to	 promote	 cell	 cycle	progression	and	increases	the	expression	of	the	anti-apoptotic	protein	BCL2L1	to	promote	cell	survival332,333.	Similarly,	overexpression	of	CTNND2	in	ovarian	cancer	cells	 promotes	 invasion	 and	 cell	 proliferation	 and	 accelerated	 cell	 cycle	progression	 by	 up	 regulating	 cyclin	 D1	 expression329.	 Until	 recently,	 CTNND2	expression	in	breast	cancer	had	not	been	reported.	Zhang	et	al.	showed	increased	expression	of	 CTNND2	 in	breast	 cancer	 tissue	 compared	 to	normal	breast,	 again	with	increased	expression	associated	with	a	higher	degree	of	malignancy	and	poor	prognosis327.	Furthermore,	 in	breast	cancer	cell	 lines	(including	ER+	MCF-7	cells)	CTNND2	has	been	shown	to	promote	cell	cycle	progression	by	accelerating	G1	to	S	phase	transition	and	has	also	been	shown	to	enhance	cell	invasion327.		Apart	 from	 array	 studies	 within	 the	 group	 showing	 antihormone-induced	expression	 of	 CTNND2	 with	 increased	 expression	 maintained	 into	 TAMR/FASR	cells304,	there	are	no	other	studies	reporting	an	association	between	CTNND2	and	antihormone	failure	and	consequently	the	development	of	resistance.	In	support	of	
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the	 previous	 findings,	 CTNND2	 expression	 increases	 in	 MCF-7	 cells	 treated	 for	10	days	 with	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 with	 expression	maintained	into	TAMR,	FASR	and	XR	cell	models.	Although	this	was	demonstrated	at	 the	mRNA	level,	 it	could	not	be	confirmed	at	 the	protein	 level	due	to	 the	poor	specificity/failure	of	the	antibody	and	indeed	the	lack	of	available	antibodies.	Regarding	a	pro-survival	 role,	previous	 studies	 in	prostate	 cancer	 cell	 lines	have	shown	 that	 increased	 CTNND2	 expression	 up	 regulates	 expression	 of	anti-apoptotic	 proteins,	 BCL2L1	 and	 survivin,	 to	 promote	 cell	 survival	 and	protection	 from	 apoptosis332.	 Interestingly,	 initial	 extensive	 analysis	 of	 the	microarray	 data	 in	 this	 study	 identified	 both	 BCL2L1	 and	 survivn/BIRC5	 as	antihormone-induced	 genes,	 with	 expression	 maintained	 into	 the	 acquisition	 of	resistance.	 BCL2L1	 expression	 was	 subsequently	 verified	 by	 PCR	 which	demonstrated	up	regulation	of	expression	following	10	day	tamoxifen,	fulvestrant	and	oestrogen	deprivation	treatments	compared	to	E2-control	in	MCF-7	cells.	It	is	possible	 from	 these	 results,	 supported	 by	 those	 from	 the	 study	 by	 Zeng	 et	 al.	 in	prostate	 cancer	 cells332,	 that	 antihormone	 induced	CTNND2	may	promote	breast	cancer	cell	survival	by	up	regulating	the	expression	of	BCL2L1.	The	anti-apoptotic	protein	BCL2L1,	also	known	as	BCL-XL,	belongs	to	the	family	of	BCL-2	proteins,	and	its	expression	has	been	associated	with	 the	progression	of	breast	cancer	and	 the	development	of	advanced	metastatic	disease387,388.	In	MCF-7	cells,	overexpression	of	HER2	has	been	shown	 to	promote	 increased	expression	of	BCL-XL	 resulting	 in	suppression	of	 tamoxifen-induced	 apoptosis267.	 Thus,	 since	 antihormones	 induce	HER2	 expression	 early	 during	 response	 as	 reported	 here	 and	 in	 previous	studies217,	 it	 is	 possible	 that	 such	 induction	 contributes	 to	 cell	 survival	 by	promoting	expression	of	CTNND2	which	subsequently	increases	the	anti-apoptotic	protein	 BCL2L1,	 resulting	 in	 de-regulation	 of	 apoptotic	 pathways	 and	consequently	constituting	a	potential	mechanism	of	resistance	to	antihormones.		However,	 although	 BIRC5	 expression	 was	 induced	 by	 antihormones	 with	expression	maintained	 into	 cell	 models	 of	 resistance,	 together	 with	marginal	 or	present	 detection	 calls	 recorded,	 this	 induction	 did	 not	 reach	 significance	 and	BIRC5	was	therefore	dismissed	from	further	study	during	the	initial	filtering	stages	of	the	microarray	data.	However,	this	does	not	rule	out	a	role	for	BIRC5	in	limiting	
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the	 efficacy	 of	 antihormones	 and	 promoting	 resistance.	 Survivin/BIRC5	 is	 a	member	 of	 the	 inhibitor	 of	 apoptosis	 protein	 family.	 These	 proteins	 block	apoptotic	cell	death	primarily	by	preventing	the	activation	and	activity	of	several	caspases.	Increased	expression	of	BIRC5	has	been	reported	in	breast	cancer389,390.	Interestingly,	HBXIP	 is	a	 co-factor	 for	BIRC5	and	when	complexed	 they	bind	and	suppress	 activation	 of	 pro-caspase-9	 to	 prevent	 downstream	 apoptosis391.	 In	support	of	this,	HBXIP	was	identified	in	the	microarray	data	of	the	present	study	as	an	 antihormone-induced	 gene	 with	 expression	 maintained	 through	 to	 the	acquisition	 of	 resistance.	 Short-term	 antihormone-induced	 expression	 of	 HBXIP	was	 also	 verified	 at	 the	mRNA	 level	 by	 PCR.	 Thus	 it	 is	 possible,	 that	HBXIP	 and	BIRC5	proteins	 complex	 following	 antihormone	 therapy	 to	 inhibit	 apoptosis	 and	consequently	contribute	to	the	emergence	of	resistant	growth.		Interestingly,	in	prostate	cancer	cells	Kim	et	al.	have	shown	that	CTNND2-induced	E-cadherin	processing	is	mediated	by	PSEN1333.	In	turn,	E-cadherin-based	cell-cell	junctions,	pivotal	in	maintaining	epithelial	tissue	integrity,	are	disrupted	resulting	in	tumour	proliferation	and	progression.	In	support	of	this,	microarray	studies	and	RT-PCR	performed	in	this	study	confirm	increased	expression	of	PSEN1	in	MCF-7	cells	 treated	 with	 antihormones	 with	 expression	maintained	 into	 the	 resistance	setting,	mirroring	CTNND2	expression.	Thus,	an	alternative	mechanism	by	which	CTNND2	 potentially	 promotes	 breast	 cancer	 progression	 early	 during	antihormone	response	may	be	through	recruitment	of	PSEN1	to	induce	E-cadherin	processing,	ultimately	stimulating	aggressive	malignant	behaviour.		The	ubiquitously	expressed	small	leucine	zipper	protein	TSC22D3	has	been	largely	studied	in	T	lymphocytes	where	it	mediates	several	glucocorticoid	functions	such	as	 T	 lymphocyte	 activation,	 apoptosis	 and	 cell	 proliferation350.	 These	 actions	 in	T	cells	 are	 accomplished	 by	 TSC22D3	 interacting	 with	 and	 modulating	 key	signalling	pathways	important	for	tumorigenesis.	For	example,	TSC22D3	binds	and	traps	 NF-κB	 in	 the	 cytosol,	 preventing	 its	 nuclear	 localisation	 and	 activation	 of	target	genes	 involved	 in	cell	proliferation	and	survival392.	Furthermore,	TSC22D3	binds	Raf	and	Ras	to	inhibit	activation	of	downstream	targets	 including	ERK	1/2,	AKT	 and	 cyclin	 D1,	 thus	 resulting	 in	 inhibition	 of	 cell	 proliferation393.	 TSC22D3	expression	 has	 been	 demonstrated	 in	multiple	myeloma,	 leukaemia	 and	 ovarian	
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cancer,	however	its	role	in	tumorigenesis	remains	elusive352–354.	In	ovarian	cancer	TSC22D3	has	been	shown	to	enhance	phosphorylated	AKT	content	and	activity	to	promote	 cell	 proliferation.	 This	 is	 in	 contrast	 to	 the	 roles	 reported	 in	 T	lymphocytes,	 where	 TSC22D3	 inhibits	 downstream	 AKT	 signalling	 cascades	resulting	in	an	anti-proliferative	effect	in	these	cells393,394.	These	opposing	roles	of	TSC22D3	 are	 likely	 due	 to	 the	 differing	 cell	 types	 and	 the	 associated	 cellular	milieus.	Furthermore,	TSC22D3	promotes	cell	cycle	progression	in	ovarian	cancer	cells	 by	 up	 regulating	 cyclin	 D1	 and	 down	 regulating	 p21	 expression,	 thus	promoting	S	phase	entry354,	again	in	contrast	to	that	observed	in	T	lymphocytes.	In	 the	 present	 study,	 TSC22D3	 expression	 was	 induced	 by	 10	 day	 tamoxifen,	fulvestrant	 and	 oestrogen	 deprivation	 in	MCF-7	 cells,	 with	 increased	 expression	maintained	into	resistance.	In	support	of	these	findings,	tamoxifen	and	fulvestrant	have	been	 shown	 to	 induce	TSC22D3	expression	 in	MCF-7	and	uterine	epithelial	cells,	respectively,	which	was	reversed	by	oestrogen351,395.	Tynan	et	al.	is	the	only	study	 demonstrating	 an	 association	 between	 TSC22D3	 and	 breast	 cancer351.	 In	contrast,	oestrogen	has	been	shown	to	up	regulate	TSC22D3	expression	in	cervical	cancer	and	human	embryonic	kidney	cells,	suggesting	that	cell	specific	factors	are	involved	in	oestrogen	regulation	of	TSC22D3	which	is	not	surprising	351.	However,	there	are	no	previous	reports	associating	TSC22D3	expression	and	 function	with	antihormone	resistance.	Furthermore,	 there	 are	no	 studies	describing	 a	pro-survival	 role	 for	TSC22D3	 in	breast	cancer.	TSC22D3	has	been	shown	to	promote	apoptosis	 in	neutrophils	(by	inhibiting	 AKT	 phosphorylation)355	 and	 chronic	 myeloid	 leukaemia	 cells	expressing	BCR-ABL	oncogene356.	However,	in	T	cells	TSC22D3	has	been	shown	to	be	protective	against	activation-induced	cell	death,	but	not	from	apoptosis	induced	by	other	apoptotic	stimuli357.	Furthermore,	 in	solid	 tumours,	particularly	ovarian	cancer,	 TSC22D3	 has	 been	 shown	 to	 promote	 AKT	 signalling	 (as	 previously	mentioned)354	which	 is	 implicated	 in	 cell	 survival,	 although	 this	was	not	directly	examined	 in	 this	 study.	 Together,	 these	 findings	 support	 the	 suggestion	 that	 the	role	of	TSC22D3	is	likely	to	be	multifaceted	and	dependent	on	the	cellular	milieu.	Thus,	 further	 studies	 are	 clearly	 required	 to	 determine	 whether	 this	 protein	promotes	 cell	 survival	 in	 breast	 cancer,	 to	 allow	 the	 cells	 to	 overcome	 the	
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antihormone	 challenge	 and	 ultimately	 contribute	 to	 the	 emergence	 of	 resistant	growth	and	poor	clinical	outcome.		In	 summary,	 this	 Chapter	 has	 identified	 a	 panel	 of	 antihormone-induced	pro-survival	 genes	 via	 extensive	 analysis	 of	 microarray	 gene	 expression	 data	combined	with	 a	 robust	 filtering	 strategy	 and	 subsequent	PCR	and	Western	blot	analysis,	 whose	 ontology	 strongly	 suggests	 a	 role	 in	 limiting	 drug	 response	 and	promoting	 the	 emergence	 of	 resistance:	 GABBR2,	 CTNND2,	 CLU,	 TSC22D3	 and	BCL3.	 However,	 additional	 experimental	 repeats	 to	 increase	 the	 n	 numbers	 are	required	 to	 increase	 the	 reliability	 of	 the	 data.	 In	 the	 following	 Chapter,	 the	expression	 of	 these	 5	 genes	 has	 been	 examined	 in	 additional	 cell	 lines	 with	differing	 HER2	 status	 to	 consider	 an	 aspect	 of	 heterogeneity	 that	 exists	 in	 ER+	breast	cancer	and	also	to	determine	whether	antihormone-induced	up	regulation	of	 these	 genes	 is	 common	 across	 several	 cell	 lines	 and	molecular	 subtypes.	 It	 is	feasible	 that	 these	 studies	 could	 identify	 an	 antihormone-induced	mechanism	 of	limiting	 drug	 response	 and	 promoting	 acquisition	 of	 hormone-independent	growth,	common	to	4	ER+	breast	cancer	cell	lines	with	differing	HER2	expression.		
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4 Results	II:	Analysis	of	genes	of	interest	in	MCF-7,	T47D,	BT474	and	MDA-MB-361	cell	lines	
4.1 Introduction	The	 research	 field	 relies	 heavily	 on	 single	 cancer	 cell	 lines	 and	 with	 regard	 to	hormone-dependent	breast	cancer	the	MCF-7	cell	 line	 is	predominantly	used	due	to	its	high	ER	expression	and	subsequent	exquisite	hormone	sensitivity,	making	it	an	 ideal	 model	 to	 study	 hormone	 response396.	 Significant	 advances	 have	 been	derived	 from	 MCF-7	 cell	 studies,	 in	 particular	 the	 recognition	 that	 tamoxifen	regulates	 oestrogen-stimulated	 tumour	 cell	 proliferation397,398	which	 steered	 the	way	for	the	ultimate	development	and	subsequent	clinical	trials	of	fulvestrant,	that	is	 now	 in	 clinical	 use	 for	 recurrent	 ER+	 advanced	 disease	 in	 postmenopausal	women399,400.	Although	significant	information	has	been	generated	from	the	use	of	individual	 cancer	 cell	 lines,	 breast	 cancer	 has	 been	 long	 established	 as	 a	heterogeneous	disease	and	 it	 is	becoming	 increasingly	recognised	that	 the	use	of	the	MCF-7	cell	 line	to	represent	all	ER+	breast	cancer	 is	 insufficient.	As	reviewed	by	Holliday	&	 Speirs,	 it	was	 concluded	 that	 studies	must	move	on	 from	 ‘the	one	marker,	one	cell	line’	approach289.		Genomic	studies	have	established	four	major	subtypes	of	breast	cancer	(shown	in	Table	 14)	 with	 each	 subtype	 exhibiting	 a	 disparate	 prognosis	 and	 treatment	response	 partly	 due	 to	 inherent	 genetic	 differences	 between	 the	 subtypes277,278.	ER+	 tumours	 occur	most	 frequently	 and	 comprise	 two	molecular	 classifications:	luminal	A	and	luminal	B.	The	former	is	the	most	common,	representing	28-31%	of	breast	 cancers277.	 Luminal	 B	 breast	 cancers	 occur	 less	 frequently,	 representing	approximately	 20%	 of	 patients,	 and	 are	 characterised	 by	 HER2	 over	 expression	together	with	ER	expression.	The	HER2	gene	encodes	a	transmembrane	RTK	that	belongs	 to	 the	EGFR	family.	Activation	of	 this	receptor	stimulates	cell	growth	via	downstream	 MAPK	 and	 PI3K	 pathways	 (detailed	 in	 sections	 1.7.4	 and	 1.7.5),	thereby	serving	as	an	oncogenic	driver	in	breast	cancer.	Hyperactivation	of	HER2	signalling	 has	 been	 heavily	 implicated	 in	 driving	 endocrine	 resistance	 as	
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previously	discussed	 in	 section	1.7.4.	 ER+	 and	HER2+	 luminal	B	 tumours	have	 a	greater	 proliferative	 index,	 characterised	 by	 high	 Ki67	 (proliferation	 marker)	expression,	 a	more	 aggressive	 phenotype	 and	worse	 prognosis	 compared	 to	 the	luminal	A	subtype401,402.		
Table	14	Major	molecular	subtypes	of	breast	cancer.	
Classification	 Immunoprofile	
Luminal	A	 ER+,	PR+,	HER2-,	Ki67-	
Luminal	B	 ER+,	PR+/-,	HER2+,	Ki67+	
Basal	 ER-,	PR-,	HER2-,	Ki67+	
HER2	 ER-,	PR-,	HER2+,	Ki67+	
ER:	oestrogen	receptor;	PR:	progesterone	receptor;	HER2:	human	epidermal	growth	
factor	receptor	2;	Ki67:	proliferation	marker.	Adapted	from	Holliday	&	Speirs289.	The	basal-like	subtype	 lacks	expression	of	 the	ER,	PR	and	HER2	(triple	negative)	and	represents	approximately	15%	of	all	breast	cancers.	These	cancers	are	highly	aggressive	and	currently	lack	any	form	of	standard	targeted	systemic	therapy	and	are	therefore	difficult	 to	treat	and	thus	have	extremely	poor	clinical	outcomes403.	These	cancers	are	associated	with	distinct	risk	factors,	including	earlier	menarche,	younger	age	at	 first	 full-term	pregnancy,	high	parity	 together	with	 lack	of	breast	feeding,	 and	 abdominal	 adiposity403,404.	 HER2+	 cancer	 represents	 approximately	17%	of	 all	 breast	 cancers.	 As	well	 as	HER2,	 these	 tumours	 are	 characterised	 by	high	 expression	 of	 genes	 associated	 with	 the	 HER2	 pathway	 e.g.	 GRB7	 (growth	factor	 receptor-bound	 protein	 7)403.	 Morphologically	 HER2+	 breast	 cancers	 are	highly	 proliferative	 and	 typically	 ER-.	 Therapies	 for	 these	 cancers	 include	HER2-targeted	 therapy	 (e.g.	 trastuzumab)	 in	 combination	 with	 cytotoxic	chemotherapy.	 However,	 HER2+	 tumours	 are	 associated	 with	 poor	 clinical	outcomes404.	 Other	 molecular	 subtypes	 such	 as	 normal-like	 have	 also	 been	identified	 in	 some	 studies,	 but	 are	 less	 well	 characterised.	 They	 tend	 to	 cluster	closely	with	normal	breast	epithelium	in	microarray	studies	and	as	such	there	are	doubts	regarding	their	existence	with	some	researches	believing	that	they	could	be	
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a	technical	artefact	from	high	contamination	with	normal	tissue	during	microarray	studies401,404.	In	the	previous	Chapter,	extensive	microarray	analysis	combined	with	verification	by	 PCR	 and	 Western	 blot	 analysis,	 in	 addition	 to	 ontological	 investigation,	identified	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	as	the	most	robust	proteins	up	regulated	by	all	three	antihormones	in	MCF-7	cells	with	expression	maintained	into	 the	 acquisition	 of	 resistance.	 It	 is	 hypothesised	 that	 induction	 of	 these	pro-survival	genes	early	during	antihormone	response	allows	a	cohort	of	cells	 to	survive	 the	 initial	 growth	 inhibitory	 actions	 of	 these	 therapies	 and	 ultimately	contributes	substantially	to	the	emergence	of	resistant	growth.	The	aim	of	this	Chapter	was	to	consider	the	heterogeneity	that	exists	in	ER+	breast	cancer	 and	 to	 build	 on	 the	 data	 presented	 in	 Chapter	 3	 to	 determine	 whether	antihormone-induced	 expression	 of	 these	 5	 genes	 is	 common	 across	 additional	models	 of	 ER+	 disease,	 encompassing	 luminal	 A	 and	 luminal	 B	 subtypes.	Microarray	 data	 obtained	 from	 four	 ER+	 breast	 cancer	 cell	 lines	 (HER2-:	MCF-7	and	T47D	and	HER2+:	BT474	and	MDA-MB-361;	characteristics	detailed	in	section	2.1.1)	 treated	 for	 10	 days	 with	 fulvestrant	 compared	 to	 untreated	 control	 was	utilised,	with	subsequent	PCR	and	Western	blot	verification	alongside	 tamoxifen,	oestrogen	deprivation	and	E2	treatments.	Ultimately,	such	studies	may	 identify	a	novel	 biomarker	 of	 endocrine	 failure	 or	 a	 potential	 therapeutic	 target	 for	resistance,	common	to	several	subtypes	of	breast	cancer	and	thus	representing	a	large	cohort	of	patients.	
4.2 Methods	
4.2.1 Microarray	analysis	Microarray	gene	expression	profiling,	 as	described	 in	 section	2.2,	was	completed	for	10	day	fulvestrant-treated	BT474,	MDA-MB-361,	MCF-7	and	T47D	cells	versus	untreated	control.	The	four	cell	lines	were	cultured	in	medium	supplemented	with	FCS	 ±	 fulvestrant.	 The	 resultant	 triplicate	 data	 were	 uploaded	 on	 to	 the	 online	bioinformatics	 software	 GeneSifter	 where	 the	 data	 was	 first	 median	 normalised	and	 log	 transformed	prior	 to	 analysis.	 This	 GeneSifter-assembled	 array	 resource	was	 interrogated	 using	 the	 gene	 probes	 representing	 GABBR2,	 CTNND2,	 CLU,	
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TSC22D3	 and	 BCL3	 as	 identified	 in	 Chapter	 3	 to	 be	 robustly	 induced	 by	antihormones	 in	 MCF-7	 cells,	 to	 determine	 whether	 fulvestrant	 promoted	 their	expression	 in	 additional	 cell	 models	 of	 ER+	 breast	 cancer,	 thus	 encompassing	HER2+	and	HER2-	disease.	ANOVA	and	post-hoc	Tukey	tests	were	used	to	analyse	the	 differences	 between	 means.	 A	 p	 value	 <0.05	 was	 considered	 statistically	significant.	
4.2.2 RT-PCR	RT-PCR	 was	 performed,	 as	 described	 in	 section	 2.4,	 to	 verify	 the	 Affymetrix	expression	profiles	 of	GABBR2,	 CTNND2,	 CLU,	 TSC22D3	 and	BCL3	 in	 the	HER2+	BT474	 and	MDA-MB-361	 and	 HER2-	MCF-7	 and	 T47D	 cell	 lines.	 Triplicate	 RNA	from	 10	 day	 untreated	 control	 and	 fulvestrant-treated	 cells	 (cultured	 under	 the	same	 conditions	 as	 those	 used	 to	 generate	 the	 samples	 for	 microarray	 gene	profiling),	in	addition	to	10	day	E2-,	tamoxifen-	and	oestrogen	deprivation-treated	cells	 were	 analysed.	 Densitometry	 analysis	 was	 performed	 and	 the	 raw	densitometry	 values	 of	 the	 genes	 of	 interest	were	 normalised	 to	 β-actin	 loading	control.	 The	 data	 were	 analysed	 using	 GraphPad	 prism.	 ANOVA	 and	 Tukey’s	multiple	 comparisons	 post-hoc	 tests	 were	 used	 to	 compare	 the	 means.	 A	p	value	<0.05	was	considered	statistically	significant.	
4.2.3 Western	blotting	The	expression	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	were	examined	at	the	 protein	 level	 by	 Western	 blotting.	 Western	 blotting	 was	 performed	 on	triplicate	 protein	 samples	 from	 10	 day	 untreated	 control,	 E2-,	 tamoxifen-,	fulvestrant-	 and	 oestrogen	 deprivation-treated	 MCF-7,	 T47D,	 BT474	 and	MDA-MB-361	 cells	 as	 described	 in	 section	 2.5.	 The	 data	 were	 analysed	 using	GraphPad	 prism.	 ANOVA	 and	 post-hoc	 Tukey’s	multiple	 comparisons	 tests	were	used	 to	 compare	 the	 means.	 A	 p	 value	 <0.05	 was	 considered	 statistically	significant.	
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4.3 Results	
4.3.1 Microarray	analysis	of	the	5	genes	of	interest	in	fulvestrant-treated	
BT474,	MDA-MB-361,	MCF-7	and	T47D	cell	lines	The	heatmap	shown	in	Figure	41,	generated	from	the	jetset	Affymetix	gene	probes,	demonstrated	up	regulation	(denoted	in	red)	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	expression	 in	 all	 four	 cell	 lines	 following	10	day	 fulvestrant	 treatment	compared	to	untreated	control.	In	the	MDA-MB-361	and	T47D	cell	lines,	TSC22D3	and	CLU	expression,	respectively,	were	similar	pre-	and	post-fulvestrant	treatment	as	 illustrated	 by	 the	 heatmap.	 The	 corresponding	 log2	 intensity	 profiles,	 fold	change	 in	 gene	 induction	 and	 detection	 calls	 for	 the	 5	 genes	 are	 illustrated	 in	Figure	42-Figure	46.		
	
Figure	41	Heatmaps	displaying	change	in	expression	of	the	5	genes	of	interest	following	
10	day	 fulvestrant	 (FAS;	 10-7	M)	 treatment	 versus	untreated	 control	 (CON)	 in	 all	 four	
oestrogen	 receptor	 positive	 cell	 lines.	 Red	 denotes	 an	 increase	 in	 gene	 expression	
compared	to	control	(shown	in	black).	
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4.3.1.1 BCL3	The	 log2	 intensity	 profile	 showed	 significant	 (p	 <0.05,	 n=3)	 induction	 of	 BCL3	expression	 (greater	 than	 1.5	 fold	 change)	 following	 fulvestrant	 treatment	 in	 all	four	cell	lines	(Figure	42A	and	B).	The	greatest	up	regulation	was	observed	in	the	T47D	cell	lines,	with	a	fold	change	of	3.29.	Present	detection	calls	were	recorded	in	all	 four	 cell	 models	 irrespective	 of	 treatment,	 indicative	 of	 reliable	 detection	 of	expression	(Figure	42C).		
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Figure	 42	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 BCL3	 (jetset	 probe	 ID:	
204908_s_at)	in	BT474,	MDA-MB-361,	MCF-7	and	T47D	cells	treated	for	10	days	with	
fulvestrant	 (FAS;	 10-7	 M)	 versus	 untreated	 control	 (CON).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 following	 fulvestrant	 treatment	 and	
(C)	 detection	 calls	 from	 the	 triplicate	 samples.	 *	 p	 <0.05	 compared	 to	 control	
treatment	of	the	equivalent	cell	line.	361:	MDA-MB-361;	P:	present.	
*	*	 *	
*	
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4.3.1.2 CLU	Fulvestrant	 promoted	up	 regulation	 of	 CLU	 expression	 in	 the	HER2+	 and	MCF-7	cell	 lines	 with	 a	 fold	 change	 greater	 than	 1.5	 (Figure	 43A	 and	 B).	 Significant	(p	<0.05,	 n=3)	 up	 regulation	 was	 observed	 in	 the	 MCF-7	 and	 BT474	 cell	 lines	combined	 with	 present	 detection	 calls	 (Figure	 43A	 and	 C).	 However,	 the	 log2	expression	of	 the	untreated	controls	(BT474	and	MCF-7)	 failed	to	reach	0,	which	was	mirrored	by	absent	detection	calls,	suggestive	of	extremely	low/no	expression	(Figure	 43C).	 Interestingly,	 the	 T47D	 cell	 line	 demonstrated	 the	 greatest	 basal	level	 of	 CLU	 expression	 with	 a	 predominantly	 present	 call	 reported.	 A	 small	induction	of	CLU	was	apparent	in	the	MDA-MB-361	(1.59	fold	changed)	and	T47D	(1.13	 fold	 change)	 cell	 lines	with	present	detection	 calls	 reported	pre-	 and	post-treatment,	indicative	of	gene	expression.		
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Figure	 43	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	replicates	±	SEM)	gene	expression	of	CLU	(jetset	probe	ID:	222043_at)	in	
BT474,	MDA-MB-361,	MCF-7	and	T47D	cells	treated	for	10	days	with	fulvestrant	(FAS;	
10-7	M)	versus	untreated	 control	 (CON).	 (B)	Table	displaying	 the	 corresponding	 fold	
change	 in	 gene	 expression	 following	 fulvestrant	 treatment	 and	 (C)	 detection	 calls	
from	the	triplicate	samples.	*	p	<0.05	compared	to	control	treatment	of	the	equivalent	
cell	line.	361:	MDA-MB-361;	P:	present;	A:	absent.	
*	 *	
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4.3.1.3 GABBR2	The	 log2	 intensity	 plot	 revealed	 up	 regulation	 of	 GABBR2	 expression	 by	 10	 day	fulvestrant	 treatment	 in	 all	 four	 ER+	 cell	 lines	 versus	 untreated	 control	 (Figure	44A).	The	greatest	induction	was	observed	in	the	MCF-7	cells,	with	almost	190	fold	change	 (Figure	 44B).	 In	 the	 MDA-MB-361	 and	 MCF-7	 cells,	 the	 log2	 expression	values	were	below	0	and	the	detection	calls	were	absent	in	the	untreated	control	cells	whereas	present	calls	were	reported	following	fulvestrant	treatment	(Figure	44A	 &	 C).	 In	 the	 BT474	 cell	 line,	 present	 detection	 calls	 were	 reported	 in	 the	control	 and	 fulvestrant-treated	 cells	 (Figure	 44C)	 Furthermore,	 fulvestrant-induced	up	regulation	of	GABBR2	in	the	BT474,	MDA-MB-361	and	MCF-7	cells	was	statistically	significant	(p	<0.05,	n=3).	Although	fulvestrant	promoted	induction	of	GABBR2	gene	expression	in	the	T47D	cell,	this	induction	failed	to	reach	statistical	significance.	Additionally,	the	detection	calls	pre-	and	post-treatment	were	absent	in	this	cell	line,	suggesting	very	low	gene	expression	(Figure	44C).	
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Figure	 44	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 GABBR2	 (jetset	 probe	 ID:	
209990_s_at)	in	BT474,	MDA-MB-361,	MCF-7	and	T47D	cells	treated	for	10	days	with	
fulvestrant	 (FAS;	 10-7	 M)	 versus	 untreated	 control	 (CON).	 (B)	 Table	 displaying	 the	
corresponding	fold	change	in	gene	expression	following	fulvestrant	treatment	and	(C)	
detection	calls	from	the	triplicate	samples.	*	p	<0.05	compared	to	control	treatment	of	
the	equivalent	cell	line.	361:	MDA-MB-361;	P:	present;	A:	absent.	
*	
*	*	
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4.3.1.4 CTNND2	The	 log2	 intensity	 plot	 showed	 up	 regulation	 (greater	 than	 1.5	 fold	 change)	 of	CTNND2	 expression	 following	 fulvestrant	 treatment	 in	 all	 four	 cell	 lines	 (Figure	45A	 and	B).	 However,	 although	 fulvestrant	 promoted	 up	 regulation	 in	 the	 T47D	cell	line,	the	induced	levels	remained	lower	than	in	the	other	3	cell	lines	and	absent	calls	 were	 recorded	 (Figure	 45C).	 Present	 detection	 calls	 were	 reported	 in	 the	BT474,	 MDA-MB-361	 and	 MCF-7	 cells	 pre-	 and	 post-treatment	 (Figure	 45C).	Furthermore,	this	was	mirrored	by	a	significant	(p	<0.05)	induction	by	fulvestrant	in	 the	 HER2+	 and	 MCF-7	 cell	 lines	 compared	 to	 control,	 however,	 the	 small	induction	 induced	by	 fulvestrant	 failed	to	reach	significance	 in	 the	T47D	cell	 line	(Figure	45A).			
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Figure	 45	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 CTNND2	 (jetset	 probe	 ID:	
209618_at)	 in	 BT474,	MDA-MB-361,	MCF-7	 and	T47D	 cells	 treated	 for	10	days	with	
fulvestrant	 (FAS;	 10-7	 M)	 versus	 untreated	 control	 (CON).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 following	 fulvestrant	 treatment	 and	
(C)	 detection	 calls	 from	 the	 triplicate	 samples.	 *	 p	 <0.05	 compared	 to	 control	
treatment	of	the	equivalent	cell	line.	361:	MDA-MB-361;	P:	present;	A:	absent.	
*	*	 *	
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4.3.1.5 TSC22D3	The	log2	intensity	plot	revealed	greater	basal	expression	of	TSC22D3	in	the	HER2+	cell	 lines	 compared	 to	 the	HER2-	models	 (Figure	46A).	 Fulvestrant	promoted	up	regulation	of	TSC22D3	expression	in	all	four	cell	lines.	However,	this	induction	was	only	significant	 (p	<0.05,	n=3)	 in	 the	BT474	and	MCF-7	cell	 lines,	with	 the	 latter	also	displaying	a	fold	change	greater	than	1.5	(Figure	46B).	Present	detection	calls	and	 log2	 expression	 values	 greater	 than	 0	 were	 apparent	 in	 all	 four	 cell	 lines	irrespective	of	treatment,	suggesting	reliable	detection	of	expression	(Figure	46C).			
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Figure	 46	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 TSC22D3	 (jetset	 probe	 ID:	
208763_s_at)	in	BT474,	MDA-MB-361,	MCF-7	and	T47D	cells	treated	for	10	days	with	
fulvestrant	 (FAS;	 10-7	 M)	 versus	 untreated	 control	 (CON).	 (B)	 Table	 displaying	 the	
corresponding	fold	change	in	gene	expression	following	fulvestrant	treatment	and	(C)	
detection	calls	from	the	 triplicate	samples.	 *	p	<0.05	compared	to	control	treatment	
of	the	equivalent	cell	line.	361:	MDA-MB-361;	P:	present.		
*	*	
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4.3.2 Verification	of	the	microarray	data	by	RT-PCR	and	Western	blotting	The	Affymetrix	expression	profiles	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	in	the	HER2+	BT474	and	MDA-MB-361	and	HER2-	MCF-7	and	T47D	cell	lines	were	verified	 by	 RT-PCR	 and	Western	 blotting.	 In	 agreement	with	 the	 findings	 of	 the	previous	Chapter,	the	CTNND2	antibody	continued	to	fail	in	all	four	cell	lines,	with	no	protein	expression	detected.	RT-PCR	and	Western	blotting	were	performed	on	triplicate	 RNA	 and	 protein	 samples	 from	 10	 day	 untreated	 control	 and	fulvestrant-treated	cells	(under	the	same	conditions	as	those	used	to	generate	the	samples	 for	 microarray	 gene	 profiling).	 Although	 there	 are	 no	 microarray	 gene	expression	 data	 for	 these	 cell	 lines	 following	 E2,	 tamoxifen	 and	 oestrogen	deprivation	 treatments,	 and	 since	 this	 project	 is	 interested	 in	 all	 three	antihormone	treatments,	the	four	cell	lines	were	exposed	to	these	treatments	and	analysed	by	RT-PCR	and	Western	Blotting.	The	results	are	illustrated	in	Figure	47	to	Figure	55	
4.3.2.1 BCL3	In	agreement	with	the	microarray	data,	fulvestrant	promoted	increased	expression	of	BCL3	mRNA	and	protein	compared	to	untreated	control	in	both	the	HER2+	and	HER2-	cell	lines	(Figure	47	and	Figure	48).	Furthermore,	BCL3	mRNA	and	protein	up	 regulation	 was	 also	 induced	 by	 tamoxifen	 and	 oestrogen	 deprivation	treatments	 in	all	 four	cell	 lines	 (Figure	47	and	Figure	48).	Densitometry	analysis	revealed	 that	 tamoxifen	 promoted	 the	 greatest	 induction	 of	 BCL3	 mRNA	 in	 the	BT474,	 MCF-7	 and	 T47D	 cell	 lines,	 with	 a	 statistically	 significant	 (p	 <0.05)	 up	regulation	observed	in	the	BT474	and	T47D	cell	lines	compared	to	control	(Figure	47A	 and	 D).	 Tamoxifen	 also	 statistically	 significantly	 increased	 BCL3	 mRNA	expression	versus	E2	treatment	in	the	BT474	(p	<0.01),	MCF-7	(p	<0.05)	and	T47D	(p	 <0.05)	 cell	 lines	 (Figure	 47A,	 C	 and	 D).	 In	 contrast,	 oestrogen	 deprivation	treatment	was	shown	to	induce	the	greatest	up	regulation,	although	not	significant,	of	BCL3	mRNA	 in	 the	MDA-MB-361	cell	 line	 (Figure	47B).	 In	 the	BT474	cell	 line,	oestrogen	 deprivation	 treatment	 induced	 significant	 (p	 <0.05)	 up	 regulation	 of	BCL3	 mRNA	 compared	 to	 E2	 treatment	 (Figure	 47A).	 Fulvestrant	 significantly	(p	<0.05)	 increased	 BCL3	 expression	 in	 the	 T47D	 cell	 line	 versus	 E2	 treatment	(Figure	47D).	There	was	very	little	expression	of	BCL3	mRNA	apparent	in	the	four	
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cell	lines	following	E2	treatment	and	in	the	untreated	control	cells	(Figure	47).	For	each	cell	line,	actin	levels	were	similar	following	all	treatments	(Figure	47).	At	 the	 protein	 level,	 densitometry	 analysis	 and	 β-actin	 normalisation	demonstrated	 that	 oestrogen	 deprivation	 treatment	 promoted	 the	 greatest	expression	 of	 BCL3	 in	 the	 BT474	 and	 MCF-7	 cell	 lines,	 which	 was	 statistically	significant	(p	<0.01)	in	the	former	cell	line	versus	E2	treatment	and	control	(Figure	48A	 and	 C).	 In	 the	 MDA-MB-361	 cell	 line,	 tamoxifen	 was	 shown	 to	 induce	 the	greatest	expression	(although	not	significant)	of	BCL3	compared	to	control	and	E2	treatment,	whereas	fulvestrant	and	oestrogen	deprivation	treatments	were	shown	to	significantly	(p	<0.001)	induce	the	greatest	expression	of	BCL3	in	the	T47D	cell	line	 (Figure	 48B	 and	 C).	 Minimal	 BCL3	 expression	 was	 observed	 at	 baseline	(control)	and	following	E2	treatment	in	the	four	cell	lines	(Figure	48).	For	each	cell	line,	actin	levels	were	similar	following	all	treatments	(Figure	48).	
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Figure	 47	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 BCL3	 mRNA	
expression	in	BT474	(A),	MDA-MB-361	(B),	MCF-7	(C)	and	T47D	(D)	cells	treated	with	
oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	*	p	<0.05;	**	p	<0.01.	
B
C
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Figure	48	Representative	Western	blot	images	and	corresponding	β-actin	normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 BCL3	 protein	
expression	in	BT474	(A),	MDA-MB-361	(B),	MCF-7	(C)	and	T47D	(D)	cells	treated	with	
oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	**	p	<0.01;	***	p	<0.001.	
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4.3.2.2 CLU	PCR	 and	 subsequent	 densitometry	 analysis	 revealed	 that	 tamoxifen,	 fulvestrant	and	 oestrogen	 deprivation	 treatments	 induced	 up	 regulation	 of	 CLU	 mRNA	expression	in	MCF-7	cell	lines	compared	to	E2	treatment	and	control	(Figure	49C).	However,	 this	 up	 regulation	 was	 not	 significant.	 Similarly,	 tamoxifen	 and	fulvestrant	 induced	 up	 regulation,	 although	 not	 significant,	 of	 CLU	 mRNA	expression	in	the	BT474	cell	line,	compared	to	E2	treatment	and	control,	however	CLU	 expression	 was	 similar	 in	 oestrogen	 deprivation-treated	 and	 control	 cells	(Figure	 49A).	 These	 data	 are	 in	 agreement	 with	 the	 microarray	 data,	 which	showed	that	fulvestrant	promoted	CLU	gene	up	regulation	in	these	cell	lines.	In	the	MDA-MB-361	 cell	 line,	 although	 tamoxifen	 induced	 increased	 expression	 of	 CLU	mRNA	expression	which	was	not	significant,	the	expression	levels	of	CLU	following	E2,	 control,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 were	 comparable	(Figure	 49B).	 There	was	 no	 obvious	 up	 regulation	 of	 CLU	 expression	 in	 this	 cell	line	following	fulvestrant	treatment	compared	to	control,	which	is	in	disagreement	with	 the	 microarray	 data.	 From	 the	 PCR	 gel,	 the	 baseline	 expression	 of	 CLU	(untreated	control)	was	greatest	in	the	MDA-MB-361	cells	compared	to	the	BT474	and	 MCF-7	 cells.	 This	 profile	 mimicked	 the	 detection	 calls	 reported	 from	 the	microarray	data	which	were	present	 in	MDA-MB-361	control	 cells	 and	absent	 in	BT474	and	MCF-7	controls.	Although	present	detection	calls	were	recorded	 from	the	 microarray	 data	 for	 CLU	 expression	 in	 the	 T47D	 cell	 lines	 pre-	 and	 post-fulvestrant	treatment,	CLU	mRNA	expression	could	not	be	detected	by	PCR	in	this	cell	 line	 following	 E2,	 control,	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	treatments	 (Figure	 49D).	 For	 each	 cell	 line,	 actin	 mRNA	 levels	 were	 constant	following	all	treatments	(Figure	49).	As	 previously	 revealed	 in	 Chapter	 3,	 the	 pro-survival	 isoform	 of	 CLU	 (known	 as	CLU-S)	 exists	 as	 a	 precursor	 and	 a	mature	 form	 composed	 of	 α-	 and	β-subunits.	The	CLU-S	antibody	used	within	this	project	recognises	the	60	kDa	precursor	and	40	kDa	CLUα	subunit.	Western	analysis	revealed	up	regulation	of	the	CLUα	subunit	following	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 compared	 to	 E2	 and	control	treatments	in	BT474,	MDA-MB-361,	MCF-7	and	T47D	cell	lines	(Figure	50).	The	 CLU	 precursor	 subunit	 was	 up	 regulated	 by	 all	 three	 antihormones	 in	 the	
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MDA-MB-361	and	MCF-7	cell	lines,	was	up	regulated	by	fulvestrant	and	oestrogen	deprivation	 treatments	 in	 the	 T47D	 cell	 line,	 and	 tamoxifen	 and	 oestrogen	deprivation	in	the	BT474	cell	 line,	compared	to	E2	treatment	and	control	(Figure	50).	In	agreement	with	the	PCR	data,	tamoxifen	promoted	the	greatest	induction	of	CLUα	 protein	 expression	 in	 the	 BT474	 cell	 line	 versus	 control,	 which	 was	statistically	 significant	 (p	<0.05)	compared	 to	E2	 treatment,	with	 less	expression	induced	by	fulvestrant	and	oestrogen	deprivation	treatments	(Figure	50A).	In	the	MDA-MB-361	cell	line,	oestrogen	deprivation	treatment	promoted	the	greatest	up	regulation	 of	 CLU	 precursor	 and	 CLUα	 expression	 followed	 by	 fulvestrant	 and	tamoxifen	treatments,	respectively	(Figure	50B).	In	fact,	oestrogen	deprivation	and	fulvestrant	 treatment	 promoted	 a	 statistically	 significant	 (p	 <0.01	 and	 p	 <0.05,	respectively)	 increase	 in	CLUα	expression	compared	to	E2	treatment	and	control	(Figure	50B).	In	MCF-7	cells,	similar	expression	of	the	CLU	precursor	was	observed	following	antihormone	treatment.	However,	CLUα	expression	was	up	regulated	by	all	 three	antihormones,	although	 it	was	not	significant	 (Figure	50C).	 In	 the	T47D	cell	 line,	 oestrogen	deprivation	 treatment	 statistically	 significantly	 induced	CLUα	expression	 versus	 control	 (p	 <0.05)	 and	 E2	 treatment	 (p	 <0.01)	 (Figure	 50D).	Tamoxifen	and	fulvestrant	treatments	also	induced	CLUα	expression	however	this	was	 only	 significant	 (p	 <0.05)	 following	 tamoxifen	 treatment	 compared	 to	 E2	treatment	 (Figure	 50D).	 CLU	 precursor	 protein	 was	 statistically	 significantly	(p	<0.05)	 up	 regulated	 by	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	compared	to	control	and	E2	treatment	(Figure	50D).	However,	less	expression	was	induced	 by	 tamoxifen	 treatment	 (Figure	 50D).	 For	 each	 cell	 line,	 actin	 protein	levels	were	constant	following	all	treatments	(Figure	50).		
	 	
	 188	
	
Figure	 49	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 CLU	 mRNA	
expression	 in	 BT474	 (A),	 MDA-MB-361	 (B),	 MCF-7	 (C)	 AND	 T47D	 (D)	 cells	 treated	
with	 oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	
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Figure	 50	 Representative	 Western	 blot	 images	 and	 corresponding	 β-actin	 normalised	 densitometry	 graphs	 from	 three	 independent	
experiments	showing	CLU	precursor	(green	graphs)	and	CLUα	(red	graphs)	protein	expression	in	BT474	(A),	MDA-MB-361	(B),	MCF-7	(C)	
AND	T47D	(D)	cells	treated	with	oestradiol	(E2;	10-9	M),	untreated	control	(CON),	tamoxifen	(TAM;	10-7	M),	fulvestrant	(FAS;	10-7	M)	and	
oestrogen	deprivation	(ED)	for	10	days.	The	results	are	expressed	as	means	±	SEM	and	the	data	were	analysed	by	an	ANOVA	and	post-hoc	
Tukey’s	multiple	comparisons	test.		*	p	<0.05;	**	p	<0.01.	
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4.3.2.3 GABBR2	In	agreement	with	the	microarray	profile,	10	day	fulvestrant	treatment	promoted	up	 regulation	of	GABBR2	mRNA	and	protein	 expression	 in	BT474,	MDA-MB-361	and	 MCF-7	 cells	 compared	 to	 untreated	 control	 (Figure	 51	 and	 Figure	 52).	However,	this	up	regulation	was	not	significant	in	the	three	cell	lines	at	the	mRNA	and	protein	 level	 compared	 to	 control.	At	 the	mRNA	 level	 in	 the	MCF-7	 cell	 line,	fulvestrant	 induced	 significant	 (p	 <0.01)	 up	 regulation	 of	 GABBR2	 expression	compared	 to	 E2	 treatment	 (Figure	 51C).	 Additionally,	 in	 accordance	 with	 the	absent	 detection	 calls	 reported	 from	 the	 microarray	 data,	 GABBR2	 mRNA	 and	protein	 expression	 was	 not	 detected	 in	 T47D	 cells	 pre-	 or	 post-fulvestrant	treatment	 (Figure	 51D	 and	 Figure	 52D).	 Furthermore,	 in	 addition	 to	 fulvestrant,	10	day	tamoxifen	and	oestrogen	deprivation	treatments	 induced	up	regulation	of	GABBR2	mRNA	and	protein	expression	 in	BT474,	MDA-MB-361	and	MCF-7	cells,	and	 actin	 levels	 remained	 constant,	 compared	 to	 E2	 treatment	 and	 untreated	control	(Figure	51	and	Figure	52).		At	 the	mRNA	 level,	 oestrogen	 deprivation	 and	 fulvestrant	 treatment	 statistically	significantly	 (p	<0.05	 and	 p	 <0.01,	 respectively)	 induced	 GABBR2	 expression	compared	to	E2	treatment	in	the	MCF-7	cell	line	(Figure	51C).	At	the	protein	level,	in	the	BT474	and	MDA-MB-361	cell	lines,	oestrogen	deprivation	treatment	induced	significant	up	regulation	of	GABBR2	expression	compared	to	control	(p	<0.05	and	p	 <0.001,	 respectively)	 and	 E2	 treatment	 (p	 <0.01	 and	 p	 <0.001,	 respectively)	(Figure	 52A	 and	 B).	 Additionally,	 fulvestrant	 promoted	 significant	 (p	 <0.05)	 up	regulation	 of	 GABBR2	 protein	 expression	 in	 the	 BT474	 cell	 line	 versus	 E2	treatment	 (Figure	52A).	Despite	 relatively	 similar	actin	mRNA	and	protein	 levels	shown	 in	 the	 T47D	 cell	 line	 following	 antihormone,	 E2	 and	 control	 treatments,	GABBR2	mRNA	and	protein	expression	was	not	detected	(Figure	51D	and	Figure	52D).	 For	 each	 cell	 line	 (not	 including	 T47D),	 GABBR2	 mRNA	 and	 protein	 was	expressed	at	low	levels	in	the	control,	and	at	lower	levels	following	E2	treatment	(Figure	51	and	Figure	52).	
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Figure	 51	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 GABBR2	mRNA	
expression	in	BT474	(A),	MDA-MB-361	(B)	MCF-7	(C)	and	T47D	(D)	cells	treated	with	
oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	 were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	*	p	<0.05;	**	p	<0.01.	
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Figure	52	Representative	Western	blot	images	and	corresponding	β-actin	normalised	
densitometry	graphs	from	three	independent	experiments	showing	GABBR2	protein	
expression	in	BT474	(A),	MDA-MB-361	(B),	MCF-7	(C)	and	T47D	(D)	cells	treated	with	
oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	*	p	<0.05;	**	p	<0.01;	***	p	<0.001.	
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4.3.2.4 CTNND2	In	 contrast	 to	 the	 microarray	 profile,	 there	 was	 no	 apparent	 up	 regulation	 of	CTNND2	 mRNA	 expression	 in	 BT474,	 MDA-MB-361	 and	 MCF-7	 cells	 following	10	day	 fulvestrant	 treatment	 compared	 to	 untreated	 control	 (Figure	 53).	 A	non-specific	 band,	 of	 a	 higher	 molecular	 weight,	 was	 detected	 by	 the	 CTNND2	primers	in	the	three	cell	lines.	Furthermore,	CTNND2	mRNA	expression	could	not	be	detected	in	T47D	cells	irrespective	of	treatment	(Figure	53D).	This	supports	the	absent	 detection	 calls	 and	 low	 log2	 expression	 values	 observed	 in	 this	 cell	 line	during	analysis	of	the	microarray	data.	Moreover,	in	the	BT474,	MDA-MB-361	and	MCF-7	 cell	 lines,	 CTNND2	mRNA	 expression	 following	 tamoxifen	 and	 oestrogen	deprivation	treatments	were	relatively	similar	to	untreated	control	and	fulvestrant	treatments	(Figure	53A,	B	and	C).	In	all	three	cell	lines,	CTNND2	mRNA	expression	was	slightly	down	regulated	by	10	day	E2	treatment	compared	to	control.	For	each	cell	line,	actin	mRNA	levels	were	constant	following	all	treatments	(Figure	53).	As	mentioned	above,	the	CTNND2	antibody	continued	to	fail	in	all	four	cell	lines,	with	no	protein	expression	detected.	
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Figure	 53	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 3	 independent	 experiments	 showing	 CTNND2	 mRNA	
expression	in	BT474	(A),	MDA-MB-361	(B),	MCF-7	(C)	and	T47D	(D)	cells	treated	with	
oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	 were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	
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4.3.2.5 TSC22D3	The	 PCR	 and	 Western	 blotting	 data	 demonstrated	 up	 regulation	 of	 TSC22D3	expression	 by	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 in	MDA-MB-361	and	MCF-7	cells	compared	to	E2	treatment	and	control	(Figure	54B	and	C,	Figure	55B	and	C).	However,	 a	 statistically	 significant	 (p	<0.05)	 induction	was	 only	 observed	 at	 the	 protein	 level	 in	 the	MDA-MB-361	 cell	 line.	 Fulvestrant	induced	 significant	 up	 regulation	 of	 TSC22D3	 protein	 expression	 compared	 to	control	 (p	 <0.001)	 and	 E2	 treatment	 (p	 <0.0001)	 in	 the	 MDA-MB-361	 cell	 line	(Figure	55B).	TSC22D3	protein	expression	was	also	significantly	up	regulated	by	tamoxifen	treatment	compared	to	control	(p	<0.05)	and	E2	treatment	(p	<0.001),	and	also	by	oestrogen	deprivation	treatment	versus	E2	treatment	(p	<0.05)	in	this	cell	 line	 (Figure	 55B).	 These	 profiles	 are	 in	 agreement	with	 the	microarray	 data	which	 revealed	 that	 fulvestrant	 promoted	TSC22D3	 expression	 in	 these	 two	 cell	lines	compared	to	control.	However,	 in	the	BT474	and	T47D	cells	 lines,	TSC22D3	mRNA	expression	was	similar	following	antihormone-,	E2-	and	control-treatments	(Figure	 54A	 and	 Figure	 54D),	whereas	 at	 the	 protein	 level,	 TSC22D3	 expression	was	 induced	by	 all	 three	 antihormones	 versus	E2	 treatment	 and	 control	 (Figure	55A	and	Figure	55D).	However,	this	up	regulation	was	only	significant	(p	<0.05)	in	oestrogen	 deprivation-treated	 BT474	 cells	 versus	 E2	 treatment	 (Figure	 55A).	These	 profiles	 are	 in	 agreement	with	 the	microarray	 data	which	 suggested	 that	fulvestrant	promoted	up	regulation	of	TSC22D3	expression	in	these	cell	lines.	Actin	mRNA	and	protein	levels	remained	constant	following	all	treatments	for	each	cell	line	(Figure	54	and	Figure	55).	Moreover,	at	the	protein	level,	very	little	TSC22D3	expression	was	detected	following	E2	and	control	treatments	(Figure	55).		
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Figure	 54	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	graphs	from	three	 independent	experiments	showing	TSC22D3	mRNA	
expression	 in	 BT474	 (A),	 MDA-MB-361	 (B),	 MCF-7	 (C)	 AND	 T47D	 (D)	 cells	 treated	
with	 oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	
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Figure	55	Representative	Western	blot	images	and	corresponding	β-actin	normalised	
densitometry	graphs	from	three	independent	experiments	showing	TSC22D3	protein	
expression	 in	 BT474	 (A),	 MDA-MB-361	 (B),	 MCF-7	 (C)	 AND	 T47D	 (D)	 cells	 treated	
with	 oestradiol	 (E2;	 10-9	 M),	 untreated	 control	 (CON),	 tamoxifen	 (TAM;	 10-7	 M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	10	days.	The	results	are	
expressed	 as	means	 ±	 SEM	 and	 the	 data	were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	
Tukey’s	multiple	comparisons	test.	*	p	<0.05;	***	p	<0.001;	****	p	<0.0001.	
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4.4 Discussion	Breast	 cancer	 is	 a	 highly	 heterogeneous	 disease	 and	 has	 been	 classified	 into	 at	least	five	subtypes,	with	each	demonstrating	a	different	prognosis	and	response	to	treatment277,278.	However,	the	majority	of	studies	have	utilised	the	MCF-7	cell	line	to	represent	ER+	breast	cancer.	It	is	becoming	increasingly	clear	that	such	studies	are	inadequate	and	equivalent	investigations	in	additional	cell	lines	are	required	to	better	 reflect	 this	 heterogeneity.	 Therefore,	 in	 this	 Chapter,	 a	 panel	 of	 four	 ER+	breast	 cancer	 cell	 lines	 with	 differing	 HER2	 status	 were	 employed	 to	 examine	antihormone-induced	 expression	 of	GABBR2,	 CTNND2,	 CLU,	 TSC22D3	 and	BCL3,	previously	 identified	 in	 Chapter	 3	 by	 microarray	 analysis	 to	 be	 significantly	 up	regulated	 by	 short	 term	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	treatments	 in	 MCF-7	 cells	 with	 expression	 maintained	 into	 the	 acquisition	 of	resistance.	 It	was	hypothesised	 that	 rapid	 antihormone-induced	up	 regulation	of	these	pro-survival	genes	during	initial	drug	response	may	allow	a	cohort	of	tumour	cells	 to	 evade	 the	 antihormone	 challenge	 and	 promote	 the	 development	 of	resistant	growth,	ultimately	resulting	in	poorer	patient	outlook.		Initially,	microarray	 gene	 expression	 data	 derived	 from	HER2-	MCF-7	 and	 T47D	cells	and	HER2+	BT474	and	MDA-MB-361	cells	were	interrogated	to	examine	the	expression	of	the	5	genes	following	10	day	fulvestrant	treatment	versus	untreated	control	in	the	panel	of	cell	lines.	Importantly,	however,	the	HER2+	cell	lines	do	not	proliferate	 very	well	 in	 stripped	 serum	 therefore	 the	microarray	data	 utilised	 in	this	 Chapter	 was	 generated	 from	 the	 four	 cell	 lines	 cultured	 in	 medium	supplemented	 with	 FCS	 ±	 fulvestrant	 for	 10	 days.	 This	 is	 in	 contrast	 to	 the	previous	 Chapter,	 whereby	 MCF-7	 cells	 were	 cultured	 for	 10	 days	 in	 medium	supplemented	 with	 sFCS	 plus	 antihormone	 or	 E2-control	 treatments.	 For	 all	subsequent	 experiments	 all	 cell	 lines	were	 cultured	 in	 FCS.	 The	microarray	data	was	verified	by	subsequent	PCR	and	Western	blot	analysis.	Additionally,	PCR	and	Western	 blotting	 were	 performed	 to	 examine	 the	 expression	 of	 the	 5	 genes	following	10	day	E2,	 tamoxifen	and	oestrogen	deprivation	treatments	 in	 the	 four	cell	 lines	 (cultured	 in	 FCS)	 for	 which	 there	 was	 no	microarray	 gene	 expression	data.	Such	studies	were	performed	to	consider	an	aspect	of	heterogeneity	and	to	determine	whether	 all	 three	 clinically	 used	 antihormone	 treatments	 (tamoxifen,	
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fulvestrant	 and	 oestrogen	 deprivation)	 induce	 expression	 of	 the	 5	 genes,	 whose	ontology	 strongly	 suggests	 a	 potential	 role	 in	 limiting	 response	 and	 promoting	resistance,	 in	 four	 ER+	 breast	 cancer	 cell	 lines	 representing	 HER2-	 and	 HER2+	disease.	Ultimately	such	studies	may	potentially	identify	an	antihormone-induced	resistant	mechanism	common	to	several	antihormone	therapies	and	breast	cancer	disease	subtypes.	Interestingly,	 from	 the	microarray	gene	expression	data	BCL3	was	 the	only	gene	identified	 to	 be	 significantly	 induced	 by	 fulvestrant	 in	 the	 four	 cell	 lines	 versus	untreated	control,	including	the	T47D	cell	line,	which	was	not	observed	with	any	of	the	other	4	genes.	This	profile	was	verified	by	RT-PCR	and	Western	blotting,	with	concurrent	 increases	 in	BCL3	mRNA	and	protein	 expression	 following	 tamoxifen	and	oestrogen	deprivation	treatments,	with	down	regulation	induced	by	E2,	versus	untreated	 control.	 At	 the	 mRNA	 level,	 such	 antihormone-induced	 expression	 of	BCL3	was	 significant	 versus	 control	 in	 the	 BT474	 and	 T47D	 cell	 lines	 following	tamoxifen	 treatment.	 At	 the	 protein	 level,	 oestrogen	 deprivation	 treatment	induced	significant	up	regulation	of	BCL3	expression	in	the	BT474	and	T47D	cell	lines	 versus	 control,	 in	 addition	 to	 fulvestrant	 treatment,	 which	 also	 induced	significant	up	regulation	of	BCL3	expression	in	the	latter	cell	line.	Together,	these	studies	 identify	 BCL3	 as	 a	 protein	 induced	 rapidly	 by	 three	 clinically	 used	antihormones	 in	 a	 panel	 of	 four	 ER+	 breast	 cancer	 cell	models,	 hypothesised	 to	play	a	significant	role	 in	 limiting	 the	efficacy	of	such	agents	during	response	and	ultimately	contributing	to	the	emergence	of	resistant	growth.		As	concluded	from	the	ontological	investigations	performed	in	Chapter	3,	BCL3	is	a	co-activator	 of	 NF-κB	 transcriptional	 activity,	 comprised	 of	 p50	 and	 p52	homodimers,	 which	 regulates	 several	 genes	 involved	 in	 immune	 response,	 cell	growth	and	survival372.	The	role	of	NF-κB	in	oncogenesis	and	indeed	breast	cancer	has	 been	 extensively	 studied.	 However,	 the	 potential	 role	 of	 BCL3	 in	 activating	aberrant	NF-κB	 signalling	 to	 induce	 cell	 proliferation	 and	 survival	 in	ER+	breast	cancer	 and	 particularly	 in	 limiting	 antihormone	 efficacy	 and	 promoting	 the	resistant	phenotype,	is	largely	unexplored.	Cogswell	et	al.	demonstrated	increased	expression	of	BCL3	in	breast	cancer	tissues	representing	a	range	of	tumour	types	(including	ER+)	and	grades360.	BCL3	expression	has	also	been	observed	in	a	range	
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of	 breast	 cancer	 cell	 lines	 comprising	 ER+/ER-	 and	 HER2+/HER2-	 disease,	including	the	MCF-7	cell	 line368.	However,	 the	precise	role	of	BCL3	remains	to	be	elucidated.	 In	 response	 to	 oestrogen	 withdrawal	 in	 MCF-7	 cells	 and	 in	 ER+	oestrogen-independent	 MCF-7	 cells	 (model	 of	 hormone	 independence),	 BCL3	expression	 has	 been	 shown	 to	 increase	 versus	 control,	 thus	 supporting	 the	 data	presented	here,	with	 concurrent	 increases	 in	NF-κB	 activity	 (predominantly	 p50	dimers)	and	cell	growth,	suggesting	the	ability	of	BCL3	to	co-activate	p50	to	allow	a	 cohort	 of	 cells	 to	 grow	 and	 survive	 oestrogen	 withdrawal	 to	 establish	 a	hormone-independent	phenotype363.	However,	studies	examining	BCL3	expression	in	ER+	breast	cancer	and	exploring	a	potential	role	in	antihormone	response	and	resistance	 have	 focussed	 on	 the	 individual	 ER+	 MCF-7	 cell	 line.	 As	 previously	mentioned,	 the	 use	 of	 MCF-7	 cells	 to	 represent	 heterogeneous	 ER+	 disease	 is	insufficient.	 The	 data	 presented	 in	 this	 Chapter	 are	 the	 first	 to	 our	 knowledge	investigating	the	expression	of	BCL3	and	its	induction	in	response	to	antihormone	treatment	 in	multiple	ER+	breast	 cancer	 cell	 lines	 comprising	HER2+	and	HER2-	disease,	thus	better	reflecting	the	heterogeneity	that	exists.	The	microarray	 data	 identified	 significant	 fulvestrant-induced	 CLU	 expression	 in	the	 BT474	 and	 MCF-7	 cell	 lines,	 with	 a	 small	 induction	 observed	 in	 the	MDA-MB-361	 and	 T47D	 cell	 lines	 versus	 untreated	 control.	 Subsequent	 RT-PCR	partially	 verified	 the	microarray	 gene	 expression	profiles	 of	 CLU,	with	 increased	mRNA	 expression	 observed	 in	 the	 BT474	 and	 MCF-7	 cell	 lines	 following	fulvestrant	 treatment,	 which	 was	 also	 apparent	 following	 10	 day	 tamoxifen	treatment	in	both	cell	lines	and	oestrogen	deprivation	treatment	in	the	MCF-7	cell	line,	 compared	 to	 E2-treated	 and	 untreated	 control	 cells.	 However,	 such	antihormone-induced	 increases	 in	 CLU	 expression	 were	 not	 significant.	Conversely,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 induced	 relatively	similar	CLU	mRNA	expression	 in	 the	MDA-MB-361	cells	 to	untreated	control	and	E2-treated	 cells,	while	 tamoxifen	 promoted	 a	 slight	 increase	 in	 gene	 expression.	Furthermore,	CLU	mRNA	could	not	be	detected	in	the	T47D	cell	line,	irrespective	of	treatment,	which	is	in	disagreement	with	the	present	detection	calls	reported	from	the	microarray	data.	However,	the	differences	in	the	microarray	and	PCR	profiles	may	 be	 due	 to	 the	 different	 regions	 of	mRNA	 recognised	 by	 the	 PCR	 primers	 to	
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those	recognised	by	the	Affymetrix	gene	chip.	Additionally,	a	splice	variant	of	CLU	(not	recognised	by	the	designed	CLU	primers)	may	be	present	in	the	T47D	cell	line,	potentially	explaining	the	lack	of	CLU	mRNA	detected	in	this	cell	line.		As	previously	described,	CLU	exists	as	two	main	forms	with	contrasting	functions	as	a	result	of	alternative	splicing.	The	cytoplasmic	secreted	(CLU-S)	form	promotes	cell	survival	and	the	nuclear	form	promotes	apoptosis.	This	project	is	interested	in	the	pro-survival	 role	 and	 therefore	 the	CLU-S	 form.	Prochnow	et	 al.	 have	 shown	that	CLU-S	represents	 the	most	abundant	(>	99%)	CLU	form	in	several	cell	 lines,	including	MCF-7	 cells295.	 Although	 the	microarray	 gene	 probes	 and	PCR	primers	did	 not	 specifically	 target	 CLU-S,	 the	 antibody	 used	 for	 Western	 analysis	 was	CLU-S-specific.	In	contrast	to	the	mRNA	profile,	at	the	protein	level,	the	secretory	CLUα	 subunit	 was	 increased	 by	 all	 antihormone	 treatments	 in	 all	 four	 ER+	 cell	lines	compared	to	E2-treated	and	untreated	control	cells.	Such	 increases	reached	statistical	significance	following	oestrogen	deprivation	treatment	in	the	T47D	and	MDA-MB-361	cell	 lines	as	well	as	 fulvestrant	treatment	 in	the	 latter	compared	to	control.	 Additionally,	 statistically	 significant	 antihormone-induced	 CLUα	expression	was	 observed	 versus	 E2	 treatment	 following	 tamoxifen	 treatment	 in	the	T47D	and	BT474	cells,	fulvestrant	treatment	in	the	MDA-MB-361	cell	line	and	oestrogen	deprivation	treatment	in	the	latter	cell	line	and	T47D	cell	line.	The	CLU	precursor	 subunit	 was	 up	 regulated	 by	 all	 three	 antihormone	 treatments	 in	 the	four	 cell	 lines	 versus	 control,	 with	 the	 exception	 of	 fulvestrant	 treatment	 in	 the	BT474	 cell	 line	 and	 tamoxifen	 treatment	 in	 the	 T47D	 cell	 line,	 which	 expressed	similar	 CLU	 precursor	 treatment	 to	 control.	 Statistically	 significant	 increases	 in	CLU	precursor	expression	were	demonstrated	versus	E2	treatment	and	control	in	the	T47D	cell	 line.	 In	summary,	 these	studies	 identify	secretory	CLU	as	a	protein	induced	 early	 during	 response	 to	 three	 clinically	 used	 antihormones	 in	multiple	ER+	breast	cancer	cell	models,	whose	expression	may	contribute	substantially	 to	the	limited	efficacy	of	these	agents	and	ultimately	the	development	of	resistance.		As	 identified	 from	 the	 ontological	 studies	 in	 Chapter	 3,	 CLU	 is	 a	 ubiquitously	expressed	glycoprotein	implicated	in	several	physiological	processes	such	as	lipid	transport	 and	 complement	 regulation.	 Increased	 CLU	 expression	 has	 been	reported	in	breast	cancer	tissues	representing	a	range	of	tumour	types	(including	
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ER+)	 and	 grades,	 as	 well	 as	 breast	 cancer	 cell	 lines,	 including	 the	 MCF-7	 cell	line335,336.	Increased	CLU	expression	in	breast	cancer	has	been	associated	with	cell	survival,	 invasion	and	metastasis.	More	recent	research	 is	emerging	 focussing	on	the	 potential	 role	 of	 CLU	 in	 limiting	 antihormone	 response	 and	 promoting	resistance.	 In	 agreement	 with	 the	 data	 presented	 in	 this	 study,	 short	 term	tamoxifen	(and	toremifene)	treatment	has	been	shown	to	increase	CLU	expression	in	MCF-7	and	T47D	cells338,339.	Furthermore,	the	combination	of	antibody	targeting	CLU	plus	 tamoxifen	 in	MCF-7	 cells	 has	been	 shown	 to	 increase	 the	 sensitivity	 of	these	cells	to	the	antihormone,	evidenced	by	a	decrease	in	cell	viability,	compared	to	 tamoxifen	 treatment	 alone339.	 However,	 3	 day	 tamoxifen	 (100	 nM)	 and	toremifene	 (100	 nM)	 treatment	 were	 shown	 to	 increase	 T47D	 cell	 growth	 and	consequently	this	cell	line	was	deemed	antihormone	resistant338.	Surprisingly,	this	observation	 is	 in	 contrast	 to	 the	 literature,	 where	 T47D	 cells	 are	 shown	 to	 be	antihormone	sensitive	(in	particular,	100	nM	tamoxifen	has	been	shown	to	inhibit	T47D	 cell	 growth	 as	 early	 as	 48	 hours405).	 It	 has	 been	 long	 established	 that	classically,	 E2	 stimulates	 T47D	 cell	 proliferation	 which	 is	 inhibited	 with	tamoxifen406,407.	 Furthermore,	 down	 regulation	of	 CLU	 in	 the	T47D	 cells	 deemed	antihormone	 resistant,	 re-sensitised	 these	 cells	 to	 toremifene338.	 Together,	 these	findings	 suggest	 that	 CLU	 up	 regulation	 in	 response	 to	 antihormone	 treatment	triggers	 an	 adaptive	 survival	 mechanism	 to	 counteract	 the	 growth	 inhibitory	effects	 of	 these	 agents,	 which	 may	 ultimately	 result	 in	 the	 development	 of	resistance.	However,	 the	majority	of	 studies	examining	 the	expression	of	CLU	 in	ER+	breast	cancer	and	exploring	a	possible	role	in	antihormone	response	and	resistance	have	predominantly	 utilised	 the	MCF-7	 cell	 line,	 with	 the	 exception	 of	 Toffanin	 et	 al.	who	performed	equivalent	 studies	 in	 the	T47D	cell	 line	although	 these	 cells	was	considered	antihormone	resistant338.	To	represent	the	heterogeneity	of	ER+	breast	cancer,	it	is	necessary	to	utilise	a	panel	of	cell	lines	to	better	reflect	the	variety	of	molecular	 subtypes.	 As	 such,	 this	 Chapter	 has	 utilised	multiple	 ER+	 cell	 lines	 to	demonstrate	antihormone-induced	CLU	expression	 in	HER2+	and	HER2-	disease.	Interestingly,	 although	 there	 are	 no	 studies	 examining	 the	 association	 between	antihormones	 and	 CLU	 in	 HER2+	 breast	 cancer,	 Biroccio	 et	 al.	 have	 identified	 a	
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strong	 link	 between	 HER2-signalling	 and	 CLU	 expression408.	 Similarly	 to	antihormones,	 the	 HER2-monoclonal	 antibody	 trastuzumab	 down	 regulates	receptor	expression	and	inhibits	cell	growth	but	promotes	very	little	apoptosis	in	BT474	 cells.	 Short-term	 trastuzumab	 treatment	 of	 these	 cells	 was	 shown	 to	increase	 CLU	 expression.	 Accordingly,	 trastuzumab	 therapy	 combined	 with	 the	antisense	 inhibitor	 of	 CLU,	 OGX-011	 (currently	 in	 clinical	 development),	significantly	enhanced	the	sensitivity	of	BT474	cells	to	trastuzumab,	evidenced	by	an	 increase	 in	 apoptosis	 and	 reduction	 in	 cell	 proliferation,	 compared	 to	 either	treatment	 alone.	 This	 study	 identifies	 CLU	 as	 a	 survival	 protein	 that	may	 play	 a	role	 in	 trastuzumab	 resistance	 through	 inhibition	 of	 apoptosis,	 and	 combined	targeting	of	HER2	and	CLU	may	provide	a	novel	approach	to	breast	cancer	therapy.	Additionally,	 combination	of	OGX-011	with	 antihormones	may	 similarly	 improve	the	anti-tumour	activity	of	these	agents	and	notably	enhance	cell	kill,	to	prevent	or	delay	the	emergence	of	resistant	growth.	The	 microarray	 gene	 expression	 data	 revealed	 that	 fulvestrant	 induced	 up	regulation	 of	 GABBR2	 and	 CTNND2	 expression	 in	 the	 four	 ER+	 cell	 lines,	which	was	 significant	 in	 the	 HER2+	 and	 MCF-7	 cell	 lines.	 The	 microarray	 profile	 of	GABBR2	was	successfully	verified	by	RT-PCR,	although	no	mRNA	expression	was	detected	 in	 the	 T47D	 cell	 line,	 irrespective	 of	 treatment,	 which	 is	 in	 agreement	with	 the	microarray	 data	 which	 revealed	 absent	 detection	 calls	 in	 this	 cell	 line.	Additionally,	10	day	 tamoxifen	and	oestrogen	deprivation	treatments	 induced	up	regulation,	while	E2	induced	down	regulation,	of	GABBR2	expression	in	the	HER2+	and	 MCF-7	 cell	 lines,	 again	 with	 no	 expression	 detected	 in	 the	 T47D	 cell	 line.	However,	 antihormone-induced	 expression	 of	 GABBR2	 mRNA	 did	 not	 reach	significance	 versus	 control	 in	 any	 of	 the	 cell	 lines.	 Statistically	 significant	antihormone-induced	 GABBR2	 mRNA	 expression	 was	 observed	 following	fulvestrant	and	oestrogen	deprivation	treatment	compared	to	E2	treatment	in	the	MCF-7	 cell	 line.	 At	 the	 protein	 level,	 this	 profile	 was	 mirrored	 with	 increased	GABBR2	expression	observed	 following	 the	 three	antihormone	 treatments	 in	 the	HER2+	and	MCF-7	cell	 lines.	Oestrogen	deprivation	treatment	 induced	significant	up	 regulation	of	GABBR2	protein	 expression	 versus	 control	 and	E2	 treatment	 in	the	HER2+	cell	 lines.	Fulvestrant	treatment	also	induced	significant	up	regulation	
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of	 GABBR2	 protein	 expression	 in	 BT474	 cells	 versus	 E2	 treatment.	 Together,	short-term	 tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 induced	up	 regulation	of	GABBR2	expression	 in	 the	HER2+	and	MCF-7	 cell	 lines,	with	no	expression	detected	in	the	T47D	cell	line.		Although	 MCF-7	 and	 T47D	 cell	 lines	 are	 both	 luminal	 A	 and	 derived	 from	 a	metastatic	 site	 of	 pleural	 effusion,	 proteomic	 analyses	have	 identified	more	 than	164	proteins	differentially	expressed	between	both	cell	lines409.	In	the	T47D	cells,	proteins	 involved	 in	 cell	 growth,	 anti-apoptosis	 and	 tumourigenesis	 were	 more	strongly	 expressed.	 In	 contrast,	 proteins	 implicated	 in	 transcription	 repression	and	 apoptosis	 regulation	 were	 more	 strongly	 expressed	 in	 MCF-7	 cells.	Furthermore,	 the	 apoptotic	 mechanisms	 of	 both	 cell	 lines	 differ,	 involving	activation	 of	 different	 caspases	 and	 mitochondrial	 changes410.	 Additionally,	 of	significant	interest	is	the	differential	expression	of	p53	in	these	cell	 lines.	Indeed,	in	contrast	to	MCF-7	cells,	 the	tumour	suppressor	protein	p53	is	mutated	on	one	allele	of	 the	gene	 in	T47D	cells411.	Thus,	 it	 is	possible	 that	GABBR2	expression	 in	MCF-7	 cells	 during	 antihormone	 response	 regulates	 p53	 activity,	 to	 induce	anti-apoptotic	functions;	a	mechanism	not	observed	in	the	p53	mutant	T47D	cells.		As	 revealed	 from	 the	 ontological	 studies	 in	 Chapter	 3,	 GABA	 B	 receptors	(composed	 of	 GABBR1	 and	 GABBR2	 subunits)	 are	 involved	 in	 mediating	GABA-induced	inhibition	of	neuronal	activity.	GABA	is	synthesised	from	glutamate	by	 GAD	 enzyme,	 of	 which	 there	 are	 two	 isoforms	 (GAD1	 and	 GAD2).	 Increased	GABA	 B	 receptor	 expression	 has	 been	 reported	 in	 several	 cancers,	 however	 the	role	 of	 this	 receptor	 and	 particularly	 the	 GABBR2	 subunit	 in	 cancer	 remains	elusive.	With	regard	to	breast	cancer,	increased	GABA	content	and	GAD	activity	has	been	 observed	 in	 tumour	 tissue	 compared	 to	 normal	 breast318,	 suggesting	abundant	 expression	 and	 synthesis	 of	 the	 ligand,	 GABA,	 and	 the	 existence	 of	GABAergic	 signalling	 within	 these	 cells.	 Furthermore,	 GABBR1	 (required	 to	heterodimerise	with	GABBR2	for	normal	receptor	function)	and	GAD	proteins	have	been	demonstrated	in	breast	cancer	cell	lines,	including	MCF-7	cells319.	Moreover,	in	triple	negative	disease,	GABA	B	receptor	activation	has	been	shown	to	promote	cell	 invasion,	 migration	 and	 metastasis	 via	 enhanced	 ERK	 1/2	 signalling	 and	MMP-2	 production319.	 However,	 GABBR2	 expression	 has	 never	 previously	 been	
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observed	 in	 ER+	 breast	 cancer	 and	 its	 association	 with	 limiting	 antihormone	response	and	contributing	to	the	emergence	of	resistance	remains	unexplored.	In	this	Chapter,	GABBR2	expression	has	been	shown	to	be	induced	by	three	clinically	used	antihormones	in	a	panel	of	ER+	breast	cancer	cell	lines,	reflecting	HER2+	and	HER2-	 disease.	 These	 findings	 suggest	 that	 GABBR2	 may	 provide	 a	 common	resistant	mechanism	 early	 during	 response	 to	 all	 three	 antihormones	 in	 several	ER+	 disease	 molecular	 subtypes.	 However,	 further	 studies	 are	 required	 to	determine	 whether	 GABBR1	 subunit	 and	 GAD	 enzymes	 are	 expressed	 together	with	GABBR2,	signifying	functional	GABA	B	receptor	and	production	of	the	ligand,	respectively,	and	ultimately	receptor	activation.		Conversely,	the	microarray	profile	of	CTNND2	expression	could	not	be	verified	by	RT-PCR.	Indeed,	CTNND2	mRNA	expression	was	similar	following	fulvestrant	and	untreated	control	treatments	in	the	three	cell	lines,	with	no	expression	detected	in	the	 T47D	 cell	 line	 which	 supports	 the	 absent	 detection	 calls	 reported	 from	 the	microarray	 gene	 expression	 profiles.	 Furthermore,	 tamoxifen	 and	 oestrogen	deprivation	 treatments	 induced	similar	CTNND2	expression	 to	 the	 control	 in	 the	three	cell	lines,	with	no	expression	detected	in	the	T47D	cell	line.	It	is	possible	that	the	 above-mentioned	 differences	 in	 protein	 expression	 and	 in	 particular	 p53	expression	 between	 the	 T47D	 cells	 and	 MCF-7	 cells	 contribute	 to	 the	 lack	 of	CTNND2	 expression	 in	 the	 former	 cell	 line.	 Furthermore,	 it	 is	 possible	 that	 the	microarray	profile	could	not	be	verified	by	RT-PCR	due	to	the	different	regions	of	mRNA	recognised	by	 the	PCR	primers	 to	 that	 recognised	by	 the	Affymetrix	 gene	chip.	Moreover,	it	was	noticed	throughout	this	Chapter	that	present	detection	calls	in	the	untreated	control	and	fulvestrant	treated	cells	recorded	from	the	microarray	data	were	more	difficult	to	verify	an	antihormone-induced	up	regulation	by	PCR	as	opposed	 to	 absent	 calls	 in	 the	 control	 and	 present	 in	 fulvestrant-treated.	 As	previously	described	in	Chapter	3,	the	CTNND2	antibody	continued	to	fail	in	all	cell	lines,	with	no	protein	expression	detected.		Increased	CTNND2	expression	has	been	reported	in	several	cancers	including	lung,	ovarian	and	prostate328–330.	 In	the	 latter,	CTNND2	has	been	shown	to	up	regulate	cyclin	 D1	 and	 the	 anti-apoptotic	 gene	 BCL2L1	 to	 promote	 cell	 proliferation	 and	survival332.	However,	 the	expression	and	 function	of	CTNND2	 in	breast	 cancer	 is	
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largely	 unexplored.	 A	 recent	 study	 by	 Zhang	 et	 al.	 demonstrated	 increased	CTNND2	 expression	 in	 breast	 cancer	 tissue	 compared	 to	 normal	 breast,	 with	increased	 expression	 associated	 with	 a	 higher	 degree	 of	 malignancy	 and	 poor	prognosis327.	 Furthermore,	 in	 ER+	MCF-7	 and	 ER-	MDA-MB-231	 cells,	 increased	CTNND2	 expression	was	 shown	 to	 promote	 cell	 proliferation	 and	 invasion327.	 In	support	of	 the	microarray	data	from	the	MCF-7	cells	reported	 in	this	Chapter	(as	well	as	Chapter	3),	previous	studies	within	the	group	have	reported	up	regulation	of	CTNND2	expression	following	short-term	tamoxifen,	 fulvestrant	and	oestrogen	deprivation	treatment	in	MCF-7	cells,	with	expression	retained	at	increased	levels	in	 our	 TAMR	 and/or	 FASR	 cell	 lines304,412.	 However,	 the	 precise	 function	 of	CTNND2	 remains	 to	 be	 deciphered.	 The	 very	 few	 studies	 examining	 CTNND2	expression	 in	 ER+	 breast	 cancer	 and	 its	 potential	 role	 in	 antihormone	 failure	 or	resistance	 have	 utilised	 the	 single	 ER+	 cell	 line,	 MCF-7.	 To	 better	 reflect	 the	heterogeneity	 of	 ER+	 disease,	 equivalent	 studies	 are	 necessary	 in	 additional	 cell	models.	 In	 light	 of	 this,	 this	 study	 is	 the	 first	 to	 our	 knowledge	 investigating	antihormone-induced	expression	of	CTNND2	 in	a	panel	of	ER+	breast	cancer	cell	lines,	 encompassing	 HER2+	 and	 HER2-	 disease.	 Although	 the	 results	 from	 the	microarray	data	in	this	Chapter	and	Chapter	3,	strongly	suggest	that	antihormones	induce	up	 regulation	of	CTNND2	 in	HER2+	and	MCF-7	 cell	 lines	with	 expression	maintained	into	resistance,	combined	with	strong	ontology	identifying	CTNND2	as	a	 potential	 significant	 player	 in	 limiting	 antihormone	 efficacy	 and	 promoting	resistance;	the	failure	to	verify	these	profiles	by	RT-PCR	in	addition	to	the	limited	availability	of	antibodies	necessary	 for	 further	evaluation	of	 the	role	of	CTNND2,	led	to	the	elimination	of	this	protein	from	further	study.	The	 microarray	 data	 identified	 significant	 fulvestrant-induced	 TSC22D3	expression	in	the	BT474	and	MCF-7	cell	 lines,	with	a	small	 induction	observed	in	the	 MDA-MB-361	 and	 T47D	 cell	 lines	 versus	 untreated	 control.	 However,	 the	microarray	 gene	 expression	 profiles	 of	 TSC22D3	 were	 only	 partly	 verified	 by	RT-PCR.	 Indeed,	 in	 agreement	 with	 the	microarray	 profile,	 TSC22D3	 expression	was	up	regulated,	although	not	significantly,	by	 fulvestrant,	along	with	tamoxifen	and	oestrogen	deprivation	treatments	versus	E2	and	untreated	control	treatments	in	 the	MCF-7	and	MDA-MB-361	cells.	However,	 there	was	no	apparent	change	 in	
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TSC22D3	 mRNA	 expression	 following	 antihormone	 or	 E2	 treatments	 versus	control	 in	 the	 BT474	 and	 T47D	 cell	 lines,	 which	 is	 in	 disagreement	 with	 the	microarray	data.	Perhaps	the	PCR	cycle	number	was	not	optimal	in	the	BT474	and	T47D	 cell	 lines,	 and	 a	 greater	 difference	 between	 TSC22D3	 mRNA	 expression	following	 antihormone	 treatment	 may	 be	 observed	 with	 a	 lower	 cycle	 number.	Conversely,	 Western	 blot	 analysis	 revealed	 antihormone-induced	 expression	 of	TSC22D3	protein	in	all	four	cell	lines	versus	E2	and	untreated	control	treatments.	Such	 increases	 were	 significant	 following	 tamoxifen	 and	 fulvestrant	 treatments	versus	 control	 in	 the	 MDA-MB-361	 cell	 line.	 Statistically	 significant	 increases	 in	TSC22D3	 protein	 expression	were	 observed	 following	 all	 three	 antihormones	 in	the	 MDA-MB-361	 cell	 line	 and	 oestrogen	 deprivation	 in	 the	 BT474	 cell	 line	compared	to	E2	treatment.	As	revealed	from	the	ontological	studies	in	Chapter	3,	TSC22D3	is	an	ubiquitously	expressed	 protein	 involved	 in	 mediating	 several	 glucocorticoid	 functions,	including	T	cell	activation,	apoptosis	and	cell	proliferation350.	TSC22D3	expression	has	been	reported	in	leukaemia	and	ovarian	cancer,	however	its	precise	function	in	tumourigenesis	remains	undefined353,354.	From	the	ontological	investigation,	it	was	strongly	evident	that	TSC22D3	exhibits	opposing	roles	dependent	on	the	cell	type	and	associated	cellular	milieu.	Indeed,	in	ovarian	cancer,	TSC22D3	has	been	shown	to	enhance	phosphorylated	AKT	content	and	activity	to	promote	cell	proliferation,	whereas	 in	 T	 lymphocytes,	 TSC22D3	 inhibits	 AKT	 signalling	 resulting	 in	 an	anti-proliferative	 effect	 in	 these	 cells354,393,394.	 Similarly,	 in	 ovarian	 cancer,	TSC22D3	 up	 regulates	 cyclin	 D1	 expression	 to	 promote	 cell	 cycle	 progression,	which	is	again	in	contrast	to	T	lymphocytes	where	cyclin	D1	activation	is	inhibited	to	 prevent	 cell	 proliferation354,393.	 To	 our	 knowledge,	 there	 is	 only	 one	 study	examining	 TSC22D3	 expression	 in	 ER+	 breast	 cancer,	 where	 24	 hour	 tamoxifen	treatment	 has	 been	 shown	 to	 increase,	 and	 E2	 treatment	 decrease,	 TSC22D3	expression	 in	MCF-7	 cells,	which	 supports	 the	 data	 presented	 here351.	 However,	Tynan	 et	 al.	 utilised	 the	 single	 ER+	MCF-7	 cell	 line,	whereas	 the	 data	 presented	here	was	extended	into	additional	ER+	cell	lines	and	also	included	fulvestrant	and	oestrogen	deprivation	treatments,	 thus	encompassing	HER2+	and	HER2-	disease,	to	 better	 reflect	 the	 heterogeneity	 present	 in	 breast	 cancer.	 Indeed,	 10	 day	
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tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 were	 shown	 to	increase	TSC22D3	protein	expression	in	HER2-	MCF-7	and	T47D	cells	and	HER2+	BT474	and	MDA-MB-361	cells	compared	to	E2-treated	and	untreated	control	cells,	thus	 identifying	 drug-induced	 expression	 of	 TSC22D3	 common	 to	 three	antihormones	and	four	ER+	cell	models,	whose	expression	is	hypothesised	to	limit	the	anti-tumour	activity	of	these	agents	and	ultimately	promote	the	emergence	of	resistant	growth.	In	 contrast,	 oestrogen	 has	 been	 shown	 to	 up	 regulate	 TSC22D3	 expression	 in	cervical	cancer	and	human	embryonic	kidney	cells351,	suggesting	that	cell	specific	factors	 are	 involved	 in	 oestrogen	 regulation	 of	 TSC22D3	 expression,	 again	supporting	the	concept	that	the	role	of	TSC22D3	is	multifaceted	and	dependent	on	the	 cellular	milieu.	 Importantly,	 with	 regard	 to	 a	 pro-survival	 role	 to	 ultimately	support	 our	 hypothesis	 and	 identify	 TSC22D3	 as	 a	 potential	 significant	 protein	involved	in	limiting	antihormone	efficacy	and	promoting	endocrine	resistance,	the	ontological	studies	in	Chapter	3	identified	pro-apoptotic	and	pro-survival	roles	of	TSC22D3	in	chronic	myeloid	leukaemia	and	ovarian	cancer	cells,	respectively354,356.	However,	there	are	no	studies	identifying	a	pro-survival	role	for	TSC22D3	in	breast	cancer,	 where	 its	 role	 remains	 elusive.	 Clearly,	 further	 studies	 are	 required	 to	decipher	 the	 role	 of	 TSC22D3	 in	 breast	 cancer	 and	 particularly	 in	 response	 to	antihormones,	 to	determine	whether	 it	promotes	survival	signalling	 to	overcome	antihormone	challenge	or	alternatively	it	may	exhibit	pro-apoptotic	functions	and	be	 a	 mechanism	 utilised	 by	 antihormones	 to	 induce	 their	 anti-proliferative	 and	weak	pro-apoptotic	effects.	Taken	together,	TSC22D3	is	a	ubiquitously	expressed	protein,	abundant	in	several	cell	types	where	it	is	involved	in	either	promoting	or	inhibiting	 cell	 proliferation	 and	 survival	 dependent	 on	 the	 cell	 type.	 The	complexity	 of	 TSC22D3	 combined	 with	 its	 ubiquitous	 and	 abundant	 expression	and	 ability	 to	 interact	 with	 a	 variety	 of	 cellular	 proteins,	 with	 limited	 literature	supporting	 a	 pro-survival	 role	 in	 breast	 cancer,	 led	 to	 the	 decision	 to	 dismiss	TSC22D3	from	further	study.	Together,	 in	 support	 of	 the	 hypothesis	 and	 building	 on	 the	 data	 generated	 from	Chapter	 3,	 this	 Chapter	 has	 revealed	 that	 the	 expression	of	 4	 pro-survival	 genes	(GABBR2,	 CLU,	 TSC22D3	 and	 BCL3)	 potentially	 involved	 in	 antihormone	 failure	
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and	promoting	the	emergence	of	resistant	growth,	is	induced	following	short-term	tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation	 treatments	 in	 four	 cell	 lines	(except	 GABBR2,	 which	 was	 not	 detected	 in	 the	 T47D	 cell	 line)	 representing	HER2+	and	HER2-	disease,	suggesting	that	a	common	resistant	mechanism	may	be	induced	 by	 all	 three	 antihormone	 therapies	 in	 several	 ER+	 disease	 subtypes.	However,	 such	 antihormone-induced	 gene	 expression	 did	 not	 always	 reach	significance	compared	to	control	at	 the	mRNA	and	protein	 level	 likely	due	 to	 the	low	number	of	experimental	repeats,	and	the	limitations	in	quantifying	end-point	PCR.	 Indeed,	 additional	 experimental	 repeats	 are	 required	 to	 increase	 the	reliability	of	 the	data.	This	 is	one	of	a	 few	studies	 that	have	utilised	multiple	cell	lines	 to	 examine	 antihormone	 response	 and	 resistance	 mechanisms	 in	 breast	cancer.	In	the	following	Chapters,	the	most	promising	genes,	BCL3	and	CLU,	which	were	induced	by	all	three	clinically	used	antihormones	in	the	four	cell	lines,	were	further	 examined	 to	 determine	 their	 role	 during	 antihormone	 response	 and	resistance	 Further	 studies	 may	 identify	 these	 proteins	 as	 a	 novel	 therapeutic	target,	 which	 during	 antihormone	 response	 could	 markedly	 improve	 the	anti-tumour	activity	of	these	therapies	and	furthermore	in	resistance	may	reverse	this	phenotype	and	re-sensitise	cells	to	endocrine	treatments.					 	
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5 Results	III:	Further	investigation	of	BCL3	function	during	antihormone-response	and	-resistance	
5.1 Introduction	BCL3	is	a	nuclear	protein	and	belongs	to	the	family	of	IκB	proteins	that	function	to	inhibit	 the	 activity	 of	 NF-κB	 transcription	 factors358.	 The	 family	 of	 NF-κB	transcription	factors	consists	of	five	members:	p65	(RelA),	RelB,	cRel,	p50/NFKB1	and	p52/NFKB2.	p50/NFKB1	and	p52/NFKB2	are	synthesised	as	large	precursors	(p105	 and	 p100,	 respectively),	 which	 upon	 activation	 are	 partially	 degraded	 to	their	 mature	 forms	 (p50/NFKB1	 and	 p52/NFKB2,	 respectively)413.	 The	 NF-κB	family	members	exist	as	hetero-	or	homodimers,	although	the	most	abundant	form	is	generally	the	p65/p50	heterodimer414.		In	unstimulated	cells,	IκB	proteins	sequester	NF-κB	in	the	cytoplasm,	thus	blocking	their	 nuclear	 translocation,	 thereby	 maintaining	 NF-κB	 in	 an	 inactive	 state	preventing	 transcription	of	a	 large	number	of	genes	 involved	 in	cell	 survival	and	proliferation358.	 Upon	 activation	 induced	 by	 various	 stimuli,	 including	inflammatory	 cytokines	and	growth	 factors,	 IκB	 is	phosphorylated	by	 IκB	kinase	and	degraded	by	the	proteasome213.	The	dissociation	of	 IκB	unmasks	the	nuclear	localisation	 sequence	 of	NF-κB,	 allowing	 translocation	 of	NF-κB	 into	 the	 nucleus	where	 it	 binds	 to	 DNA	 at	 specific	 NF-κB	 response	 elements	 to	 activate	transcription	of	genes	involved	in	cell	proliferation,	survival	and	the	inflammatory	response414,415.	 RelA,	RelB	 and	 cRel	 proteins	 contain	 a	 transactivation	domain	 at	the	 C-terminus,	 which	 facilitates	 the	 recruitment	 of	 coactivators	 and	 the	displacement	 of	 repressors,	 necessary	 for	 transactivation	 by	 these	 proteins.	However,	p50/NFKB1	and	p52/NFKB2	homodimers	lack	transactivation	domains	and	 thus	 are	 inactive	 and	 unable	 to	 drive	 transcription.	 In	 fact,	 nuclear	translocation	of	p50/NFKB1	and	p52/NFKB2	homodimers	and	binding	to	κB	sites	results	in	the	repression	of	NF-κB-dependent	genes414.	However,	BCL3	functions	to	provide	 transactivating	 domains	 to	 these	 otherwise	 inactive	 homodimers	 to	activate	transcription	of	cell	growth	and	survival	genes372.	Initial	studies	suggested	
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that	 BCL3	 binds	 and	 removes	 repressive	 p50/NFKB1	 and	 p52/NFKB2	homodimers	 from	 κB	 sites,	 to	 allow	 the	 engagement	 of	 transcriptionally	 active	dimers	 (e.g.	 p65/p50)	 to	 drive	 transcription416,417.	 However,	 subsequent	 studies	have	 suggested	 that	 BCL3	 forms	 transcriptionally	 active	 complexes	 with	p50/NFKB1and	p52/NFKB2	homodimers	to	activate	transcription418,419.	The	 general	 consensus	 surrounding	 antihormone	 therapy	 is	 that	 they	 exert	significant	 anti-proliferative	 actions	 but	 are	 unable	 to	 promote	 significant	 cell	death.	Antihormones	exert	their	anti-proliferative	activity	through	suppression	of	growth	promoting	genes	and	also	through	induction	of	negative	regulators	of	cell	proliferation.	However,	this	inductive	capacity	is	likely	to	be	a	double-edged	sword	since	 it	 has	 also	 been	 demonstrated	 that	 oestrogens	 can	 suppress,	 and	antihormones	 induce,	 pro-proliferative	 and	 pro-survival	 genes.	 Thus,	 the	 weak	pro-apoptotic	activity	of	 antihormones	may	be	 reflected	by	a	 significant	 capacity	for	 induction	 of	 pro-survival	 mechanisms	 alongside	 their	 weak	 pro-apoptotic	actions.		It	 was	 hypothesised	 that	 antihormones	 induce	 expression	 of	 pro-survival	 genes	early	during	response,	allowing	a	cohort	of	cells	to	evade	the	therapeutic	challenge	resulting	 in	 anti-tumour	 responses	 of	 finite	 duration	 and	 ultimately	 the	development	 of	 resistant	 growth.	 Microarray	 analysis	 in	 Chapters	 3	 and	 4	examined	 10	 day	 antihormone-treated	 ER+	 breast	 cancer	 cell	 lines	 and	corresponding	 resistant	 cell	 models	 and	 aimed	 to	 identify	 antihormone-induced	pro-survival	 genes	 that	 may	 subsequently	 limit	 the	 efficacy	 of	 such	 agents	 and	contribute	towards	the	emergence	of	resistance.	Further	study	of	the	most	robust	candidate	 genes	 could	 prove	 significant	 in	 identifying	 biomarkers	 of	 limited	response	 or	 targets	 for	 novel	 therapeutic	 strategies	 to	 enhance	 antihormone	response	and	significantly	delay	or	prevent	the	development	of	resistance.		To	 this	 regard,	 the	microarray	 gene	 expression	 profiling	 data	 identified	BCL3	 as	the	only	gene	significantly	induced	by	fulvestrant	treatment	in	4	ER+	breast	cancer	cell	lines,	encompassing	both	HER2+	and	HER2-	disease.	The	microarray	data	were	verified	 by	 RT-PCR	 and	 Western	 blotting	 and	 equivalent	 increases	 in	 BCL3	expression	 was	 apparent	 following	 tamoxifen	 and	 oestrogen	 deprivation	
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treatments	 in	 all	 4	 cell	 lines	which	was	 reversed	 by	 E2	 treatment.	 Additionally,	ontological	 investigations	 strongly	 suggested	 a	 role	 for	 BCL3	 in	 disease	progression	 by	 promoting	 cell	 growth	 and	 survival	 potentially	 via	 activation	 of	NF-κB-mediated	 transcription	 of	 pro-proliferative	 and	 pro-survival	 genes.	Together,	 this	suggests	 that	all	 three	antihormone	therapies	rapidly	 induce	BCL3	expression	 during	 response	 in	 several	 subtypes	 of	 breast	 cancer,	 possibly	activating	 a	 common	 survival	 mechanism	 to	 promote	 resistance.	 Indeed,	 initial	microarray	 studies	 (Chapter	 3)	 in	 models	 of	 endocrine	 resistance	 derived	 from	MCF-7	 cells	 revealed	 increased	 BCL3	 expression	 maintained	 through	 to	 the	acquisition	of	resistance	to	tamoxifen,	fulvestrant	and	oestrogen	deprivation.		In	 this	 Chapter,	 several	 experimental	 approaches	 have	 thus	 been	 performed	 to	further	determine	 the	 role	 of	BCL3	during	 antihormone	 response	 and	 resistance	and	whether	its	induction	early	during	response	contributes	to	the	limited	efficacy	of	 these	 agents	 and	 ultimately	 promotes	 the	 development	 of	 the	hormone-independent	 phenotype.	 Initially,	 the	 microarray	 profile	 of	 BCL3	 in	TAMR	and	XR	cells	 (Chapter	3)	was	verified	by	RT-PCR	and	Western	blotting,	 to	determine	whether	BCL3	expression	was	maintained	at	 increased	 levels	 through	to	 the	 acquisition	 of	 resistance.	 Studies	 with	 BCL3	 siRNA	 were	 subsequently	performed	 to	 determine	whether	 BCL3	 knockdown	 combined	with	 antihormone	treatment	 improves	 the	 growth-inhibitory	 actions	 of	 these	 agents	 and	 as	 such	identifies	 BCL3	 as	 a	 gene	 involved	 in	 promoting	 cell	 growth	 and	 survival,	 as	examined	 by	 cell	 growth	 and	 apoptosis	 assays.	 Additionally,	 similar	BCL3	 siRNA	studies	 were	 performed	 in	 antihormone-resistant	 cell	 models	 to	 determine	whether	 such	 knockdown	 can	 inhibit	 cell	 growth	 and	 promote	 apoptosis	 in	resistance.		To	 investigate	 whether	 antihormone-induced	 BCL3	 expression	 contributes	 to	limited	 antihormone	 response	 and	 the	 development	 of	 resistance	 by	 activating	NF-κB-mediated	 transcription	 of	 pro-survival	 and/or	 pro-proliferative	 genes,	Western	blotting	studies	were	first	performed	to	determine	whether	p50/NFKB1	and	 p52/NFKB2	 proteins	were	 expressed	 in	 ER+	 breast	 cancer	 cell	 lines	 during	antihormone-response	 and	 following	 the	 acquisition	 of	 resistance.	 Subsequent	studies,	 including	 immunofluorescence	 and	 immunoprecipitation,	 examined	 the	
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potential	 association	 between	 BCL3	 and	 p50/NFKB1	 and	 p52/NFKB2	 during	antihormone-response	and-resistance	to	further	support	the	hypothesis.	
5.2 Methods	
5.2.1 Cell	Culture	Antihormone-treated	MCF-7	and	T47D	cells	were	re-suspended	in	phenol-red-free	RPMI	medium	 supplemented	with	 5%	 FCS,	 penicillin-streptomycin	 (10	 IU/ml	 to	10	µg/ml),	 fungizone	 (2.5	 µg/ml)	 and	 glutamine	 (4	mM)	 and	 allowed	 to	 adhere	overnight	 prior	 to	 the	 addition	 of	 antihormone,	 E2	 and	 control	 (untreated	medium)	treatments,	as	described	in	Chapter	2,	section	2.1.2.	The	 (short-term)	 TAMR,	 FASR,	 XR	 and	 T47D	 TAMR	 cell	 models	 and	 wild	 type	control	 cells	were	 cultured	 in	phenol-red-free	RPMI	medium	supplemented	with	5%	sFCS,	 penicillin-streptomycin	 (10	 IU/ml	 to	10	µg/ml),	 fungizone	 (2.5	µg/ml),	glutamine	(4	mM)	and	respective	antihormone	treatment,	as	described	in	Chapter	2,	 section	 2.1.2.	 The	 long-term	 antihormone	 resistant	 cell	 models,	 derived	 from	MCF-7,	T47D,	BT474	and	MDA-MB-361	cells,	and	the	wild	type	control	cells	were	cultured	in	phenol-red-free	RPMI	medium	supplemented	with	FCS	(5%:	MCF-7	and	T47D,	 10%:	 BT474	 and	 MDA-MB-361),	 penicillin-streptomycin	 (10	 IU/ml	 to	10	µg/ml),	 fungizone	 (2.5	 µg/ml),	 glutamine	 (4	mM)	 and	 the	 respective	antihormone	treatment,	as	detailed	in	Chapter	2,	section	2.1.2.	
5.2.2 RT-PCR	Antihormone-treated	cells	and	antihormone-resistant	cells	were	prepared	for	RNA	analysis	as	described	above	(section	5.2.1).	RT-PCR	was	performed,	as	described	in	section	 2.4,	 to	 determine	 RNA	 expression	 of	 BCL3.	 Densitometry	 analysis	 was	performed	and	 the	 raw	densitometry	values	of	BCL3	were	normalised	 to	β-actin	loading	control.		
5.2.3 Western	blotting	Antihormone-treated	 and	 resistant	 cells	 were	 prepared	 for	 Western	 blotting	 as	described	 above	 (section	 5.2.1).	 Twenty	 micrograms	 of	 protein	 was	 loaded	 and	separated	by	SDS-PAGE	and	probed	 for	BCL3,	 total	and	phosphorylated	 forms	of	ERBB2,	AKT,	ERK	and	EGFR,	NFKB1	and	NFKB2	antigens,	as	described	in	section	
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2.5.	Densitometry	analysis	was	performed	and	the	raw	densitometry	values	of	the	proteins	of	interest	were	normalised	to	β-actin	loading	control.		
5.2.4 Microarray	analysis	Triplicate	 mRNA	 preparations	 of	 resistant	 cell	 models	 were	 hybridised	 to	Affymetrix	 Human	 Genome	 U133Aplus2	 gene	 chips,	 as	 described	 in	 section	 2.2.	These	 data	 were	 analysed	 to	 identify	 expression	 of	 BCL3,	 p50/NFKB1	 and	p52/NFKB2	during	antihormone-resistance,	using	the	‘jetset’	probes:	204908_s_at,	209239_at	and	209636_at,	respectively.		
5.2.5 BCL3	knockdown	To	decipher	 the	role	of	BCL3	during	antihormone	response	and	resistance,	BCL3	knockdown	studies	were	performed	utilising	siRNA	as	described	 in	section	2.6.1.	Briefly,	cells	were	grown	until	approximately	60%	confluency	prior	to	the	addition	of	 the	 siRNA	 tranfection	 reagent	 mix.	 Cells	 were	 incubated	 for	 4	 days	 (unless	stated	 otherwise)	 prior	 to	 RNA	 and	 protein	 lysis	 for	 subsequent	 RT-PCR	 and	Western	blot	analysis	(as	described	above).	Since	BCL3	is	expressed	at	low	levels	in	wild	type	MCF-7	and	T47D	cells,	fulvestrant	was	added	to	the	medium	48	hours	post	siRNA	transfection	to	induce	BCL3	expression.	
5.2.6 Apoptosis	assay	An	 Annexin	 V-FITC	 and	 PI	 apoptosis	 detection	 kit	 was	 utilised	with	 subsequent	flow	 cytometery	 analysis,	 as	 described	 in	 section	 2.6.2.1,	 to	 determine	 whether	BCL3	 plays	 a	 pro-survival	 role	 during	 antihormone	 response	 and	 resistance.	Positive	 control	 cells	 were	 treated	 with	 the	 apoptosis	 inducer	 thapsigargin	 48	hours	prior	to	analysis,	as	detailed	in	section	2.6.2.1.		
5.2.7 Cell	counting	Cell	counting	studies	were	performed	to	determine	the	effect	of	BCL3	knockdown	on	cell	growth	during	antihormone	response	and	resistance.	Cells	were	transfected	with	BCL3	siRNA	(as	described	above)	in	triplicate	and	incubated	for	4	days	prior	to	the	measurement	of	cell	number,	as	described	in	section	2.6.3.	
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5.2.8 Cell	cycle	distribution	The	effect	of	BCL3	on	the	cell	cycle	of	antihormone-treated	and	–resistant	cells	was	investigated	 by	 PI	 stain	 and	 flow	 cytometry	 analysis,	 as	 described	 in	 section	2.6.2.2.	
5.2.9 Immunofluorescence	The	 cellular	 localisation	 of	 BCL3	 and	 p50/NFKB1	 during	 antihormone	 response	and	 resistance	 was	 examined	 by	 immunofluorescence	 studies	 as	 described	 in	section	 2.6.4.	 Briefly,	 cells	were	 grown	 on	 glass	 coverslips,	 incubated	with	BCL3	and	 p50/NFKB1	 primary	 antibodies,	 followed	 by	 appropriate	fluorphore-conjugated	secondary	antibodies	prior	to	examination	on	a	fluorescent	microscope.		
5.2.10 Immunoprecipitation	Immunoprecipitation	 studies	 were	 performed	 to	 determine	 whether	 BCL3	 is	associated	with	p50/NFKB1	during	antihormone	response	and	resistance.	Briefly,	protein	cell	lysates	were	incubated	with	an	antibody	(e.g.	p50/NFKB1)	to	form	an	antibody/antigen	 complex.	 This	 complex	 was	 captured	 on	 a	 solid	 support,	separated	 by	 SDS-PAGE	 and	 Western	 blotting	 and	 probed	 for	 the	 protein	 of	interest	(e.g.	BCL3),	as	described	in	section	2.6.5.	
5.2.11 	Statistical	analysis	The	data	were	 analysed	using	GraphPad	prism.	An	unpaired	 t-test	 or	 an	ANOVA	(with	 a	 Tukey’s	 multiple	 comparisons	 post-hoc	 test)	 were	 used	 to	 compare	 the	means.	A	p	value	<0.05	was	considered	statistically	significant.	
5.3 Results	Initial	 microarray	 studies	 (Chapter	 3)	 revealed	 increased	 BCL3	 expression	maintained	through	to	the	acquisition	of	resistance.	Indeed,	BCL3	expression	was	significantly	up	regulated	(fold	change	>	1.5)	in	(short-term)	TAMR,	XR	and	FASR	cells	versus	E2-treated	control	MCF-7	cells	(as	demonstrated	in	Chapter	3,	section	3.3.2.6).	Additionally,	present	detection	calls	were	reported	 in	the	three	resistant	cell	models,	implying	reliable	gene	expression,	whereas	predominantly	absent	calls	were	recorded	in	the	untreated	control,	suggesting	very	low	gene	expression.		
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5.3.1 Verification	of	the	microarray	data	by	RT-PCR	The	microarray	expression	profiles	of	BCL3	in	(short-term)	TAMR	and	XR	cell	lines	were	 next	 verified	 by	 RT-PCR.	 To	 consider	 the	 heterogeneity	 of	 breast	 cancer,	BCL3	 RNA	 expression	 was	 also	 examined	 in	 a	 tamoxifen-resistant	 cell	 model	derived	 from	 T47D	 cells	 (T47D	 TAMR).	 This	 project	 eliminated	 FASR	 cells	 from	further	 study	 since	we	wished	 to	 focus	 on	 the	 first-line	 therapies	 (i.e.	 tamoxifen	and	 AIs)	 and	 the	 resistance	 that	 develops	 from	 such	 agents.	 RT-PCR	 was	performed	 on	 triplicate	 RNA	 from	wild	 type	 control	 cells	 (i.e.	MCF-7	 and	 T47D)	and	 (short-term)	 TAMR,	 XR	 and	 T47D	 TAMR	 cells	 (cultured	 under	 the	 same	conditions	as	those	used	to	generate	the	samples	for	microarray	gene	expression	profiling).	In	agreement	with	the	microarray	profiles,	BCL3	RNA	expression	was	up	regulated	 in	 the	 TAMR	 and	 XR	 cells	 models,	 with	 parallel	 up	 regulation	 also	observed	in	the	T47D	TAMR	cell	line	compared	to	control	(Figure	56).		
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Figure	 56	 Representative	 PCR	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 BCL3	 mRNA	
expression	 in	 tamoxifen	 resistant	 (TAMR)	 (A)	 and	 oestrogen	 deprived-resistant	 (XR)	
(B)	MCF-7	cells	versus	wild	type	control	cells	and	TAMR	T47D	cells	(C)	versus	wild	type	
control	cells.	The	results	are	expressed	as	means	±	SEM	and	the	data	were	analysed	by	
an	unpaired	T-test.	
B
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5.3.2 BCL3	protein	expression	in	resistance	BCL3	 expression	 was	 next	 examined	 at	 the	 protein	 level	 by	 Western	 blotting.	Western	 blotting	 was	 performed	 on	 triplicate	 protein	 samples	 from	 wild	 type	control	cells	and	(short-term)	TAMR,	XR	and	T47D	TAMR	cells.	In	agreement	with	the	previous	microarray	and	PCR	data,	Western	analysis	revealed	increased	BCL3	expression	in	the	TAMR	and	XR	cell	lines	compared	to	parental	MCF-7	cells	(Figure	57A	 and	 B).	 However,	 BCL3	 protein	 expression	 was	 not	 detected	 in	 the	 T47D	TAMR	cell	line	(Figure	57C).		
Figure	 57	 Representative	 Western	 blot	 images	 and	 corresponding	 β-actin	 normalised	
densitometry	 graphs	 from	 three	 independent	 experiments	 showing	 BCL3	 protein	
expression	in	tamoxifen	resistant	(TAMR)	(A)	and	oestrogen	deprived-resistant	(XR)	(B)	
MCF-7	 cells	 versus	 wild	 type	 control	 cells	 and	 TAMR	 T47D	 cells	 (C)	 versus	 wild	 type	
control	cells.	The	results	are	expressed	as	means	±	SEM	and	the	data	were	analysed	by	an	
unpaired	T-test.	*	p	<0.05.	
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5.3.3 Microarray	profile	of	BCL3	and	RT-PCR	verification	in	long-term	
antihormone-resistant	cell	models	Towards	 the	 end	 of	 this	 project,	 microarray	 gene	 expression	 profiling	 was	completed	on	a	panel	of	long-term	(3	year)	antihormone-resistant	cell	models.	To	determine	 whether	 increased	 BCL3	 expression	 was	 maintained	 through	 to	long-term	resistance,	 the	expression	of	BCL3	was	next	 examined	 in	 this	panel	of	resistant	 cell	 lines:	 TAMR,	 XR	 and	 FASR	 cell	models	 derived	 from	MCF-7,	 T47D,	BT474	 and	 MDA-MB-361	 cells.	 The	 microarray	 log2	 intensity	 plot	 (Figure	 58A)	demonstrated	 increased	expression	of	BCL3	in	the	TAMR	and	XR	models	derived	from	MCF-7	and	T47D	cells,	versus	wild	type	control.	However,	 in	the	FASR	cells	derived	 from	 T47D	 and	 MCF-7	 cells,	 similar	 levels	 of	 BCL3	 expression	 were	observed	to	the	control.	In	the	BT474	cell	line,	decreased	levels	of	BCL3	expression	were	apparent	in	TAMR	and	FASR	cells,	with	an	increase	in	the	XR	cells	compared	to	control.	In	the	MDA-MB-361	cells	a	statistically	significant	(p	<0.05)	increase	in	BCL3	 expression	 was	 demonstrated	 in	 the	 TAMR	 cells	 versus	 control,	 however	BCL3	 expression	 was	 similar	 in	 the	 FASR	 and	 control	 cells.	 Microarray	 gene	expression	 profiling	 of	 the	 long	 term	 XR	 cell	 model	 derived	 from	MDA-MB-361	cells	is	yet	to	be	completed.	The	 microarray	 profile	 was	 subsequently	 verified	 by	 RT-PCR.	 RT-PCR	 was	performed	 on	 triplicate	 RNA	 from	 wild	 type,	 TAMR	 and	 XR	 cells	 derived	 from	MCF-7,	T47D,	BT474	and	MDA-MB-361	cells,	cultured	under	the	same	conditions	as	those	used	to	generate	the	samples	for	microarray	gene	expression	profiling.	As	previously	mentioned	above,	 FASR	 cells	were	 eliminated	 from	 further	 study	 and	thus	 their	microarray	profile	was	not	verified	by	RT-PCR.	 In	agreement	with	 the	microarray	profiles,	BCL3	mRNA	expression	was	up	regulated	in	the	TAMR	and	XR	cells	 derived	 from	 T47D	 cells,	 in	 the	 XR	 cells	 derived	 from	 BT474	 cells	 and	 the	TAMR	cells	derived	from	MDA-MB-361	cells	(Figure	58B).	However,	in	the	MCF-7	cell	lines,	increased	BCL3	mRNA	expression	was	demonstrated	in	the	TAMR	cells,	but	could	not	be	verified	in	the	XR	cells	(Figure	58B).		
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Figure	 58	 (A)	 Log2	 intensity	 plot	 displaying	 the	 normalised	 (mean	 of	 three	
independent	 replicates	 ±	 SEM)	 gene	 expression	 of	 BCL3	 (jetset	 probe	 ID:	
204908_s_at)	in	long-term	resistnat	tamoxifen	resistant	(TAMR),	fulvestrant	resistant	
(FASR),	 oestrogen	 deprivation	 resistant	 (XR)	 cells	 and	 wild	 type	 (WT)	 control,	
derived	 from	 MCF-7,	 T47D,	 BT474	 and	 MDA-MB-361	 (MDA361)	 cells.	 (B)	
Representative	PCR	images	from	three	independent	experiments	showing	BCL3	and	
β-actin	RNA	expression	in	the	resistant	cell	lines.	*	p	<0.05.	
A	
B	
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5.3.4 BCL3	knockdown		BCL3	knockdown	studies,	utilising	siRNA,	were	performed	to	determine	whether	BCL3	 plays	 a	 pro-survival/pro-proliferative	 role	 during	 antihormone-response	and	 –resistance	 and	 to	 determine	 whether	 such	 knockdown	 can	 improve	 the	growth-inhibitory	 actions	 of	 antihormones	 during	 response	 and	 promote	 cell	death	in	resistance.	
5.3.4.1 BCL3	knockdown	optimisation	Initially,	 optimisation	 studies	 were	 conducted	 to	 determine	 the	 optimum	 siRNA	incubation	conditions	for	the	best	gene	knockdown.	5.3.4.1.1 BCL3	knockdown	in	antihormone-responsive	MCF-7	and	T47D	cells	Since	BCL3	is	expressed	at	low	levels	in	wild	type/untreated	MCF-7	and	T47D	cells	particularly	at	the	protein	level	(as	previously	demonstrated	in	Chapter	4,	section	4.3.2.1),	 it	 was	 necessary	 to	 combine	 the	 siRNA	with	 an	 antihormone	 to	 induce	BCL3	expression.	The	pure	antioestrogen	 fulvestrant	was	chosen	to	be	combined	with	 siRNA	 since	 it	 exhibits	 the	 greatest	 affinity	 for	 the	 ER	 and	 in	 addition	 to	inhibiting	 E2	 binding,	 fulvestrant	 also	 promotes	 degradation	 of	 the	 receptor.	 To	increase	the	efficiency	of	siRNA	transfection,	siRNA	was	added	to	rapidly	dividing	cells	prior	to	the	addition	of	the	growth-inhibitor	fulvestrant.	Initially,	 a	 fulvestrant	 time	 point	 experiment	 was	 performed	 to	 determine	 how	early	 post-fulvestrant	 treatment	 BCL3	 is	 induced	 and	 ultimately	 determine	 the	necessary	 incubation	 of	 siRNA	 with	 fulvestrant	 to	 induce	 BCL3	 expression.	 As	illustrated	in	Figure	59A	and	Figure	60A,	BCL3	mRNA	and	protein	expression	was	up	 regulated	 by	 fulvestrant	 as	 early	 as	 day	 1	 treatment	 in	MCF-7	 cells	with	 this	increased	 level	 of	 expression	maintained	 through	 to	day	2.	However,	mRNA	and	more	substantially	protein	expression	of	BCL3	decreased	at	day	4	together	with	a	corresponding	 decrease	 in	 actin	 expression	 indicative	 of	 mRNA	 and	 protein	loading	errors.	At	the	mRNA	level,	BCL3	expression	was	consistent	from	day	4	to	day	 7,	 with	 a	 small	 increase	 at	 day	 10.	 At	 the	 protein	 level,	 BCL3	 expression	remained	 low	 at	 day	 5	 and	 increased	 at	 day	 7	 and	 10	 fulvestrant	 treatment,	together	 with	 an	 increase	 in	 actin	 expression.	 As	 illustrated	 in	 Figure	 59B	 and	Figure	60B,	1	day	fulvestrant	treatment	induced	up	regulation	of	BCL3	mRNA	and	
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protein	 in	T47D	 cells	 compared	 to	untreated	 control.	 BCL3	 and	 actin	 expression	remained	relatively	consistent	at	the	mRNA	and	protein	level	during	day	1	to	day	10	treatment.		PCR	and	Western	analysis	revealed	fulvestrant-induced	BCL3	expression	as	early	as	day	2	in	MCF-7	and	T47D	cells	(Figure	59	and	Figure	60).	Subsequently,	a	siRNA	time	point	experiment	(including	 initial	2,	3	and	4	day	siRNA	incubation	prior	 to	the	 addition	 of	 2	 day	 fulvestrant	 treatment)	 was	 performed	 in	 MCF-7	 cells	 to	determine	optimum	siRNA	and	 fulvestrant	 incubation	 for	best	BCL3	knockdown.	Western	 analysis	 revealed	 similar	 levels	 of	 gene	 knockdown	 following	 all	 three	incubation	periods	 (Figure	61).	Thus,	 since	 siRNA	silencing	 is	 transient	 and	only	lasts	 approximately	 4	 days	 in	 rapidly	 dividing	 cells,	 to	minimise	 the	 expense	 of	additional	administration	of	siRNA	required	to	maintain	knockdown,	2	day	siRNA	plus	 2	 day	 fulvestrant	 treatment	 (total	 4	 day)	 incubation	 was	 chosen	 as	 the	optimum	 conditions	 for	 best	 gene	 knockdown	 and	 utilised	 for	 the	 remainder	 of	this	project.			
	223		
		
Figure	 59	 Representative	 PCR	 images	 from	 two	 independent	 experiments	 showing	
BCL3	mRNA	expression	and	β-actin	loading	control	in	 (A)	MCF-7	and	(B)	T47D	cells	
treated	 with	 fulvestrant	 (FAS;	 10-7	 M)	 for	 up	 to	 10	 days	 versus	 untreated	 control	
(CON).	
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Figure	 60	 Representative	 Western	 blot	 images	 from	 two	 independent	 experiments	
showing	 BCL3	 protein	 expression	 and	 β-actin	 loading	 control	 in	 (A)	 MCF-7	 and	 (B)	
T47D	 cells	 treated	with	 fulvestrant	 (FAS;	10-7	M)	 for	up	 to	10	days	versus	untreated	
control	(CON).	
B
A	
T47D 
CON								 1								 2 4 5 7 10 BCL3 
β-actin 
CON								 1								 2 4 5 7 10 BCL3 
β-actin 
MCF-7 
Days 
Days 
	 	 					 		 				
	225		
Figure	 61	 Western	 blot	 images	 (n=1)	 showing	 BCL3	 protein	 expression	 and	 β-actin	
loading	control	in	MCF-7	cells	treated	with	media	only,	lipid	only,	unscrambled	control	
small	interfering	RNA	(CON	siRNA)	and	BCL3	siRNA	for	(A)	2,	(B)	3	and	(C)	4	days	prior	
to	the	addition	of	fulvestrant	(FAS;	10-7	M)	for	a	further	2	days.	
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Following	 the	 identification	 of	 the	 optimum	 BCL3	 knockdown	 conditions	 by	Western	analysis	in	MCF-7	cells,	PCR	studies	were	performed	on	MCF-7	and	T47D	cells	to	examine	the	magnitude	of	knockdown	at	the	mRNA	level.	As	illustrated	in	Figure	 62,	 2	 day	 fulvestrant	 treatment	 induced	 up	 regulation	 of	 BCL3	 mRNA	expression	 in	 MCF-7	 and	 T47D	 cells	 (depicted	 by	 the	 ‘media’	 treatment	 arm)	compared	to	untreated	control.	Similarly,	2	day	lipid	and	control	siRNA	treatment	which	 was	 combined	 with	 a	 further	 2	 day	 treatment	 with	 fulvestrant	 induced	similar	BCL3	expression	to	fulvestrant	alone	(‘media’	arm),	implying	that	lipid	and	control	 siRNA	 had	 no	 effect	 on	 BCL3	 expression.	 BCL3	 siRNA	 treatment	 (which	was	 combined	with	 fulvestrant	 to	 induce	BCL3	 expression)	 successfully	 reduced	BCL3	mRNA	expression	in	the	MCF-7	and	T47D	cell	lines.			
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Figure	 62	 Representative	 PCR	 images	 from	 three	 independent	 experiments	 showing	
BCL3	 mRNA	 expression	 and	 β-actin	 loading	 control	 in	 (A)	 MCF-7	 and	 (B)	 T47D	 cells	
treated	 with	 media	 only,	 lipid	 only,	 unscrambled	 control	 small	 interfering	 RNA	 (CON	
siRNA)	and	BCL3	siRNA	for	2	days	prior	to	the	addition	of	fulvestrant	(FAS;	10-7	M)	for	a	
further	2	days.	Untreated	control	is	also	shown.	
fulvestrant	(FAS;	10-7	M)	for	up	to	10	days	versus	untreated	control	(CON).	
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In	 agreement	 with	 the	 PCR	 data,	Western	 analysis	 revealed	 fulvestrant-induced	(2	day	 treatment)	 up	 regulation	 of	 BCL3	 protein	 expression	 in	MCF-7	 and	 T47D	cells	 versus	 untreated	 control	 (Figure	 63).	 Similarly,	 lipid	 and	 control	 siRNA	treatment	 had	 no	 effect	 on	 BCL3	 protein	 expression.	 BCL3	 siRNA	 treatment	induced	 a	 substantial	 knockdown	 of	 BCL3	 expression	 demonstrated	 by	 the	minimal	BCL3	expression	detected	in	the	T47D	cell	line,	and	even	less,	if	any	at	all,	in	the	MCF-7	cells.			
Figure	 63	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	BCL3	protein	expression	and	β-actin	loading	control	in	(A)	MCF-7	and	(B)	T47D	
cells	 treated	 with	 media	 only,	 lipid	 only,	 unscrambled	 control	 small	 interfering	 RNA	
(CON	siRNA)	and	BCL3	siRNA	for	2	days	prior	to	the	addition	of	fulvestrant	(FAS;	10-7	M)	
for	a	further	2	days.	Untreated	control	is	also	shown.	
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5.3.4.1.2 BCL3	knockdown	in	antihormone-resistant	cell	lines	In	 contrast	 to	 the	 antihormone	 responsive	 cells,	 the	 antihormone-resistant	 cell	models	 (short-term	TAMR,	 XR	 and	 T47D	 TAMR)	 constitutively	 express	 BCL3,	 as	previously	 demonstrated	 (section	 5.3.1	 and	 5.3.2).	 Therefore,	 unlike	 the	antihormone	responsive	cells,	it	is	not	necessary	to	induce	BCL3	expression	in	the	antihormone	 resistant	 cell	 lines	 for	 subsequent	 knockdown	 via	 siRNA,	 to	ultimately	decipher	the	role	of	BCL3.	Simply,	BCL3	knockdown	was	achieved	in	the	resistant	cell	models	by	4	day	incubation	with	BCL3	siRNA.	As	illustrated	in	Figure	64,	TAMR,	XR	and	T47D	TAMR	cells	express	BCL3	at	the	messenger	level,	which	is	not	 affected	 by	 lipid	 and	 control	 siRNA	 treatments.	 Four	 day	 BCL3	 siRNA	incubation	 induced	 down	 regulation	 of	 BCL3	 mRNA	 expression	 in	 the	 three	antihormone	 resistant	 cell	 models,	 with	 the	 greatest	 magnitude	 of	 knockdown	observed	in	the	MCF-7-derived	models	(i.e.	TAMR	and	XR,	Figure	64A	and	Figure	64B).			
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Figure	 64	 Representative	 PCR	 images	 from	 three	 independent	 experiments	 showing	
BCL3	mRNA	expression	and	 β-actin	 loading	 control	 in	 (A)	 tamoxifen-resistant	 (TAMR),	
(B)	 oestrogen	 deprivation-resistant	 (XR)	 and	 (C)	 TAMR	 cells	 derived	 from	 T47D	 cells	
(T47D	TAMR)	treated	with	media	only,	lipid	only,	unscrambled	control	small	interfering	
RNA	(CON	siRNA)	and	BCL3	siRNA	for	4	days.	
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In	 agreement	 with	 the	 PCR	 data,	 Western	 analysis	 demonstrated	 a	 substantial	decrease	 in	 BCL3	 protein	 expression	 mediated	 by	 4	 day	 incubation	 with	 BCL3	siRNA	in	the	TAMR	and	XR	cell	models	(Figure	65A	and	B).	Lipid	and	control	siRNA	treatments	 had	 no	 effect	 on	 BCL3	 protein	 expression	 in	 both	 cell	 lines.	 As	previously	reported	in	section	5.3.2,	BCL3	expression	could	not	be	detected	in	the	T47D	TAMR	cell	line	and	thus	BCL3	knockdown	in	this	cell	line	at	the	protein	level	could	not	be	examined	(Figure	65C).			
Figure	65	Representative	Western	blot	 images	 from	 three	 independent	experiments	
showing	 BCL3	 protein	 expression	 and	 β-actin	 loading	 control	 in	 (A)	
tamoxifen-resistant	 (TAMR),	 (B)	oestrogen	deprivation-resistant	 (XR)	 and	(C)	TAMR	
cells	 derived	 from	 T47D	 cells	 (T47D	 TAMR)	 treated	 with	 media	 only,	 lipid	 only,	
unscrambled	control	small	interfering	RNA	(CON	siRNA)	and	BCL3	siRNA	for	4	days.	
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5.3.5 Effect	of	BCL3	knockdown	on	survival	of	antihormone-responsive	and	
–resistant	cells	Following	 the	 accomplishment	 of	 substantial	 BCL3	 knockdown	 in	 the	antihormone-responsive	 and	 -resistant	 cell	 lines,	 cell	 survival	 studies	 were	performed	to	determine	whether	BCL3	is	a	pro-survival	gene	and	ultimately	plays	a	role	 in	the	survival	of	breast	cancer	cells	 in	response	to	antihormone	challenge	and	the	emergence	and	maintenance	of	resistant	cell	growth.	An	Annexin	V	and	PI	stain	was	utilised	with	subsequent	flow	cytometery	analysis.		
5.3.5.1 Effect	of	antihormones	on	the	survival	of	MCF-7	and	T47D	cells	Initially,	 baseline	 studies	 were	 performed	 on	 7	 day	 antihormone-treated	 MCF-7	cells.	 Seven	 day	 treatment	 was	 selected	 over	 the	 usual	 10	 day	 treatment	 used	throughout	 this	 project	 because	 the	 10	 day	 untreated	 control	 cells	 became	 over	confluent	and	thus	gave	rise	to	false	positive	data.	The	breast	cancer	cell	lines	used	throughout	 this	 study	were	 adherent	 and	 the	dead/apoptotic	 cells	 floated	 in	 the	medium.	Typically,	the	cell	medium	was	removed	and	replaced	with	fresh	medium	every	4	days.	Thus,	we	first	wanted	to	determine	whether	changing	the	medium	at	day	 4	 influenced	 the	 apoptotic	 data,	 since	 any	 dead	 floating	 cells	 would	 be	discarded.	As	illustrated	in	Figure	66,	7	day	antihormone	treatment	(including	the	removal	 of	 the	 medium	 comprising	 any	 dead	 floating	 cells	 at	 day	 4	 which	 was	replaced	with	fresh	medium)	had	no	effect	on	the	percentage	of	apoptotic	cells.			
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	To	 determine	 whether	 removing	 the	 cell	 medium	 affected	 the	 apoptotic	 data,	survival	 assays	were	next	 performed	on	7	day	 antihormone-treated	MCF-7	 cells,	with	 fresh	medium	added	on	day	4	without	 the	removal	of	 the	old	medium,	 thus	not	discarding	any	apoptotic	cells	floating	in	the	medium.	As	illustrated	in	Figure	67,	tamoxifen	and	oestrogen	deprivation	treatments	promoted	a	small	increase	in	apoptosis,	reflected	by	a	small	increase	in	the	percentage	of	apoptotic	cells	versus	untreated	 control,	 whereas	 a	 similar	 percentage	 of	 apoptotic	 cells	 were	 present	following	 control	 and	 fulvestrant	 treatment.	 However,	 the	 small	 tamoxifen	 and	oestrogen	 deprivation-induced	 apoptosis	 was	 not	 statistically	 significant	compared	to	untreated	control	and	the	levels	of	apoptosis	were	much	lower	than	the	 positive	 control.	 The	 levels	 of	 apoptotic	 cells	 were	 statistically	 significantly	(p	<0.05)	 greater	 in	 the	 positive	 control	 compared	 to	 the	 untreated	 control.	Together,	 it	 was	 concluded	 that	 changing	 the	 medium	 at	 day	 4	 influenced	 the	apoptotic	data,	 likely	due	 to	 the	removal	and	 loss	of	apoptotic	cells.	Therefore,	 it	
Figure	 66	Graph	displaying	 the	percentage	 of	 apoptotic	 cells	 in	MCF-7	 cells	 treated	
with	untreated	control	(CON)	medium,	tamoxifen	(TAM;	10-7	M),	fulvestrant	(FAS;	10-7	
M)	 and	 oestrogen	 deprivation	 (ED)	 for	 7	 days	 alongside	 the	 positive	 control	
thapsigargin	(1	µM	for	48	hours;	n=1).	The	medium	was	removed	and	replaced	with	
fresh	medium	at	day	3.		
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was	decided	that	for	subsequent	cell	survival	studies	requiring	greater	than	4	days	incubation,	 fresh	 medium	 would	 be	 added	 without	 removing	 the	 old	 medium	containing	apoptotic	cells.		
		 	
Figure	67	Graph	displaying	the	percentage	of	apoptotic	cells	in	MCF-7	cells	treated	with	
untreated	 control	 (CON)	 medium,	 tamoxifen	 (TAM;	 10-7	 M),	 fulvestrant	 (FAS;	 10-7	 M)	
and	oestrogen	deprivation	(ED)	for	7	days	alongside	 the	positive	control	thapsigargin	
(1	µM	for	48	hours).	Fresh	medium	was	added	at	day	3.	The	results	are	expressed	as	
the	 means	 ±	 SEM	 of	 three	 independent	 experiments	 and	 presented	 as	 the	 %	 of	 the	
control.	 The	 data	 were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	 Tukey’s	 multiple	
comparisons	test	*	p	<0.05	compared	to	control.	
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Subsequently,	 cell	 survival	 assays	 were	 performed	 to	 determine	 the	 baseline	apoptotic	 levels	of	7	day	antihormone	treated	T47D	cells.	As	shown	in	Figure	68,	tamoxifen	 and	 fulvestrant	 treatments	 promoted	 a	 small	 and	 non-significant	increase	 in	 apoptosis	 compared	 to	 control.	 Oestrogen	 deprivation	 treatment	induced	 a	 statistically	 significant	 (p	 <0.05)	 increase	 in	 apoptosis	 compared	 to	untreated	 control.	 However,	 the	 levels	 of	 apoptosis	 observed	 following	antihormone	treatments	were	less	than	the	levels	induced	by	the	positive	control.	Indeed,	the	positive	control	promoted	a	statistically	significant	(p	<0.01)	increase	in	apoptosis	compared	to	untreated	control.		
		
	
Figure	68	Graph	displaying	 the	percentage	of	apoptotic	cells	 in	T47D	cells	treated	
with	untreated	 control	 (CON)	medium,	 tamoxifen	 (TAM;	10-7	M),	 fulvestrant	 (FAS;	
10-7	 M)	 and	 oestrogen	 deprivation	 (ED)	 for	 7	 days	 alongside	 the	 positive	 control	
thapsigargin	(1	µM	for	48	hours).	Fresh	medium	was	added	at	day	3.	The	results	are	
expressed	as	the	means	±	SEM	of	three	independent	experiments	and	presented	as	
the	%	 of	 the	 control.	 The	 data	were	 analysed	 by	 an	 ANOVA	and	post-hoc	 Tukey’s	
multiple	comparisons	test.	*	p	<	0.05		and	**	p	<0.01	compared	to	control.	
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5.3.5.2 Effect	of	BCL3	knockdown	on	the	survival	of	antihormone-responsive	
MCF-7	cells	Following	the	optimisation	of	 the	cell	survival	experiment	and	the	determination	of	baseline	apoptosis	in	antihormone	treated	MCF-7-	and	T47D	cells,	the	effect	of	BCL3	 knockdown	 on	 the	 survival	 of	 fulvestrant-treated	 MCF-7	 cells	 was	investigated	 to	 determine	 whether	 BCL3	 plays	 a	 pro-survival	 role	 during	antihormone	response	and	to	determine	whether	targeting	this	protein	alongside	antihormone	treatment	enhances	the	apoptotic	action	of	these	agents.	As	revealed	in	Figure	69,	targeted	down	regulation	of	BCL3	via	siRNA	had	very	little	effect	on	the	 apoptosis	 of	 fulvestrant-treated	 MCF-7	 cells	 versus	 control	 siRNA.	 Both	 the	control	 and	 BCL3	 siRNA	 treatments	 induced	 a	 slight	 increase	 in	 apoptosis,	although	 not	 significant,	 compared	 to	 the	 untreated	 control	 and	 fulvestrant	treatment	 alone	 (Figure	 69).	 The	 levels	 of	 apoptotic	 cells	 were	 statistically	significantly	 greater	 in	 the	 positive	 control	 arm	 compared	 to	 untreated	 control,	fulvestrant	 (p	 <	 0.0001,	 for	 both),	 control	 siRNA	 and	BCL3	 siRNA	 (p	 <0.001,	 for	both)	(Figure	69).		
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Figure	69	Graph	displaying	the	percentage	of	apoptotic	cells	in	MCF-7	cells	treated	with	
untreated	control	(CON)	medium,	fulvestrant	(FAS;	10-7	M),	CON	siRNA	plus	FAS	(2	day	
siRNA	followed	by	2	day	FAS)	and	BCL3	siRNA	plus	FAS	alongside	thapsigargin	positive	
control	 (1	 µM	 for	 48	 hours).	 The	 results	 are	 expressed	 as	 the	means	 ±	 SEM	 of	 three	
independent	 experiments	 and	 presented	 as	 the	 %	 of	 the	 control.	 The	 data	 were	
analysed	by	 an	ANOVA	and	post-hoc	Tukey’s	multiple	 comparisons	 test.	 ***	p	<0.001;	
****	p	<0.0001.	
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5.3.5.3 Effect	of	BCL3	knockdown	on	the	survival	of	TAMR	and	XR	cells	To	 determine	 whether	 BCL3	 plays	 a	 pro	 survival	 role	 during	 resistance,	 cell	survival	assays	were	next	performed	on	TAMR	and	XR	cells.	As	shown	in	Figure	70,	targeted	down	 regulation	of	BCL3	by	 siRNA	 in	TAMR	and	XR	 cell	 lines	 had	 very	little	 effect	 on	 the	 percentage	 of	 apoptotic	 cells	 versus	 control,	 suggesting	 that	BCL3	 is	 not	 involved	 in	 the	 survival	 of	 resistant	 cells.	 In	 the	 XR	 cells,	 4	 day	incubation	with	 control	 and	 BCL3	 siRNA	 resulted	 in	 the	 production	 of	 an	 equal	percentage	of	apoptotic	cells	(Figure	70B);	whereas	BCL3	knockdown	in	the	TAMR	cell	line	appeared	to	result	in	a	slightly	lower	production	of	apoptotic	cells	versus	control	(Figure	70A),	possibly	suggesting	a	pro-apoptotic	role	of	BCL3	in	this	cell	line.	 However,	 this	 observation	 in	 the	 TAMR	 cell	 line	 was	 marginal	 and	 not	statistically	 significant.	 In	 this	 cell	 line,	 the	 levels	 of	 apoptotic	 cells	 were	statistically	significantly	greater	in	the	positive	control	arm	compared	to	untreated	control,	control	siRNA	(p	<	0.05,	for	both)	and	BCL3	siRNA	(p	<0.01)	(Figure	70A).		
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Figure	70	Graph	displaying	the	percentage	of	apoptotic	cells	in	(A)	tamoxifen-resistant	
(TAMR)	and	(B)	oestrogen	deprivation-resistant	(XR)	cells	treated	with		control	(CON)	
medium	only,	CON	siRNA	plus	fulvestrant	(FAS;	10-7	M)	(2	day	siRNA	followed	by	2	day	
FAS)	 and	 BCL3	 siRNA	 plus	 FAS	 alongside	 thapsigargin	 positive	 control	 (1	 µM	 for	 48	
hours).	 The	 results	 are	 expressed	 as	 the	 means	 ±	 SEM	 of	 three	 independent	
experiments	 and	 presented	 as	 the	 %	 of	 the	 control.	 The	 data	 were	 analysed	 by	 an	
ANOVA	and	post-hoc	Tukey’s	multiple	comparisons	test.	*	p	<	0.05;	**	p	<0.01.	
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5.3.6 Effect	of	BCL3	knockdown	on	cell	growth	during	antihormone	
response	and	resistance	To	 further	 investigate	 the	 role	 of	 BCL3	 during	 antihormone	 response	 and	resistance	cell	 counting	experiments	were	next	performed	 to	determine	whether	BCL3	 expression	 has	 any	 effect	 on	 the	 cell	 growth.	 The	 rationale	 was	 that	 a	decrease	 in	 cell	 number/cell	 growth	 mediated	 by	 BCL3	 siRNA	 versus	 control,	suggests	that	BCL3	plays	a	role	in	promoting	cell	growth	potentially	via	increasing	cell	proliferation.		
5.3.6.1 Antihormone	response	As	 illustrated	 in	 Figure	 71,	 BCL3	 knockdown	 (2	 day	 BCL3	 siRNA	 incubation	followed	by	a	further	2	day	combined	incubation	with	fulvestrant)	had	no	effect	on	the	 growth	 of	 fulvestrant-treated	 MCF-7	 cells,	 but	 promoted	 a	 small,	 yet	 non-significant,	decrease	in	T47D	cell	growth	versus	control.		
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Figure	 71	 Effect	 of	 BCL3	 knockdown	 (with	 2	 day	 BCL3	 siRNA	 followed	 by	 2	 day	
fulvestrant	(FAS;	10-7	M))	compared	to	control	(CON;	2	day	control	siRNA	followed	by	
2	day	fulvestrant)	and	FAS	alone	on	the	growth	of	(A)	MCF-7	and	(B)	T47D	cells.	The	
results	 are	 expressed	as	 the	means	±	 SEM	of	 three	 independent	 experiments	 (n=3)	
and	presented	as	the	%	of	the	control.	The	data	were	analysed	by	an	ANOVA	and	post-
hoc	Tukey’s	multiple	comparisons	test.	
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5.3.6.2 Antihormone	resistance	In	 contrast,	 targeted	 down	 regulation	 of	 BCL3	 using	 siRNA	 in	 the	 antihormone	resistant	TAMR	and	XR	cell	 lines	reduced	cell	growth	by	approximately	40%	and	20%,	respectively,	versus	control	siRNA	(Figure	72A	and	B).	However,	such	effects	on	the	growth	of	TAMR	and	XR	cells	did	not	reach	significance.	BCL3	knockdown	was	without	effect	on	the	growth	of	T47D	TAMR	cells	(Figure	72C).		
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Figure	72	 Effect	 of	 BCL3	knockdown	 (with	4	 day	 BCL3	 siRNA)	 compared	 to	 control	
(CON;	 4	 day	 control	 siRNA)	 and	 untreated	 CON	 on	 the	 growth	 of	 (A)	 tamoxifen-
resistant	 (TAMR)	 (n=3),	 (B)	 oestrogen	 deprivation-resistant	 (XR)	 (n=6)	 and	 (C)	
TAMR	cells	derived	 from	T47D	cells	 (T47D-TAMR)	(n=3).	The	results	are	expressed	
as	the	means	±	SEM	and	presented	as	the	%	of	the	control.	The	data	were	analysed	by	
an	ANOVA	and	post-hoc	Tukey’s	multiple	comparisons	test.	
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5.3.6.3 Effect	of	BCL3	knockdown	on	EGFR/HER2/MAPK	signalling	The	 group	 has	 previously	 reported	 that	 TAMR	 cell	 growth	 is	 regulated	 by	EGFR/HER2	 driven	 MAPK	 and	 AKT	 signalling	 pathways185.	 To	 verify	 that	 the	siRNA	 used	 in	 the	 present	 study	 specifically	 targeted	 BCL3	 and	 not	 elements	 of	these	signalling	pathways,	Western	blot	analysis	of	these	proteins	was	performed	in	 the	TAMR	cell	 line	 following	 incubation	with	either	BCL3	or	control	siRNA.	As	shown	in	Figure	73,	BCL3	siRNA	had	no	effect	on	total	and	phosphorylated	forms	of	ERBB2,	AKT,	ERK	and	EGFR.		
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Figure	 73	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	 protein	 expression	of	phosphorylated	 (P)	 and	 total	 (T)	ERBB2,	 ERK1/2,	 EGFR	
and	 AKT	 in	 tamoxifen-resistant	 (TAMR)	 cells	 incubated	 for	 4	 days	 with	 unscrambled	
control	(CON)	and	BCL3	siRNA.	
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5.3.7 Effect	of	BCL3	knockdown	on	cell	cycle	distribution	during	
antihormone-response	and	–resistance	Cell	cycle	studies,	utilising	a	PI	stain	and	subsequent	flow	cytometry	analysis,	were	next	performed	to	investigate	whether	BCL3	plays	a	role	in	regulating	progression	of	cells	through	the	cell	cycle	during	antihormone-response	and	in	resistance.			
5.3.7.1 Effect	of	antihormones	on	the	cell	cycle	distribution	of	MCF-7	and	T47D	
cells	Initially,	the	effect	of	7	day	antihormone	treatment	on	the	cell	cycle	distribution	of	MCF-7	and	T47D	cells	was	examined.	Figure	74	displays	the	percentage	of	cells	in	each	phase	of	the	cell	cycle	following	antihormone,	E2	and	control	treatments.	All	three	antihomrones	induced	G1	arrest	of	MCF-7	cells	compared	to	control,	with	the	greatest	 arrest	 induced	 by	 fulvestrant	 treatment	 (Figure	 74A).	 However,	 such	effects	 did	 not	 reach	 significance.	 E2-	 and	 control-treated	 cells	 had	 a	 relatively	equal	percentage	of	cells	in	each	stage	of	the	cell	cycle	(i.e.	G1,	S	and	G2/M	phases)	in	MCF-7	cells.	Following	antihormone	treatment,	the	percentage	of	cells	in	S	phase	decreased,	 although	 not	 significant,	 versus	 E2-	 and	 control-treated	 cells	 (Figure	74A).	 The	 percentage	 of	 cells	 in	 G2/M	 phase	 was	 relatively	 similar	 following	antihormone,	E2	and	control	treatments,	with	a	small	and	non-significant	decrease	apparent	following	fulvestrant	treatment	(Figure	74A).	Similarly,	tamoxifen	and	fulvestrant	induced	G1	arrest	(although	not	significant)	of	T47D	 cells	 versus	 control	 (Figure	 74B).	 Surprisingly,	 however,	 oestrogen	deprivation	 treatment	 induced	 a	 decrease	 in	 the	 percentage	 of	 cells	 in	 G1	compared	 to	 control,	with	 a	 statistically	 significant	 (p	 <0.05)	 decrease	 observed	versus	E2	treatment	(Figure	74B).	The	percentage	of	cells	in	S	phase	was	relatively	similar	 following	 tamoxifen,	 fulvestrant,	 E2	 and	 control	 treatments.	 However,	oestrogen	 deprivation	 treatment	 induced	 a	 statistically	 significant	 (p	 <0.05)	increase	 in	 the	 percentage	 of	 cells	 in	 S	 phase,	 indicative	 of	 increased	 DNA	replication,	 compared	 to	 control	 and	 E2	 treatment	 (Figure	 74B).	 Tamoxifen	 and	fulvestrant	 treated	 cells	 had	 a	 slightly	 lower,	 whereas	 oestrogen	 deprivation	treated	cells	had	a	slightly	higher,	percentage	of	cells	in	the	G2/M	phase	compared	to	 control	 (Figure	 74B).	 However,	 such	 effects	 were	 not	 significant.	 A	 similar	
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distribution	of	cells	in	each	phase	of	the	cell	cycle	was	apparent	following	E2	and	control	treatments.			
		
	
Figure	 74	 Effect	 of	 7	 day	 oestradiol	 (E2;	 10-9	 M),	 tamoxifen	 (TAM;	 10-7	 M),	 fulvestrant	
(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	treatment	on	cell	cycle	distribution	versus	
untreated	 control	 (CON)	 in	MCF-7	 (A)	 and	T47D	 (B)	 cells.	The	 results	 are	 expressed	as	
the	means	±	SEM	of	three	independent	experiments.	*	p	<0.05.	The	data	were	analysed	by	
a	one-way	ANOVA	and	post-hoc	Tukey’s	multiple	comparisons	test	
A	
B	
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Tamoxifen	has	been	widely	recognised	as	a	strong	 inducer	of	G1	arrest	 in	MCF-7	cells311,420,	although	such	effects	were	not	observed	in	the	current	study.	However,	the	majority	of	studies	examined	short	term	antihormone	treatment,	ranging	from	24	 to	 96	 hours.	 Thus,	 it	 is	 highly	 likely	 that	 such	 antihormone-induced	dysregulation	of	the	cell	cycle	was	missed	following	7	day	treatment.	Therefore,	a	time	 course	 study	 was	 performed,	 comprising	 day	 1	 to	 day	 4	 antihormone	treatments.	As	illustrated	in	Figure	75,	tamoxifen	induced	G1	arrest	of	MCF-7	cells	compared	to	control	as	early	as	day	2	treatment,	which	was	maintained	through	to	day	4	(n=1).	However,	as	these	experiments	were	only	performed	once,	statistical	analysis	 could	 not	 be	 applied.	 Concurrently,	 the	 percentage	 of	 tamoxifen-treated	cells	decreased	 in	S	and	G2/M	phases,	 compared	 to	control,	 from	day	2	 to	day	4	treatment.	Following	24	hours	of	tamoxifen	treatment,	there	was	very	little,	if	any,	difference	in	the	percentage	of	cells	in	each	phase	of	the	cycle,	compared	to	control	(Figure	75A).	 Fulvestrant	 promoted	G1	 arrest,	 together	with	 a	 small	 decrease	 in	the	percentage	of	cells	entering	S	and	G2/M	phases,	compared	to	control,	following	3	 and	 4	 day	 treatment	 (Figure	 75C	 and	 D).	 However,	 following	 day	 1	 and	 2	treatment,	 fulvestrant	had	very	 little	effect	on	 the	 cell	 cycle	 compared	 to	 control	(Figure	 75A	 and	 B).	 Interestingly,	 oestrogen	 deprivation	 treatment	 induced	marked	 G1	 arrest	 following	 1	 day	 treatment	 with	 concurrent	 decreases	 in	 the	percentage	 of	 cells	 in	 S	 phase	 and	 G2/M	 phase	 versus	 control	 (Figure	 75A).	Following	2	day	oestrogen	deprivation	treatment,	the	percentage	of	MCF-7	cells	in	G1	 was	 similar	 to	 control,	 whereas	 the	 percentage	 in	 S	 phase	 and	 G2/M	 phase	were	 decreased	 and	 increased,	 respectively,	 versus	 control	 (Figure	 75B).	Following	3	and	4	day	oestrogen	deprivation	treatment,	the	percentage	of	cells	in	each	phase	of	 the	 cell	 cycle	was	 relatively	 similar	 to	 control	 (Figure	75C	and	D).	Unsurprisingly,	the	percentage	of	cells	arrested	in	G1	was	lower	following	day	1	to	day	4	E2	treatment	compared	to	control	(Figure	75).	Additionally,	the	percentage	of	cells	in	S	phase	was	slightly	greater	following	E2	treatment	compared	to	control,	with	 the	 greatest	 induction	 apparent	 at	 day	 1	 (Figure	 75A).	 Interestingly,	 the	percentage	 of	 E2	 treated	 cells	 in	 G2/M	 phase	was	marginally	 less	 at	 day	 1,	 but	greater	at	day	2	to	day	4,	compared	to	control.		
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	Figure	75	Effect	of	oestradiol	 (E2;	10-9	M),	 tamoxifen	 (TAM;	10-7	M),	 fulvestrant	 (FAS;	
10-7	 M)	 and	 oestrogen	 deprivation	 (ED)	 on	 cell	 cycle	 distribution	 versus	 untreated	
control	(CON)	in	MCF-7	cells	following	1	(A),	2	(B),	3	(C)	and	4	(D)	days	treatment	(n=1).	
A	
B	
C	
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5.3.7.2 Effect	of	BCL3	knockdown	on	the	cell	cycle	distribution	of	antihormone-
responsive	MCF-7	and	T47D	cells	The	 effect	 of	BCL3	knockdown	on	 the	 cell	 cycle	 of	MCF-7	 and	T47D	 cells	 during	antihormone	response	was	next	 investigated	 to	determine	whether	BCL3	plays	a	role	 in	promoting	cell	 cycle	progression	and	 to	determine	whether	 targeting	 this	protein	alongside	antihormone	treatment	enhances	the	growth	inhibitory	action	of	these	agents.	MCF-7	and	T47D	cells	were	incubated	with	BCL3	or	control	siRNA	for	2	 days	 prior	 to	 the	 addition	 of	 fulvestrant	 for	 a	 further	 2	 days.	 As	 illustrated	 in	Figure	76,	BCL3	knockdown	had	no	effect	on	 the	cell	 cycle	of	 fulvestrant-treated	MCF-7	and	T47D	cells	 compared	 to	 control	 siRNA.	To	a	 certain	degree,	 this	 is	 in	agreement	with	the	cell	growth	data	(Figure	71)	which	demonstrated	no	effect	of	targeted	 BCL3	 down	 regulation	 on	 the	 growth	 of	 fulvestrant-treated	MCF-7	 and	T47D	cells,	 indirectly	suggesting	that	BCL3	is	not	 involved	in	cell	proliferation	or	survival	during	antihormone	response.	Similarly,	2	day	fulvestrant	treatment	had	very	little	effect	on	the	cell	cycle	of	MCF-7	and	T47D	cells	compared	to	media	alone	(Figure	 76).	 This	 is	 in	 agreement	 with	 the	 data	 presented	 in	 Figure	 75,	 which	demonstrated	 that	 2	 day	 fulvestrant	 treatment	 had	 no	 effect	 on	 the	 cell	 cycle	 of	MCF-7	cells.			
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	 Figure	 76	 Effect	 of	 BCL3	 knockdown	 (with	 2	 day	 BCL3	 siRNA	 followed	 by	 2	 day	fulvestrant	 (FAS;	10-7	M))	compared	to	control	 (CON;	2	day	control	siRNA	followed	by	2	
day	FAS)	on	the	cell	cycle	distribution	of	MCF-7	(A;	n=2;	expressed	as	the	means	±	SEM)	
and	T47D	(n=1)	cells.	The	cell	 cycle	distributions	of	untreated	control	 (CON)	and	2	day	
FAS-treated	cells	are	also	shown.	
B	
A	
	252		
5.3.7.3 Effect	of	BCL3	knockdown	on	the	cell	cycle	distribution	of	TAMR	and	XR	
cells	As	previously	demonstrated	in	Figure	72,	BCL3	knockdown	in	TAMR	and	XR	cells	led	to	a	substantial	decrease	in	cell	growth.	To	determine	whether	BCL3	promotes	cell	cycle	progression	in	these	resistant	cell	models,	thus	potentially	explaining	the	decrease	 in	 cell	 growth	 observed	 following	 targeted	 knockdown	 of	 this	 protein,	cell	 cycle	 assays	 were	 next	 performed	 on	 TAMR	 and	 XR	 cells.	 As	 illustrated	 in	Figure	 77,	 BCL3	 knockdown	 by	 siRNA	 in	 TAMR	 and	 XR	 cell	 lines	 had	 very	 little	effect	on	the	cell	cycle	compared	to	control	siRNA,	suggesting	that	BCL3	does	not	regulate	 the	cell	 cycle.	Media	only-treated	TAMR	and	XR	cells	exhibited	a	similar	percentage	of	 cells	 in	each	phase	of	 the	cell	 cycle	compared	 to	control	and	BCL3	siRNA-treated	cells,	with	 the	exception	of	XR	cells	 in	S	phase	and	G2/M	phase.	A	lower	percentage	of	XR	cells	were	in	S	phase,	whereas	a	slightly	higher	percentage	were	 in	 G2/M	 phase	 following	 control	 siRNA	 and	 BCL3	 siRNA	 treatment	 versus	control	(Figure	77).	However,	such	effects	were	not	significant.	Subsequently,	BCL3	knockdown	comprised	of	2	and	3	day	siRNA	 incubation	was	performed	on	TAMR	 cells	 and	 the	 cell	 cycle	was	 assessed	 to	 determine	whether	shorter	BCL3	knockdown	disrupted	the	cell	cycle.	As	revealed	in	Figure	78,	2	and	3	day	BCL3	knockdown	had	very	 little	 effect	on	 the	 cell	 cycle	 compared	 to	 control	siRNA.				
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Figure	77	Effect	of	BCL3	knockdown	(with	4	day	BCL3	siRNA)	compared	to	control	(CON	
siRNA;	4	day	control	siRNA)	on	the	cell	cycle	distribution	of	tamoxifen-resistant	(TAMR)	
(A)	 and	 oestrogen	 deprivation-resistant	 (XR)	 (B)	 cells.	 The	 cell	 cycle	 distribution	 of	
untreated	 control	 (CON)	 cells	 is	 also	 shown.	The	 results	 are	 expressed	 as	 the	means	±	
SEM	of	three	independent	experiments.	The	data	were	analysed	by	an	ANOVA	and	post-
hoc	Tukey’s	multiple	comparisons	test.	
B	
A	
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Figure	78	Effect	of	2	(A;	n=1)	and	3	(B;	n=1)	day	BCL3	siRNA	incubation	on	the	cell	cycle	
distribution	 of	 tamoxifen-resistant	 (TAMR)	 cells	 versus	 control	 (CON	 siRNA).	 The	 cell	
cycle	distribution	of	untreated	control	(CON)	cells	is	also	shown.	
B
A
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5.3.8 Investigation	of	potential	mechanisms	mediated	by	BCL3	to	promote	
proliferation	of	antihormone-resistant	MCF-7	cells	As	 determined	 from	 the	 ontological	 studies	 reported	 in	 Chapter	 3,	 BCL3	 is	 a	nuclear	protein	with	both	transactivation	and	transrepressor	functions,	which	are	mediated	 by	 its	 association	 with	 the	 NF-κB	 homodimers,	 p50/NFKB1	 and	p52/NFKB2359.	 Furthermore,	 increased	 BCL3	 expression	 and	 NF-κB	 activity	(comprised	 predominantly	 of	 p50/NFKB1	dimers)	 have	 been	 reported	 in	MCF-7	cells	following	oestrogen	deprivation	treatment,	with	BCL3	expression	and	NF-κB	activity	enhanced	further	in	a	ER+	MCF-7	cell	model	of	oestrogen	independence363,	strongly	suggesting	a	positive	correlation	and	association	between	both	BCL3	and	NF-κB	activity,	culminating	in	the	activation	of	downstream	NF-κB-regulated	genes	involved	 in	 tumourigenesis.	 In	 support	 of	 the	BCL3	and	NF-κB	 connection,	BCL3	has	 been	 shown	 to	 coactivate	 p52/NFKB2	 dimers	 in	 normal	 breast	 cell	 lines,	resulting	 in	 the	 transcription	of	 the	 cyclin	D1	gene	ultimately	promoting	G1	 to	S	phase	cell	cycle	transition	and	cell	cycle	progression361.		To	 further	 explore	 the	 relationship	 between	 BCL3	 and	 NF-κB,	 this	 project	 next	aimed	to	determine	whether	p50/NFKB1	and	p52/NFKB2	proteins	are	expressed	alongside	 BCL3	 during	 antihormone-response	 and	 -resistance	 and	 ultimately	investigate	whether	they	interact	with	BCL3	and	thus	play	a	role	in	BCL3-mediated	cell	growth	observed	particularly	during	resistance.		
5.3.8.1 Microarray	analysis	of	p50/NFKB1	and	p52/NFKB2	expression	during	
antihormone	response	Initially,	 the	microarray	data	utilised	 in	Chapter	3	was	 interrogated	to	determine	whether	p50/NFKB1	and	p52/NFKB2	are	expressed	together	with	BCL3	in	MCF-7	cells	 during	 antihormone	 response	 and	 hence	 may	 contribute	 to	 aberrant	 cell	growth.	 Microarray	 gene	 expression	 profiling	 was	 completed	 for	 10	 day	antihormone-treated	 (tamoxifen,	 fulvestrant	 and	 oestrogen	 deprivation)	 MCF-7	cells	cultured	in	sFCS	versus	E2-treated	control.	The	resultant	triplicate	data	were	uploaded	on	to	the	bioinformatics	software	GeneSifter	and	first	median	normalised	and	 log	 transformed	prior	 to	 analysis.	 This	 GeneSifter-assembled	 array	 resource	was	 interrogated	 using	 the	 ‘jetset’	 probes	 representing	 p50/NFKB1	 and	p52/NFKB2:	209239_at	and	209636_at	respectively.	
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Figure	79	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	±	SEM)	gene	expression	of	p50/NFKB1	(jetset	probe	ID:	209239_at)	in	MCF-7	
cells	 treated	 for	 10	 days	 with	 oestradiol	 (E2	 control;	 10-9	 M),	 oestrogen	 deprivation	
(ED),	 tamoxifen	 (TAM;	 10-7	M)	 and	 fulvestrant	 (FAS;	 10-7	 M).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	 from	 the	 triplicate	
samples.	P:	present.				
FAS	
The	 log2	 intensity	 plot	 and	 corresponding	 fold	 change	 revealed	 a	 small,	 non-significant	 increase	 in	 p50/NFKB1	 expression	 following	 oestrogen	 deprivation	versus	 E2-treated	 control	 (Figure	 79).	 Ten	 day	 tamoxifen	 and	 fulvestrant	treatment	 induced	 similar	 p50/NFKB1	 expression	 to	 E2-treated	 control.	 Present	detection	calls	were	recorded	 in	 the	antihormone-	and	E2-treated	cells,	 implying	reliable	detection	of	gene	expression	(Figure	79B).	
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The	 log2	 intensity	plot	revealed	a	small	and	a	non-significant	down	regulation	of	p52/NFKB2	 expression	 following	 all	 three	 antihormone	 treatments	 compared	 to	E2-treated	control	(Figure	80).	Tamoxifen	induced	the	greatest	down	regulation	of	p52/NFKB2	 expression	 (fold	 change	 >	 1.5)	 followed	 by	 fasldox	 and	 oestrogen	deprivation.	The	log2	expression	values	in	antihormone-	and	control-	treated	cells	failed	to	rise	above	0	and	absent	calls	were	recorded	suggesting	relatively	low/no	gene	expression.	
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Figure	80	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	±	SEM)	gene	expression	of	p52/NFKB2	(jetset	probe	ID:	209636_at)	in	MCF-7	
cells	treated	for	10	days	with	oestradiol	(E2	control;	10-9	M),	oestrogen	deprivation	(ED),	
tamoxifen	 (TAM;	 10-7	 M)	 and	 fulvestrant	 (FAS;	 10-7	 M).	 (B)	 Table	 displaying	 the	
corresponding	 fold	 change	 in	 gene	 expression	 and	 detection	 calls	 from	 the	 triplicate	
samples.	M:	marginal;	A:	absent.				
FAS	
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Figure	81	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	 ±	 SEM)	 gene	 expression	 of	 p50/NFKB1	 (jetset	 probe	 ID:	 209239_at)	 in	
tamoxifen-resistant	 MCF-7	 cells	 (TAMR)	 versus	 wild	 type	 MCF-7	 cells.	 (B)	 Table	
displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	from	the	
triplicate	samples.	P:	present.				
5.3.8.2 Microarray	analysis	of	p50/NFKB1	and	p52/NFKB2	expression	during	
antihormone	resistance	p50/NFKB1	and	p52/NFKB2	expression	were	next	examined	 in	the	antihormone	resistant	cell	models.	The	microarray	gene	expression	profiling	for	TAMR	and	XR	models	of	acquired	(short-term)	resistance	derived	from	MCF-7	cells	versus	wild	type	 control,	 utilised	 in	 Chapter	 3,	 was	 interrogated	 using	 the	 ‘jetset’	 probes	representing	p50/NFKB1	and	p52/NFKB2.	5.3.8.2.1 TAMR	The	 log2	 intensity	 plot	 shown	 in	 Figure	 81	 revealed	 a	 small,	 non-significant	increase	 in	 p50/NFKB1	 expression	 in	 the	TAMR	 cell	 line	 compared	 to	wild	 type	MCF-7	cells.	Present	detection	calls	were	recorded	in	the	TAMR	and	wild	type	cells,	indicative	of	reliable	gene	expression.	
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Figure	82	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	 ±	 SEM)	 gene	 expression	 of	 p52/NFKB2	 (jetset	 probe	 ID:	 209636_at)	 in	
tamoxifen-resistant	 MCF-7	 cells	 (TAMR)	 versus	 wild	 type	 MCF-7	 cells.	 (B)	 Table	
displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	from	the	
triplicate	samples.	A:	absent.				
In	contrast,	the	log2	intensity	plot	demonstrated	a	non-significant	down	regulation	(fold	 change	>	1.5)	of	p52/NFKB2	expression	 in	TAMR	cells	 compared	 to	MCF-7	control	(Figure	82).	Additionally	absent	detection	calls	were	recorded	in	both	the	control	and	TAMR	cells,	implying	relatively	low/no	gene	expression.			
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5.3.8.2.2 XR	The	log2	intensity	plot	revealed	a	significant	increase	in	p50/NFKB1	expression	in	XR	cells	versus	wild	type	MCF-7	control	(Figure	83).	Present	detection	calls	were	reported	in	the	XR	and	control	cells	implying	reliable	detection	of	gene	expression.	
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Figure	83	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	 ±	 SEM)	 gene	 expression	 of	 p50/NFKB1	 (jetset	 probe	 ID:	 209239_at)	 in	
oestrogen	 deprived-resistant	 MCF-7	 cells	 (XR)	 versus	 wild	 type	 MCF-7	 cells.	 (B)	 Table	
displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	from	the	
triplicate	samples.	*	p	<0.05	compared	to	control.	P:	present					
*	
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Figure	84	(A)	Log2	intensity	plot	displaying	the	normalised	(mean	of	three	independent	
replicates	 ±	 SEM)	 gene	 expression	 of	 p52/NFKB2	 (jetset	 probe	 ID:	 209636_at)	 in	
oestrogen	 deprived-resistant	 MCF-7	 cells	 (XR)	 versus	 wild	 type	 MCF-7	 cells.	 (B)	 Table	
displaying	the	corresponding	fold	change	in	gene	expression	and	detection	calls	from	the	
triplicate	samples.	A:	absent.				
p52/NFKB2	 expression	 was	 also	 marginally	 (non-significantly)	 increased	 in	 XR	cells	versus	MCF-7	cells	as	demonstrated	by	the	log2	intensity	plot	shown	in	Figure	84.	However,	the	log2	expression	levels	failed	to	rise	above	0	and	absent	detection	calls	were	recorded	in	the	control	and	XR	cells,	indicative	of	very	low,	if	any,	gene	expression.				
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5.3.8.3 Protein	expression	of	p50/NFKB1	and	p52/NFKB2	during	
antihormone-response	and	-resistance	The	 Affymetrix	 expression	 profiles	 of	 p50/NFKB1	 and	 p52/NFKB2	 were	subsequently	 verified	 at	 the	 protein	 level	 by	 Western	 analysis.	 Additionally,	p50/NFKB1	 and	 p52/NFKB2	 protein	 expression	 was	 examined	 in	antihormone-treated	 T47D	 cells	 and	 T47D	 TAMR	 cells	 for	 which	 there	 was	 no	microarray	 data.	 Importantly	 however,	 the	 microarray	 data	 of	 the	antihormone-treated	MCF-7	cells	was	generated	from	10	day	culture	of	these	cells	in	medium	supplemented	with	sFCS	comprising	tamoxifen,	 fulvestrant,	oestrogen	deprivation	or	E2-control	treatments;	whereas	Western	blotting	was	performed	on	triplicate	 protein	 from	 10	 day	 antihormone-treated	 (tamoxifen,	 fulvestrant	 and	oestrogen	 deprivation)	 MCF-7	 (and	 T47D)	 cells	 cultured	 in	 FCS	 alongside	 E2	treatment	and	untreated	control.	As	previously	revealed	in	Chapter	4,	the	HER2+	cell	 lines	do	not	proliferate	well	 in	stripped	serum,	therefore	 it	was	concluded	to	culture	all	cell	lines	in	FCS	for	subsequent	experiments.	Western	analysis	was	also	performed	 on	 triplicate	 protein	 from	 antihormone	 resistant	 cell	 models	 versus	E2-treated	control,	cultured	under	the	same	conditions	as	those	used	to	generate	the	samples	for	microarray	gene	profiling.		In	agreement	with	the	absent	detection	calls	reported	from	the	microarray	data	for	p52/NFKB2	 during	 antihormone	 response	 and	 in	 the	 endocrine	 resistant	 cell	models,	p52/NFKB2	protein	expression	could	not	be	detected	by	Western	blotting	(Figure	 85	 and	 Figure	 86).	 In	 contrast,	 as	 illustrated	 in	 Figure	 87A	 p50/NFKB1	protein	expression	was	observed	in	untreated	MCF-7	cells	and	was	unaffected	by	E2	and	antihormone	treatments.	Additionally,	expression	of	the	precursor	protein,	p105,	 was	 also	 expressed	 in	 untreated	 control,	 E2-	 and	 antihormone-treated	MCF-7	 cells,	 with	 the	 greatest	 expression	 induced	 by	 oestrogen	 deprivation	treatment.	However,	p50/NFKB1	expression	was	markedly	stronger	than	p105	in	the	 MCF-7	 cells,	 regardless	 of	 treatment.	 Similarly,	 comparable	 p50/NFKB1	expression	 was	 detected	 in	 untreated,	 E2-,	 tamoxifen-	 and	 fulvestrant-treated	T47D	cells,	with	 slightly	 less	detected	 following	oestrogen	deprivation	 treatment	(Figure	 87B).	 However,	 the	 lower	 expression	 of	 p50/NFKB1	 observed	 in	 the	oestrogen	deprived	T47D	cells	may	be	explained	by	the	marginally	lower	protein	
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expression	 of	 the	 housekeeping	 gene,	 actin,	 observed	 following	 this	 treatment.	Additionally,	 in	 contrast	 to	 the	MCF-7	 cell	 line,	 p105	protein	 expression	was	not	detected	in	the	T47D	cells,	irrespective	of	treatment.			
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Figure	 85	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	p52/NFKB2	and	p100	protein	expression	and	β-actin	loading	control	in	MCF-7	
(A)	 and	T47D	(B)	cells	 treated	with	oestradiol	 (E2;	10-9	M),	 untreated	 control	 (CON),	
tamoxifen	(TAM;	10-7	M),	fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	
10	days.		
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Figure	 86	 Representative	 Western	 blot	 mages	 from	 three	 independent	 experiments	
showing	 p52/NFKB2	 and	 p100	 protein	 expression	 and	 β-actin	 loading	 control	 in	
tamoxifen	resistant	(TAMR)	(A)	and	oestrogen	deprived-resistant	(XR)	(B)	MCF-7	cells	
versus	wild	type	MCF-7	cells	and	T47D	TAMR	cells	(C)	versus	wild	type	T47D	cells.	
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Figure	 87	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	p50/NFKB1and	p105	protein	expression	and	β-actin	loading	control	in	MCF-7	
(A)	 and	T47D	(B)	cells	 treated	with	oestradiol	 (E2;	10-9	M),	untreated	 control	 (CON),	
tamoxifen	(TAM;	10-7	M),	fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	
10	days.		
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In	the	endocrine	resistant	cell	models,	similar	p50/NFKB1	protein	expression	was	observed	 in	 the	 TAMR	 and	MCF-7	 control	 cells	 (Figure	 88A).	 Additionally,	 p105	was	 equally	 expressed	 in	 the	 TAMR	 and	 control	 cells;	 however,	 p50/NFKB1	expression	was	marginally	greater	than	p105	in	both	the	TAMR	and	control	cells.	Interestingly,	p105	and	p50/NFKB1	expression	was	up	regulated	in	the	XR	cell	line	versus	 MCF-7	 control	 cells,	 and	 both	 proteins	 were	 equally	 expressed	 in	 the	resistant	 and	 control	 cells	 (Figure	 88B).	 Likewise,	 p105	 and	 p50/NFKB1	expression	was	up	regulated	in	T47D	TAMR	cells	compared	to	T47D	control	cells	(Figure	 88C).	 Additionally,	 greater	 expression	 of	 p50/NFKB1	 than	 p105	 was	observed	 in	 the	 control	 and	 resistant	 cells,	 with	minimal	 p105	 detected	 in	wild	type	control	cells.	Together,	 p50/NFKB1	 is	 expressed	 during	 antihormone	 response	 in	 MCF-7	 and	T47D	 cells	 and	 is	 maintained	 in	 cell	 models	 of	 acquired	 endocrine	 resistance	(TAMR,	XR	and	T47D	TAMR),	which	is	 in	parallel	to	BCL3	expression	(previously	shown	 in	 Chapter	 4,	 Figure	 48	 and	 Figure	 57	 of	 the	 present	 Chapter),	 with	 the	exception	of	T47D	TAMR	cells.		
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Figure	 88	 Representative	 Western	 blot	 mages	 from	 three	 independent	 experiments	
showing	 p50/NFKB1	 and	 p105	 protein	 expression	 and	 β-actin	 loading	 control	 in	
tamoxifen	resistant	(TAMR)	(A)	and	oestrogen	deprived-resistant	(XR)	(B)	MCF-7	cells	
versus	MCF-7	parental	cells	and	TAMR	T47D	cells	(C)	versus	T47D	parental	cells.		
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5.3.8.4 Cellular	localisation	of	BCL3	during	antihormone-response	
and	-resistance	As	 previously	 described,	 BCL3	 is	 a	 predominantly	 nuclear	 protein	 and	 is	 a	co-activator	 of	 otherwise	 inactive	 p50/NFKB1	 homodimers,	 and	 subsequently	promotes	 NF-κB-mediated	 transcription	 of	 genes	 involved	 in	 cell	 survival	 and	proliferation.	Thus,	 to	be	co-activated	by	BCL3	and	consequently	bind	to	κB	sites	on	 target	 DNA,	 p50/NFKB1	 must	 be	 located	 in	 the	 nucleus.	 Therefore,	 cellular	localisation	 studies,	 via	 immunofluorescence,	were	 next	 performed	 to	 determine	whether	 BCL3	 and	 p50/NFKB1	 are	 co-located	 in	 the	 nucleus,	 thus	 suggesting	active	p50/NFKB1-mediated	gene	transcription.	Immunofluorescence	staining	revealed	very	little,	if	any,	BCL3	in	untreated	control	and	7	day	E2-treated	MCF-7	cells	with	a	marked	increase	in	expression	following	tamoxifen,	fulvestrant	and	oestrogen	deprivation	treatments	(Figure	89).	This	is	in	agreement	 with	 the	Western	 blotting	 data,	 which	 showed	 antihormone-induced	BCL3	 expression	 in	 the	MCF-7	 cells	 (Chapter	 4,	 Figure	 48).	 Immunofluorescence	staining	 revealed	 relatively	 equal	 p50/NFKB1	 expression	 in	 the	 control,	 E2-	 and	antihormone-treated	cells	(Figure	89),	which	is	again	in	parallel	with	the	Western	blotting	 data	 (Figure	 87A).	 BCL3	 was	 located	 in	 the	 nucleus	 of	 fulvestrant-	 and	oestrogen	 deprivation-treated	 cells,	 whereas	 p50/NFKB1	 was	 predominantly	located	 in	 the	 cytoplasm.	 Interestingly,	 BCL3	 and	 p50/NFKB1	 were	 similarly	expressed	in	the	cytoplasm	and	nucleus	of	tamoxifen-treated	MCF-7	cells.			
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Figure	89	Immunofluorescence	images	of	MCF-7	cells	treated	with	oestradiol	(E2;	10-9	M),	untreated	control	(CON),	tamoxifen	(TAM;	10-7	M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	7	days.	Cells	were	stained	for	primary	antibodies:	BCL3	(green)	and	p50/NFKB1	
(red),	followed	by	staining	with	appropriate	Alexa-fluor	488/594-conjugated	secondary	antibodies	and	counterstained	with	the	nuclear	dye	
DAPI	(blue).	Magnification:	x63.		
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In	the	T47D	cell	 line,	 immunofluorescence	studies	demonstrated	very	 low,	 if	any,	BCL3	expression	in	the	control	and	E2-treated	cells,	with	a	marked	up	regulation	of	expression	in	the	antihormone-treated	cells	(Figure	90).	This	expression	profile	mirrored	 the	 Western	 blotting	 data,	 which	 also	 showed	 antihormone-induced	BCL3	expression	in	T47D	cells	(Chapter	4,	Figure	48).	Again,	in	agreement	with	the	Western	 blot	 data	 (Figure	 87B),	 immunofluorescence	 studies	 revealed	 relatively	consistent	p50/NFKB1	expression	 in	control,	E2-	and	antihormone-treated	T47D	cells	(Figure	90).	BCL3	was	predominantly	located	in	the	nucleus	of	antihormone-treated	 T47D	 cells,	 with	 some	 cytoplasmic	 BCL3	 observed	 in	 tamoxifen-treated	cells;	 however,	 in	 contrast	 to	 MCF-7	 cells,	 some	 BCL3	 was	 also	 located	 in	 the	cytoplasm	 of	 fulvestrant-	 and	 oestrogen	 deprivation-treated	 T47D	 cells,	 with	greater	 cytoplasmic	 staining	 apparent	 in	 the	 latter.	 p50/NFKB1	 was	predominantly	expressed	in	the	nucleus	of	untreated	control	T47D	cells,	with	both	nuclear	 and	 cytoplasmic	 staining	 observed	 in	 the	 E2-	 and	 antihormone-treated	cells.			
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Figure	90	Immunofluorescence	images	of	T47D	cells	treated	with	oestradiol	(E2;	10-9	M),	untreated	control	(CON),	tamoxifen	(TAM;	10-7	M),	
fulvestrant	(FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	7	days.	Cells	were	stained	for	primary	antibodies:	BCL3	(green)	and	p50/NFKB1	
(red),	followed	by	staining	with	appropriate	Alexa-fluor	488/594-	conjugated	secondary	antibodies	and	counterstained	with	the	nuclear	dye	
DAPI	(blue).	Magnification:	x63.	
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Figure	 91	 Immunofluorescence	 images	 of	 tamoxifen-resistant	 MCF-7	 (TAMR),	
oestrogen	 deprivation-resistant	 MCF-7	 (XR)	 and	 T47D	 TAMR	 cells.	 Cells	 were	
stained	 for	 primary	 antibodies:	 BCL3	 (green)	 and	 P50/NFKB1	 (red),	 followed	 by	
staining	 with	 appropriate	 Alexa-fluor	 488/594-conjugated	 secondary	 antibodies	
and	counterstained	with	the	nuclear	dye	DAPI	(blue).	Magnification:	x63.	
	
In	the	(short-term)	endocrine	resistant	cell	models,	 immunofluorescence	staining	identified	BCL3	and	p50/NFKB1	expression	in	TAMR,	XR	and	T47D	TAMR	(Figure	91).	 This	 is	 in	 agreement	 with	 the	 Western	 blotting	 data,	 which	 also	 showed	expression	 of	 both	 proteins	 in	 the	 three	 cell	 lines,	 with	 the	 exception	 of	 T47D	TAMR	cells	 in	which	BCL3	protein	 expression	 could	not	be	 identified	 (Figure	57	and	 Figure	 88).	 Interestingly,	 in	 the	 TAMR	 and	 XR	 cell	 lines,	 both	 BCL3	 and	p50/NFKB1	 were	 predominantly	 located	 together	 in	 the	 nucleus,	 whereas	 both	proteins	were	primarily	located	in	the	cytoplasm	of	T47D	TAMR	cells	(Figure	91).	
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Together,	 the	 immunofluorescence	 studies	 revealed	 co-expression	 of	 BCL3	 and	p50/NFKB1	in	the	cytoplasm	and	nucleus	of	antihormone-treated	T47D	cells	and	tamoxifen-treated	MCF-7	cells,	with	contrasting	cellular	locations	observed	in	the	falsodex-	and	oestrogen	deprivation-treated	MCF-7	cells	(BCL3	was	located	in	the	nucleus	 and	 p50/NFKB1	 located	 in	 the	 cytoplasm).	 Interestingly,	 in	 the	 (short-term)	 antihormone-resistant	 cell	 lines,	BCL3	and	p50/NFKB1	were	 co-expressed	either	in	the	nucleus	(TAMR	and	XR)	or	cytoplasm	(T47D	TAMR).		
5.3.8.5 Immunoprecipitation	To	determine	whether	BCL3	and	p50/NFKB1	are	complexed	 together	when	 they	are	 co-located	 in	 the	 nucleus,	 cytoplasm	 or	 both,	with	 particular	 interest	 on	 the	co-expression	 and	 binding	 of	 both	 proteins	 in	 the	 nucleus	 to	 support	 the	hypothesis	 that	 BCL3	 coactivates	 p50/NFKB1	 to	 promote	 NF-κB-mediated	 gene	transcription,	 immunoprecipitation	 experiments	 were	 next	 performed	 during	antihormone-response	and	in	resistance.	Since	BCL3	is	expressed	at	low	levels	in	untreated	and	E2-treated	MCF-7	and	T47D	cells	(as	demonstrated	by	the	Western	blots	shown	in	Chapter	4,	Figure	48),	10	day	antihormone-treated	 MCF-7	 and	 T47D	 cells	 alongside	 untreated	 control	 and	 E2	treatment	 were	 immunoprecipitated	 with	 p50/NFKB1	 antibody	 and	 probed	 by	Western	blotting	for	BCL3.	As	illustrated	in	Figure	92,	no	association	was	observed	between	 the	 two	 proteins	 in	 MCF-7	 and	 T47D	 cells,	 irrespective	 of	 treatment.	Following	 immunoprecipitation,	 p50/NFKB1	 levels	 remained	 unchanged	suggesting	equivalent	protein	 loading	on	 the	gel,	with	 the	exception	of	untreated	control	MCF-7	cells,	in	which	the	protein	loading	was	likely	to	be	less.		
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Figure	 92	 Co-immunoprecipitation	 of	 BCL3	 with	 p50/NFKB1	 in	 antihormone-treated	
MCF-7	(A)	and	T47D	 (B)	cells.	MCF-7	 and	T47D	cells	were	 treated	with	oestradiol	 (E2;	
10-9	M),	untreated	control	 (CON),	 tamoxifen	 (TAM;	10-7	M),	 fulvestrant	 (FAS;	10-7	M)	
and	oestrogen	deprivation	(ED)	for	7	days.	Following	cell	 lysis,	protein	expression	was	
assessed	by	Western	blot	analysis	(n=1)	for	BCL3	and	p50/NFKB1	following	p50/NFKB1	
immunoprecipitation.		
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Similarly,	endocrine	resistant	cell	models	(short-term	TAMR,	XR	and	T47D	TAMR)	and	wild	type	parental	cells	were	immunoprecipitated	with	p50/NFKB1	antibody	and	 probed	 by	 Western	 blotting	 for	 BCL3.	 In	 contrast	 to	 the	antihormone-responsive	 cells,	 a	 strong	 direct	 physical	 association	was	 apparent	between	BCL3	 and	 p50/NFKB1	 in	 the	 endocrine	 resistant	 (TAMR,	 XR	 and	 T47D	TAMR)	cells	compared	to	a	very	weak	association	in	the	parental	cells	(Figure	93).	p50/NFKB1	 expression	 remained	 unchanged	 indicative	 of	 equivalent	 protein	loading	on	the	gel.	Since	the	p50/NFKB1	antibody	also	binds	to	and	recognises	the	p105	precursor	protein	 (as	 illustrated	 in	Figure	88),	 the	endocrine	 resistant	and	respective	 control	 cells	 were	 immunoprecipitated	 with	 BCL3	 and	 probed	 for	p50/NFKB1	to	determine	whether	the	association	was	indeed	between	BCL3-p50	and/or	BCL3-p105.	As	shown	 in	Figure	93A	and	Figure	93B,	Western	analysis	of	TAMR	and	XR	cells	 immunoprecipitated	with	BCL3	antibody	and	probed	 for	p50	revealed	strong	expression	of	p50,	thus	indicative	of	a	strong	association	between	BCL3	 and	 p50.	 However,	 p105	 expression	 was	 not	 detected	 in	BCL3-immunoprecipitated	 TAMR	 and	 XR	 cells,	 suggesting	 no	 presence	 of	BCL3-p105	 complexes.	 BCL3	 immunoprecipitation	 in	 T47D	 TAMR	 cells	 was	inconclusive.		
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E2 
	
Figure	93	Co-immunoprecipitation	of	BCL3	with	p50/NFKB1	in	tamoxifen-resistant	MCF-
7	(TAMR)	(A),	oestrogen	deprivation-resistant	MCF-7	(XR)	(B)	and	T47D	TAMR	(C)	cells	
versus	wild	 type	 control	 cells.	 Following	 cell	 lysis,	 protein	 expression	was	 assessed	by	
Western	 blot	 analysis	 (n=1)	 for	 BCL3	 and	 p50/NFKB1	 following	 p50/NFKB1	 and/or	
BCL3	immunoprecipitation.			
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5.3.8.6 Effect	of	BCL3	knockdown	on	p50/NFKB1	expression	Although	BCL3	 is	predominantly	a	nuclear	protein,	 some	cytoplasmic	expression	was	 detected	 by	 immunofluorescence	 during	 antihormone-response	 and	 in	 the	T47D-TAMR	cells,	with	 less	detected	 in	the	TAMR	and	XR	cells	(Figure	89-Figure	91).	 A	 cytoplasmic	 form	 of	 BCL3	 has	 previously	 been	 detected	 in	 293T	 (human	embryonic	kidney)	 cells421.	This	 study	 reported	 that	 cytoplasmic	BCL3	promotes	release	of	p50	from	the	p50-p105	cytoplasmic	pool	and	subsequently	translocates	the	 homodimer	 into	 the	 nucleus	 without	 effect	 on	 the	 proteolytic	 processing	 of	p105	 to	p50.	We	were	 interested	 to	 investigate	whether	BCL3	 is	 involved	 in	 the	proteolytic	processing	of	p105	to	p50	in	our	cells.	To	 determine	 whether	 BCL3	 regulates	 p50/NFKB1	 expression	 in	 resistance,	Western	 analysis	was	 performed	 on	TAMR	 cells	 incubated	with	 control	 or	BCL3	siRNA.	 As	 illustrated	 in	 Figure	 94,	 BCL3	 knockdown	 in	 TAMR	 cells	 results	 in	 a	decrease	in	p50	expression	but	up	regulates	p105	expression	compared	to	control.			
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Figure	 94	 Representative	 Western	 blot	 mages	 from	 three	 independent	 experiments	
showing	p50/NFKB1	and	p105,	BCL3	and	β-actin	loading	control	protein	expression	in	
tamoxifen	resistant	cells	incubated	for	4	days	with	unscrambled	control	(CON)	or	BCL3	
siRNA.	
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5.4 Discussion	Extensive	 microarray	 gene	 profiling	 studies	 performed	 in	 Chapters	 3	 and	 4	identified	BCL3	as	the	most	robust	antihormone-induced	gene	in	four	ER+	breast	cancer	 cell	 lines,	 encompassing	 HER2+	 and	 HER2-	 disease,	 with	 increased	expression	maintained	through	to	 the	acquisition	of	resistance.	Therefore,	 in	 this	Chapter	 the	 role	 of	 BCL3	 was	 further	 examined	 to	 explore	 the	 hypothesis	 that	BCL3	 is	 a	 pro-survival	 gene,	 induced	 early	 during	 response	 and	 subsequently	allows	a	cohort	of	breast	cancer	cells	to	escape	antihormone	challenge,	resulting	in	a	 limited	 efficacy	 of	 these	 agents	 and	 ultimately	 the	 development	 of	 resistant	growth.		Initially,	 microarray	 gene	 expression	 data	 examining	 BCL3	 expression	 in	(short-term)	antihormone-resistant	TAMR	and	XR	cells	(Chapter	3)	was	verified	at	the	mRNA	and	protein	levels	and	confirmed	an	increase	in	BCL3	expression	during	resistance	versus	wild	type	MCF-7	cells.	In	agreement	with	these	findings,	Pratt	et	al.	 previously	 demonstrated	 increased	 BCL3	 expression	 in	 ER+,	 E2-independent	MCF-7	cells	compared	with	the	parental	cell	line363.	To	consider	the	heterogeneity	that	 exists	 in	 breast	 cancer,	 BCL3	 expression	 was	 also	 examined	 in	 a	 model	 of	(short-term)	tamoxifen	resistance	derived	from	T47D	cells.	Similarly,	BCL3	mRNA	expression	was	increased	in	these	resistant	cells	compared	to	wild	type	T47D	cells.	However,	BCL3	protein	expression	could	not	be	detected.	It	 is	possible	that	BCL3	mRNA	was	not	translated	into	protein	in	the	T47D-TAMR	cells	or	that	the	protein	was	 rapidly	 degraded.	 Furthermore,	 towards	 the	 end	 of	 this	 project,	microarray	gene	 expression	 profiling	 was	 completed	 for	 a	 panel	 of	 long-term	 (3	 year)	antihormone-resistant	 cell	 models.	 Thus,	 to	 determine	 whether	 increased	expression	 of	 BCL3	 is	maintained	 during	 antihormone	 resistance,	 its	 expression	was	 examined	 and	 verified	 by	 RT-PCR	 in	 these	 cell	 models.	 Indeed,	 increased	mRNA	 expression	 of	 BCL3	 was	 demonstrated	 in	 long	 term	 TAMR	 cells	 derived	from	MCF-7	and	MDA-MB-361	cells,	TAMR	and	XR	cells	derived	from	T47D	cells,	and	XR	cells	derived	from	BT474	cells	versus	wild	type	control.	This	suggests	that	increased	BCL3	expression	 is	maintained	 into	 long	 term	resistance.	Due	 to	 these	models	becoming	available	for	characterisation	and	further	study	at	the	end	of	this	
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project,	additional	examination	of	BCL3	expression	and	function	in	these	resistant	models	could	not	be	performed.		Following	 the	 identification	 of	 up	 regulated	 BCL3	 expression	 in	 antihormone	resistance	(as	well	as	during	response	as	demonstrated	in	the	previous	Chapters),	subsequent	studies	aimed	 to	establish	whether	BCL3	expression	correlated	with,	and	 ultimately	 contributed	 to,	 the	 limited	 efficacy	 of	 antihormones	 and	 the	consequent	development	of	 resistance.	Transient	BCL3	knockdown	studies	using	siRNA	 were	 conducted	 to	 determine	 the	 importance	 of	 BCL3	 expression,	particularly	 its	potential	 role	 in	promoting	 cell	 survival	 and	proliferation,	during	antihormone-response	 and	 -resistance.	 Since	 BCL3	 is	 antihormone-induced	 in	MCF-7	 and	 T47D	 cells,	 with	 very	 little	 expression	 present	 in	 untreated	 cells;	fulvestrant	 combined	 with	 siRNA	 incubation	 was	 required	 to	 increase	 BCL3	expression	and	to	determine	what	effect	subsequent	BCL3	knockdown	had	on	cell	growth	 and	 survival	 and	 whether	 such	 knockdown	 enhanced	 the	growth-inhibitory	actions	of	fulvestrant.	Optimisation	studies	were	first	performed	to	 determine	 the	 optimum	 siRNA	 plus	 fulvestrant	 incubation	 conditions	 for	 the	best	knockdown.	 Interestingly,	a	 fulvestrant	time	course	study	from	day	1	to	day	10	 in	 MCF-7	 and	 T47D	 cells	 revealed	 the	 greatest	 BCL3	 mRNA	 and	 protein	expression	as	early	as	day	1	and	day	2	post-fulvestrant	treatment.	BCL3	expression	remained	 relatively	 consistent	 during	 the	 10	 day	 treatment	 of	 T47D	 cells.	However,	 BCL3	 protein	 expression	 decreased	 at	 day	 4	 and	 day	 5	 fulvestrant	treatment	 in	 the	MCF-7	cells,	which	was	mirrored	by	a	marked	decrease	 in	actin	expression	at	day	4,	 suggesting	unequal	protein	 loading.	Similarly,	 at	 the	protein	level	 it	 is	 likely	 that	 a	 loading	 error	 occurred	 at	 day	 5,	 since	 at	 the	mRNA	 level	BCL3	was	expressed;	yet	at	the	protein	level	very	little	BCL3	was	apparent.	BCL3	protein	expression	increased	following	day	7	and	day	10	treatment,	together	with	an	increase	in	actin	expression	compared	to	day	4.	Two	day	fulvestrant	treatment	was	 decided	 as	 the	 optimal	 treatment	 time	 for	 sufficient	 BCL3	 up	 regulation	necessary	for	subsequent	knockdown.		Subsequently,	a	time	course	study	examining	the	optimal	siRNA	incubation	periods	was	performed.	For	the	greatest	transfection	efficiency,	siRNA	is	added	to	rapidly	dividing	cells.	However,	since	fulvestrant	treatment	inhibits	cell	growth,	siRNA	was	
		 280	
first	 added	 and	 allowed	 to	 be	 incorporated	 into	 the	 cells	 prior	 to	 fulvestrant	treatment.	A	time	point	study	comprising	day	2	to	day	4	siRNA	incubation	prior	to	48	 hours	 fulvestrant	 treatment	 was	 performed	 to	 determine	 the	 optimal	 siRNA	incubation	 period.	 Indeed,	 day	 2,	 3	 and	 4	 siRNA	 incubation	 followed	 by	 2	 day	fulvestrant	treatment	induced	similar	levels	of	BCL3	protein	knockdown.	Thus,	to	minimise	 the	 expense	 of	 re-administrating	 siRNA,	 which	 is	 necessary	 for	incubations	longer	than	a	total	of	4	days,	2	day	siRNA	followed	by	2	day	fulvestrant	treatment	 was	 chosen	 as	 the	 optimal	 conditions	 for	 BCL3	 knockdown	 and	 was	employed	 for	 subsequent	 studies.	With	 regard	 to	 the	 antihormone-resistant	 cell	models,	 BCL3	 is	 constitutively	 expressed,	 thus	 targeted	 BCL3	 knockdown	 was	induced	by	4	day	 incubation	with	 the	siRNA.	BCL3	knockdown	was	confirmed	at	the	mRNA	and	protein	 level	by	RT-PCR	and	Western	blotting,	respectively,	 in	the	TAMR	and	XR	 cell	models.	However,	BCL3	knockdown	was	only	observed	at	 the	mRNA	level	in	the	T47D	TAMR	cells,	with	BCL3	protein	expression	not	detected	(as	previously	discussed	above).	Cell	 survival	 studies	 were	 performed	 to	 determine	 whether	 BCL3	 plays	 a	pro-survival	 role,	 thus	 supporting	 the	 hypothesis	 that	 BCL3	 is	 an	antihormone-induced	pro-survival	gene.	Baseline	antihormone-induced	apoptosis	was	 first	 examined	 during	 response	 to	 7	 day	 treatment.	 The	 cell	 lines	 used	throughout	 this	 project	 are	 adherent	 and	 the	 dead/apoptotic	 cells	 float	 in	 the	medium.	 Thus,	 optimisation	 studies	 were	 initially	 performed	 to	 determine	whether	removing	the	medium	(and	the	floating	dead	cells)	at	day	4	during	7	day	treatment	and	replacing	with	fresh	antihormone-treated	medium	had	any	effect	on	the	number	of	apoptotic	cells.	Indeed,	as	expected,	the	removal	of	the	cell	medium	at	 day	4	 resulted	 in	 a	 decrease	 in	 the	percentage	of	 apoptotic	 cells	 compared	 to	adding	 fresh	 medium	 without	 removing	 the	 old	 medium.	 Therefore,	 for	subsequent	studies	the	medium	was	not	removed	and	fresh	medium	was	added	on	top.	Seven	day	antihormone	treatment	induced	very	little	apoptosis	in	MCF-7	and	T47D	cells.	This	is	in	agreement	with	the	initial	rationale	that	antihormones	exert	significant	anti-proliferative	effects	but	promote	only	modest	cell	kill.	Indeed,	Gee	et	 al.	 previously	 demonstrated	 that	 tamoxifen	 promotes	 significant	 growth	inhibition	but	minimal	apoptosis	in	MCF-7	cells216.	
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To	 determine	 whether	 BCL3	 is	 indeed	 a	 pro-survival	 gene,	 BCL3	 knockdown	studies	were	performed	and	 the	 impact	on	 cell	 survival/apoptosis	was	assessed.	BCL3	had	no	effect	on	 the	survival	of	MCF-7	and	T47D	cells	during	antihormone	response.	 In	 contrast	 to	 these	 findings,	 a	 pro-survival	 effect	 of	 BCL3	 in	 breast	cancer	 has	 been	 reported.	 Indeed,	 Choi	 et	 al.	 have	 demonstrated	 a	 novel	 link	between	BCL3	and	 the	anti-apoptotic	protein	CtBP1	 in	 several	breast	 cancer	 cell	lines,	 including	MCF-7	 cells	 and	 also	 in	 human	 clinical	 breast	 cancer	 samples368.	CtBP1	promotes	cell	survival	by	transcriptionally	repressing	pro-apoptotic	genes.	In	response	to	apoptotic	stimuli,	CtBP1	is	degraded	by	ubiquitination	which	results	in	the	derepression	of	pro-apoptotic	genes	to	allow	apoptosis	to	proceed375.	BCL3	has	been	shown	to	increase	the	stability	of	CtbP1,	thus	preventing	its	degradation	by	 ubiquitination.	 Consequently,	 CtBP1-mediated	 repression	 of	 pro-apoptotic	genes	 is	 sustained	 and	 cells	 become	 resistant	 to	 apoptotic	 stimuli,	 subsequently	promoting	 cell	 survival368.	 Together,	 this	 evidence	 suggests	 that	 stabilisation	 of	CtBP1	by	BCL3	may	provide	a	potential	molecular	mechanism	underlying	the	pro-survival	 role	 of	 BCL3.	 However,	 although	 this	 study	 strongly	 indicates	 a	 pro-survival	 role	 for	 BCL3,	 such	 an	 effect	 was	 only	 indirectly	 examined	 by	measurement	 of	 the	 expression	 of	 two	 CtBP1-target	 pro-apoptotic	 genes368.	Additional	 studies,	 including	 apoptosis	 assays	 would	 further	 confirm	 a	 pro-survival	role.	Moreover,	 an	 alternative	 proposed	 mechanism	 by	 which	 BCL3	 promotes	 cell	survival	is	via	inhibition	of	the	expression	of	the	tumour	suppressor	gene,	p53367.	In	 MCF-7	 cells,	 UV-induced	 DNA	 damage	 has	 been	 shown	 to	 increase	 BCL3	expression.	 Additionally,	 constitutive	 BCL3	 expression	 in	 MCF-7	 cells	 has	 been	shown	 to	 inhibit	 p53	 expression	 and	 consequently	 prevent	 the	 induction	 of	pro-apoptotic	p53-target	genes	to	prevent	the	activation	of	DNA-damage-induced	cell	 death.	 The	 dominant	 proposed	 mechanism	 in	 this	 regulatory	 circuit	 is	 the	ability	of	BCL3	to	 induce	up	regulation	of	 the	p53	 inhibitor	Hdm2.	However,	 it	 is	possible	 that	 BCL3-mediated	 p53	 suppression	 and	 consequent	 cell	 survival	 was	not	 observed	 in	 our	 study	 since,	 in	 addition	 to	 inducing	 BCL3	 expression,	fulvestrant	 also	 potentiates	 p53	 activity422.	 Thus,	 it	 is	 plausible	 that	fulvestrant-induced	 p53	 activity	 outweighs	 BCL3	 mediated	 p53	 inhibition.	
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Additionally	as	previously	discussed	in	Chapter	4,	p53	is	mutated	on	one	allele	of	the	 gene	 in	 T47D	 cells,	 thus	 such	 BCL3-mediated	 regulation	 of	 this	 gene	 in	 the	T47D	cell	line	would	not	be	observed.		Disappointingly,	 BCL3	 had	 no	 effect	 on	 the	 survival	 of	 TAMR	 and	 XR	 cells.	However,	cell	survival	was	assessed	by	an	Annexin	V/PI	apoptosis	assay	on	TAMR	and	XR	cells	following	4	day	incubation	with	BCL3	siRNA.	Thus,	it	is	possible	that	such	 transient	 BCL3	 knockdown	 is	 insufficient	 to	 promote	 significant	 apoptosis,	which	 would	 perhaps	 be	 apparent	 with	 stable	 BCL3	 knockdown.	 Thus	 with	 the	elimination	 of	 a	 pro-survival	 role,	 subsequent	 studies	 aimed	 to	 further	 elucidate	the	role	of	BCL3	during	antihormone	response	and	resistance.	The	effect	of	BCL3	on	cell	growth	was	next	examined.	The	targeted	down	regulation	of	BCL3	correlated	with	a	substantial	decrease	in	the	cell	 growth	 of	 TAMR	 and	 to	 a	 lesser	 degree	 XR	 cells,	 but	was	without	 effect	 on	T47D	TAMR	cells.	However,	the	decrease	in	cell	growth	observed	in	the	TAMR	and	XR	 cells	 following	 BCL3	 knockdown	 did	 not	 reach	 significance.	 Undoubtedly,	additional	experimental	repeats	are	required	to	increase	the	reliability	of	the	data.	These	findings	suggests	that	BCL3	may	play	a	role	in	promoting	TAMR	and	XR	cell	growth	 with	 no	 such	 effect	 apparent	 in	 the	 T47D	 TAMR	 cells.	 However,	 BCL3	knockdown	 in	 the	 T47D	 TAMR	 cells	 could	 not	 be	 verified	 at	 the	 protein	 level.	Therefore,	 it	 is	 possible	 that	 such	 knockdown	was	 not	 translated	 to	 the	 protein	level,	thus	explaining	why	no	effect	on	cell	growth	was	observed.	Alternatively,	as	previously	 discussed	 in	 Chapter	 4,	 more	 than	 150	 proteins	 are	 differentially	expressed	between	the	MCF-7	and	T47D	cell	lines,	of	particular	significance	is	the	p53	 tumour	 suppressor	gene409,411.	As	discussed	above,	 in	 contrast	 to	 the	MCF-7	cell	line,	p53	is	mutated	on	one	allele	of	the	gene	in	T47D	cells.	Thus,	it	is	possible	that	BCL3-induced	growth	of	MCF-7-derived	resistant	cell	models	is	mediated	via	negative	regulation	of	the	p53	gene;	a	mechanism	not	observed	in	the	p53	mutant	T47D	cells.	To	our	knowledge,	these	are	the	first	studies	to	date	that	demonstrate	a	role	for	BCL3	in	antihormone-resistant	breast	cancer	cell	growth.	Interestingly,	BCL3	knockdown	had	no	effect	on	the	cell	growth	of	MCF-7	cells,	but	a	 very	 small,	 yet	 non-significant,	 effect	 on	 the	 growth	 of	 T47D	 cells	 during	
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antihormone	 response.	 Similarly,	 BCL3	 has	 been	 previously	 shown	 to	 have	 no	effect	on	the	growth	of	HER2+	mammary	tumour	cells	in	vivo362.	The	magnitude	of	BCL3	 knockdown	 was	 greater	 in	 the	 TAMR	 and	 XR	 cells	 compared	 to	 the	antihormone-responsive	 MCF-7	 and	 T47D	 cells,	 possibly	 due	 to	 fulvestrant	inhibiting	 MCF-7	 and	 T47D	 cell	 proliferation,	 thus	 leading	 to	 a	 reduced	transfection	 efficiency	 of	 the	 siRNA.	 Together,	 these	 studies	 suggest	 that	 during	antihormone	 resistance	 BCL3	may	 play	 a	 role	 in	 promoting	 cell	 growth	with	 no	such	effect	apparent	early	during	response.	In	contrast	to	these	studies,	Pratt	et	al.	have	 previously	 shown	 that	 BCL3	 augments	 MCF-7	 tumour	 cell	 growth363.	Ovariectomised	 mice	 injected	 with	 MCF-7	 cells	 ectopically	 expressing	 BCL3	displayed	a	markedly	higher	 tumour	growth	rate	 compared	 to	 control.	However,	there	are	significant	experimental	differences	between	Pratt	et	al.	and	the	current	study,	 likely	contributing	to	the	contrasting	results.	 Indeed,	 in	Pratt	et	al.’s	study,	MCF-7	 cells	 were	 transfected	 with	 BCL3	 (MCF-7-BCL3)	 and	 injected	 into	 mice	whereas	 in	the	current	study	MCF-7	cells	were	treated	with	the	growth	 inhibitor	fulvestrant	 to	 induce	BCL3	 expression	 in	 two	dimension.	 Pratt	 et	 al.’s	 study	was	performed	 in	 vivo	 and	 therefore	 likely	 influenced	 by	 the	 stroma	 and	 tumour	microenvironment,	whereas	the	present	study	was	conducted	in	vitro	thus	lacking	the	complex	inter-relationships	that	exist	between	cells	in	vivo.	Another	opposing	variable	 is	 the	 exposure	 period	 of	 MCF-7	 cells	 to	 increased	 BCL3	 expression.	 A	stable	BCL3	 expressing	 system	was	 used	 in	 vivo	and	 the	MCF-7-BCL3	 cells	were	allowed	to	form	tumours	over	a	period	of	4-6	weeks,	whereas	in	the	present	study	MCF-7	cells	were	exposed	to	a	transient	increase	in	BCL3	expression	for	2	days.	It	is	possible	that	long	term	BCL3	expression	contributes	to	the	reorganisation	of	the	cellular	networks	 to	promote	cell	growth,	which	would	not	be	possible	 following	short	term	BCL3	exposure.	Thus,	 it	 is	conceivable	that	 longer	BCL3	expression	in	MCF-7	 cells,	 either	via	 fulvestrant	 treatment	or	more	preferably	via	 transfection,	would	result	in	enhanced	cell	growth.	The	growth	of	our	TAMR	cell	model	has	previously	been	reported	to	be	regulated	via	EGFR/HER2	driven	MAPK	and	AKT	signalling	pathways185.	BCL3	knockdown	in	this	 cell	 line	 had	 no	 effect	 on	 these	 key	 signalling	 proteins	 confirming	 that	 the	siRNA	 used	 was	 specific	 to	 BCL3.	 Additionally,	 these	 findings	 suggest	 that	
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BCL3-mediated	 cell	 growth	 apparent	 in	 the	 resistant	 cell	model	 does	not	 exploit	the	dominant	MAPK	and	AKT	growth	signalling	pathways.	Cell	 cycle	 studies	were	next	performed	 to	 investigate	whether	BCL3	 induces	 cell	proliferation	 via	 dysregulation	 of	 the	 cell	 cycle.	 Baseline	 studies	 were	 first	performed	to	examine	the	distribution	of	MCF-7	and	T47D	cells	within	each	phase	of	 the	 cell	 cycle	 following	 7	 day	 antihormone	 treatment.	 Tamoxifen	 has	 been	widely	 reported	 to	 induce	 significant	 G1	 arrest	 of	 MCF-7	 cells	 with	 concurrent	decreases	 of	 cells	 in	 S	 and	 G2/M	 phases	 compared	 to	 untreated	 control311,420.	However,	 such	 tamoxifen-induced	 G1	 arrest	 of	 MCF-7	 cells	 was	 not	 apparent	following	7	day	treatment.	Similarly,	although	tamoxifen	induced	a	small	increase	in	 the	 percentage	 of	 T47D	 cells	 in	 G1	 compared	 to	 control,	 this	 effect	 was	 not	significant.	However,	 there	 are	 substantial	 differences	between	 the	 experimental	design	 of	 this	 study	 and	 those	 of	 Osborne	 et	 al.	 and	 Sutherland	 et	 al311,420.	 Of	particular	 significance	 is	 the	 shorter	 duration	 of	 tamoxifen	 treatment	 and	increased	 drug	 concentration.	 Indeed,	 Osborne	 et	 al.	 demonstrated	 a	 marked	accumulation	 of	 MCF-7	 cells	 in	 G1	 with	 a	 reduction	 of	 cells	 from	 S	 and	 G2/M	phases	following	3	day	tamoxifen	(10-6	M)	treatment311	Similarly,	Sutherland	et	al.	demonstrated	a	marked	 increase	 in	 the	percentage	of	MCF-7	cells	arrested	 in	G1	together	with	 a	 decrease	 in	 S	 phase	 from	 day	 1	 to	 day	 3	 tamoxifen	 (10-5	M)420.	Thus,	 it	 is	 possible	 that	 7	 day	 treatment	 may	 promote	 growth	 inhibition	 in	 a	density-dependent	 manner	 as	 the	 monolayer	 of	 cells	 neared	 confluence.	 To	eliminate	 this	possibility,	 a	 time	 course	 experiment	was	 subsequently	 conducted	including	day	1	to	day	4	antihormone	treatment	of	MCF-7	cells.	An	increase	in	G1	arrest,	together	with	a	small	depletion	of	cells	from	S	phase	and	G2/M	phase	was	apparent	following	day	2	to	day	4	tamoxifen	(10-7	M)	treatment.	These	findings	are	in	agreement	with	Sutherland	et	al.’s	study,	which	demonstrated	a	small	 increase	in	G1	arrest,	 induced	by	 tamoxifen	 (of	 equivalent	 concentration	 i.e.	 10-7	M)	 from	day	1	to	day	3	treatment,	together	with	a	decrease	in	the	percentage	of	cells	 in	S	phase420.	 However,	 this	 experiment	 was	 only	 completed	 once	 (n=1)	 and	 more	experimental	 repeats	 are	 necessary	 to	 perform	 statistical	 analysis,	 which	 may	prove	 significant.	 Additionally,	 it	 is	 highly	 likely	 that	 a	 higher	 concentration	 of	
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tamoxifen	 (in	 line	with	Osborne	 et	 al.	 and	 Sutherland	 et	 al.	 studies311,420)	would	enhance	G1	arrest.		With	regard	to	fulvestrant	and	oestrogen	deprivation	treatment,	a	similar	cell	cycle	distribution	 profile	 to	 tamoxifen	 treatment	 (i.e.	 increase	 in	 G1	 arrest	 with	 a	decrease	 in	 S	 and	 G2/M	 phases),	 although	 to	 a	 lesser	 degree,	 was	 observed	following	3	and	4	day	treatment	in	MCF-7	cells	compared	to	untreated	control.	In	agreement	with	this	data,	Watts	et	al.	have	previously	demonstrated	an	increase	in	the	 proportion	 of	 fulvestrant-treated	 MCF-7	 cells	 in	 G1	 arrest	 mirrored	 by	 a	decrease	of	cells	 in	S	phase	during	24–28	hour	treatment	compared	to	untreated	control165.	 Following	 7	 day	 treatment,	 fulvestrant	 and	 oestrogen	 deprivation	treatments	 promoted	 a	 small	 increase	 in	 G1	 arrest	 of	 MCF-7	 cells,	 with	 a	 small	decrease	 in	 the	 percentage	 of	 cells	 in	 S	 and	 G2/M	 phases	 compared	 to	 control.	However,	such	effects	were	not	significant.	 In	the	T47D	cell	 line,	7	day	oestrogen	deprivation	treatment	induced	significant	depletion	of	cells	from	G1	together	with	a	significant	accumulation	of	cells	in	S	phase,	suggesting	enhanced	DNA	replication,	compared	to	control.	Interestingly,	the	percentage	of	cells	in	S	phase,	irrespective	of	treatment,	decreased	from	day	1	to	day	4	possibly	due	to	depletion	of	nutrients	from	the	medium	in	addition	 to	density-dependent	growth	 inhibition	as	 the	cells	became	confluent.		To	 determine	 whether	 BCL3	 dysregulates	 the	 cell	 cycle	 to	 promote	 cycle	progression	and	growth,	BCL3	knockdown	studies	were	performed	and	the	impact	on	the	cell	cycle	was	assessed.	In	agreement	with	the	cell	growth	data,	BCL3	had	no	effect	 on	 the	 cell	 cycle	 distribution	 of	 fulvestrant-treated	MCF-7	 and	 T47D	 cells	during	response.	However,	these	studies	comprised	of	a	n=2	and	n=1,	respectively,	thus	 further	 repeats	 are	 necessary	 to	 clarify	 this	 data	 and	 to	 allow	 statistical	analysis	to	be	performed.	In	human	breast	epithelial	cells,	Westerheide	et	al.	have	previously	 demonstrated	 that	 BCL3	 stimulates	 cyclin	 D1	 expression	 and	phosphorylation	 of	 the	 retinoblastoma	 protein	 and	 consequent	 G1	 to	 S	 phase	progression361.	However,	such	events	did	not	promote	enhanced	cell	proliferation,	suggesting	that	despite	BCL3	promoting	G1	to	S	transition,	 it	has	no	effect	on	the	proliferation	 of	 human	 breast	 epithelial	 cells.	 It	 is	 possible	 that	 additional	oncogenic	 events	 are	 required	 to	 promote	 BCL3-mediated	 cell	 growth.	 In	
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antihormone-responsive	 breast	 cancer	 cells,	 we	 have	 shown	 that	 BCL3	 down	regulation	 has	 no	 effect	 on	 the	 cell	 cycle	 and	 ultimately	 no	 effect	 on	 cell	growth/proliferation.	 However,	 such	 effects	 were	 only	 examined	 following	transient	 BCL3	 knockdown,	 which	 may	 be	 insufficient	 to	 promote	 significant	alterations	 in	 the	 cell	 cycle.	 In	 addition	 to	 stable	BCL3	 gene	 knockdown,	 further	studies	examining	the	protein	expression	of	cell	cycle	regulators,	such	as	cyclin	D1	and	phosphorylation	of	 the	 retinoblastoma	protein,	 are	necessary	 to	 support	 the	cell	cycle	analysis	data.		In	 the	 antihormone-resistant	 cell	 lines	 (TAMR	 and	 XR),	 BCL3	 was	 shown	 to	promote	substantial	 (although	not	significant)	cell	growth.	However,	 such	effects	were	not	mediated	via	dysregulation	of	the	cell	cycle.	Indeed,	incubation	of	TAMR	and	XR	cells	with	BCL3	siRNA	for	4	days	had	no	effect	on	the	cell	cycle	distribution.	Interestingly,	 a	 substantial	 increase	 in	 the	 proportion	 of	 XR	 cells	 in	 S	 phase,	mirrored	 by	 a	 slight	 increase	 in	 G2/M	 phase	 and	 a	 decrease	 in	 G1	 phase	irrespective	 of	 treatment,	 was	 observed	 compared	 to	 TAMR	 cells,	 suggesting	increased	DNA	replication	in	the	former	cell	line.	The	cell	cycle	of	TAMR	cells	was	also	 examined	 following	2	 and	3	 day	 incubation	with	BCL3	 siRNA.	 Equally,	 such	transient	 knockdown	 had	 no	 effect	 on	 the	 cell	 cycle.	 Stable	 BCL3	 knockdown	 is	unquestionably	required	in	order	to	more	effectively	examine	the	effects	of	BCL3	on	 the	 cell	 cycle.	 Additionally,	 examination	 of	 the	 cell	 cycle	 regulators,	 as	mentioned	above,	would	further	support	the	cell	cycle	analysis	data.	As	previously	discussed	above,	BCL3	is	a	co-activator	of	the	otherwise	inactive	p50	and	p52	homodimers	of	the	NF-κB	family,	and	as	a	result	activates	transcription	of	genes	 involved	 in	 cell	 proliferation	 and	 survival372.	 Thus,	 the	 remainder	 of	 this	Chapter	 focussed	on	the	potential	activation	of	NF-κB	signalling	by	BCL3	and	the	transcription	 of	 target	 genes	 involved	 in	 cell	 growth/survival.	 Initially,	 the	expression	of	p50/NFKB1	and	p52/NFKB2	were	examined	in	the	microarray	gene	expression	 data	 of	 10	 day	 antihormone-treated	MCF-7	 cells	 and	 in	 the	 resistant	TAMR	 and	 XR	 cell	 models,	 to	 determine	 whether	 such	 an	 association	 between	these	 proteins	 and	 BCL3	 is	 likely.	 Interestingly,	 p50/NFKB1	 expression	 was	present	 in	 E2-treated	 MCF-7	 cells,	 with	 similar	 expression	 observed	 following	antihormone	treatment.	In	resistance,	p50/NFKB1	expression	was	up	regulated	in	
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TAMR	and	significantly	in	XR	cells	compared	to	wild	type	control	cells.	In	contrast,	absent	 detection	 calls	 were	 reported	 for	 p52/NFKB2	 expression	 during	antihormone	 response	 in	 MCF-7	 cells	 and	 also	 in	 the	 resistant	 cell	 models.	Subsequent	studies	verified	p50/NFKB1	and	p52/NFKB2	expression	at	the	protein	level.	In	agreement	with	the	microarray	data,	p52/NFKB2	protein	expression	was	not	 detected	 in	 antihormone-responsive	 or	 –resistant	 cell	 models.	 However,	protein	expression	of	p50/NFKB1	and	its	precursor	p105	(which	is	also	detected	by	 the	 p50/NFKB1	 antibody)	 were	 apparent	 in	 control-,	 antihormone-	 and	E2-treated	MCF-7	cells	and	also	in	the	TAMR	and	XR	cell	lines.	In	accordance	with	the	 microarray	 profile,	 p50/NFKB1	 protein	 expression	 was	 unaffected	 by	antihormone	treatment.	In	support	of	this	data,	Yde	et	al.	demonstrated	consistent	protein	expression	of	p50/NFKB1	 in	untreated	MCF-7	cells	and	those	 treated	 for	48	 hours	 with	 tamoxifen	 and	 fulvestrant358.	 The	 precursor	 protein,	 p105,	 was	weakly	 expressed	 in	E2-,	 control-,	 tamoxifen	 and	 fulvestrant-treated	MCF-7	 cells	but	 markedly	 increased	 following	 oestrogen	 deprivation	 treatment.	 To	 consider	the	heterogeneity	of	breast	cancer,	p50/NFKB1	and	p105	protein	expression	were	subsequently	 examined	 in	 T47D	 cells.	 In	 agreement	 with	 the	 MCF-7	 cell	 line,	p50/NFKB1	 was	 similarly	 expressed	 in	 untreated	 control	 and	 10	 day	 E2-	 and	antihormone-treated	T47D	cells.	However,	p105	expression	was	not	observed.	It	is	possible	 that	 p105	 is	 weakly	 expressed	 in	 T47D	 cells	 compared	 to	 p50/NFKB1.	Thus,	with	extended	development	of	the	Western	blot,	p105	expression	may	have	been	detected.	In	agreement	with	these	studies,	Cogswell	et	al.	have	demonstrated	protein	expression	of	p50/NFKB1	in	nuclear	extracts	of	MCF-7	and	T47D	cells,	but	failed	to	identify	p52/NFKB2	expression360.	Additionally,	Yde	et	al.	failed	to	detect	expression	 of	 p52/NFKB2	 in	 MCF-7	 and	 TAMR	 cells358.	 Furthermore,	 parallel	increases	 in	 p50/NFKB1	 and	 BCL3	 expression	 have	 been	 reported	 in	 clinical	human	breast	tumours	compared	to	adjacent	normal	breast	tissue360.	In	the	endocrine	resistant	cell	lines,	p50/NFKB1	and	p105	were	equally	expressed	in	the	TAMR	and	MCF-7	control	cells,	but	were	markedly	increased	in	the	XR	cell	line	 versus	 control.	 In	 support	 of	 these	 findings,	 Zhou	 et	 al.	 have	 demonstrated	equal	 protein	 expression	 of	 p50/NFKB1	 in	 untreated	 MCF-7	 and	tamoxifen-resistant	MCF-7	cells,	in	concert	with	increased	DNA	binding	and	NF-κB	
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transcriptional	 activity	 in	 the	 resistant	 cell	 line423.	 Furthermore,	Pratt	 et	 al.	 have	reported	 increased	 NF-κB	 activity,	 comprised	 predominantly	 of	 p50/NFKB1	homodimers,	 in	parallel	with	 increased	BCL3	expression	 in	ER+,	E2-independent	MCF-7	cells	compared	with	the	parental	cell	 line363.	Similarly,	 in	 the	T47D	TAMR	cell	line,	p50/NFKB1	and	p105	were	up	regulated	compared	to	control.	Together,	these	 studies	 demonstrate	 that	 p50/NFKB1	 is	 expressed	 alongside	 BCL3	 during	antihormone-response	and	–resistance	(with	the	exception	of	only	mRNA	and	not	protein	 expression	 of	 BCL3	 in	 T47D	 TAMR	 detected),	 strongly	 supporting	 the	hypothesis	 that	 BCL3	 coactivates	 p50/NFKB1	 homodimers	 to	 promote	transcription	of	target	genes.		NF-κB	 signalling	 has	 been	 shown	 to	 play	 a	 significant	 role	 in	 the	 growth	 of	antihormone-resistant	breast	cancer	cells.	Indeed,	Yde	et	al.	demonstrated	growth	inhibition	 of	 tamoxifen-resistant	 and	 fulvestrant-resistant	 MCF-7	 cells	 via	abrogation	 of	 NF-κB	 signalling	 utilising	 and	 IκB	 kinase	 inhibitor358.	 Further	investigation	 of	 the	 tamoxifen-resistant	 cell	 line	 demonstrated	 that	 p65	contributes	 to	 the	 resistant	 phenotype	 since	 down	 regulation	 of	 this	 protein	re-sensitised	 the	 cells	 to	 tamoxifen.	However,	 such	 cells	 did	not	 regain	 complete	sensitivity	 towards	 tamoxifen,	 suggesting	 that	 additional	 signalling	 molecules	contribute	 to	 resistant	 cell	 growth.	 Since	 p50/NFKB1	 is	 expressed	 in	antihormone-resistant	 cells,	 perhaps	 this	 protein	 plays	 a	 role	 in	 their	 growth.	Similarly,	 during	 antihormone	 response,	 IκB	 kinase	 inhibition	 hypersensitised	MCF-7	 cells	 to	 fulvestrant,	 highlighting	 a	 possible	 avenue	 for	 combined	 therapy	including	fulvestrant	and	NF-κB	inhibition	for	hormone	responsive	breast	cancer.		To	further	support	the	hypothesis	that	BCL3	coactivates	p50/NFKB1	homodimers	during	antihormone-response	and	particularly	during	resistance,	with	such	events	contributing	to	the	growth-regulatory	effects	of	BCL3	observed	during	resistance,	localisation	 studies	 were	 next	 performed	 to	 determine	 whether	 both	 BCL3	 and	p50/NFKB1	are	co-located	in	the	nucleus,	thus	suggesting	activation	of	NF-κB	and	transcription	 of	 target	 genes.	 However,	 a	 major	 limitation	 of	 the	immunofluorescence	 studies	 was	 the	 inability	 to	 distinguish	 between	 p50	 and	p105	isoforms,	since	the	NFKB1	antibody	recognised	both.	It	is	strongly	likely	that	nuclear	p50/NFKB1	expression	represents	the	p50	isoform,	whereas	cytoplasmic	
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expressions	 represent	 both	 isoforms	 since	 p105	 behaves	 as	 an	 IκB	 protein	 and	sequesters	p50	in	an	inactive	form	in	the	cytoplasm424.		In	 agreement	 with	 BCL3	 being	 a	 nuclear	 protein,	 immunofluorescence	 studies	revealed	 that	 during	 antihormone	 response	 BCL3	 was	 indeed	 predominantly	located	in	the	nucleus	of	MCF-7	cells.	However,	in	the	tamoxifen-treated	cells,	BCL3	was	 also	 located	 in	 the	 cytoplasm.	 Although	 BCL3	 is	 predominantly	 a	 nuclear	protein,	 an	 apparent	 cytoplasmic	 form	 has	 been	 previously	 detected	 in	 293T	(human	 embryonic	 kidney)	 cells421.	 This	 study	 reported	 that	 cytoplasmic	 BCL3	promotes	 release	 of	 p50	 from	 the	 p50-p105	 cytoplasmic	 pool	 and	 subsequently	translocates	 the	 homodimer	 into	 the	 nucleus.	 Thus,	 cytoplasmic	 expression	 of	BCL3	 is	 likely	 to	 be	 transient	 since	 the	 release	 of	 p50	 occurs	 rapidly.	 A	 similar	mechanism	 for	 BCL3	 has	 been	 reported	 in	 COS-1	 cells	 whereby	 BCL3	 promotes	release	of	cytoplasmic	p50	homodimers	from	IκB425.	Therefore,	 it	 is	possible	that	cytoplasmic	 expression	 of	 BCL3	 in	 tamoxifen-treated	 MCF-7	 cells	 functions	 to	promote	 dissociation	 of	 p50	 from	 p105/IκB	 in	 the	 cytoplasm	 and	 promote	subsequent	nuclear	translocation	of	 the	homodimer.	Accordingly,	 in	parallel	with	BCL3	 expression,	 immunofluorescence	 studies	 revealed	 both	 cytoplasmic	 and	nuclear	expression	of	NFKB1	in	tamoxifen-treated	MCF-7	cells.	Moreover,	nuclear	BCL3	 expression	 in	 fulvestrant-	 and	 oestrogen	 deprivation-treated	 MCF-7	 cells	was	mirrored	by	cytoplasmic	NFKB1	expression,	with	very	little,	if	any	expression	detected	in	the	nucleus.	This	supports	the	concept	that	cytoplasmic	BCL3	promotes	nuclear	expression	of	p50/NFKB1.		In	 line	with	 the	Western	 analysis	 data,	 very	 little,	 if	 any,	 BCL3	was	 detected	 by	immunofluorescence	 in	 the	 control	 and	 E2-treated	MCF-7	 cells.	 Interestingly,	 in	these	 cells,	 p50/NFKB1	 was	 predominantly	 located	 in	 the	 nucleus	 with	 little	expression	 in	the	cytoplasm.	This	 is	 in	agreement	with	the	Western	blotting	data	which	 showed	very	 little	p105	expression	 in	 control	 and	E2-treated	MCF-7	 cells.	Very	 little	BCL3	is	expressed	in	these	cells	and	therefore	unlikely	to	promote	the	release	of	p50	from	the	p50-p105/IκB	cytoplasmic	pool.	In	these	cells	it	is	possible	that	 various	 stimuli,	 including	 growth	 factors,	 activate	 IκB	 kinase	which	 in	 turn	phosphorylates	 and	 subsequently	 degrades	 IκB,	 to	 release	p50	homodimers	 into	the	 nucleus213.	 Additionally,	 activation	 of	 IκB	 kinases	 has	 been	 shown	 to	
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phosphorylate	 p105	 and	 subsequently	 promote	 degradation	 by	 the	 26S	proteasome	and	 release	 of	 p50/NFKB1426,427.	 The	20S	proteasome	has	 also	been	reported	 to	 constitutively	 process	 p105	 to	 p50427.	 It	 is	 possible	 that	 such	mechanisms	 are	 regulated	 by	 the	 ER	 and	 therefore	 inhibited	 by	 antihormones,	thus	 potentially	 explaining	 the	 cytoplasmic	 localisation	 of	 p50/NFKB1	 in	 the	antihormone-treated	 cells.	 Additionally,	 the	 ER	 agonist	 activities	 exhibited	 by	tamoxifen	may	explain	 the	presence	of	 some	p50/NFKB1	 in	 the	nucleus	of	 these	cells.	 However,	 further	 studies	 are	 undoubtedly	 required	 to	 investigate	 the	possible	E2/ER-regulation	of	IκB	kinase	activation.	Interestingly,	 previous	 studies	 have	 reported	 very	 little	 NF-κB	 activity	 in	 ER+	breast	cancer	cell	lines	and	human	samples	compared	to	constitutive	activation	in	ER-	 disease428.	 Equal	 p65	 expression	 was	 demonstrated	 in	 ER+	 and	 ER-	 breast	cancer	 cell	 lines;	however,	p105	 to	p50/NFKB1	processing	was	more	efficient	 in	the	 ER+	 cell	 lines.	 In	 the	 absence	 of	 a	 transactivation	 domain	 (e.g.	 provided	 by	co-activator	 BCL3	 or	 p65	 subunit),	 p50/NFKB1	 homodimers	 function	 to	 inhibit	NF-κB	activity414.	Thus,	it	is	possible	that	in	E2-treated	and	untreated	MCF-7	cells,	nuclear	p50/NFKB1	homodimers	bind	DNA	and	repress	transcriptional	activation	of	 NF-κB-target	 genes.	 Furthermore,	 Cogswell	 et	 al.	 have	 reported	 absent	 p65	nuclear	 expression,	but	present	nuclear	p50/NFKB1	expression	 in	human	breast	tumours,	further	supporting	the	hypothesis	that	inactive	p50/NFKB1	homodimers	exist	in	the	nucleus	of	MCF-7	cells360.	Together,	this	data	suggests	that	despite	an	increase	 in	 nuclear	BCL3	 expression	 during	 antihormone	 response,	 it	 is	 unlikely	that	 BCL3	 co-activates	 p50/NFKB1	 homodimers	 (reported	 to	 be	 its	 principal	mechanism)	to	subsequently	promote	transcription	of	target	genes.		The	cellular	localisation	of	p50/NFKB1	was	next	examined	in	T47D	cells.	Similar	to	the	MCF-7	cells,	p50/NFKB1	was	predominantly	located	in	the	nucleus	of	control	and	E2-treated	T47D	cells,	with	some	cytoplasmic	staining	in	the	latter.	However,	in	 contrast	 to	 the	 MCF-7	 cells,	 during	 antihormone-response	 p50/NFKB1	 was	located	 in	 the	 nucleus	 and	 cytoplasm,	 with	 the	 greatest	 cytoplasmic	 staining	apparent	 in	 the	 oestrogen	 deprived	 T47D	 cells.	 As	 previously	mentioned	 above,	cytoplasmic	staining	of	p50/NFKB1	is	likely	characteristic	of	p50/NFKB1	and	p105	expression.	Surprisingly,	Western	analysis	failed	to	detect	any	p105	expression	in	
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the	 T47D	 cells	 irrespective	 of	 antihormone	 treatment.	 However,	 the	 antibody	concentration	 was	 markedly	 increased	 for	 immunofluorescence	 compared	 to	Western	 blotting.	 Thus,	 it	 is	 possible	 that	 Western	 blotting	 performed	 with	 a	higher	concentration	of	p50/NFKB1	antibody	would	result	in	the	detection	of	p105	in	 these	cells.	 In	agreement	with	 the	Western	blotting	data,	 immunofluorescence	studies	failed	to	identify	BCL3	in	the	E2-treated	and	control	T47D	cells.	However,	during	 antihormone	 response,	 BCL3	 was	 located	 in	 both	 the	 nucleus	 and	cytoplasm	of	T47D	cells,	with	the	greatest	cytoplasmic	staining	of	BCL3	apparent	in	the	oestrogen	deprived	cells.	This	profile	strongly	mirrors	the	expression	profile	of	p50/NFKB1	in	this	cell	 line	during	antihormone-response,	possibly	supporting	the	hypothesis	 that	 cytoplasmic	BCL3	 regulates	dissociation	of	p50/NFKB1	 from	p105	 in	 the	 cytoplasm	 and	 consequently	 promotes	 nuclear	 localisation	 of	p50/NFKB1.		The	localisation	of	p50/NFKB1	and	BCL3	are	markedly	different	in	the	MCF-7	and	T47D	 cell	 lines,	 highlighting	 the	 heterogeneity	 of	 breast	 cancer;	 in	 the	 former,	during	antihormone	response,	BCL3	and	p50/NFKB1	are	not	co-located,	whereas	in	the	T47D	cells,	BCL3	and	p50/NFKB1	are	both	expressed	in	the	cytoplasm	and	nucleus.	 This	 suggests	 that	 there	 may	 be	 some	 BCL3-mediated	 p50/NFKB1	homodimer	activation	in	the	T47D	cells	during	antihormone	response,	which	is	not	apparent	 in	the	MCF-7	cells.	However,	as	previously	discussed	above,	ER+	breast	cancer	 cells	 are	 reported	 to	have	very	 little	NF-κB	activity.	Thus,	 it	 is	 likely	 that,	rather	than	co-activating	p50/NFKB1	homodimers	in	T47D	cells,	BCL3	functions	to	repress	 NF-κB	 activation	 by	 facilitating	 the	 binding	 of	 inactive	 p50/NFKB1	homodimers	 to	 the	 κB	 sites	 on	 DNA,	 to	 prevent	 the	 binding	 of	 transactivating	dimers429,430.	Moreover,	 further	 studies	are	 required	 to	determine	whether	BCL3	and	 p50/NFKB1	 are	 indeed	 bound	 in	 the	 nucleus	 of	 T47D	 cells	 during	antihormone	response.		Interestingly,	 following	the	acquisition	of	resistance,	 immunofluorescence	studies	revealed	 strong	 expression	 and	 co-localisation	 of	 p50/NFKB1	 and	 BCL3	 in	 the	nucleus	of	TAMR	and	XR	cell	models,	thus	suggesting	transcriptional	activation	of	p50/NFKB1	 homodimers.	 In	 the	 TAMR	 cells,	 there	 was	 also	 some	 cytoplasmic	staining	 of	 BCL3	 and	 p50/NFKB1,	 with	 stronger	 cytoplasmic	 staining	 of	
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p50/NFKB1	apparent	 in	 the	XR	cells	but	 exclusively	nuclear	expression	of	BCL3.	Interestingly,	 immunofluorescence	 studies	 of	 the	 T47D	 TAMR	 cell	 line	 revealed	co-localisation	of	BCL3	and	p50/NFKB1	 in	 the	 cytoplasm,	with	 very	 little,	 if	 any,	staining	of	each	protein	observed	in	the	nucleus.	The	identification	of	BCL3	protein	in	T47D	TAMR	cells	by	 immunofluorescence	is	surprising,	since	Western	blotting	failed	to	detect	protein	expression	of	BCL3	in	this	cell	line.	Therefore,	it	is	possible	that	experimental	errors	 in	 the	Western	blotting	contributed	 to	 the	 lack	of	BCL3	protein	 detection,	 rather	 than	 the	 absence	 of	 BCL3	 protein	 in	 these	 cells.	 In	 the	T47D-TAMR	cells,	it	is	possible	that	IκB	proteins	are	strongly	expressed	compared	to	 resistant-MCF-7	 cells,	 together	 with	 minimal	 IκB	 kinase-mediated	 IκB	degradation,	 thus	 sequestering	 p50/NFKB1	 in	 the	 cytoplasm	 and	preventing/outweighing	 cytoplasmic	 BCL3-mediated	 p50/NFKB1	 nuclear	translocation.	 In	 contrast	 to	 the	 MCF-7-derived	 resistant	 cell	 models,	 these	findings	 suggest	 the	 absence	 of	 BCL3-mediated	 p50/NFKB1	 homodimer	transcriptional	activity	in	the	T47D	TAMR	cell	lines.		Remarkably,	such	studies	may	have	identified	a	potential	mechanism	responsible	for	the	previously	demonstrated	growth	regulatory	role	of	BCL3	in	the	TAMR	and	XR	 cell	 lines	 via	 BCL3-mediated	 co-activation	 of	 p50/NFKB1	 transcriptional	activity	 characterised	 by	 the	 co-localisation	 of	 both	 proteins	 in	 the	 nucleus.	Accordingly,	 BCL3	was	 previously	 shown	 to	 have	 no	 effect	 on	 the	 growth	 of	 the	T47D	 TAMR	 cells	 possibly	 due	 to	 the	 co-localisation	 of	 both	 proteins	 in	 the	cytoplasm	 and	 subsequently	 no	 activation	 of	 NF-κB	 and	 transcription	 of	 growth	regulatory	 proteins.	 Similarly,	 despite	 an	 increase	 in	 BCL3	 expression	 during	antihormone	response	of	MCF-7	and	T47D	cells,	BCL3	played	no	role	in	the	growth	of	 these	 cells.	 With	 regard	 to	 the	 MCF-7	 cells,	 the	 immunofluorescence	 studies	concluded	 no	 co-localisation	 of	 BCL3	 and	 p50/NFKB1	 in	 the	 nucleus,	 thus	suggesting	 no	 activation	 of	 NF-κB	 and	 the	 downstream	 transcription	 of	 growth	regulatory	proteins.	Surprisingly,	during	antihormone	response	in	the	T47D	cells,	the	immunofluorescence	studies	suggested	a	possible	co-localisation	of	BCL3	and	p50/NFKB1	in	the	nucleus.	However,	in	contrast	to	the	resistant	cell	models,	such	nuclear	co-localisation	had	no	effect	on	the	growth	regulatory	role	of	BCL3	during	antihormone	 response	 in	 the	 T47D	 cells.	 Thus,	 it	 is	 possible	 that	 additional	
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oncogenic	events,	present	 in	resistance	(TAMR	and	XR)	but	not	during	response,	are	 required	 to	 drive	 BCL3-mediated	 p50/NFKB1	 activation	 and	 downstream	growth	regulation.	To	 further	 confirm	 the	 co-localisation	 data,	 immunoprecipitation	 studies	 were	performed	to	examine	whether	BCL3	and	p50/NFKB1	are	complexed,	particularly	in	 the	 TAMR	 and	 XR	 cell	 lines,	 to	 support	 the	 hypothesis	 that	 BCL3	 coactivates	p50/NFKB1	 to	 promote	 NF-κB-mediated	 gene	 transcription.	 In	 support	 of	 the	Western	 analysis	 and	 immunofluorescence	 data,	 BCL3	 expression	 was	 not	detected	in	E2-treated	and	control	MCF-7	and	T47D	cells	immunoprecipitated	with	p50/NFKB1.	Additionally,	according	to	the	nuclear	and	cytoplasmic	expression	of	BCL3	 and	 p50/NFKB1,	 respectively,	 in	 fulvestrant-	 and	 oestrogen	deprivation-treated	 MCF-7	 cells,	 immunoprecipitation	 studies	 demonstrated	 no	interaction	 between	both	 proteins.	 Surprisingly,	 BCL3	 and	p50/NFKB1	were	 not	complexed	in	tamoxifen-treated	MCF-7	cells	and	antihormone-treated	T47D	cells.	This	 is	 surprising	since	 immunofluorescence	studies	 revealed	a	co-localisation	of	both	proteins	in	the	nucleus	and	cytoplasm.	Further	studies	including	nuclear	and	cytoplasmic	 fractionation	 of	 these	 cells	 followed	 by	 Western	 blotting	 to	 detect	BCL3	 and	 p50/NFKB1	 would	 confirm	 the	 immunofluorescene	 data.	 Thus,	cytoplasmic	 BCL3-mediated	 p50/NFKB1	 translocation	 is	 likely	 to	 occur	 via	 an	intermediary	protein	and	not	via	direct	association	between	BCL3	and	p105/p50.	In	 the	 nucleus	 of	 tamoxifen-treated	MCF-7	 and	 antihormone-treated	 T47D	 cells,	p50/NFKB1	 possibly	 exists	 as	 an	 inactive	 homodimer.	 However,	 further	 studies	are	clearly	required	to	rule	out	the	possible	existence	of	p50/NFKB1	heterodimers	with	alternative	NF-κB	subunits,	which	contain	a	transactivation	domain	(e.g.	p65)	to	 subsequently	 activate	 NF-κB-mediated	 gene	 transcription.	 Furthermore,	 the	role	of	BCL3	during	antihormone-response	remains	to	be	elucidated.	In	 antihormone	 resistance,	BCL3	 expression	was	 strongly	 apparent	 in	TAMR,	XR	and	T47D-TAMR	cells	immunoprecipitated	with	p50/NFKB1.	The	identification	of	BCL3	 protein	 expression	 in	 these	 T47D	 TAMR	 cells	 strongly	 suggests	 (as	previously	 mentioned	 above)	 that	 experimental	 errors	 in	 the	 Western	 blotting	experiments	 of	 wild	 type	 versus	 T47D	 TAMR	 cells	 led	 to	 the	 failure	 of	 BCL3	detection.	 These	 findings	 are	 in	 agreement	 with	 the	 immunofluorescence	 data,	
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which	demonstrated	co-localisation	of	both	proteins	 in	 the	nucleus	of	TAMR	and	XR	cells,	and	in	the	cytoplasm	of	T47D-TAMR	cells.	To	further	distinguish	whether	BCL3	was	 bound	 to	 p50	 or	 p105,	 TAMR	 and	 XR	 cells	were	 immunoprecipitated	with	 BCL3	 and	 probed	 with	 the	 p50/NFKB1	 antibody.	 As	 predicted,	 BCL3	 was	associated	with	 p50/NFKB1	 in	 the	 nucleus	 of	 TAMR	and	XR	 cell	 lines.	However,	such	 studies	were	not	performed	 in	 the	T47D	TAMR	cell	 line.	 It	 is	 possible	 that,	since	p50/NFKB1	and	BCL3	are	co-located	 in	 the	cytoplasm	of	T47D	TAMR	cells,	BCL3	 is	bound	 to	both	p50/NFKB1	and	p105	 isoforms.	To	 further	 confirm	BCL3	and	p50	and/or	p105	interactions	in	the	nucleus	of	TAMR	and	XR	or	cytoplasm	of	T47D-TAMR	 cells,	 immunoprecipitation	 could	 be	 performed	 on	 nuclear	 and	cytoplasmic	 extracts	 individually.	 Interestingly,	 a	 weak	 association	 between	p50/NFKB1	and	BCL3	was	observed	in	wild	type	control	cells	cultured	in	sFCS	(i.e.	MCF-7	and	T47D),	with	such	an	association	not	apparent	 in	 the	wild	 type	MCF-7	and	T47D	 cells	 cultured	 in	 FCS.	 These	 differences	may	 be	 due	 to	 growth	 factors	present	in	FCS	cross-talking	with	the	ER	to	facilitate	BCL3	down	regulation,	which	is	incomplete	following	incubation	with	growth	factor-depleted	sFCS.	Importantly,	all	 immunoprecipitation	 studies	 were	 performed	 only	 once	 (n=1).	 Thus,	 further	experiments	are	clearly	necessary	to	clarify	this	data.		As	previously	discussed,	Watanabe	et	al.	have	demonstrated	that	cytoplasmic	BCL3	promotes	 release	 of	 p50	 from	 the	 p50-p105	 cytoplasmic	 pool	 and	 subsequently	translocates	 the	 homodimer	 into	 the	 nucleus421.	 They	 also	 reported	 that	 such	events	were	without	effect	on	the	proteolytic	processing	of	p105	to	p50.	We	were	interested	to	investigate	whether	BCL3	effects	the	proteolytic	processing	of	p105	to	p50	in	our	cells.	The	protein	expression	of	p105	and	p50/NFKB1	was	examined	in	BL3	knockdown	TAMR	cells.	Interestingly,	BCL3	down	regulation	resulted	in	an	increase	in	p105	expression	and	a	decrease	in	p50	expression.	This	suggests	that	BCL3	 may	 play	 a	 role	 in	 promoting	 p105	 processing	 to	 p50,	 subsequently	increasing	the	levels	of	p50	produced	and	translocated	into	the	nucleus	ultimately	increasing	NF-κB	 activity	 and	 transcription	 of	 genes	 involved	 in	 cell	 growth	 and	survival.	To	our	knowledge,	these	are	the	first	experiments	to	demonstrate	a	role	for	BCL3	in	p105	to	p50	processing.	Certainly,	additional	experiments	are	required	
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to	further	explore	this	idea,	including	similar	knockdown	studies	in	XR	and	T47D	TAMR	cells	as	well	as	during	antihormone	response.			In	summary,	this	Chapter	has	revealed	a	role	for	BCL3	in	promoting	resistant	cell	growth;	however	in	contrast	to	what	was	first	hypothesised,	there	was	no	evidence	to	 suggest	 a	 role	 for	 BCL3	 in	 limiting	 antihormone	 response.	 Indeed,	 BCL3	promoted	 growth	 (although	 not	 significant)	 of	 TAMR	 and	 XR	 MCF-7-derived	resistant	cells	 together	with	nuclear	 localisation	and	direct	binding	of	BCL3	with	p50	in	the	nucleus.	Although	BCL3	knockdown	failed	to	significantly	decrease	cell	growth	 in	 the	 resistant	 cells,	 it	 is	 possible	 that	with	more	 experimental	 repeats,	such	effects	may	prove	significant.	Such	nuclear	 localisation	of	both	proteins	and	their	direct	 association	 suggests	 that	BCL3	co-activates	p50/NFKB1	homodimers	to	 promote	 NF-κB-mediated	 gene	 transcription	 and	 ultimately	 cell	 growth.	However,	 further	studies,	 such	as	a	NF-κB	reporter	gene	assay	or	a	DNA-binding	ELISA	are	required	to	confirm	p50/NFKB1	homodimer	activation.	Furthermore,	it	would	 be	 interesting	 to	 examine	 the	 expression	 of	 other	 NF-κB	 subunits,	particularly	those	that	contain	a	transactivation	domain	(e.g.	p65,	RelB	and	cRel)	to	determine	 whether	 they	 contribute	 to	 the	 predicted	 NF-κB	 activity	 apparent	 in	TAMR	 and	 XR	 cells.	 Additionally	 chromatin	 immunoprecipitation	 (ChIP)	sequencing	would	 identify	 the	 potential	 pro-proliferative	 and	 pro-survival	 genes	regulated	by	BCL3-activated	p50/NFKB1	homodimers.	To	consider	 the	heterogeneity	of	breast	cancer,	 the	role	of	BCL3	 in	an	additional	tamoxifen	 resistance	 ER+	 cell	 line	 (i.e.	 T47D-TAMR)	was	 assessed.	 Interestingly,	BCL3	 did	 not	 promote	 the	 growth	 of	 T47D-TAMR	 cells.	 Although	immunoprecipitation	 studies	 revealed	 an	 association	 between	 BCL3	 and	p50/NFKB1	 in	 the	 T47D	 TAMR	 cell	 line,	 both	 proteins	were	 sequestered	 in	 the	cytoplasm	together	with	p105	and	therefore	unable	to	promote	gene	transcription.	The	 role	 of	BCL3	 in	 the	 cytoplasm	 remains	 largely	 unexplored.	 There	 are	 only	 a	couple	of	studies	which	have	demonstrated	cytoplasmic	expression	of	BCL3,	with	both	 suggesting	 that	 in	 the	 cytoplasm,	 BCL3	 plays	 a	 role	 in	 the	 nuclear	translocation	 of	 p50/NFKB1	 from	p105	 and	 IκB	 proteins	 in	 the	 cytoplasm421,425.	However,	 the	 exact	 mechanisms	 of	 such	 BCL3-mediated	 p50/NFKB1	 nuclear	translocation	are	unclear.	It	is	possible	that	IκB	protein	expression	is	increased	in	
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the	T47D-TAMR	cells	compared	to	TAMR	and	XR	cells	(which	could	be	examined	by	 Western	 blotting),	 therefore	 retaining	 p50/NFKB1	 in	 the	 cytoplasm	 and	preventing	 BCL3-mediated	 p50/NFKB1	 nuclear	 translocation.	 Alternatively,	 it	 is	possible	 that	 additional	 proteins	 required	 to	 promote/facilitate	 BCL3-mediated	p50/NFKB1	 translocation	 are	 absent	 in	 the	T47D	 cell	 line	 versus	 the	MCF-7	 cell	line.		Similarly,	 during	 antihormone	 response,	 BCL3	 had	 no	 effect	 on	 the	 growth	 of	fulvestrant-treated	MCF-7	and	T47D	cells.	In	the	MCF-7	cells,	BCL3	was	located	in	the	 nucleus	 and	 p105/p50	 was	 located	 in	 the	 cytoplasm.	 Unsurprisingly,	immunoprecipitation	 studies	 failed	 to	 identify	 an	 association	 between	 both	proteins.	In	the	T47D	cell	line,	although	both	proteins	were	located	in	the	nucleus,	immunoprecipitation	 studies	 failed	 to	 demonstrate	 a	 direct	 physical	 association	between	 these	 proteins.	 Therefore,	 these	 findings	 suggest	 that	 BCL3	 does	 not	co-activate	 p50/NFKB1	 homodimers	 during	 antihormone	 response	 to	 promote	downstream	transcription	of	genes	involved	in	cell	proliferation	and	survival,	and	in	 the	antihormone-treated	MCF-7	cells,	p50/NFKB1	is	not	 translocated	 from	the	cytoplasm	to	the	nucleus.		However,	 cell	 survival	 and	 cell	 cycle	 assays	 failed	 to	 identify	 a	 role	 for	 BCL3	 in	either	promoting	cell	survival	or	dysregulating	the	cell	cycle	during	antihormone	response	and	resistance.	However,	it	is	possible	that	such	studies	were	insufficient	to	 fully	determine	a	role	 for	BCL3	and	the	mechanisms	by	which	BCL3	promotes	cell	 growth	 in	 the	 TAMR	 and	 XR	 cell	 lines	 requires	 further	 study.	 Such	 studies	could	 include	 examination	 of	 cell	 cycle	 regulators	 to	 determine	whether	 nuclear	BCL3:p50	 complexes	 alter	 their	 expression,	 alongside	 examination	 of	 PARP	cleavage,	 characteristic	 of	 apoptosis.	Moreover,	 it	 is	possible	 that	 transient	BCL3	knockdown	is	insufficient	to	promote	significant	apoptosis	and/or	dysregulation	of	the	cell	cycle,	which	may	be	apparent	following	stable	gene	knockdown.		Furthermore,	preliminary	studies	suggest	that	BCL3	may	play	a	role	in	p105	to	p50	processing	 in	 TAMR	 cells.	 However,	 further	 studies	 are	 required	 to	 determine	whether	 BCL3	 plays	 an	 equivalent	 role	 in	 additional	 models	 of	 endocrine	resistance	 and	 also	 during	 response.	 Together,	 these	 are	 the	 first	 studies	 to	 our	
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knowledge	that	demonstrate	that	BCL3	promotes	growth	of	antihormone	resistant	cells	(derived	from	MCF-7	cells)	by	potentially	enhancing	p105	to	p50	processing	and	 promoting	 nuclear	 localisation	 of	 p50,	 to	 facilitate	 BCL3-mediated	 p50	homodimer	 activation	 and	 subsequent	 transcription	 of	 NF-κB-regulated	 genes.	However,	although	BCL3	expression	is	up	regulated	during	antihormone	response,	its	role	remains	to	be	elucidated.				
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6 Results	IV:	Further	investigation	of	CLU	function	during	antihormone-response	and	-resistance	
6.1 Introduction	CLU	 is	 a	 ubiquitously	 expressed	 glycoprotein	 implicated	 in	 several	 physiological	processes	 important	 for	 carcinogenesis	 and	 tumour	 progression,	 including	apoptosis,	 cell	 cycle	 regulation	 and	 DNA	 repair371,431,432.	 Deciphering	 the	 role	 of	CLU	has	been	 challenging	due	 to	 the	existence	of	 two	main,	 functionally	diverse,	isoforms,	 as	 a	 result	 of	 alternative	 splicing.	 The	 cytoplasmic	 secretory	 isoform,	CLU-S,	 functions	 to	promote	cell	 survival,	whereas	 the	nuclear	 isoform	promotes	cell	death.	Prochnow	et	al.	have	extensively	studied	the	different	CLU	isoforms	in	non-cancer	and	cancer	cell	lines	(including	MCF-7	cells)295.	They	identified	that	the	CLU	gene	encodes	at	least	three	different	mRNA	variants	which	are	transcribed	as	pre-mRNAs,	 each	comprising	9	exons	and	8	 introns	 (Figure	95).	Each	pre-mRNA	variant	 contained	 a	 unique	 exon	 1	 sequence.	 Variant	 1	 encodes	 CLU-S,	 which	 is	translated	 from	 a	 start	 codon	 located	 upstream	 of	 the	 signal	 sequence	 coding	region	 (SSCR)	 on	 exon	 2.	 An	 alternative	 spliced	mRNA	of	 variant	 1	 is	 translated	from	a	start	codon	which	resides	on	exon	3	and	 thus	 lacks	exon	2	and	 the	SSCR.	Consequently,	this	protein	lacks	the	signal	sequence,	yielding	an	intracellular	CLU	isoform	 known	 as	 the	 nuclear	 CLU	 protein.	 Translation	 of	 the	 other	 two	 pre-mRNAs	gives	rise	to	Variant	2	and	Variant	3	CLU.	However,	RT-PCR	using	variant-specific	 primers	 in	MCF-7	 cells	 revealed	 that	 Variant	 1	 (CLU-S)	 represented	 the	most	 abundant	 mRNA,	 whereas	 Variant	 1	 excluding	 exon	 2	 (nuclear	 CLU)	represented	approximately	0.01%	of	total	CLU	mRNA,	with	even	less	represented	by	Variant	2	and	3295.		CLU-S	is	synthesised	as	a	pre-pro-protein	comprised	of	449	amino	acids,	where	the	first	 22	 amino	 acids	 represent	 the	 secretory	 signal	 sequence.	 The	 primary	translation	molecule	 is	 converted	 to	a	high-mannose	60	kDa	 form,	 located	 in	 the	endoplasmic	 reticulum.	 Subsequently,	 the	 protein	 is	 glycosylated	 and	 cleaved	 in	the	 Golgi	 to	 α-	 and	 β-chains	 (34-36	 kDa	 and	 37-39	 kDa,	 respectively)	 which	
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heterodimerise	(70-80	kDa)	yielding	the	mature	secreted	CLU	protein371.	Nuclear	CLU	(~55	kDa)	protein	 is	 translated	from	the	alternatively	spliced	Variant	1	CLU	transcript,	lacking	exon	2.			
CLU	is	expressed	in	many	human	cancers,	including	breast,	bladder,	colon,	kidney	and	 prostate335,433–435.	 CLU	 plays	 a	 significant	 role	 in	 the	 tumorigenesis	 and	metastasis	 of	 several	 human	 cancers	 and	 is	 up	 regulated	 by	 many	 anti-cancer	therapies	to	confer	treatment	resistance335,436–438.	In	prostate,	CLU-S	expression	is	very	 low	 in	benign	 epithelial	 cells,	 but	 increases	 in	prostate	 cancers	with	higher	Gleason	 scores435.	 Furthermore,	 CLU-S	 expression	 has	 been	 shown	 to	 be	significantly	 increased	 in	 prostate	 cancer	 cells	 following	 androgen	 deprivation	therapy439,440.	 Overexpression	 of	 CLU-S	 in	 prostate	 cancer	 cells	 has	 also	 been	demonstrated	 to	 protect	 these	 cells	 from	 chemotherapy-induced	 apoptosis,	 thus	
	
Figure	 95	 Structure	 of	 CLU	 gene	 and	 transcription	 products.	 The	 human	 CLU	 gene	
comprises	9	 exons	 and	encodes	 at	 least	3	different	pre-mRNAs	which	 contain	unique	
exons	 1.	 Splicing	 of	 variant	 1	 pre-mRNA	 generates	 the	 cytoplasmic	 secretory	 mRNA	
form	 (CLU-S)	 which	 includes	 the	 signal	 sequence	 coding	 region	 (SSCR).	 Alternative	
splicing	 of	 variant	 1	 pre-mRNA	 generates	 an	 mRNA	 that	 lacks	 exon	 2	 and	 the	 SSCR.	
Splicing	of	 the	other	2	pre-mRNAs	gives	rise	 to	Variants	2	and	3.	Figure	adapted	from	
Prochnow	et	al.295.	
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aiding	 acquisition	 of	 a	 chemo-resistant	 phenotype441.	 Similarly,	 in	 breast,	 CLU	expression	is	very	low	in	normal	epithelial	cells,	but	is	very	high	in	breast	cancer	cells	 and	 is	 associated	 with	 metastatic	 progression335.	 Tamoxifen	 and	 cytotoxic	treatments	have	been	demonstrated	 to	 increase	CLU	expression	 in	breast	 cancer	cell	lines	which	subsequently	protects	the	cells	from	cell	death339.	Mechanisms	by	which	 CLU	 exerts	 its	 pro-survival	 activity	 are	 not	 fully	 elucidated.	 Proposed	mechanisms	 include	 inhibition	 of	 the	 apoptotic	 protein	 Bax344,	 enhancement	 of	NF-κB	 transcriptional	 activity349	 and	 activation	 of	 the	 PI3K/AKT	 survival	pathway348.		It	was	hypothesised	that	antihormones	induce	up	regulation	of	pro-survival	genes	early	during	response,	allowing	a	cohort	of	cells	to	escape	antihormone	challenge	and	 ultimately	 contribute	 to	 the	 emergence	 of	 resistant	 growth.	 The	microarray	work	 in	 Chapters	 3	 and	 4	 aimed	 to	 identify	 antihormone-induced	 pro-survival	genes	 that	 may	 subsequently	 limit	 the	 efficacy	 of	 such	 agents	 and	 contribute	towards	 the	 acquisition	 of	 resistance.	 Further	 study	 of	 strong	 candidates	 could	prove	 significant	 in	 identifying	 novel	 therapeutic	 strategies	 to	 enhance	antihormone	response,	as	well	as	biomarkers	representing	drug	outcome.	To	 this	 regard,	 Western	 blotting	 data	 indicated	 that	 CLU-S	 expression	 was	 up	regulated	 by	 all	 three	 antihormone	 treatments	 in	 4	 ER+	 cell	 lines	 encompassing	HER2+	 and	 HER2-	 disease	 (Chapter	 4).	 Additionally,	 ontological	 investigations	identified	a	breadth	of	literature	exploring	CLU	expression	in	breast	cancer	where	its	 increased	 expression	 has	 been	 associated	 with	 metastasis,	 cell	 survival	 and	ultimately	poor	outcome335,336.	Together,	this	suggests	that	CLU/CLU-S	expression	is	 rapidly	 induced	 in	 response	 to	 all	 three	 antihormone	 therapies	 in	HER2+	 and	HER2-	 disease,	 potentially	 activating	 a	 common	 survival	mechanism	 to	 promote	the	development	of	resistance.	Indeed,	initial	microarray	studies	in	cell	models	of	acquired	 endocrine	 resistance	 identified	 increased	 CLU	 expression	 maintained	through	 to	 the	 emergence	 of	 resistance	 to	 tamoxifen,	 fulvestrant	 and	 oestrogen	deprivation.	In	this	Chapter,	targeted	CLU	knockdown	studies	have	thus	been	performed	to	aim	to	 identify	 the	 role	 of	 CLU	 during	 antihormone-response	 and	 –resistance	 and	 to	
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determine	 whether	 its	 up	 regulation	 early	 during	 response	 contributes	 to	 the	limited	 efficacy	 of	 these	 agents	 and	 subsequently	 promotes	 the	 development	 of	resistance.	Firstly,	the	log2	intensity	plots,	generated	from	the	microarray	data,	of	CLU	expression	in	the	antihormone-resistant	cell	models	(i.e.	TAMR	and	XR)	were	examined	 and	 subsequently	 verified	 by	 RT-PCR	 and	 Western	 blotting,	 to	determine	whether	 increased	 CLU/CLU-S	 expression	was	maintained	 through	 to	emergence	of	 resistance.	 Subsequently,	CLU	knockdown	studies,	 via	 siRNA,	were	performed	 to	 determine	 whether	 CLU	 limits	 the	 growth	 inhibitory	 actions	 of	antihormones	 during	 response	 and/or	 promotes	 the	 growth	 of	antihormone-resistant	cells.		
6.2 Methods	
6.2.1 Cell	culture	Antihormone-treated	MCF-7	and	T47D	cells	were	re-suspended	in	phenol-red-free	RPMI	medium	 supplemented	with	 5%	 FCS,	 penicillin-streptomycin	 (10	 IU/ml	 to	10	µg/ml),	 fungizone	 (2.5	 µg/ml)	 and	 glutamine	 (4	mM)	 and	 allowed	 to	 adhere	overnight	 prior	 to	 the	 addition	 of	 antihormone,	 E2	 and	 control	 (untreated	medium)	treatments,	as	described	in	Chapter	2,	section	2.1.2.	The	 (short-term)	 TAMR,	 FASR,	 XR	 and	 T47D	 TAMR	 cell	 models	 and	 wild	 type	control	 cells	were	 cultured	 in	phenol-red-free	RPMI	medium	supplemented	with	5%	sFCS,	 penicillin-streptomycin	 (10	 IU/ml	 to	10	µg/ml),	 fungizone	 (2.5	µg/ml),	glutamine	(4	mM)	and	respective	antihormone	treatment,	as	described	in	Chapter	2,	section	2.1.2.		
6.2.2 RT-PCR	Cells	 were	 prepared	 for	 RNA	 analysis	 as	 outlined	 in	 section	 6.2.1.	 RT-PCR	 was	performed,	as	described	 in	section	2.4,	 to	determine	RNA	expression	of	CLU.	The	CLU	 primers	 used	were	 previously	 designed	 by	 Prochnow	 et	 al.295.	 The	 forward	primer	was	complementary	to	exon	1a	and	the	reverse	primer	complementary	to	exon	5	(Table	3).	The	nuclear	and	secretory	isoforms	of	CLU	exhibit	similar	mRNA	sequences,	with	 the	exception	of	 the	 former	 lacking	exon	2;	 thus	PCR	resulted	 in	the	amplification	of	both	isoforms,	characterised	by	individual	products	of	271	bp	and	 400	 bp,	 respectively.	 Densitometry	 analysis	 was	 performed	 and	 the	 raw	
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densitometry	values	of	CLU	were	normalised	to	β-actin	 loading	control.	The	data	were	 analysed	 using	 GraphPad	 prism.	 An	 unpaired	 t-test	 or	 an	 ANOVA	 (with	 a	Tukey’s	multiple	comparisons	post-hoc	test)	were	used	to	compare	the	means.	A	p	value	<0.05	was	considered	statistically	significant.	
6.2.3 Western	blotting	Cells	 were	 prepared	 for	 Western	 blotting	 as	 outlined	 in	 section	 6.2.1.	 Twenty	micrograms	 of	 protein	 was	 loaded	 and	 separated	 by	 SDS-PAGE	 and	 probed	 for	secretory	 CLU	 antigen,	 as	 described	 in	 section	 2.5.	 The	 secretory	 CLU	 antibody	used	within	this	project	recognises	the	60	kDa	precursor	and	40	kDa	CLUα	subunit.	Densitometry	 analysis	 was	 performed	 and	 the	 raw	 densitometry	 values	 of	 CLU	were	 normalised	 to	 β-actin	 loading	 control.	 The	 data	 were	 analysed	 using	GraphPad	 prism.	 An	 unpaired	 t-test	 or	 an	 ANOVA	 (with	 a	 Tukey’s	 multiple	comparisons	post-hoc	test)	were	used	to	compare	the	means.	A	p	value	<0.05	was	considered	statistically	significant.	
6.2.4 CLU	knockdown	To	 decipher	 the	 role	 of	 CLU	 during	 antihormone	 response	 and	 resistance,	 CLU	knockdown	studies	were	performed	utilising	siRNA	as	described	 in	section	2.6.1.	Briefly,	cells	were	grown	until	approximately	60%	confluency	prior	to	the	addition	of	the	siRNA	tranfection	reagent	mix.	Cells	were	incubated	for	4	days	(unless	sated	otherwise)	prior	to	RNA	and	protein	lysis	for	subsequent	RT-PCR	and	Western	blot	analysis	(as	described	above).	Since	CLU-S	is	expressed	at	 low	levels	 in	wild	type	MCF-7	and	T47D	cells,	fulvestrant	was	added	to	the	medium	48	hours	post	siRNA	transfection	to	induce	CLU-S	expression.	
6.2.5 Cell	counting	Cell	 counting	studies	were	performed	 to	determine	 the	effect	of	CLU	knockdown	on	cell	growth	during	antihormone	response	and	resistance.	Cells	were	transfected	with	CLU	siRNA	(as	described	above)	in	triplicate	and	incubated	for	4	days	prior	to	the	measurement	of	cell	number,	as	described	in	section	2.6.3.	
6.2.6 Immunofluorescence	The	 cellular	 localisation	 of	 secretory	 CLU	 during	 antihormone	 response	 and	resistance	was	examined	by	 immunofluorescence	 studies	 as	described	 in	 section	
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2.6.4.	 Briefly,	 cells	were	 grown	 on	 glass	 coverslips,	 incubated	with	 CLU	 primary	antibody,	 followed	 by	 appropriate	 fluorphore-conjugated	 secondary	 antibody	prior	to	examination	on	a	fluorescent	microscope.		
6.2.7 Cellular	fractionation	Nuclear	and	cytoplasmic	fractions	of	MCF-7,	TAMR	and	XR	cells	were	prepared	as	described	 in	section	2.5.2.	The	resultant	protein	were	separated	by	SDS-PAGE	as	described	 above	 and	 probed	 for	 secretory	 CLU	 antigen,	 and	 the	 nuclear	 and	cytoplasmic	markers,	SP-1	and	Grb2,	respectively.	
6.3 Results	Initial	 microarray	 studies	 (Chapter	 3)	 revealed	 increased	 CLU	 expression	maintained	 through	 to	 the	 acquisition	 of	 resistance.	 Indeed,	 up	 regulation	 (fold	change	 >	 1.5)	 of	 CLU	 expression	was	 demonstrated	 in	 TAMR	 and	 XR	 cells,	 with	significant	 up	 regulation	 in	 the	 FASR	 cells	 versus	MCF7	 control	 cells	 (Chapter	 3,	Figure	18).	Additionally,	 predominantly	 present	 detection	 calls	were	 reported	 in	the	XR	and	FASR	 cell	models,	 implying	 reliable	 gene	expression,	whereas	 absent	calls	 were	 recorded	 in	 the	 TAMR	 and	 MCF7	 control,	 suggesting	 very	 low	 gene	expression	(Chapter	3,	Figure	18).	
6.3.1 Verification	of	the	microarray	data	by	RT-PCR	As	 previously	 described,	 CLU	 has	 two	 main	 isoforms	 as	 a	 result	 of	 alternative	splicing.	The	cytoplasmic	secreted	form	promotes	cell	survival	whereas	the	nuclear	form	 is	 associated	 with	 cell	 death.	 Since	 this	 project	 is	 interested	 in	 the	pro-survival	role	of	CLU,	PCR	primers	complementary	to	the	DNA	sequence	of	the	pro-survival	 form	were	utilised.	The	PCR	primers	used	were	previously	designed	by	Prochnow	et	al.295,	with	the	forward	primer	complementary	to	exon	1a	and	the	reverse	 primer	 complementary	 to	 exon	 5.	 However,	 since	 the	 nuclear	 and	secretory	 isoforms	 exhibit	 similar	 mRNA	 sequences,	 with	 the	 exception	 of	 the	former	 lacking	 exon	 2,	 PCR	 resulted	 in	 the	 amplification	 of	 both	 forms,	characterised	by	individual	products	of	different	base	pair	sizes.		The	microarray	expression	profiles	of	CLU	in	TAMR	and	XR	cell	lines	were	verified	by	RT-PCR.	To	consider	the	heterogeneity	of	breast	cancer,	CLU-S	expression	was	also	examined	by	RT-PCR	in	T47D	TAMR	cells.	This	project	eliminated	FASR	cells	
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from	 further	 study	 since	 we	 wished	 to	 focus	 on	 the	 first-line	 therapies	 (i.e.	tamoxifen	and	AIs)	and	the	resistance	that	develops	from	such	agents.	RT-PCR	was	performed	 on	 triplicate	 mRNA	 from	 wild	 type	 cells	 (i.e.	 MCF-7	 and	 T47D)	 and	TAMR,	XR	and	T47D	TAMR	cells	(cultured	under	the	same	conditions	as	those	used	to	 generate	 the	 samples	 for	microarray	gene	expression	profiling).	 In	 agreement	with	the	microarray	profile,	CLU-S	mRNA	expression	was	significantly	(p	<0.01)	up	regulated	 in	 the	 XR	 cell	 line	 compared	 to	 control	 (Figure	 96B).	 However,	 in	 the	TAMR	 cells,	 CLU-S	 expression	was	 less	 than	MCF-7	 control	 (Figure	 96A).	 In	 the	T47D	 TAMR	 cell	 line,	 CLU-S	 expression	 was	 significantly	 (p	 <0.05)	 increased	versus	control	(Figure	96C).	Interestingly,	nuclear	CLU	mRNA	was	not	detected	by	PCR	in	any	of	the	three	antihormone-resistant	cell	lines	(Figure	96).		
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Figure	96	Representative	PCR	images	from	three	independent	experiments	showing	pro-
survival	 CLU	 isoform	 (CLU-S)	 and	 pro-apoptotic	 nuclear	 CLU	 isoform	 (CLU-N)	 RNA	
expression	and	β-actin	loading	control	in	tamoxifen	resistant	(TAMR)	(A)	and	oestrogen	
deprived-resistant	 (XR)	 (B)	MCF-7	 cells	 versus	 parental	 cells	 and	TAMR	T47D	 cells	 (C)	
versus	 parental	 cells.	 The	 corresponding	 β-actin	 normalised	 densitometry	 graphs	
showing	 CLU-S	 expression	 in	 the	 three	 cell	 lines	 is	 also	 shown,	 expressed	 as	means	 ±	
SEM.	The	data	were	analysed	by	an	unpaired	T-test.	*	p	<0.05;	**	p	<0.01	
B
C
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6.3.2 CLU-S	protein	expression	in	resistance	CLU-S	 expression	 was	 next	 examined	 at	 the	 protein	 level	 by	 Western	 blotting.	Western	 blotting	 was	 performed	 on	 triplicate	 protein	 samples	 from	 wild	 type	control	and	TAMR,	XR	and	T47D	TAMR	cells	(cultured	under	the	same	conditions	as	 those	used	 to	generated	 the	samples	 for	microarray	gene	expression	profiling	and/or	RT-PCR).	As	previously	revealed	in	Chapter	3,	CLU-S	exists	as	a	precursor	and	 a	mature	 form	 composed	 of	 α-	 and	 β-subunits.	 The	 secretory	 CLU	 antibody	used	within	this	project	recognises	the	60	kDa	precursor	and	40	kDa	CLUα	subunit.	In	 agreement	 with	 the	 previous	 microarray	 and	 PCR	 data,	 Western	 analysis	revealed	a	significant	(p	<0.05)	increase	in	CLU-S	precursor	and	a	marked	increase,	although	not	significant,	in	CLUα	expression	in	the	XR	cell	line	compared	to	control	(Figure	97B).	In	the	TAMR	cell	 line,	a	small	and	non-significant	increase	in	CLU-S	precursor	and	CLUα	protein	expression	was	apparent	versus	control	(Figure	97A).	However,	in	comparison	to	the	XR	cell	line,	CLU-S	precursor	and	CLUα	expression	was	 evidently	 weaker	 in	 the	 TAMR	 cells.	 In	 the	 T47D	 TAMR	 and	 control	 cells,	CLU-S	 precursor	 protein	 expression	 was	 strong,	 whereas	 CLUα	 expression	 was	markedly	 less,	 with	 similar	 expression	 levels	 in	 the	 control	 and	 resistant	 cells	observed	(Figure	97C).		
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Figure	 97	 Representative	 Western	 blot	 images	 and	 corresponding	 β-actin	 normalised	 densitometry	 graphs	 from	 three	 independent	
experiments	showing	pro-survival	CLU	isoform	precursor	(green	graphs)	and	CLUα	(red	graphs)	protein	expression	in	tamoxifen	resistant	
(TAMR)	(A)	and	oestrogen	deprived-resistant	(XR)	(B)	MCF-7	cells	versus	parental	cells	and	TAMR	T47D	cells	(C)	versus	parental	cells.	The	
results	are	expressed	as	means	±	SEM.	The	data	were	analysed	by	an	ANOVA	and	post-hoc	Tukey’s	multiple	comparisons	test	.	*	p	<0.05.	
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6.3.3 CLU	knockdown	Targeted	CLU	knockdown,	via	siRNA,	was	performed	to	investigate	whether	CLU-S	promotes	 cell	 survival	 or	 proliferation	 during	 antihormone	 response	 and	resistance	 and	 to	 determine	 whether	 such	 knockdown	 can	 enhance	 the	 growth	inhibitory	 actions	 of	 antihormones	 during	 response	 and/or	 reverse	antihormone-resistance.	 The	 CLU	 siRNA	 utilised	 comprised	 of	 a	 pool	 of	 4	 siRNA	targeting	 different	 regions	 of	 the	 mRNA	 for	 optimal	 knockdown.	 Consequently,	total	CLU	was	 targeted	 for	knockdown	as	opposed	 to	 specific	CLU-S	knockdown.	However,	Prochnow	et	al.	have	shown	that	CLU-S	represents	the	most	abundant	(>	99%)	CLU	form	in	several	cell	lines,	including	MCF-7	cells295.	
6.3.3.1 Antihormone	response	Since	 CLU-S	 expression	 is	 very	 weak	 in	 wild	 type	 MCF-7	 and	 T47D	 cells	 (as	previously	demonstrated	by	Western	blotting	in	Chapter	4,	Figure	49),	CLU	siRNA	was	 combined	 with	 fulvestrant	 treatment	 to	 induce	 CLU-S	 expression	 to	subsequently	allow	the	effect	of	CLU	knockdown	to	be	examined.	Consistent	with	BCL3	knockdown	performed	 in	Chapter	5,	MCF-7	and	T47D	cells	were	 incubated	with	CLU	siRNA	for	2	days	prior	to	the	addition	of	fulvestrant	for	a	further	2	days.		The	 magnitude	 of	 CLU	 knockdown,	 specifically	 the	 CLU-S	 isoform,	 in	fulvestrant-treated	MCF-7	and	T47D	cells	was	examined	at	the	mRNA	and	protein	level.	As	demonstrated	in	Figure	98,	2	day	fulvestrant	treatment	(depicted	by	the	‘media’	treatment	arm)	induced	up	regulation	of	CLU-S	mRNA	expression	in	MCF-7	and	 to	 a	 greater	 degree	 in	 T47D	 cells	 compared	 to	 untreated	 control.	 Similarly,	lipid	and	control	siRNA	treatment	combined	at	day	2	with	fulvestrant	for	a	further	48	 hours	 induced	 similar	 CLU-S	 mRNA	 expression	 to	 fulvestrant	 alone	 (‘media’	arm)	in	the	MCF-7	and	T47D	cells,	indicating	that	the	lipid	and	control	siRNA	had	no	 effect	 on	 CLU-S	 expression.	 CLU	 siRNA	 treatment	 (comprised	 of	 2	 day	 CLU	siRNA	 incubation	prior	 to	a	 further	2	days	combined	with	 fulvestrant	 treatment)	successfully	reduced	CLU-S	mRNA	expression	in	the	MCF-7	and	T47D	cell	lines.		Disappointingly,	 due	 to	 problems	 and	 difficulties	 with	 Western	 blotting	experiments,	CLU-S	knockdown	in	fulvestrant-treated	MCF-7	and	T47D	cells	could	not	be	verified	at	the	protein	level.		
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Figure	98	Representative	PCR	images	from	three	independent	experiments	showing	the	
mRNA	expression	of	the	pro-survival	CLU	isoform	(CLU-S)	and	β-actin	loading	control	in	
(A)	MCF-7	 and	 (B)	T47D	 cells	 treated	with	media	only,	 lipid	only,	 unscrambled	 control	
small	 interfering	 RNA	 (CON	 siRNA)	 and	 CLU	 siRNA	 for	 2	 days	 prior	 to	 the	 addition	 of	
fulvestrant	(FAS;	10-7	M)	for	a	further	2	days.	Untreated	control	is	also	shown.	
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6.3.3.2 Antihormone	resistance	In	 contrast	 to	 wild	 type	 antihormone	 responsive	 MCF-7	 and	 T47D	 cells,	 the	antihormone-resistant	 cell	 models,	 particularly	 XR	 and	 T47D	 TAMR	 cells,	constitutively	 express	 CLU-S	 with	 weaker	 protein	 expression	 detected	 in	 TAMR	cells,	 as	 previously	 demonstrated	 in	 Figure	 97.	 Therefore,	 CLU	 knockdown	 was	simply	 induced	 via	 4	 day	 incubation	 with	 CLU	 siRNA.	 The	 magnitude	 of	 CLU-S	knockdown	was	examined	at	the	mRNA	and	protein	level.	At	the	messenger	level,	CLU-S	expression	in	TAMR	and	XR	cells	was	not	affected	by	4	day	lipid	and	control	siRNA	incubations.	However	a	small	decrease	in	CLU-S	expression	was	apparent	in	the	control	siRNA-treated	T47D-TAMR	cells	compared	to	 lipid	and	control	which	was	mirrored	by	a	decrease	 in	actin	expression	(Figure	99).	Four	day	CLU	siRNA	incubation	 induced	 down	 regulation	 of	 CLU-S	 mRNA	 expression	 in	 the	 three	antihormone	resistant	cell	models.		
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Figure	99	Representative	PCR	images	from	three	independent	experiments	showing	pro-
survival	 secretory	 CLU	 (CLU-S)	 mRNA	 expression	 and	 β-actin	 loading	 control	 in	 (A)	
tamoxifen-resistant	 (TAMR)	 and	 (B)	oestrogen	 deprivation-resistant	 (XR)	 cells	derived	
from	 MCF-7	 cells	 and	 (C)	 T47D-TAMR	 cells	 treated	 with	 media	 only,	 lipid	 only,	
unscrambled	control	small	interfering	RNA	(CON	siRNA)	and	CLU	siRNA	for	4	days.	
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At	the	protein	level,	lipid	and	control	siRNA	had	no	effect	on	CLUα	expression	in	XR	cells	 (Figure	100A).	 In	 agreement	with	 the	PCR	data,	 4	day	 incubation	with	CLU	siRNA	 resulted	 in	 a	 substantial	 decrease	 in	 CLUα	protein	 expression	 in	 XR	 cells.	Interestingly,	CLU-S	precursor	protein	was	not	detected	in	XR	cells	irrespective	of	treatment.	 Similarly,	 in	 the	T47D-TAMR	cell	 line,	 lipid	 and	 control	 siRNA	had	no	effect	on	the	protein	expression	of	CLU-S	precursor	and	CLUα,	whereas	CLU	siRNA	resulted	in	a	decrease	in	expression	of	both	proteins	compared	to	control	(Figure	100B).	Unfortunately,	CLU-S	expression	could	not	be	detected	in	the	TAMR	cell	line	(Figure	100A).	This	 is	unsurprising	 since	CLU-S	protein	expression	 in	 these	 cells	has	been	previously	demonstrated	to	be	very	weak	(Figure	97A).		
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Figure	 100	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	 pro-survival	 CLU	 isoform	 precursor	 and	 CLUα	 protein	 expression	 and	 β-actin	
loading	 control	 in	 (A)	 tamoxifen-resistant	 (TAMR)	 and	 (B)	 oestrogen	 deprivation-
resistant	 (XR)	 cells	 derived	 from	 MCF-7	 cells	 and	 (C)	 T47D-TAMR	 cells	 treated	 with	
media	only,	 lipid	only,	unscrambled	control	small	interfering	RNA	(CON	siRNA)	and	CLU	
siRNA	for	4	days.	
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6.3.4 Effect	of	CLU	knockdown	on	cell	growth	during	antihormone-response	
and	–resistance	Following	 the	 establishment	 of	 substantial	 CLU-S	 knockdown	 in	 the	antihormone-responsive	and	–resistant	cell	 lines,	cell	counting	experiments	were	next	 performed	 to	 determine	 whether	 CLU-S	 expression	 has	 any	 effect	 on	 cell	growth.	The	rationale	was	that	a	decrease	in	cell	number/cell	growth	mediated	by	CLU	siRNA,	suggests	that	CLU	plays	a	role	in	promoting	cell	growth	potentially	via	increasing	cell	proliferation	or	survival.		
6.3.4.1 Antihormone	response	As	 illustrated	 in	 Figure	 101A,	 CLU	 knockdown	 (2	 day	 CLU	 siRNA	 incubation	followed	 by	 fulvestrant	 treatment	 for	 a	 further	 2	 days)	 reduced	 cell	 growth	 of	fulvestrant-treated	 MCF-7	 cells	 by	 approximately	 20%	 compared	 to	 control.	However,	 this	 reduction	 was	 not	 significant.	 Targeted	 CLU	 knockdown	 had	 no	effect	on	the	growth	of	fulvestrant-treated	T47D	cells	(Figure	101B).		
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Figure	101	Effect	of	CLU	knockdown	(2	day	CLU	siRNA	followed	by	2	day	fulvestrant	
(FAS;	10-7	M))	compared	to	control	 (CON	siRNA;	2	day	CON	siRNA	followed	by	2	day	
FAS)	and	FAS	alone	on	 the	growth	of	 (A)	MCF-7	and	 (B)	T47D	cells.	The	results	 are	
expressed	as	 the	means	±	 SEM	of	 three	 independent	experiments	 and	presented	as	
the	 %	 of	 the	 control.	 The	 data	 were	 analysed	 by	 an	 ANOVA	 and	 post-hoc	 Tukey’s	
multiple	comparisons	test.	
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6.3.4.2 Antihormone	resistance	During	 antihormone	 resistance,	 targeted	 down	 regulation	 of	 CLU	 using	 siRNA	resulted	 in	 a	 small	 and	 non-significant	 decrease	 in	 TAMR	 cell	 growth	 (Figure	102A).	 However,	 CLU	 knockdown	 was	 without	 effect	 on	 the	 growth	 of	 XR	 and	T47D-TAMR	cells	(Figure	102B	and	C).			
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Figure	102	 Effect	 of	 CLU	knockdown	 (4	 day	CLU	 siRNA)	 compared	 to	 control	 (CON	
siRNA;	4	day	CON	siRNA)	on	the	growth	of	(A)	tamoxifen-resistant	(TAMR;	n=4)	and	
(B)	oestrogen	deprivation-resistant	(XR;	n=3)	cells	derived	from	MCF-7	cells	and	(C)	
T47D-TAMR	 (n=2)	 cells.	 The	 results	 are	 expressed	 as	 the	 means	 ±	 SEM	 and	
presented	 as	 the	 %	 of	 the	 control.	 The	 TAMR	 and	 XR	 data	 were	 analysed	 by	 an	
ANOVA	and	post-hoc	Tukey’s	multiple	comparisons	test.	
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6.3.5 Cellular	localisation	of	CLU-S	during	antihormone-response	
and	-resistance	
6.3.5.1 Immunofluorescence		As	 previously	 described,	 CLU	 has	 two	 main	 isoforms,	 exhibiting	 functionally	distinct	 activities.	 The	 nuclear	 isoform	 promotes	 cell	 death	 whereas	 the	cytoplasmic	 secretory	 isoform	 promotes	 cell	 survival.	 Thus,	 cellular	 localisation	studies,	 via	 immunofluorescence,	were	 next	 performed	 to	 determine	 the	 cellular	localisation	of	CLU-S	during	antihormone-response	and	–resistance.		Interestingly,	 during	 antihormone	 response	 in	MCF-7	 cells,	 immunofluorescence	studies	 revealed	 relatively	 equal	 staining	 of	 CLU-S	 in	 the	 nucleus	 and	 cytoplasm	(Figure	 103).	 In	 agreement	 with	 previous	 PCR	 and	Western	 blotting	 data,	 very	little,	if	any,	CLU-S	was	identified	by	immunofluorescence	in	untreated	control	and	E2-treated	MCF-7	cells	(Figure	103).			
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Figure	103	Immunofluorescence	images	of	MCF-7	cells	 treated	with	oestradiol	 (E2;	10-9	M),	untreated	control	 (CON),	tamoxifen	(TAM;	10-7	
M),	fulvestrant	 (FAS;	10-7	M)	and	oestrogen	deprivation	(ED)	for	7	days.	Cells	were	stained	with	CLU-S/CLUα	primary	antibody,	followed	by	
staining	with	Alexa-fluor	594-conjugated	secondary	antibody	(red)	and	counterstained	with	the	nuclear	dye	DAPI	(blue).	Magnification:	x63.	
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During	 antihormone	 resistance,	 a	 similar	 CLU-S	 cellular	 localisation	 profile	 was	observed	to	antihormone	response.	 Indeed,	 in	the	TAMR	and	XR	cells,	CLU-S	was	located	 both	 in	 the	 cytoplasm	 and	 nucleus	 (Figure	 104).	 Interestingly,	 nuclear	CLU-S	appeared	stronger,	and	cytoplasmic	CLU-S	appeared	weaker,	in	the	XR	cells	versus	the	TAMR	cells.				
	
Figure	 104	 Immunofluorescence	 images	 of	 tamoxifen-resistant	 (TAMR)	 and	
oestrogen	 deprivation-resistant	 (XR)	 cells.	 Cells	 were	 stained	 with	 CLU-S/CLUα	
primary	 antibody	 followed	 by	 staining	 with	 Alexa-fluor	 594-conjugated	 secondary	
antibody	and	counterstained	with	the	nuclear	dye	DAPI	(blue).	Magnification:	x63.	
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6.3.5.2 Cellular	fractionation	and	subsequent	Western	blotting	CLU-S	 is	 a	 cytoplasmic	 secretory	 protein.	 However,	 immunofluorescence	 studies	revealed	 equal	 expression	 of	 the	 protein	 in	 the	 nucleus	 and	 cytoplasm.	 Thus	 to	verify	 this	 data,	 cellular	 fractionation	 and	 subsequent	 Western	 blotting	 studies	were	next	performed	in	untreated	MCF-7,	TAMR	and	XR	cells.	 In	agreement	with	the	immunofluorescence	studies,	very	little	CLU-S	expression	was	detected	in	the	untreated	MCF-7	cells	(Figure	105).	Additionally,	CLU-S	expression	was	observed	in	 the	 cytoplasm	 of	 TAMR	 and	 XR	 cells,	 however	 in	 contrast	 to	 the	immunofluorescence	 data,	 very	 little	 CLU-S	 expression	 was	 apparent	 in	 the	nucleus	of	such	cells	(Figure	105).	The	SP-1	nuclear	transcription	factor	was	used	as	a	nuclear	marker	and	as	demonstrated	 in	Figure	105	 it	was	only	expressed	 in	the	 nucleus.	 However,	 although	 strongly	 expressed	 in	 the	 cytoplasm,	 some	expression	of	 the	 cytoplasmic	marker,	Grb2,	was	detected	 in	 the	nucleus	 (Figure	105).		
	
	
Figure	 105	 Representative	 Western	 blot	 images	 from	 three	 independent	 experiments	
showing	pro-survival	CLU	isoform	precursor	and	CLUα	protein	expression,	SP-1	nuclear	
marker	 and	 Grb2	 cytoplasmic	 marker	 in	 the	 cytoplasmic	 and	 nuclear	 fractions	 of	
untreated	MCF-7,	 tamoxifen	resistant	 (TAMR)	and	oestrogen	deprivation	resistant	 (XR)	
cells.	
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6.4 Discussion	Extensive	microarray	gene	profiling,	together	with	Western	blotting,	in	Chapters	3	and	4	identified	CLU	as	an	antihormone-induced	protein	up	regulated	by	all	three	antihormone	treatments	in	four	ER+	breast	cancer	cell	lines,	encompassing	HER2+	and	 HER2-	 disease,	 with	 increased	 expression	 maintained	 through	 to	 the	emergence	of	resistance.	Thus,	in	this	Chapter	preliminary	studies	were	performed	to	 explore	 the	 hypothesis	 that	 CLU	 is	 a	 pro-survival	 gene,	 induced	 early	 during	antihormone	 response	 and	 functions	 to	 allow	 a	 cohort	 of	 tumour	 cells	 to	 evade	antihormone	 challenge,	 and	 subsequently	 contributes	 to	 the	 limited	 efficacy	 of	these	agents	and	ultimately	the	development	of	resistance.		CLU	has	been	widely	studied	in	breast	cancer,	where	it	has	been	demonstrated	to	promote	 cell	 survival,	 invasion	 and	metastasis	 and	ultimately	 contribute	 to	poor	patient	survival335,336.	However,	the	role	of	CLU	during	antihormone-	response	and	-resistance	 remains	 largely	 unexplored.	 Initially,	 the	 expression	 of	 CLU	 in	antihormone-resistant	cell	models	was	examined.	The	microarray	gene	expression	profile	 of	 CLU	 in	 antihormone-resistant	 TAMR	 and	 XR	 cells	 was	 verified	 at	 the	messenger	 and	protein	 levels.	However,	 in	 comparison	 to	 the	microarray	 ‘jetset’	probe	 which	 was	 complementary	 to	 both	 nuclear	 and	 CLU-S	 isoforms,	 the	 PCR	primers	 and	 CLU	 antibody	were	 specific	 to	 the	 pro-survival	 CLU-S	 isoform.	 The	CLU	antibody	recognised	the	CLUα	chain	together	with	the	60	kDa	CLU	precursor	protein.	 In	 agreement	 with	 the	 microarray	 data,	 CLU-S	 mRNA	 and	 protein	expression	 (CLUα	 and	 precursor)	 was	 increased	 in	 the	 XR	 cells	 versus	 control.	Similarly,	 CLU-S	protein	 expression	 (CLUα	 and	precursor)	 in	TAMR	 cells	was	up	regulated	 versus	 control.	 Interestingly,	 CLU-S	 protein	 expression	 was	 markedly	less	in	the	TAMR	cell	line	compared	to	the	XR	cells.	To	 consider	 the	 heterogeneity	 of	 breast	 cancer,	 CLU-S	 expression	 was	 also	examined	in	a	tamoxifen-resistant	model	derived	from	T47D	cells.	Similarly,	CLU-S	mRNA	 expression	 was	 increased	 in	 these	 resistant	 cells	 compared	 to	 control.	However,	at	the	protein	level,	relatively	equal	expression	of	the	precursor,	with	a	small	 increase	 in	 CLUα	 was	 apparent	 between	 the	 control	 and	 resistant	 cells.	Interestingly,	 in	 contrast	 to	 the	 wild	 type	 MCF-7	 cells,	 strong	 CLU	 precursor	protein	 expression	 was	 apparent	 in	 the	 wild	 type	 T47D	 cells.	 Surprisingly,	 CLU	
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precursor	 protein	was	 not	 apparent	 in	 untreated	 T47D	 cells	 cultured	 in	 FCS	 (as	previously	demonstrated	in	Chapter	4,	Figure	50),	but	was	apparent	in	untreated	T47D	cells	cultured	in	sFCS.	These	differences	are	likely	due	to	the	growth	factors	present	 in	 FCS	 potentially	 cross-talking	 with	 the	 ER	 to	 promote	 CLU	 down	regulation,	which	is	not	mediated	in	the	presence	of	growth	factor-depleted	sFCS.	In	 support	 of	 this,	 Chapter	 4	 previous	 revealed	 that	 CLU	 is	 ER	 regulated:	 E2	suppressed,	 and	 antihormones	 induced,	 CLU	 expression.	 Together,	 these	 studies	demonstrate	increased	CLU-S	expression	in	antihormone-resistant	cells	compared	to	parental	control	cells.		To	 our	 knowledge	 this	 is	 the	 first	 study	 to	 identify	 CLU	 expression	 in	antihormone-resistant	breast	cancer	cells.	However,	Toffanin	et	al.	and	Cappelletti	et	 al.	 have	 reported	 increased	 CLU-S	 expression	 in	 antihormone-resistant	 T47D	cells	 versus	 antihormone-sensitive	MCF-7	 cells309,338.	 Since	 3	 day	 tamoxifen	 and	toremifene	treatment	led	to	an	increase	in	T47D	cell	growth,	the	authors	deemed	the	cell	 line	antihormone	resistant.	However,	 this	 is	 in	 significant	contrast	 to	 the	literature,	 whereby	 T47D	 cells	 have	 been	 long	 established	 as	 antihormone	sensitive.	 Indeed,	 E2	 stimulates	 T47D	 cell	 proliferation	 which	 is	 inhibited	 by	tamoxifen	 within	 48	 hours405–407.	 A	 clinical	 study	 examining	 the	 effects	 of	toremifene	 in	 breast	 cancer	 patients	 prior	 to	 surgery	 revealed	 an	 association	between	increased	CLU	expression	and	poor	antihormone	response309.		Following	 the	 identification	 of	 increased	 CLU-S	 expression	 in	 antihormone	resistance,	 together	with	 increased	 expression	 during	 antihormone	 response	 (as	demonstrated	 in	Chapters	3	and	4,	Figure	38	and	Figure	50),	 subsequent	studies	aimed	to	determine	whether	CLU-S	expression	contributed	to	the	limited	efficacy	of	 antihormones	 and	 the	 consequent	 development	 of	 resistance.	 Transient	 CLU	knockdown	studies,	utilising	 siRNA,	were	performed	and	 the	effect	on	growth	of	antihormone-treated	 and	 antihormone-resistant	 cells	 was	 examined.	 Since	untreated	 MCF-7	 and	 T47D	 cells	 express	 very	 little,	 if	 any,	 CLU-S,	 fulvestrant	treatment	was	combined	with	siRNA	to	induce	CLU-S	expression	to	allow	the	effect	of	subsequent	knockdown	on	cell	growth	to	be	determined.	CLU	knockdown	was	performed	by	 incubating	 the	 cells	 for	2	days	with	 siRNA	prior	 to	 the	addition	of	fulvestrant	 for	 a	 further	 2	 days.	 CLU-S	 knockdown	was	 confirmed	 at	 the	mRNA	
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level.	 Unfortunately,	 due	 to	 difficulties	with	Western	 blotting,	 CLU-S	 knockdown	could	not	be	verified	at	 the	protein	 level.	Since	 this	Western	blot	was	performed	towards	the	end	of	the	project,	 it	 is	possible	that	the	CLU	antibody	may	have	lost	its	activity.		With	regard	to	the	antihormone-resistant	cells,	CLU-S	is	constitutively	expressed,	thus	 targeted	 gene	 knockdown	 was	 achieved	 by	 4	 day	 incubation	 with	 siRNA.	CLU-S	knockdown	was	 confirmed	at	 the	messenger	and	protein	 levels	of	XR	and	T47D-TAMR	cells,	but	could	only	be	verified	at	the	mRNA	level	in	TAMR	cells.	This	is	not	surprising,	since	protein	expression	of	CLU-S	was	previously	demonstrated	to	be	very	weak	in	this	cell	line	compared	to	the	other	resistant	cells.	Importantly,	CLU	siRNA	comprised	of	a	pool	of	4	siRNA	complementary	to	different	regions	of	the	mRNA	and	therefore	not	specific	to	CLU-S.	Since	CLU-S	and	nuclear	CLU	have	very	similar	mRNA	sequences,	apart	 from	the	 latter	 lacking	exon	2,	 it	 is	 strongly	possible	that	this	isoform	was	also	targeted	for	knockdown.	However,	since	CLU-S	represents	more	 than	 99%	 of	 total	 CLU	 in	MCF-7	 cells295,	 it	 is	 likely	 that	 down	regulation	of	the	nuclear	isoform	is	insignificant.		Transient	 CLU	 knockdown	 resulted	 in	 a	 small	 decrease	 in	 fulvestrant-treated	MCF-7	 cell	 growth	 but	 was	 without	 effect	 on	 the	 growth	 of	 fulvestrant-treated	T47D	cells.	This	suggests	that	CLU/CLU-S	may	play	a	role	in	the	limited	efficacy	of	fulvestrant	during	antihormone	response	in	MCF-7	cells	and	its	targeting	alongside	antihormones	 may	 improve	 the	 growth	 inhibitory	 actions	 of	 these	 agents.	 The	growth	promoting	role	of	CLU/CLU-S	may	be	more	enhanced	following	stable	gene	knockdown.	However,	CLU-S	knockdown	could	not	be	verified	at	the	protein	level,	as	previously	discussed.	Therefore,	it	is	possible	that	the	magnitude	of	knockdown	was	 greater	 in	 the	 MCF-7	 cells	 versus	 the	 T47D	 cells,	 or	 perhaps	 the	 mRNA	knockdown	was	not	 translated	 into	 knockdown	 at	 the	 protein	 level	 in	 the	T47D	cells.	 Alternatively,	 since	 more	 than	 150	 proteins	 are	 differentially	 expressed	between	both	MCF-7	and	T47D	cells	as	previously	discussed	in	Chapter	4409,	 it	 is	not	surprising	that	CLU	knockdown	exerts	different	effects	on	the	growth	of	both	cell	lines.	Indeed,	CLU	may	regulate	the	activity	of	a	protein	expressed	only	in	the	MCF-7	cells	to	promote	cell	growth,	with	such	a	protein	mutated	in	T47D	cells	and	therefore	not	 regulated	by	CLU	 to	promote	cell	 growth.	 In	agreement	with	 these	
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findings,	Redondo	et	al.	have	demonstrated	a	 significant	 increase	 in	cell	death	of	tamoxifen-treated	 MCF-7	 cells	 plus	 antisense	 CLU	 oligonucleotide	 versus	tamoxifen	 treatment	 alone339.	 Similarly,	 down	 regulation	 of	 CLU-S	 via	 siRNA	 in	tamoxifen-treated	MCF-7	cells	has	been	shown	to	promote	a	small	decrease	in	cell	growth338.		Interestingly,	 CLU	 knockdown	 had	 no	 effect	 on	 the	 growth	 of	antihormone-resistant	 cell	 models.	 This	 suggests	 that	 during	 response	 to	fulvestrant,	CLU	 transiently	promotes	 the	growth	and/or	survival	of	MCF-7	cells,	possibly	facilitating	and	allowing	the	re-organisation	of	cellular	networks	and	the	emergence	 of	 the	 dominant	 EGFR/HER2-driven	 MAPK	 and	 AKT	 signalling	pathways	 to	 promote	 resistant	 cell	 growth.	 Toffanin	 et	 al.	 have	 reported	 a	significant	 decrease	 in	 T47D	 (deemed	 antihormone-resistant,	 as	 previously	discussed	above)	cell	growth	following	CLU-S	knockdown338.	However,	such	effects	were	 not	 significant	 in	 tamoxifen-treated	 T47D	 cells	 plus	 CLU-S	 knockdown,	possibly	 due	 to	 tamoxifen-induced	 increased	 CLU-S	 expression	 in	 these	 cells.	Interestingly,	 it	 was	 strongly	 apparent	 in	 Toffanin	 et	 al.'s	 study	 that	 down	regulation	 of	 CLU-S	 in	 T47D	 cells	 promoted	 a	 greater	 effect	 on	 cell	 growth	compared	to	knockdown	of	both	the	CLU-S	and	nuclear	isoforms338.	This	suggests	that	 the	 pro-apoptotic	 nuclear	 CLU	 form	may	 play	 a	 role	 in	 T47D	 cells	 and	may	represent	a	larger	percentage	of	total	CLU	present	in	this	cell	line	compared	to	the	<1%	previously	reported	in	MCF-7	cells295.	Increased	expression	of	pro-apoptotic	nuclear	 CLU	 in	 T47D	 cells	 may	 have	 contributed	 to	 the	 lack	 of	 effect	 of	 CLU	knockdown	 on	 the	 growth	 of	 T47D	 cells	 versus	 MCF-7	 cells,	 since	 the	 nuclear	isoform	is	likely	to	have	been	down	regulated	together	with	CLU-S.	Thus,	since	this	project	 is	 interested	 in	 the	 pro-survival	 role	 of	 CLU,	 further	 studies	 specifically	down	 regulating	 the	 CLU-S	 isoform	 are	 necessary	 to	 precisely	 examine	 its	 role	without	 contamination	 from	 the	 nuclear	 isoform.	 Such	 studies	 should	 include	apoptosis	assays	and	cell	cycle	analysis	to	determine	whether	CLU-S	promotes	cell	survival	 (thus	supporting	 the	hypothesis	 that	 it	 is	 indeed	a	pro-survival	gene)	or	cell	proliferation	during	antihormone-response	and	–resistance.	Studies	 in	 triple	negative	breast	 cancer	cell	 lines	have	reported	a	 significant	 role	for	 CLU-S	 in	 tumour	 growth	 and	 metastatic	 progression.	 Indeed,	 CLU-S	 was	
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demonstrated	 to	 promote	 cell	 survival	 via	 inhibiting	 apoptosis	 as	 well	 as	increasing	the	ability	of	cells	to	survive	the	multiple	stages	of	metastasis337.	Similar	roles	 of	 CLU-S	 may	 be	 identified	 in	 ER+	 disease,	 or	 perhaps	 such	 unfavourable	effects	are	confined	to	the	more	aggressive	ER-	phenotype.	Interestingly,	a	strong	link	 between	 HER2	 signalling	 and	 CLU	 expression	 has	 been	 demonstrated	 in	ER+/HER2+	 BT474	 breast	 cancer	 cells.	 Biroccio	 et	 al.	 demonstrated	 that	trastuzumab	 treatment	 induces	 CLU	 protein	 expression	 in	 BT474	 cells408.	Furthermore,	 CLU	 inhibition	 increased	 the	 growth	 inhibitory	 action	 of	trastuzumab	together	with	increasing	apoptosis,	suggesting	that	CLU	may	exhibit	a	pro-survival	 role,	 induced	 by	 trastuzumab.	 Thus,	 it	 is	 plausible	 that	antihormone-induced	CLU-S	expression	may	play	a	role	in	promoting	cell	survival	which	 may	 be	 reversed	 by	 specific	 targeting	 of	 CLU-S	 alongside	 antihormone	therapy.	Similarly,	 in	hormone-dependent	prostate	 cancer,	 androgen	withdrawal,	chemotherapy	 and	 radiation	 therapy	 induce	 CLU-S	 expression,	 with	 such	expression	providing	a	protective	role	against	apoptotic	cell	death	and	is	therefore	associated	 with	 disease	 progression377,442,443.	 Inhibition	 of	 CLU-S	 expression	 in	prostate	cancer	cells	enhances	TNFα-mediated	apoptosis444,	potentially	identifying	CLU-S	as	a	valid	target	for	new	cancer	treatment.	An	 antisense	 oligonucleotide	 blocking	 CLU-S	 mRNA,	 OGX-011,	 is	 currently	 in	clinical	development.	In	a	Phase	II	trial	of	OGX-011	in	combination	with	docetaxel	in	metastatic	breast	cancer,	OGX-011	was	well	tolerated	and	decreased	CLU	levels,	however	 the	 number	 of	 responses	 were	 limited	 and	 insufficient	 to	 meet	 the	criteria	for	proceeding	to	the	second	stage	of	accrual342.	This	may	be	due	in	part	to	the	 limited	 sample	 size.	 In	 contrast,	 several	 trials	 have	 examined	 OGX-011	treatment	in	prostate	cancer	patients,	with	promising	results.	Indeed,	in	a	Phase	II	trial	 of	 OGX-011	 in	 combination	 with	 docetaxel	 and	 prednisone,	 in	chemotherapy-naïve	patients	with	metastatic	castration-resistant	prostate	cancer	(mCRPC),	OGX-011	was	well	tolerated	and	markedly	improved	survival	compared	to	docetaxel	and	prednisone	alone	(23.8	months	versus	16.9	months)382.	Similarly,	in	 mCRPC	 patients	 progressing	 on	 first-line	 docetaxel,	 OGX-011	 plus	 docetaxel	(Phase	 II)	 was	 shown	 to	 be	 a	 feasible	 and	 safe	 second-line	 treatment,	 with	
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increased	 pain	 relief445.	 Subsequent	 Phase	 III	 trials	 evaluating	 OGX-011	 in	combination	with	chemotherapy	in	prostate	cancer	patients	are	underway.	Several	studies	have	demonstrated	potential	mechanisms	by	which	CLU	promotes	cell	 survival.	 For	 example,	 CLU	 has	 been	 reported	 to	 bind	 to	 the	 pro-apoptotic	protein	 Bax,	 interfering	 with	 its	 activation	 and	 subsequently	 preventing	downstream	 apoptosis344.	 Such	 an	 interaction	 between	 CLU	 and	 Bax,	 by	co-immunoprecipitation,	 has	 been	 demonstrated	 in	 tamoxifen-treated	 MCF-7	cells344.	Moreover,	CLU	has	been	shown	to	regulate	NF-κB	actions.	In	MCF-7	cells,	overexpression	of	CLU-S	has	been	demonstrated	to	promote	NF-κB	activation	and	transcription	 of	 downstream	 pro-survival	 genes,	 particularly	 BCL2,	 which	subsequently	 prevents	 TNFα-induced	 apoptosis446.	 Targeted	 down	 regulation	 of	the	p65	subunit	of	NF-κB	enhanced	the	sensitivity	of	CLU-S-overexpressing	MCF-7	cells	to	TNFα-mediated	apoptosis,	confirming	the	significant	role	of	p65/NF-κB	in	this	 pathway.	 Similarly,	 in	 prostate	 cancer	 cells,	 CLU-S	 has	 been	 reported	 to	promote	 IκB	 degradation,	 thus	 allowing	 nuclear	 translocation	 of	 NF-κB	 and	increasing	 transcription	 of	 genes	 implicated	 in	 cell	 survival	 and	 proliferation349.	Another	 mechanism	 involved	 in	 CLU-S	 pro-survival	 activity	 is	 by	 modulating	ERK1/2	activity347.	ERK1/2	are	members	of	 the	MAPK	super	 family	 that	mediate	cell	 proliferation	 and	 survival	 and	 have	 been	 largely	 implicated	 in	 endocrine	resistance447–450.	 In	 chemo	 resistant	 pancreatic	 cancer	 cells,	 CLU	 silencing	 via	OGX-011	has	been	shown	to	re-sensitise	the	cells	to	chemotherapy	via	inhibition	of	chemotherapy-induced	CLU-ERK1/2	activation345.	Similarly	in	osteosarcoma	cells,	increased	 CLU-S	 expression	 has	 been	 reported	 to	 promote	 cell	 growth	 and	increase	chemo	resistance	via	activation	of	ERK1/2	347.	The	functionally	distinct	CLU	isoforms,	involved	in	apoptosis	and	cell	survival,	are	located	 in	 the	 nucleus	 and	 cytoplasm,	 respectively.	 Thus,	 to	 clarify	 the	 cellular	localisation	 of	 CLU-S	 during	 antihormone-response	 and	 –resistance,	immunofluorescence	 studies	 were	 performed.	 Unexpectedly,	 CLU-S	 (CLU	precursor	and	CLUα)	staining	was	identified	equally	in	the	cytoplasm	and	nucleus	of	MCF-7	cells	treated	with	antihormones	and	in	the	TAMR	and	XR	cell	models.	A	major	 limitation	 of	 the	 fluorescence	 microscopy	 used	 in	 this	 project	 for	distinguishing	 nuclear	 and	 cytoplasmic	 protein	 expression	 is	 the	 contribution	 of	
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signals	 from	 structures	 above	 and	 below	 the	 plane	 of	 focus	 as	 a	 result	 of	illuminating	 the	whole	specimen451	 i.e.	 the	 fluorescent	signal	 from	the	cytoplasm	above	and	below	the	nucleus.	Therefore,	it	is	possible	that	the	nuclear	staining	of	CLU-S	 observed	 was	 indeed	 that	 from	 the	 cytoplasm.	 Possible	 means	 of	circumventing	this	limitation	are	confocal	microscopy	and	nuclear	and	cytoplasmic	fractionation	with	subsequent	Western	blotting.	The	latter	was	next	performed	on	untreated	MCF-7,	 TAMR	 and	 XR	 cells	 to	 verify	 the	 cellular	 localisation	 of	 CLU-S.	Interestingly	 in	 contrast	 to	 the	 immunofluorescence	 data,	 such	 studies	 revealed	cytoplasmic	expression	of	CLU-S	(CLU	precursor	and	CLUα)	protein	in	TAMR	and	XR	cells	with	very	little	expression	observed	in	the	nuclear	extracts.	Therefore,	it	is	very	 likely	 that	 the	 above-mentioned	 limitation	 of	 the	 fluorescene	 microscopy	contributed	to	the	nuclear	staining	of	CLU-S	observed.	Small	levels	of	Grb2	protein,	the	cytoplasmic	marker,	were	detected	in	the	nuclear	fractions,	and	thus	the	CLU-S	apparent	 in	 the	 nuclear	 fraction,	 particularly	 in	 the	 XR	 cells,	 may	 reflect	contamination	 from	 the	 cytoplasmic	 fraction	 proteins.	 Cellular	 fractionation	studies	 are	 required	 to	 verify	 the	 localisation	 of	 CLU-S	 during	antihormone-response.	 It	 is	 hypothesised	 that	 such	 studies	 would	 identify	cytoplasmic	expression	of	CLU-S.	Collectively,	 this	 Chapter	 has	 built	 on	 the	 data	 presented	 in	 Chapter	 4,	 and	demonstrated	that	antihormone-induced	CLU-S	expression	is	maintained	through	to	 the	 acquisiton	 of	 resistance.	 However,	 the	 role	 of	 CLU-S	 remains	 largely	unexplored.	 Early	 induction	 of	 CLU-S	was	 hypothesised	 to	 promote	 cell	 survival	and	 consequently	 allow	 a	 cohort	 of	 cells	 to	 evade	 antihormone	 challenge,	ultimately	contributing	to	the	emergence	of	resistant	cell	growth.	CLU	knockdown	studies	revealed	a	potential	role	for	CLU	in	limiting	the	growth	inhibitory	actions	of	fulvestrant	during	antihormone-response	in	MCF-7	cells.	Such	effects	were	only	transient	 and	 were	 not	 demonstrated	 during	 antihormone-resistance.	 Similarly,	such	effects	were	not	demonstrated	during	antihormone-response	or	–resistance	in	 the	 T47D	 cell	 line.	 However,	 since	 the	 CLU	 siRNA	 likely	 targeted	 both	 the	pro-survival	 CLU-S	 and	 pro-apoptotic	 nuclear	 CLU	 isoforms,	 it	 is	 possible	 that	downregulation	 of	 the	 latter	 obscured	 the	 growth	 inhibition	 induced	 by	 CLU-S	knockdown.	 Additionally,	 T47D	 cells	 may	 express	 greater	 nuclear	 CLU	 to	 the	
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MCF-7	 cells,	 potentially	 explaining	 the	 differences	 of	 CLU	 knockdown	 on	fulvestrant-treated	 cell	 growth.	 Although	 cellular	 localisation	 studies	 via	immunofluorescence	identified	equal	nuclear	and	cytoplasmic	expression	of	CLU-S	(precursor	 and	 CLUα)	 in	 antihormone-treated	 and	 antihormone-resistant	MCF-7	cells,	 subsequent	 cellular	 fraction	 and	 Western	 blotting,	 confirmed	 cytoplasmic	expression	 of	 CLU-S	 protein	 during	 resistance.	 Further	 studies	 are	 necessary	 to	confirm	such	localisation	of	the	CLU-S	protein	during	antihormone	response.	It	is	unquestionable	that	further	studies	are	required	to	precisely	examine	the	role	of	the	CLU-S	isoform.	Such	studies	include	designing	a	siRNA	specific	to	CLU-S,	or	more	 preferably	 inducing	 stable	 CLU-S	 gene	 knockdown.	 Additionally,	 cell	 cycle	analysis	and	apoptosis	assays	could	be	performed	to	determine	whether	CLU-S	is	indeed	a	survival	protein	and/or	promotes	dysregulation	of	the	cell	cycle.	Several	studies	 have	 identified	 a	 role	 for	 CLU-S	 in	 activating	 NF-κB-mediated	 gene	transcription	 and	 ERK1/2	 signalling	 to	 promote	 cell	 survival	 and	 prolfieration.	Thus,	 further	 studies	 could	 explore	 these	 potential	 cell	 survival	 pathways	regulated	 by	 CLU-S.	 Such	 studies	 could	 include	 NF-κB	 reporter	 gene	 assays	 and	examination	 of	 phosphorylated-ERK1/2	 expression	 in	 CLU-S-knockdown	 cells.	Since	CLU-S	is	a	secretory	protein,	its	expression	in	the	culture	media	should	also	be	examined.	Such	studies	may	identify	CLU-S	as	a	therapeutic	target	in	ER+	breast	cancer	to	enhance	endocrine	response	or	reverse	the	resistant	phenotype,	or	as	a	novel	biomarker	indicative	of	endocrine	therapy	outcome.		
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7 Conclusion	and	future	studies	
Although	 antihormones	 are	 the	 mainstay	 treatment	 for	 ER+	 breast	 cancer	 and	have	contributed	to	a	substantial	decrease	in	mortality	over	recent	decades,	their	growth	inhibitory	actions	are	compromised	by	the	emergence	of	resistance.	More	than	 40%	 of	 ER+	 patients	 acquire	 resistance	 and	 virtually	 all	 advanced	 disease	patients	 eventually	 relapse.	 In	 both	 instances,	 resistance	 is	 characterised	 by	accelerated	tumour	growth	and	increased	aggressive	behaviour,	together	resulting	in	poorer	patient	outlook.	Therefore,	it	is	crucial	to	understand	the	complexities	of	the	 underlying	 mechanisms	 of	 resistant	 growth	 to	 provide	 novel	 therapeutic	options	for	such	patients	and	ultimately	improvement	in	patient	outcome.	Several	 mechanisms	 of	 endocrine	 resistance	 have	 been	 proposed.	 Of	 which,	 the	most	 extensively	 studied	 is	 the	 alteration	 of	 ER	 expression	 and	 activity.	 Indeed,	approximately	 20%	 of	 antihormone-treated	 ER+	 patients	 lose	 expression	 of	 the	receptor	 and	 as	 such	 become	 insensitive	 to	 antihormone	 therapy115,116.	 The	mechanisms	 involved	 in	 causing	 down-regulation	 or	 complete	 loss	 of	 the	 ER	include	hypermethylation	of	the	ER	promoter,	MAPK-induced	ER	down	regulation	and	microRNA-mediated	ER	down	regulation117,118,120,123.	ER	activity	is	deregulated	by	a	shift	in	the	balance	of	coactivators	and	corepressors.	Coactivators	function	to	enhance	ER-mediated	gene	transcription	and	overexpression	of	such	proteins	can	directly	 influence	 the	 agonistic	 versus	 antagonistic	 activities	 of	 SERMs	 including	tamoxifen,	thus	enhancing	their	agonistic	activity,	ultimately	leading	to	resistance.	Indeed,	 overexpression	 of	 the	 ER	 coactivator	 AIB1	 is	 associated	 with	 increased	relapse	 and	 death	 of	 tamoxifen-treated	 patients	 with	 HER3-overexpressing	tumours133,134.	Hyperactivation	of	growth	factor	signalling	pathways	has	been	heavily	implicated	in	driving	resistant	cell	growth.	Increased	expression	of	the	RTKs	EGFR,	HER2	and	IGF-1R	 have	 been	 demonstrated	 in	 endocrine-resistance	 cell	 lines	 and	 clinical	samples184–188.	Besides	the	capacity	to	promote	cell	growth	in	their	own	right,	such	signalling	 can	 also	 phosphorylate	 and	 subsequently	 activate	 the	 ER	 and	 its	co-regulatory	proteins,	 increasing	the	receptor	 transcriptional	activity,	ultimately	promoting	 antihormone-resistant	 cell	 growth.	 Such	 signalling	 circumvents	 the	
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inhibitory	 effects	 of	 antihormones	 via	 bidirectional	 cross-talk	 and	modulation	 of	the	 ER	 to	 promote	 re-expression	 of	 oestrogen	 regulated	 genes	 in	 a	ligand-independent	 manner	 and	 in	 the	 presence	 of	 antihormones190,191.	Paradoxically,	sustained	hyperactivation	of	growth	factor	signalling	has	also	been	associated	 with	 reducing	 ER	 expression,	 and	 thus	 such	 cells	 do	 not	 respond	 to	further	 antihormone	 therapy,	 indicating	 a	 loss	 of	 reliance	 on	 ER-mediated	growth121.		There	 is	 a	 large	 body	 of	 evidence	 implicating	 the	 role	 of	 antihormone-induced	compensatory	 signalling	 as	 a	 mechanism	 of	 endocrine	 resistance.	 Surprisingly,	upon	E2	challenge	the	majority	(70%)	of	oestrogen-regulated	genes	are	repressed	in	ER+	breast	cancer	cells38.	However,	many	of	these	oestrogen-suppressed	genes	are	 anti-proliferative	 and	 pro-apoptotic.	 The	 benefit	 of	 antihormone	 therapy	therefore	 arises	 by	 counteracting	 these	 E2-induced	 repressive	 events,	 thus	triggering	 re-expression	 of	 these	 negative	 regulators	 of	 cell	 proliferation259.	Indeed,	 the	 main	 mechanism	 of	 action	 of	 antihormones	 is	 to	 inhibit	 cell	proliferation	 and	 as	 such	 these	 agents	 are	 very	 anti-proliferative.	 However,	antihormones	 are	 not	 particularly	 pro-apoptotic	 and	 are	 unable	 to	 promote	significant	levels	of	cell	death216.	The	weak	pro-apoptotic	activity	of	antihormones	may	reflect	a	significant	capacity	for	induction	of	pro-survival	mechanisms	by	such	agents	 during	 response.	 Such	 events	 may	 limit	 the	 anti-tumour	 activity	 of	antihormones	and	provide	a	mechanism	to	aid	cells	to	survive	the	initial	impact	of	these	agents	and	subsequently	promote	the	emergence	of	resistant	growth.	This	inductive	capacity	of	antihormones	may	be	a	double-edged	sword,	since	more	recent	 research	 has	 revealed	 that	 these	 agents	 can	 induce,	 and	 oestrogens	suppress,	genes	involved	in	cell	proliferation	and	survival197,216,259.	One	such	gene	that	 has	 been	 largely	 studied	 is	 the	 EGFR.	 Oestrogen	 suppresses	 EGFR	 at	 the	transcriptional	level	in	ER+	breast	cancer	cell	models260,261,	and	in	turn,	tamoxifen	induces	EGFR	expression	 in	ER+	MCF-7	cells	during	antihormone	 response,	with	such	an	effect	observed	from	as	early	as	one	week	of	treatment216.	EGFR-activated	MAPK	and	AKT	pathways	cross-talk	with,	and	phosphorylate,	 the	ER	to	maintain	transcriptional	activation.	Subsequent	expression	of	the	ER-regulated	pro-survival	gene	BCL2	has	been	demonstrated,	thus	potentially	allowing	cells	to	escape	growth	
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inhibition.	 As	 such,	 the	 anti-tumour	 activities	 of	 tamoxifen	 are	 incomplete,	 with	only	 partial	 anti-proliferative	 effects	 and	 minimal	 induction	 of	 apoptosis	demonstrated216.	Following	three	months	of	tamoxifen	treatment,	increased	EGFR	expression	 is	 maintained	 in	 MCF-7	 cells	 with	 substantial	 downstream	 kinase	activity.	Interestingly,	these	events	parallel	the	emergence	of	tamoxifen	resistance	coincident	with	restoration	of	ER	activity	and	expression	of	ER-regulated	growth	factor	 ligands,	 particularly	 the	 EGFR	 ligand	 amphiregulin196.	 Consequently,	 a	self-propagating	 EGFR-driven	 autocrine	 growth-regulatory	 loop	 is	 generated	 in	these	cells,	in	which	amphiregulin	expression	is	induced	by	ligand-independent	ER	phosphorylation.	 Together,	 early	 tamoxifen-induced	 EGFR	 expression	 limits	 the	anti-tumour	 response	 and	 provides	 protective	 mechanisms	 to	 a	 cohort	 of	 cells	from	which	resistance	subsequently	emerges.	In	addition	to	EGFR,	HER2	has	also	been	established	as	oestrogen-suppressed	and	antihormone-induced	in	a	panel	of	ER+	 breast	 cancer	 cell	 lines217.	 Antihormones	 also	 induce	 expression	 of	 the	pro-invasive	 genes,	 RhoE	 and	 δ-catenin,	 with	 expression	maintained	 through	 to	the	 acquisition	 of	 resistance,	 potentially	 contributing	 to	 the	 small	 antihormone-induced	invasiveness	observed	in	MCF-7	cells	304,305.	Despite	 considerable	 evidence	 implicating	 the	 role	 of	 antihormone-induced	pro-proliferative	genes	contributing	to	the	emergence	of	endocrine	resistance,	the	role	 played	 by	 antihormone-induced	 pro-survival	 genes	 remains	 largely	unexplored.	 Antihormones	 have	 been	 shown	 to	 promote	 activation	 of	 the	pro-survival	 gene	 AKT	 in	 MCF-7	 cells	 with	 such	 activation	 associated	 with	decreased	sensitivity	of	these	cells	to	the	growth	inhibitory	action	of	these	agents	246,262–264.	 This	 is	 complemented	 by	 studies	 of	 antihormone-treated	 tumour	specimens	which	revealed	a	correlation	between	shorter	disease	free	survival	and	activated	 AKT,	 supporting	 the	 link	 between	 the	 AKT	 pathway	 and	 antihormone	failure265.	 Tamoxifen	 and	 oestrogen	 deprivation	 (mimicking	 AI	 therapy)	treatments	 have	 also	 been	 shown	 to	 induce	 expression	 of	 the	 pro-survival	 gene	BCL2,	 thus	 decreasing	 the	 anti-tumour	 responses	 to	 these	 agents267,269.	 More	recently,	 increased	 expression	 of	 the	 pro-survival	 gene	 14-3-3ζ	 has	 been	associated	 with	 antihormone	 resistance.	 Down	 regulation	 of	 14-3-3ζ	 in	
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endocrine-resistant	 cells	 led	 to	 the	 restoration	 of	 antihormone	 sensitivity,	 with	parallel	reduction	in	the	expression	of	pro-proliferative	and	pro-survival	genes270.	Although	 these	 studies	 are	 limited,	 they	 reveal	 promising	 results	 for	 the	 role	 of	antihormone-induced	 pro-survival	 genes	 in	 the	 development	 of	 endocrine	resistance.	 Certainly,	 further	 studies	 are	 required	 to	 identify	 and	 characterise	novel	 antihormone-induced	 pro-survival	 genes	 early	 during	 response	 that	 may	limit	the	pro-apoptotic	actions	of	antihormones	and	allow	a	cohort	of	cells	to	evade	the	growth	inhibitory	actions	of	these	agents,	resulting	in	anti-tumour	response	of	finite	duration	and	ultimately	the	emergence	of	resistant	cell	growth.	Such	findings	may	provide	novel	 therapeutic	 strategies	 to	 delay,	 reverse	 or	 ultimately	 prevent	the	development	of	resistance.	To	this	regard,	this	thesis	has	explored	the	role	of	antihormone-induced	 pro-survival	 genes	 in	 ER+	 breast	 cancer	 cell	 lines,	 whose	expression	 may	 contribute	 substantially	 to	 the	 emergence	 of	 resistance	 and	investigated	the	potential	of	targeting	such	genes.	The	aims	of	this	study	were:	i) to	 identify	 novel	 pro-survival	 genes	 induced	 by	 currently-used	endocrine	therapies	(tamoxifen,	fulvestrant	and	oestrogen	deprivation)	via	Affymetrix	microarray	gene	expression	profiling	ii) to	 determine	 whether	 the	 expression	 of	 such	 genes	 persist	 into	 the	acquisition	of	resistance		iii) to	 determine	whether	 such	 genes	 contribute	 to	 the	 limited	 efficacy	 of	antihormones	and	subsequently	the	development	of	resistance.	Initially,	a	stringent	filtering	process	was	utilised	to	maximise	the	identification	of	the	 most	 robust	 antihormone-induced	 pro-survival	 genes	 (n=248;	 identified	 by	ontology	 and	 website	 resources)	 via	 Affymetrix	 microarray	 gene	 expression	profiling	of	ER+	MCF-7	cells	following	10	day	antihormone	treatment	(Chapter	3).	The	key	filtering	stages	included:	
• genes	 with	 a	 consistent	 expression	 profile	 observed	 for	 all	 of	 the	 gene	probes	representing	that	gene		
• genes	 with	 a	 ‘marginal’	 or	 ‘present’	 detection	 call,	 signifying	 partial	 and	reliable	 detection	 of	 gene	 expression,	 respectively,	 in	 at	 least	 one	antihormone	treatment	and	resistant	cell	line	
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• genes	 up	 regulated	 by	 antihormone	 treatment	 and	 maintained	 into	 the	appropriate	resistant	setting	(e.g.	tamoxifen	and	TAMR)	
• genes	 significantly	 (p	 <0.05)	 induced	 by	 at	 least	 one	 antihormone	treatment	versus	control	
• genes	 induced	 by	 a	 fold	 change	 greater	 than	 1.5	 by	 at	 least	 one	antihormone	treatment		versus	control	Together,	 this	 stringent	 filtering	 process	 identified	 14	 genes	 significantly	 up	regulated	by	at	least	one	antihormone	treatment	during	response,	with	expression	maintained	 into	 antihormone	 resistance.	 Such	 genes	 included	 those	 involved	 in	signal	 transduction	 (GABBR2,	 CXCR4,	 AKT1	 and	 PSEN1)	 and	 the	 NF-κB	 cascade	(BCL3	and	ERC1)	as	well	as	chaperone	proteins	(BAG1	and	CLU),	 the	survivn	co-factor	HBXIP,	the	cell	adhesion	protein	CTNND2,	the	caspase	inhibitor	BCL2L1;	in	addition	 to	 the	 nitric	 oxide	 generator	 DDAH2,	 the	 small	 leucine	 zipper	 protein	TSC22D3	and	IGFBP5	which	regulates	IGF	activity.	It	was	hypothesised	that	these	antihormone-induced	genes	may	allow	a	cohort	of	cells	to	survive	the	growth-inhibitory	actions	of	these	agents	early	during	response	and	 subsequently	 contribute	 substantially	 to	 the	 emergence	 of	 resistance	 and	ultimately	poorer	patient	outcome.	The	majority	of	the	microarray	profiles	of	the	14	 genes	 were	 successfully	 verified	 by	 RT-PCR,	 with	 the	 exception	 of	 BAG1,	DDAH2	 and	 HBXIP,	 which	 showed	 similar	 levels	 of	 RNA	 expression	 following	E2-control	 and	 antihormone	 treatments.	 Additionally,	 RT-PCR	 verification	 of	IGFBP5	continued	to	fail,	with	no	mRNA	expression	detected.	This	was	likely	due	to	the	PCR	primers	recognising	an	alternative	region	of	mRNA	to	that	recognised	by	the	probes	on	the	Affymetrix	gene	chip.	The	genes	of	particular	interest	and	therefore	considered	for	further	investigation	were	 those	 significantly	 induced	 by	 all	 three	 antihormone	 treatments	 (i.e.	tamoxifen,	 fulvestrant	and	oestrogen	deprivation).	The	rationale	was	that	 further	study	 of	 these	 genes	may	 identify	 an	 antihormone-induced	 resistant	mechanism	common	to	three	antihormone	therapies	used	clinically.	Such	genes	may	ultimately	provide	a	novel	biomarker	indicative	of	treatment	response	or	a	therapeutic	target	common	 to	 resistance	 to	 all	 three	 antihormones	 and	 thus	 offering	 a	 therapeutic	
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option	to	a	significant	cohort	of	breast	cancer	patients.	These	genes	were:	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3.	The	Affymetrix	microarray	profiles	of	 these	5	genes	 in	short-term	antihormone-treated	MCF-7	cells	were	verified	at	 the	mRNA	and	 protein	 level	 by	 RT-PCR	 and	Western	 blotting.	 However	 due	 to	 the	 lack	 of	available	antibodies,	CTNND2	expression	could	not	be	verified	at	the	protein	level.	Increased	 expression	 of	 these	 genes	 has	 been	 identified	 in	 several	 cancers,	including	 breast,	 prostate	 and	 ovarian,	 and	 ontological	 investigation	 confirmed	tumour-promoting	 functions317,329,336,354,360.	 However,	 very	 few	 studies	 have	demonstrated	their	induction	by	antihormones	in	breast	cancer	and	have	explored	their	 potential	 role	 in	 limiting	 antihormone-response	 and	 promoting	 the	acquisition	of	resistance.		Breast	 cancer	 has	 been	 long	 established	 as	 a	 heterogeneous	 disease	 and	 it	 is	becoming	increasingly	recognised	that	the	use	of	the	MCF-7	cell	 line	to	represent	all	ER+	breast	cancer	is	 insufficient.	Genomic	studies	have	established	four	major	subtypes	of	breast	cancer	with	each	subtype	exhibiting	a	disparate	prognosis	and	treatment	 response	 partly	 due	 to	 inherent	 genetic	 differences	 between	 the	subtypes277,278.	 These	 subtypes	 include	 luminal	 A	 (ER+/HER2-),	 luminal	 B	(ER+/HER2+),	basal	(ER-/HER2-)	and	HER2	(ER-/HER2+).		To	better	reflect	this	heterogeneity,	equivalent	examination	of	GABBR2,	CTNND2,	CLU,	TSC22D3	and	BCL3	was	performed	during	antihormone	response	in	a	panel	of	four	ER+	breast	cancer	cell	lines	with	differing	HER2	status,	thus	encompassing	luminal	A	and	 luminal	B	subtypes	(Chapter	4).	All	 three	antihormone	 treatments	induced	 increased	 mRNA	 and	 protein	 expression	 of	 these	 genes	 in	 ER+/HER2-	MCF-7	 and	 T47D	 and	 ER+/HER2+	 BT474	 and	 MDA-MB-361	 cell	 lines,	 with	 the	exception	of	GABBR2	in	T47D	cells.	Additionally,	as	in	Chapter	3,	CTNND2	protein	expression	 could	 not	 be	 detected.	 These	 key	 findings	 suggest	 that	 all	 three	antihormones	 induce	expression	of	 common	pro-survival	genes	 in	 luminal	A	and	luminal	B	subtypes.	Furthermore,	common	resistant	mechanisms	may	be	induced	by	all	three	antihormone	therapies	in	these	breast	cancer	subtypes.	Further	study	of	 the	 most	 robust	 candidate	 genes	 could	 prove	 significant	 in	 identifying	biomarkers	 of	 limited	 response	 or	 targets	 for	 novel	 therapeutic	 strategies	 to	enhance	 antihormone	 response	 and	 significantly	 delay,	 prevent	 or	 reverse	 the	
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development	 of	 resistance.	 The	 most	 promising	 genes	 (BCL3	 and	 CLU)	 were	subsequently	taken	forward	for	investigation.	BCL3	is	a	nuclear	protein	and	belongs	to	the	family	of	IκB	proteins	that	function	to	inhibit	 the	 activity	 of	 NF-κB	 transcription	 factors358.	 In	 unstimulated	 cells,	 IκB	proteins	sequester	NF-κB	in	the	cytoplasm,	preventing	their	nuclear	translocation	and	downstream	transcriptional	activation	of	a	large	number	of	genes	involved	in	cell	 survival	 and	 proliferation358.	 Upon	 stimulation	 via	 several	 stimuli,	 including	growth	factors,	IκB	is	degraded	by	IκB	kinase,	thus	allowing	translocation	of	NF-κB	dimers	 into	 the	 nucleus	 where	 they	 bind	 to	 DNA	 at	 specific	 NF-κB	 response	elements	 to	 activate	 gene	 transcription414,415.	 The	 NF-κB	 family	 consists	 of	 five	members:	 RelA,	 RelB	 and	 cRel	 proteins	 contain	 a	 transactivation	 domain	 at	 the	C-terminus	 thus	 facilitating	 the	 recruitment	 and	displacement	 of	 coativators	 and	corepressors,	 respectively,	 necessary	 for	 transcriptional	 activation;	 however	p50/NFKB1	and	p52/NFKB2	proteins	lack	transactivation	domains	and	thus	such	homodimers	are	inactive	and	unable	to	drive	gene	transcription414.	BCL3	functions	to	 provide	 transactivating	 domains	 to	 these	 otherwise	 inactive	 homodimers	 to	activate	transcription	of	cell	growth	and	survival	genes372.	Antihormone-induced	BCL3	protein	expression	in	a	panel	of	ER+	breast	cancer	cell	lines	was	maintained	through	to	the	acquisition	of	resistance	as	demonstrated	 in	short-term	(i.e.	6	months)	TAMR	and	XR	cell	models	derived	from	MCF-7	cells	and	T47D	 TAMR	 cell	models.	 Furthermore,	 BCL3	 expression	was	maintained	 in	 long	term	(3	years)	resistance	(TAMR	and	XR)	cell	models	derived	from	MCF-7,	T47D,	BT474	and	MDA-MB-361	cells	(Chapter	5).	In	support	of	these	findings,	a	previous	study	has	 also	demonstrated	 increased	BCL3	expression	 in	ER+,	E2-independent	MCF-7	cells	versus	the	parental	cell	line363.	Subsequent	studies	aimed	to	establish	whether	 BCL3	 expression	 correlated	 with,	 and	 ultimately	 contributed	 to,	 the	limited	 efficacy	 of	 antihormones	 and	 the	 consequent	 development	 of	 resistance.	However,	 in	 contrast	 to	what	was	 first	hypothesised,	a	pro-survival	 role	of	BCL3	during	 antihormone	 response	 and	 resistance	 was	 not	 identified.	 This	 is	 in	disagreement	with	the	literature	which	supports	a	role	for	BCL3	in	the	survival	of	breast	 cancer	 cells.	 The	 mechanisms	 proposed	 by	 which	 BCL3	 promotes	 cell	survival	 in	 breast	 cancer	 cells	 include	 stabilisation	 of	 the	 anti-apoptotic	 protein	
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CtBP1	which	represses	the	transcription	of	pro-apoptotic	genes,	as	well	as	BCL3-mediated	 inhibition	 of	 the	 tumour	 suppressor	 gene,	 p53367,368.	 However,	 the	survival	 role	 of	 BCL3	 was	 assessed	 in	 this	 thesis	 by	 siRNA	 mediated	 BCL3	knockdown	in	antihormone	responsive	and	resistant	cells.	It	is	possible	that	such	transient	knockdown	is	insufficient	to	promote	significant	apoptosis,	which	may	be	apparent	with	stable	gene	knockdown.		Interestingly,	 targeted	 down	 regulation	 of	 BCL3	by	 siRNA	was	 associated	with	 a	substantial	 decrease	 in	 the	 growth	 of	 TAMR	and	 to	 a	 lesser	 degree	XR	 cells,	 but	was	without	an	effect	on	the	growth	of	T47D-TAMR	and	antihormone-responsive	cells.	These	findings	suggest	that	BCL3	may	play	a	role	in	promoting	TAMR	and	XR	cell	 growth	 with	 no	 such	 effect	 apparent	 in	 the	 T47D	 TAMR	 cells	 or	 during	antihormone	 response.	 However,	 BCL3	 knockdown	 could	 not	 be	 verified	 at	 the	protein	level	 in	the	T47D	TAMR	cells,	potentially	explaining	why	no	effect	on	cell	growth	 was	 observed.	 In	 contrast	 to	 these	 findings,	 BCL3	 has	 previously	 been	demonstrated	to	enhance	the	growth	of	MCF-7	cells	in	vivo363.	However,	there	are	significant	 experimental	differences	between	 these	 studies,	 likely	 contributing	 to	the	contrasting	results.	Indeed,	Pratt	et	al.’s	study	utilised	a	stable	BCL3	expressing	system	and	was	performed	 in	 vivo	 and	 therefore	 likely	 influenced	by	 the	 stroma	and	 tumour	 microenvironment.	 In	 contrast,	 in	 our	 study	 BCL3	 expression	 was	induced	by	fulvestrant	treatment	and	cells	were	exposed	to	a	transient	increase	in	gene	expression.	 It	 is	possible	 that	 long	 term	BCL3	expression	contributes	 to	 the	re-organisation	of	 the	cellular	networks	to	promote	cell	growth	which	would	not	be	 possible	 following	 short	 term	 BCL3	 exposure.	 Thus,	 it	 is	 feasible	 that	 with	long-term	 BCL3	 expression	 an	 increase	 in	 cell	 growth	 of	 antihormone-treated	MCF-7	 cells	 may	 be	 observed.	 Cell	 cycle	 studies	 were	 performed	 to	 investigate	whether	 BCL3	 promotes	 TAMR	 and	 XR	 cell	 growth	 via	 dysregulation	 of	 the	 cell	cycle.	 However,	 such	 studies	 failed	 to	 identify	 such	 a	 role	 for	 BCL3.	Unquestionably,	 stable	BCL3	knockdown	 is	 required	 to	more	effectively	examine	the	effects	of	BCL3	on	cell	survival,	cell	proliferation	and	the	cell	cycle.	The	 association	 between	 BCL3	 and	 activation	 of	 NF-κB-mediated	 gene	transcription	was	 examined.	 Interestingly,	 p50/NFKB1	 expression	was	 observed	in	MCF-7	and	T47D	cells	±	E2	and	antihormone	treatments,	and	also	in	the	TAMR,	
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XR	and	T47D	TAMR	cell	lines.	However,	p52/NFKB2	expression	was	not	detected	in	 antihormone-responsive	 or	 resistant	 cell	 lines.	 These	 findings	 suggest	 that	p50/NFKB1	 is	 expressed	 alongside	 BCL3	 during	 antihormone	 response	 and	 in	resistance,	 supporting	 the	 hypothesis	 that	 BCL3	 co-activates	 p50/NFKB1	homodimers	 to	 promote	 transcription	 of	 target	 genes.	 In	 agreement	 with	 these	findings,	 previous	 studies	 have	 demonstrated	 p50/NFKB1	 expression	 in	 MCF-7	and	 T47D	 cells,	 in	 addition	 to	 tamoxifen	 resistant	 cells,	 but	 failed	 to	 identify	p52/NFKB2	 expression358,360,423.	 Immunofluorescence	 and	 immunoprecipitation	studies	 revealed	 nuclear	 localisation	 and	 direct	 association	 of	 BCL3	 and	p50/NFKB1	 in	 TAMR	 and	 XR	 cells	 thus	 suggesting	 that	 BCL3	 co-activates	p50/NFKB1	 homodimers	 to	 promote	 NF-κB-mediated	 gene	 transcription	 and	ultimately	 cell	 growth.	 Although	 immunoprecipitation	 studies	 revealed	 an	association	 between	 both	 proteins	 in	 T47D	 TAMR	 cells,	 immunofluorescence	studies	demonstrated	cytoplasmic	expression	of	both	proteins.	Since	p50/NFKB1	must	be	located	in	the	nucleus	to	bind	to	DNA	and	activate	gene	transcription,	it	is	unlikely	that	such	an	event	was	occurring	in	the	T47D	TAMR	cells.	This	supports	the	absence	of	BCL3-mediated	cell	growth	demonstrated	in	these	cells,	 likely	due	to	 cytoplasmic	 localisation	of	BCL3	and	p50/NFKB1	proteins,	 thus	not	activating	NF-κB-mediated	gene	transcription	and	subsequent	cell	growth.		During	antihormone	response	in	MCF-7	cells,	BCL3	was	predominantly	located	in	the	nucleus	and	p50/NFKB1	was	predominantly	located	in	the	cytoplasm	and	thus	were	not	associated.	This	mirrors	the	cell	growth	studies	which	demonstrated	that	BCL3	had	no	effect	on	the	growth	of	fulvestrant-treated	MCF-7	cells.	Surprisingly,	both	proteins	were	 co-located	 in	 the	nucleus	of	 antihormone-treated	T47D	cells,	however	 immunoprecipitation	 studies	 failed	 to	 identify	 a	 direct	 association	between	them.	Additionally,	cell	growth	studies	demonstrated	that	BCL3	does	not	promote	 the	 growth	 of	 fulvestrant-treated	 T47D	 cells.	 Therefore	 it	 is	 likely	 that	rather	 than	 co-activating	 p50/NFKB1	 homodimers	 in	 fulvestrant-treated	 T47D	cells,	 BCL3	 functions	 to	 repress	 NF-κB	 activation	 by	 promoting	 the	 binding	 of	inactive	p50/NFKB1	homodimers	to	the	κB	sites	on	DNA,	to	prevent	the	binding	of	transactivating	dimers429,430.		
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Further	 studies,	 including	 a	 NF-κB	 reporter	 gene	 assay,	 are	 required	 to	 confirm	p50/NFKB1	 homodimer	 activation	 in	 TAMR	 and	 XR	 cells	 in	 addition	 to	 ChIP	sequencing	which	would	 identify	 the	potential	pro-proliferative	and	pro-survival	genes	 regulated	 by	 such	 transcriptional	 activation.	 Furthermore,	 examination	 of	the	other	NF-κB	subunits	which	contain	a	 transactivation	domain	would	confirm	whether	they	are	involved	in	the	predicted	NF-κB	activity	apparent	in	TAMR	and	XR	cells.		The	second	antihormone-induced	protein	of	interest,	CLU,	was	studied	in	Chapter	6.	CLU	is	a	ubiquitously	expression	glycoprotein	involved	in	several	physiological	processes	 important	 for	 tumorigenesis,	 including	 apoptosis	 and	 cell	 cycle	regulation371,431,432.	CLU	exists	as	two	main	isoforms:	nuclear	CLU	and	cytoplasmic	CLU-S.	The	former	functions	to	promote	cell	death	whereas	the	latter	promotes	cell	survival.	 A	 previous	 study	 has	 demonstrated	 that	 CLU-S	 represents	 the	 most	abundant	 isoform	 in	MCF-7	 cells,	with	 approximately	 0.01%	 represented	 by	 the	nuclear	isoform295.	Increased	 CLU-S	 protein	 expression	 was	 demonstrated	 in	 TAMR,	 XR	 and	 T47D	TAMR	cells.	Interestingly,	CLU	expression	was	associated	with	a	small	induction	in	fulvestrant-treated	 MCF-7	 cell	 growth	 but	 was	 without	 effect	 on	 the	 growth	 of	fulvestrant-treated	T47D	cells.	However,	due	to	difficulties	with	Western	blotting,	CLU-S	knockdown	was	not	confirmed	at	the	protein	levels	in	these	cells.	Therefore,	it	 is	possible	 that	 the	 conditions	were	not	optimum	 for	CLU-S	knockdown	 in	 the	T47D	 cells.	 In	 support	 of	 these	 findings,	 down	 regulation	 of	 CLU-S	 via	 siRNA	 in	tamoxifen	treated	MCF-7	cells	has	been	demonstrated	to	promote	a	small	decrease	in	cell	growth338.	Additionally,	 in	ER+/HER2+	BT474	cells,	 trastuzumab	has	been	shown	to	 increase	CLU	expression	with	an	associated	 increase	 in	cell	 survival408.	However,	CLU	was	without	effect	on	the	growth	of	our	antihormone-resistant	cells.	This	suggests	that	during	antihormone-response	CLU	may	transiently	promote	the	growth	and/or	survival	of	MCF-7	cells,	possibly	promoting	the	reprogramming	of	intracellular	 signalling	 networks	 and	 the	 emergence	 of	 dominant	EGFR/HER2-driven	MAPK	and	AKT	signalling	pathways	to	promote	resistant	cell	growth.	 Although	 CLU	 knockdown	 resulted	 in	 a	 substantial	 decrease	 in	 CLU-S	expression,	the	CLU	siRNA	utilised	was	comprised	of	a	pool	of	siRNA	and	thus	not	
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specific	 to	 the	 CLU-S	 isoform.	 Therefore	 it	 is	 possible	 that	 nuclear	 CLU	was	 also	targeted	 for	 knockdown.	 However,	 as	 mentioned	 above,	 the	 majority	 of	 CLU	present	 in	 MCF-7	 cells	 is	 the	 secretory	 cytoplasmic	 isoform.	 Further	 studies,	including	specific	CLU-S	stable	knockdown	and	cell	survival	assays	are	required	to	confirm	whether	 this	protein	promotes	cell	 survival,	 thus	allowing	cells	 to	evade	the	 growth	 inhibitory	 actions	 of	 antihormones	 and	 ultimately	 promote	 the	emergence	of	antihormone-resistant	cell	growth.	Together,	 this	 thesis	 has	 demonstrated	 that	 antihormone-induced	 events,	particularly	 the	 induction	 of	 pro-proliferative	 and	 pro-survival	 genes	 may	 be	 a	mechanism	involved	in	the	emergence	of	endocrine	resistance.	Indeed,	this	study	identified	induction	of	CLU	expression	by	short	term	antihormone	treatment,	with	such	induction	potentially	involved	in	promoting	the	growth	of	breast	cancer	cells	during	 antihormone	 response,	 thus	 limiting	 the	 anti-tumour	 activities	 of	 these	agents	 and	 possibly	 facilitating	 the	 re-organisation	 of	 cellular	 networks	 and	 the	emergence	of	dominant	MAPK	and	AKT	signalling	pathways	to	promote	resistant	cell	growth.	The	potential	growth-promoting	role	of	CLU	was	transient,	with	such	an	 effect	 not	 apparent	 in	 the	 endocrine	 resistant	 cell	 models.	 The	 second	 gene,	BCL3,	was	also	induced	by	short	term	antihormone	treatment,	however	in	contrast	to	 CLU,	 BCL3	may	 play	 a	 role	 in	 promoting	 resistant	 cell	 growth	 but	 is	without	effect	on	the	growth	of	cells	during	antihormone	response.	The	role	of	BCL3	during	response	remains	to	be	elucidated.		Although	 such	 inductive	 events	 are	 complex	with	multiple	 pathways	 induced	 by	antihormones,	 as	 demonstrated	 by	 the	 several	 antihormone-induced	 genes	identified	 in	 this	 study	as	well	 as	 the	more	established	EGFR	and	HER2	proteins	with	 subsequent	 activation	of	 downstream	MAPK	and	AKT	pathways;	 this	 thesis	has	 demonstrated	 that	 common	 genes	 can	 be	 up	 regulated	 by	 several	antihormones	in	multiple	cell	types.	Therefore,	targeting	these	genes	and	treating	resistant	disease	may	be	possible	and	an	effective	therapy,	despite	the	complexity	surrounding	antihormone-induced	events.		Although	 this	 thesis	 has	 identified	 a	 role	 for	 antihormone-induced	 BCL3	 in	promoting	 resistant	 cell	 growth	 and	 BCL3	 appears	 a	 promising	 target	 for	 novel	
		 341	
therapies	 to	 decrease/prevent	 resistant	 cell	 growth,	 it	 is	 clear	 that	antihormone-induced	deregulation	of	single	genes	fails	to	fully	explain	the	limited	response	 to	 antihormones	 and	 subsequent	 development	 of	 resistance.	Identification	 of	 the	 additional	 mechanisms	 contributing	 to	 limited	 endocrine	response	 and	 resistance	 (perhaps	 involving	 antihormone-induction	 of	 the	 other	genes	 identified	 in	 this	 thesis)	may	allow	novel	 therapies	 to	be	devised	targeting	multiple	 pathways	 simultaneously	 to	 maximise	 therapeutic	 response	 to	antihormones.	From	the	findings	of	our	study,	it	is	possible	that	common	pathways	are	activated	by	several	antihormone	therapies	in	multiple	cell	types	and	therefore	targeting	 such	 pathways	 may	 be	 an	 effective	 therapy	 for	 several	 breast	 cancer	subtypes	 treated	with	 several	 antihormone	 therapies.	 The	 findings	 of	 this	 thesis	further	support	the	rationale	for	studying	the	inductive	capacity	of	antihormones	and	 in	 particular	 the	 induction	 of	 pro-survival	 and	 pro-proliferative	 genes	 as	 a	mechanism	of	endocrine	resistance.	Significantly,	 breast	 cancer	 is	 a	 highly	 heterogeneous	 disease	 and	 although	 this	study	 utilised	 several	 cell	 lines,	 encompassing	 HER2+	 and	 HER2-	 disease,	equivalent	 investigations	 in	 additional	 cell	 lines	 to	 further	 reflect	 this	heterogeneity	 are	 necessary.	 Additionally,	 the	 Breast	 Cancer	 Molecular	Pharmacology	 Group	 have	 also	 developed	 (short-term)	 acquired	 tamoxifen-	 and	fulvestrant-resistant	 cell	models	 in	BT474	and	MDA-MB-361	 cells,	 as	well	 as	 the	long-term	resistant	cell	models	briefly	examined	in	Chapter	5.	These	models	were	not	extensively	studied	in	this	thesis,	but	future	work	in	such	models	may	validate	the	findings	presented	here.	Furthermore,	although	human	breast	cancer	cell	lines	are	 powerful	 experimental	 tools,	 they	 do	 not	 take	 into	 account	 the	 tumour	microenvironment,	paracrine	signalling	and	complex	inter-relationships	that	exist	between	 cells	 in	 vivo.	 Additionally,	 the	 ontology	 of	 some	 genes	 identified	 in	 this	project	 suggested	 a	 greater	 role	 in	 the	 in	 vivo	 setting	 e.g.	 CXCR4.	Therefore,	 it	 is	unquestionable	that	further	examination	in	in	vivo	models	would	prove	beneficial	and	will	also	address	characteristics	unique	to	the	in	vivo	setting	(e.g.	hypoxia	and	angiogenesis),	 which	 may	 contribute	 to	 limited	 antihormone	 responses.	 Over	recent	 years	 unprecedented	 developments	 in	 cancer	 organoids	 as	 pre-clinical	cancer	 models	 have	 been	 observed.	 Tumour-derived	 organoids	 are	 cultured	 in	
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vitro	 and	 maintain	 their	 genetic	 integrity	 over	 months	 in	 culture452.	 Organoids	display	hallmarks	of	the	original	tumour,	including	the	3	dimensional	architecture	and	 the	 ability	 to	 self-renew.	 Additionally,	 organoids	 recapitulate	 molecular	features	 of	 the	 original	 tumour	 and	 can	 model	 clinically	 relevant	 drug	responses453,454.	 Therefore,	 it	 is	 unquestionable	 that	 the	 establishment	 of	 breast	cancer	organoids	will	provide	a	powerful	new	tool	for	biomarker	identification	and	drug	development.		Ideally,	 to	 further	 verify	 the	 genes	 of	 interest	 as	 biomarkers	 or	 promoters	 of	limited	antihormone	response,	consecutive	tumour	samples	at	baseline	and	during	neoadjuvant	antihormone	therapy	are	required.	However,	this	would	be	a	burden	for	 the	 patient	 and	 is	 therefore	 almost	 impossible.	 Additionally,	 neoadjuvant	therapy	 is	 usually	 short-term	 and	 therefore	 such	 studies	would	 not	 address	 the	long-term	 responses	 to	 a	 drug.	 To	 overcome	 these	 issues,	 non-invasive	methods	are	 required	 for	 monitoring	 tumour	 genomes	 and	 identifying	 biomarkers	 at	various	 time	points	during	 the	course	of	disease.	To	 this	end,	 circulating	 tumour	cells	 and	 tumour	 DNA	 have	 been	 identified	 in	 the	 bloodstream	 which	 are	 shed	from	primary	and	metastatic	tumours	and	are	potential	surrogates	for	the	tumour	itself455.	 Thus,	 analysis	 of	 such	 cells	 in	 the	 blood	 may	 provide	 a	 suitable	non-invasive	tool	for	examining	sequential	samples	during	therapy	and	obtaining	genetic	follow-up	data	that	are	urgently	needed.		
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9 Appendices	
Table	 15	 The	 list	 of	 pro-survival	 genes	 (n=248)	 examined	 by	 microarray	 gene	
expression	profiling.	AATF	 CD28	 FGFR3	 MAP3K2	 NOTCH2	 SERPINB2	AKT1	 CD40LG	 FGFR4	 MAP3K3	 NPM1	 SERPINB9	AKT2	 CD59	 FLT1	 MAP3K4	 NRG2	 SFRP1	AKT3	 CDC123	 FOXO1	 MAP3K5	 NTF3	 SH3GLB1	ALOX12	 CDC20	 GABBR2	 MAP3K6	 OPA1	 SHC1	ANXA1	 CDC25A	 GDNF	 MAPK1	 OR7A17	 SKP2	API5	 CDC25B	 GLO1	 MAPK14	 PAK1	 SNCA	ASCL1	 CDC25C	 GRB7	 MAPK3	 PAK7	 SON	ATF5	 CDC6	 GSK3A	 MAPK8	 PAX7	 SP1	AURKA	 CDK1	 GSK3B	 MAPK8IP2	 PEA15	 SPHK1	AVEN	 CDK10	 GSTP1	 MCL1	 PELP1	 SPP1	AZU1	 CDK19	 HAX1	 MCM2	 PIK3CA	 SRC		BAG1	 CDK4	 HBXIP	 MCM3	 PIK3R1	 STAMBP	BAG3	 CDK6	 HDAC1	 MCM5	 PIK3R2	 STAT3	BAG4	 CDK7	 HIF1A	 MKL1	 PIM2	 STK38	BCAR3	 CEBPB	 HIPK3	 MMP1	 POGK	 TAX1BP1	BCL2	 CFDP1	 HMGB1	 MMP13	 POLA1	 TBX3	BCL2A1	 CFL1	 HSP90B1	 MMP14	 POLB	 TGFB1	BCL2L1	 CFLAR	 HSPA1A	 MMP2	 POSTN	 TMX1	BCL2L10	 CHUK	 HSPA1B	 MMP3	 PRDX2	 TNF	BCL2L2	 CLU	 HSPA5	 MMP7	 PRKAA1	 TNFAIP3	BCL3	 CPM	 HSPA9	 MMP9	 PRKCZ	 TNFAIP8	BDNF	 CREBBP	 HSPB1	 MPO	 PRLR	 TNFRSF10D	BECN1	 CRYAA	 HTT	 MTA1	 PRMT1	 TNFSF18	BFAR	 CRYAB	 IER3	 MTA2	 PRSS23	 TPT1	BIRC2	 CTCFL	 IFI6	 MTL5	 PSEN1	 TRIAP1	BIRC3	 CTNND1	 IGF1	 MTOR	 PTK6	 TSC22D3	BIRC5	 CTNND2	 IGF1R	 MYBL2	 RAB30	 TXN2	BIRC6	 CXCR4	 IGF2	 MYC	 RAC1	 VEGFA	BIRC7	 DAD1	 IGFBP5	 MYO18A	 RAF1	 VHL	BNIP1	 DAXX	 IKBKB	 NAIP	 RAN	 WT1	BNIP2	 DDAH2	 IL10	 NCOA1	 RASA1	 XIAP	BNIP3	 DLC1	 IL1A	 NCOA2	 RELA	 YWHAZ	BRAF	 EEF1A2	 IL2	 NCOA3	 RND3	 	BRE	 ELK1	 IRS1	 NFKB1	 RNF7	BUB1	 EP300	 ITGB1	 NFKB2	 RPS6KA1	CASP2	 ERC1	 KRAS	 NME1	 RPS6KA2	CBX4	 FAIM	 KRT13	 NME2	 RPS6KA3	CCL2	 FAIM2	 LOC441453	 NME3	 RPS6KA6	CCNA2	 FARP1	 LTBP1	 NME4	 RTEL1	
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Table	16	List	 of	 163	pro-survival	 genes	up	 regulated	by	 at	 least	 one	 antihormone	
treatment	and	in	at	least	one	antihormone–resistant	cell	line	versus	control.	
AATF	 CTCFL		 MAP3K4	 POLB	
AKT1	 CTNND2	 MAP3K5	 POSTN	
AKT2	 CXCR4	 MAPK1	 PRDX2	
AKT3	 DAD1	 MAPK14	 PRKAA1	
ALOX12	 DDAH2	 MAPK3	 PRKCZ	
API5	 DLC1	 MAPK8	 PRLR	
ASCL1	 EEF1A2	 MAPK8IP2	 PRMT1	
ATF5	 ELK1	 MCL1	 PSEN1	
AURKA	 ERC1	 MCM3	 RAB30	
AVEN	 FAIM	 MCM5	 RAF1	
BAG1	 FAIM2	 MKL1	 RAN	
BAG3	 FAS	 MMP14	 RELA	
BAG4	 FGFR1	 MMP2	 RNF7	
BCAR3	 FGFR3	 MMP7	 RPS6KA1	
BCL2	 FLT1	 MMP9	 RPS6KA6	
BCL2L1	 FOXO1	 MPO	 RTEL1		
BCL2L10	 GDNF	 MTA2	 SERPINB2	
BCL2L2	 GRB7	 MTOR	 SERPINB9	
BCL3	 GSK3A	 MYO18A		 SFRP1	
BDNF	 GSTP1	 NCOA1	 SKP2	
BECN1	 HAX1	 NCOA2	 SNCA	
BIRC3	 HBXIP	 NFKB1	 SON	
BIRC5	 HDAC1	 NFKB2	 SP1	
BIRC6	 HIPK3	 NME1	 SPHK1	
BNIP1	 HSP90B1	 NME3	 SPP1	
BRE	 HSPA1A	 NME4	 SRC	
BUB1	 HSPA9	 NME5	 STAMBP	
CASP2	 IER3	 NME6	 STAT3	
CBX4	 IGF1	 NOL3	 STK38	
CCL2	 IGF2	 NOTCH2	 TAX1BP1	
CCNE1	 IGFBP5	 NRG2	 TBX3	
CD27	 IKBKB	 NTF3	 TNF	
CD28	 IL10	 OPA1	 TNFRSF10D	
CDC123	 IL1A	 OR7A17	 TNFSF18	
CDC25A	 IL2	 PAK1	 TPT1	
CDK10	 ITGB1	 PAK7	 TRIAP1	
CDK4	 LTBP1	 PAX7	 TSC22D3	
CDK6	 MALT1	 PEA15	 TXN2	
CFLAR	 MAP2K1	 PELP1	 VHL	
CLU	 MAP3K3	 PIK3R2	 WT1	
CPM	 	 PIM2	 XIAP		
CCND1	 FAS	 MALT1	 NME5	 RTN4	CCNE1	 FGF17	 MAP2K1	 NME6	 RXRA	CD27	 FGFR1	 MAP3K1	 NOL3	 SEMA4D	
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Table	17	List	of	the	92	genes	identified	with	a	detection	call	of	marginal	or	present	
in	 at	 least	 one	 treatment	 and	maintained	 into	 the	 appropriate	 resistant	 setting	of	
MCF-7	cells.	AATF	 ERC1	 NME4	AKT1	 FAS	 NME6	AKT3	 FGFR1	 NOL3	API5	 FGFR3	 NOTCH2	ATF5	 FOXO1	 OPA1	AURKA	 GABBR2	 PEA15	AVEN	 GRB7	 PELP1	BAG1	 GSK3A	 PIK3R2	BCL2L1	 HAX1	 PIM2	BCL2L2	 HBXIP	 POLB	BCL3	 HDAC1	 POSTN	BECN1	 HSPA1A	 PRDX2	BIRC5	 HSPA1B	 PRKAA1	BNIP1	 IGFBP5	 PRKCZ	BRE	 IKBKB	 PRLR	CASP2	 LTBP1	 PRMT1	CBX4	 MAP2K1	 PSEN1	CCNE1	 MAP3K3	 RAF1	CDC123	 MAPK1	 RELA	CDK10	 MAPK14	 RNF7	CDK4	 MAPK3	 RPS6KA1	CFLAR	 MAPK8IP2	 RTEL1	CLU	 MCL1	 SFRP1	CPM	 MCM3	 SNCA	CTCFL	 MCM5	 SPHK1	CTNND2	 MMP9	 STAMBP	CXCR4	 MYO18A	 STAT3	DAD1	 NFKB1	 TAX1BP1	DDAH2	 NFKB2	 TRIAP1	ELK1	 NME1	 TSC22D3		 NME3	 TXN2		 	 		
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Table	18	List	of	the	17	pro-survival	genes	significantly	(p	<0.05)	induced	by	10	day	
antihormone	treatment	compared	to	control.	AKT1	 CXCR4	 NME6	BAG1	 DDAH2	 PSEN1	BCL2L1	 ERC1	 STAMBP	BCL3	 GABBR2	 STAT3	CLU	 HBXIP	 TSC22D3	CTNND2	 IGFBP5	 	
	
